

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/56990 A2

(51) International Patent Classification⁷: C07D 213/42,
213/40, 405/12, 213/643, 213/89, 213/38, 409/12, A61K
31/4406, 31/4427, A61P 25/06, 25/18, 25/08

(21) International Application Number: PCT/US01/00643

(22) International Filing Date: 22 January 2001 (22.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/180,047 3 February 2000 (03.02.2000) US
60/180,089 3 February 2000 (03.02.2000) US

(71) Applicant (for all designated States except US): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COLEMAN, Dar-
rell, Stephen [US/US]; 1036 Waterford Forest Circle,
Cary, NC 27513 (US). JAGDMANN, Gunnar, Erik,
Junior [US/US]; 1027 Oakgate Court, Apex, NC 27502
(US). JOHNSON, Kirk, Willis [US/US]; 1177 Helford
Lane, Carmel, IN 46032 (US). JOHNSON, Michael,
Parvin [US/US]; 4308 Powderhorn Court, Carmel, IN
46033 (US). LARGE, Thomas, Hallett [US/US]; 1357
James Court, Zionsville, IN 46077 (US). MONN, James,
Allen [US/US]; 7518 Allenwood Court, Indianapolis,
IN 46268 (US). SCHOEPP, Darryle, Darwin [US/US];
638 North Senate Avenue, Indianapolis, IN 46202 (US).
TIZZANO, Joseph, Patrick [US/US]; 6682 West Sweet
Creek Drive, New Palestine, IN 46163 (US). BARDA,
David, Anthony [US/US]; 6857 Washington Boulevard

West Drive, Indianapolis, IN 46220 (US). BRITTON,
Thomas, Charles [US/US]; 4700 Royal Oak Lane,
Carmel, IN 46033 (US). DRESSMAN, Bruce, Anthony
[US/US]; 1430 North New Jersey, Indianapolis, IN 46202
(US). FICHTNER, Michael, William [US/US]; 6405
Stonecreek Drive, Indianapolis, IN 46268 (US). HENRY,
Steven, Scott [US/US]; 3362 South Southway Drive,
New Palestine, IN 46163 (US). HORNBACK, William,
Joseph [US/US]; 10063 Bent Tree Lane, Fishers, IN
46038 (US).

(74) Agents: STEMERICK, David, M. et al.; Eli Lilly and
Company, Lilly Corporate Center, Indianapolis, IN 46285
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/56990 A2

(54) Title: POTENTIATORS OF GLUTAMATE RECEPTORS



(57) Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

-1-

POTENTIATORS OF GLUTAMATE RECEPTORS

The present invention provides potentiators of glutamate receptors (compounds of formula I), pharmaceutical
5 compositions thereof, and methods of using the same, processes for preparing the same, and intermediates thereof.

BACKGROUND OF THE INVENTION

The excitatory amino acid L-glutamate (sometimes
10 referred to herein simply as glutamate) through its many receptors mediates most of the excitatory neurotransmission within the mammalian central nervous system (CNS). The excitatory amino acids, including glutamate, are of great physiological importance, playing a role in a variety of
15 physiological processes, such as long-term potentiation (learning and memory), the development of synaptic plasticity, motor control, respiration, cardiovascular regulation, and sensory perception.

Glutamate acts via at least two distinct classes
20 of receptors. One class is composed of the ionotropic glutamate (iGlu) receptors that act as ligand-gated ionic channels. Via activation of the iGlu receptors, glutamate is thought to regulate fast neuronal transmission within the synapse of two connecting neurons in the CNS. The second
25 general type of receptor is the G-protein or second messenger-linked "metabotropic" glutamate (mGlu) receptor. Both types of receptors appear not only to mediate normal synaptic transmission along excitatory pathways, but also participate in the modification of synaptic connections
30 during development and throughout life. Schoepp, Bockaert, and Sladeczek, *Trends in Pharmacol. Sci.*, 11, 508 (1990); McDonald and Johnson, *Brain Research Reviews*, 15, 41 (1990).

The present invention relates to potentiators of mGlu receptors. The mGlu receptors belong to the Type III G-
35 protein coupled receptor (GPCR) superfamily. This superfamily of GPCR's, including the calcium-sensing receptors, GABA_B receptors and pheromone receptors, which

-2-

are unique in that they are activated by binding of effectors to the amino-terminus portion of the receptor protein. The mGlu receptors are thought to mediate glutamate's demonstrated ability to modulate intracellular signal transduction pathways. Ozawa, Kamiya and Tsuzuski, *Prog. Neurobio.*, **54**, 581 (1998). They have been demonstrated to be localized both pre- and post-synaptically where they can regulate neurotransmitter release, either glutamate or other neurotransmitters, or modify the post-synaptic response of neurotransmitters, respectively.

At present, there are eight distinct mGlu receptors that have been positively identified, cloned, and their sequences reported. These are further subdivided based on their amino acid sequence homology, their ability to effect certain signal transduction mechanisms, and their known pharmacological properties. Ozawa, Kamiya and Tsuzuski, *Prog. Neurobio.*, **54**, 581 (1998). For instance, the Group I mGlu receptors, which include the mGlu₁ and mGlu₅, are known to activate phospholipase C (PLC) via Gαq-proteins thereby resulting in the increased hydrolysis of phosphoinositides and intracellular calcium mobilization. There are several compounds that are reported to activate the Group I mGlu receptors including DHPG, (R/S)-3,5-dihydroxyphenylglycine. Schoepp, Goldworthy, Johnson, Salhoff and Baker, *J. Neurochem.*, **63**, 769 (1994); Ito, et al., *Neurorep.*, **3**, 1013 (1992). The Group II mGlu receptors consist of the two distinct receptors, mGlu₂ and mGlu₃ receptors. Both have been found to be negatively coupled to adenylate cyclase via activation of Gαi-protein. These receptors can be activated by a group-selective compound such as 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate. Monn, et al., *J. Med. Chem.*, **40**, 528 (1997); Schoepp, et al., *Neuropharmacol.*, **36**, 1 (1997). Similarly, the Group III mGlu receptors, including mGlu₄, mGlu₆, mGlu₇ and mGlu₈, are negatively coupled to adenylate cyclase via Gαi and are potently activated by L-AP₄ (L-(+)-2-amino-4-

-3-


phosphonobutyric acid). Schoepp, *Neurochem. Int.*, **24**, 439 (1994).

It should be noted that many of the available pharmacological tools are not ideal in that they cross react not only on the receptors within a Group of mGlu receptors but also often have some activity between Groups of mGlu receptors. For instance, compounds such as 1S,3R-ACPD, (1S,3R)-1-aminocyclopentane-trans-1,3-dicarboxylic acid, are believed to activate all of the Group I, II and III mGlu receptors depending upon the dose utilized while others, such as 1S,3S-ACPD, (1S,3S)-1-aminocyclopentane-trans-1,3-dicarboxylic acid, are more selective for the Group II receptors (mGlu_{2/3}) than the Group I (mGlu_{1/5}) or Group III (mGlu_{4/6/7/8}). Schoepp, *Neurochem. Int.*, **24**, 439 (1994). To date, there are very few examples of selective agents for the mGlu receptors. Schoepp, Jane, and Monn, *Neuropharmacol.*, **38**, 1431 (1999).

It has become increasingly clear that there is a link between modulation of excitatory amino acid receptors, including the glutamatergic system, through changes in glutamate release or alteration in postsynaptic receptor activation, and a variety of neurological and psychiatric disorders. e.g. Monaghan, Bridges and Cotman, *Ann. Rev. Pharmacol. Toxicol.*, **29**, 365-402 (1989); Schoepp and Sacann, *Neurobio. Aging*, **15**, 261-263 (1994); Meldrum and Garthwaite, *Tr. Pharmacol. Sci.*, **11**, 379-387 (1990). The medical consequences of such glutamate dysfunction makes the abatement of these neurological processes an important therapeutic goal.

SUMMARY OF THE INVENTION

This invention provides compounds of formula I:



formula I

wherein

-4-

R₁ is selected from the group consisting of -C(O)R₃,
-C(O)OR₄, and -SO₂R₅

5 wherein R₃ is selected from the group consisting
 of alkyl and cycloalkyl, R₄ is selected from the
 group consisting of alkyl and cycloalkyl, R₅ is
 selected from the group consisting of alkyl,
 cycloalkyl, and fluorinated alkyl;

10 R₂ is from 1 to 3 substituents independently selected
 from the group consisting of hydrogen, hydroxy,
 trisubstituted silyloxy, alkyl, substituted alkyl,
 alkenyl, substituted alkenyl, alkoxy, substituted
 alkoxy, cycloalkoxy, substituted cycloalkoxy,
15 cycloalkyl, substituted cycloalkyl, halogen, cyano,
 nitro, phenyl, substituted phenyl, pyridyloxy,
 thiophenoxy, substituted thiophenoxy, phenylsulfinyl,
 substituted phenylsulfinyl, phenylsulfonyl, substituted
 phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy,
 and substituted phenoxy;

20

or

 two R₂ substituents are taken together, on adjacent
 positions, to form a fused cycloalkyl or a
25 methylenedioxy ring, and one R₂ substituent is selected
 from the group consisting of hydrogen, hydroxy,
 trisubstituted silyloxy, alkyl, substituted alkyl,
 alkenyl, substituted alkenyl, alkoxy, substituted
 alkoxy, cycloalkoxy, substituted cycloalkoxy,
30 cycloalkyl, substituted cycloalkyl, halogen, cyano,
 nitro, phenyl, substituted phenyl, pyridyloxy,
 thiophenoxy, substituted thiophenoxy, phenylsulfinyl,
 substituted phenylsulfinyl, phenylsulfonyl, substituted
 phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy,
35 and substituted phenoxy;

-5-

R_6 is from 1 to 2 substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, trifluoromethyl, halogen, phenoxy, and substituted phenoxy;

5

X is selected from the group consisting of a bond, $-CH_2-$, $-CHR_7-$, and $-CH_2CH_2-$ wherein R_7 is lower alkyl;

10

Y is selected from the group consisting of a bond, $-CH_2-$, $-CHR_8-$, $-CH_2CH_2-$, $-CHR_9CH_2-$, and $-CH_2CHR_9$ wherein R_8 is lower alkyl and R_9 is lower alkyl;

and the pharmaceutically acceptable salts thereof and the pyridyl N-oxide thereof.

15

The present invention also provides for novel pharmaceutical compositions, comprising: a compound of the formula I and a pharmaceutically acceptable diluent.

Because the compounds of formula I enhance the normal physiological function of the mGlu receptors, the compounds of formula I are useful for the treatment of a variety of neurological and psychiatric disorders associated with glutamate dysfunction, including: acute neurological and psychiatric disorders such as cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia (including AIDS-induced dementia), Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, migraine (including migraine headache), urinary incontinence, substance tolerance, substance withdrawal (including, substances such as opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, hypnotics, etc.), psychosis,

schizophrenia, anxiety (including generalized anxiety disorder, panic disorder, and obsessive compulsive disorder), mood disorders (including depression, mania, bipolar disorders), trigeminal neuralgia, hearing loss, 5 tinnitus, macular degeneration of the eye, emesis, brain edema, pain (including acute and chronic pain states, severe pain, intractable pain, neuropathic pain, and post-traumatic pain), tardive dyskinesia, sleep disorders (including narcolepsy), attention deficit/hyperactivity disorder, and 10 conduct disorder.

In another embodiment the present invention provides methods of treating neurological and psychiatric disorders associated with glutamate dysfunction, comprising: 15 administering to a patient in need thereof an effective amount of a compound of formula I. That is, the present invention provides for the use of a compound of formula I or pharmaceutical composition thereof for the treatment neurological and psychiatric disorders associated with glutamate dysfunction.

20 Of the disorders above, the treatment of migraine, anxiety, schizophrenia, and epilepsy are of particular importance.

In a preferred embodiment the present invention provides a method for treating migraine, comprising: 25 administering to a patient in need thereof an effective amount of a compound of formula I.

In another preferred embodiment the present invention provides a method for treating anxiety, comprising: 30 administering to a patient in need thereof an effective amount of a compound of formula I. Particularly preferred anxiety disorders are generalized anxiety disorder, panic disorder, and obsessive compulsive disorder.

In another preferred embodiment the present invention provides a method for treating schizophrenia, comprising: 35 administering to a patient in need thereof an effective amount of a compound of formula I.

-7-

In yet another preferred embodiment the present invention provides a method for treating epilepsy, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

5 In another embodiment of the present invention provides methods of treating neurological and psychiatric disorders associated with glutamate dysfunction, comprising: administering to a patient in need thereof an effective amount of a potentiator of metabotropic glutamate receptors.

10 Specifically, the present invention provides a method of treating neurological and psychiatric disorders associated with glutamate dysfunction, comprising: administering to a patient in need thereof an effective amount of a potentiator of mGlu₂ and/or mGlu₃ receptors.

15 In a preferred embodiment the present invention provides a method for treating migraine, comprising: administering to a patient in need thereof an effective amount of a metabotropic glutamate potentiator, in particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

20 In another preferred embodiment the present invention provides a method for treating anxiety, comprising: administering to a patient in need thereof an effective amount of a metabotropic glutamate potentiator, in particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

25 Particularly preferred anxiety disorders are generalized anxiety disorder, panic disorder, and obsessive compulsive disorder.

In another preferred embodiment the present invention provides a method for treating schizophrenia, comprising: administering to a patient in need thereof an effective amount of a metabotropic glutamate potentiator, in particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

35 In yet another preferred embodiment the present invention provides a method for treating epilepsy, comprising: administering to a patient in need thereof an effective amount of a metabotropic glutamate potentiator, in particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

Because such potentiators, including the compounds of formula I, positively modulate metabotropic glutamate receptor response to glutamate, it is an advantage that the present methods utilize endogenous glutamate.

5 Because such potentiators positively modulate metabotropic glutamate receptor response to glutamate agonists it is understood that the present invention extends to the treatment of neurological and psychiatric disorders associated with glutamate dysfunction by administering an effective amount of a metabotropic glutamate potentiator, including the compounds of formula I, in combination with a potentiated amount of a metabotropic glutamate receptor agonist. Such a combination may be advantageous in that it may augment the activity and selectivity of an agonist of metabotropic glutamate receptors, in particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides methods of potentiating metabotropic glutamate receptors, in particular a mGlu₂ and/or mGlu₃ receptors. In the present methods an effective amount of a potentiator of metabotropic glutamate receptors, including a compound of formula I, is administered which positively modulates the effect of glutamate or glutamate agonists on the subject receptors.

25 Before describing the present invention in greater detail, it is understood that the invention in its broadest sense is not limited to particular embodiments described herein, as variations of the particular embodiments described herein are within the scope of the claimed invention.

30 Thus, compounds useful in the present invention are those which are potentiators of metabotropic glutamate receptors, particularly, those that potentiate the effects of glutamate and glutamate agonists at Group II metabotropic glutamate receptors, and even more particularly, those that potentiate the effects of glutamate and glutamate agonists at mGlu₂ receptors and/or mGlu₃ receptors. Useful compounds

are varied in structure, and so long as they embrace the above properties, they are suitable for use in the present invention. Preferred compounds include, but are not limited to, those described herein.

- 5 The compounds of formula I potentiate the function of glutamate receptors. Specifically, the compounds of formula I are potentiators of the Group II metabotropic glutamate receptors, and in particular, the compounds of formula I are potentiators of the mGlu₂ receptor and/or the mGlu₃
10 receptor.

As used herein, the following terms have the meanings indicated:

- The term "alkyl" refers to a straight or branched alkyl chain having from one to ten carbon atoms, and includes
15 methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like.

- The term "substituted alkyl" refers to a straight or branched alkyl chain having from one to ten carbon atoms,
20 and includes methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like having from 1 to 3 substituents selected from the group consisting of hydroxy, halogen, alkoxy, acyloxy, carboxy, alkoxycarbonyl, amido, substituted
25 amido, amino, acylamino, sulfonylamido, sulfonamide, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyloxy, substituted benzyloxy, pyridyl, substituted pyridyl, thienyl, and substituted thienyl.

- The term "lower alkyl" refers to a straight or branched
30 alkyl chain having from one to four carbon atoms, and includes methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, and t-butyl.

- The term "alkenyl" refers to a straight or branched alkyl chain having from one to ten carbon atoms and one or
35 more carbon-carbon double bonds, and includes ethylene, propylene, iso-propylene, butylene, iso-butylene, sec-


butylene, pentylene, hexylene, heptylene, octylene, nonylene, decylene, and the like.

The term "substituted alkenyl" refers to a straight or branched alkyl chain having from one to ten carbon atoms and one or more carbon-carbon double bonds, and includes ethylene, propylene, iso-propylene, butylene, iso-butylene, sec-butylene, pentylene, hexylene, heptylene, octylene, nonylene, decylene, and the like having from 1 to 3 substituents selected from the group consisting of carboxy, alkoxy, carbonyl, amido, substituted amido, phenyl, and substituted phenyl.

The term "cycloalkyl" refers to saturated cyclic alkyl group having from three to seven carbon atoms and includes, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and
15 cycloheptyl.

The term "substituted cycloalkyl" refers to saturated cyclic alkyl group having from three to seven carbon atoms and includes, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl having from 1 to 3 substituents selected from the group consisting of hydroxy, halogen, alkoxy, acyloxy, carboxy, alkoxycarbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyloxy, and substituted benzyloxy.

25 The terms "benzyloxy and substituted benzyloxy" refer
to a radical of the formula



wherein R_b is from 1 to 3 groups independently selected
30 from the group consisting of hydrogen, alkyl, alkoxy, cyano,
nitro, trifluoromethyl, halogen, phenyl, and substituted
phenyl. The substituent is benzyloxy where each R_b is
hydrogen and is a substituted benzyloxy where at least one
 R_b is not hydrogen.

-11-

The term "halogen" refers to a chloro, fluoro, bromo or iodo atom.

The term "fluorinated alkyl" refers to a straight or branched alkyl chain having from one to ten carbon atoms substituted with one or more fluorine atoms, and includes fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and the like.

The term "alkoxy" refers to straight or branched alkyl chain having from one to ten carbon atoms attached to an oxygen atom, and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, t-butoxy, pentoxy, hexoxy, heptoxy, octoxy, nonoxy, decoxy, and the like.

The term "substituted alkoxy" refers to a straight or branched alkyl chain having from one to ten carbon atoms attached to an oxygen atom, and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, t-butoxy, pentoxy, hexoxy, heptoxy, octoxy, nonoxy, decoxy, and the like having from 1 to 3 substituents selected from the group consisting of hydroxy, halogen, alkoxy, acyloxy, carboxy, alkoxycarbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyloxy, and substituted benzyloxy; and when one or more of the substituents is hydroxy, halogen, alkoxy, acyloxy, amino, acylamino, sulfonamide, phenoxy, substituted phenoxy, benzyloxy, or substituted benzyloxy then those substituents are not attached to the same carbon as the alkoxy oxygen atom.


The term "cycloalkoxy" refers to saturated cyclic alkyl group having from three to seven carbon atoms attached to an oxygen atom, and includes, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and cycloheptyloxy.

The term "substituted cycloalkoxy" refers to saturated cyclic alkyl group having from three to seven carbon atoms attached to an oxygen atom, and includes, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and

-12-


cycloheptyloxy having from 1 to 3 substituents selected from the group consisting of hydroxy, halogen, alkoxy, acyloxy, carboxy, alkoxy carbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyloxy, and substituted benzyloxy; and when one or more of the substituents is hydroxy, halogen, alkoxy, acyloxy, amino, acylamino, sulfonamide, phenoxy, substituted phenoxy, benzyloxy, or substituted benzyloxy then those substituents are not attached to the same carbon as the cycloalkoxy oxygen atom.

The term "pyridyloxy" refers to a radical of the formula



wherein G is selected from the group consisting of pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl.


The terms "phenoxy and substituted phenoxy" refer to a radical of the formula



wherein R_c is from 1 to 3 groups independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, halogen, acyloxy, carboxy, alkoxy carbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, cyano, nitro, phenyl, substituted phenyl, and $-S(O)_p$ alkyl (wherein p is 0, 1, or 2). The substituent is phenoxy where each R_c is hydrogen and is a substituted phenoxy where at least one R_c is not hydrogen.


The terms "thiophenoxy and substituted thiophenoxy" refer to a radical of the formula

-13-




wherein R_d is from 1 to 3 groups independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, halogen, acyloxy, carboxy, alkoxycarbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, cyano, nitro, phenyl, substituted phenyl, and $-S(O)_p$ alkyl (wherein p is 0, 1, or 2). The substituent is thiophenoxy where each R_d is hydrogen and is a substituted thiophenoxy where at least one R_d is not hydrogen.

The term "trisubstituted silyloxy" refer to a radical of the formula



wherein R_f is independently selected from the group consisting of alkyl, phenyl, and benzyl.

The terms "phenylsulfinyl and substituted phenylsulfinyl" refer to a radical of the formula




wherein R_g is from 1 to 3 groups independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, halogen, acyloxy, carboxy, alkoxycarbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, cyano, nitro, phenyl,

-14-


substituted phenyl, and $-S(O)_p\text{alkyl}$ (wherein p is 0, 1, or 2). The substituent is phenylsulfinyl where each R_g is hydrogen and is a substituted phenylsulfinyl where at least one R_g is not hydrogen.

- 5 The term "phenylsulfonyl and substituted phenylsulfonyl, refer to a radical of the formula



- wherein R_h is from 1 to 3 groups independently selected from
10 the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, halogen, acyloxy, carboxy, alkoxycarbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, cyano, nitro, phenyl,
15 substituted phenyl, and $-S(O)_p\text{alkyl}$ (wherein p is 0, 1, or 2). The substituent is phenylsulfonyl is where each R_h is hydrogen and is a substituted phenylsulfonyl where at least one R_h is not hydrogen.

- 20 The term "benzoyl and substituted benzoyl refer to a radical of the formula




- wherein R_i is from 1 to 3 groups independently selected from
25 the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, halogen, acyloxy, carboxy, alkoxycarbonyl, amido, substituted amido, amino, acylamino,

-15-


sulfonylamido, sulfonamide, cyano, nitro, phenyl, substituted phenyl, and $-S(O)_p$ alkyl (wherein p is 0, 1, or 2). The substituent is benzoyl where each R_i is hydrogen and is a substituted benzoyl where at least one R_i is not hydrogen.

The term "acyloxy" refers to a radical of the formula




wherein R_j is selected from the group consisting of alkyl, phenyl, and benzyl.

The term "carboxy" refers to a radical of the formula




The term "alkoxycarbonyl" refers to a radical of the formula




wherein R_k is selected from the group consisting of alkyl, benzyl, and substituted benzyl.

The term "amido" refers to a radical of the formula



The term "substituted amido" refers to a radical of the formula




wherein R_m is selected from the group consisting of alkyl and benzyl and R_n is selected from the group

-16-


consisting of hydrogen, alkyl, benzyl, substituted benzyl, phenyl and substituted phenyl.

The term "acylamino" refers to a radical of the formula



5 wherein R_0 is selected from the group consisting of alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl.


The term "sulfonylamido" refers to a radical of the formula



10

wherein R_p is selected from the group consisting of alkyl, phenyl, and substituted phenyl; and $\text{R}_{p'}$ is selected from the group consisting of hydrogen and alkyl.

The term "sulfonamide" refers to a radical of the formula




15

wherein R_q is selected from the group consisting of alkyl, phenyl, and substituted phenyl.

The terms "phenyl and substituted phenyl" refer to a radical of the formula

20




wherein R_r is from 1 to 3 groups independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,

-17-

alkoxy, substituted alkoxy, halogen, acyloxy, carboxy, alkoxy carbonyl, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, cyano, nitro, phenyl, substituted phenyl, and $-S(O)_p$ alkyl (wherein p is 0, 1, or 2). The substituent is phenyl where each R_x is hydrogen and is a substituted phenyl where at least one R_x is not hydrogen.


The terms "pyridyl and substituted pyridyl" refer to a radical of the formula



10

wherein R_s is from 1 to 2 groups independently selected from the group consisting of hydrogen, alkyl, halogen, and trifluoromethyl. The substituent is pyridyl where each R_s is hydrogen and is a substituted pyridyl where at least one R_s is not hydrogen. It is understood that the radical may be attached by the 2-, 3-, or 4-positions.

The terms "thienyl and substituted thienyl" refer to a radical of the formula




20

wherein R_t is from 1 to 2 groups independently selected from the group consisting of hydrogen and alkyl. The substituent is thienyl where each R_t is hydrogen and is a substituted thienyl where at least one R_t is not hydrogen. It is understood that the radical may be attached by the 2- or 3-positions.

25

The terms "benzyl or substituted benzyl" refer to a radical of the formula


-18-



wherein R_e is from selected from the group consisting of hydrogen, hydroxy, lower alkyl, and fluoro; and


wherein R_a is from 1 to 3 groups independently selected from the group consisting of hydrogen, alkyl, alkoxy, cyano, nitro, trifluoromethyl, and halogen. The substituent is benzyl where each R_a is hydrogen (which term includes compounds having all the allowed values of R_e) and is a substituted benzyl where at least one R_a is not hydrogen, including those compounds having all the allowed values of R_e .

Two R_2 substituents taken together, on adjacent positions, to form a "fused cycloalkyl" having from 5 to 7 carbon atoms refers to compounds in which a cycloalkyl ring having a total of 5 to 7 ring atoms is formed on adjacent positions of the phenyl to which they are attached. For example, the compound of formula I in which two R_2 substituents are taken together to form a fused cycloalkyl having 5 carbon atoms at the adjacent 3- and 4-positions and having hydrogen as the other R_2 is depicted by the formula below:




It is understood that formula I encompasses the compounds in which the X is attached to the pyridyl moiety in the 2-position, the 3-position, and the 4-position. For example, the compound of formula I in which X is attached to the pyridyl moiety in the 3-position is depicted by the formula below:

-19-



The term "pyridyl N-oxide" refers to the compounds of the formula



5 The term "pharmaceutically-acceptable addition salt" refers to an acid addition salt.

 The compound of formula I and the intermediates described herein form pharmaceutically acceptable acid addition salts with a wide variety of organic and inorganic acids and include the physiologically acceptable salts which are often used in pharmaceutical chemistry. Such salts are also part of this invention. A pharmaceutically-acceptable addition salt is formed from a pharmaceutically-acceptable acid as is well known in the art. Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) which are known to the skilled artisan. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydriodic, nitric, sulfuric, phosphoric, hypophosphoric, metaphosphoric, pyrophosphoric, and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanolic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate,

10
15
20
25

-20-

naphthalene-2-benzoate, isobutyrate, phenylbutyrate, α -hydroxybutyrate, butyne-1,4-dicarboxylate, hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, teraphthalate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, benzenesulfonate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.

As with any group of pharmaceutically active compounds, some groups are preferred in their end use application. Preferred embodiments of the present invention are given below:

Compounds in which R_1 is selected from the group consisting of $-C(O)OR_4$, and $-SO_2R_5$ are preferred.

When R_1 is $-SO_2R_5$, compounds in which R_5 is selected from the group consisting of alkyl and fluorinated alkyl are preferred.

When R_1 is $-C(O)OR_4$, compounds in which R_4 is alkyl are preferred.

As potentiators of $mGluR_2$, the compounds in which the pyridyl moiety is attached to X at the 3-position and R_1 is $-SO_2R_5$ are preferred.

As potentiators of $mGluR_3$, compounds in which the pyridyl moiety is attached to X at the 4-position and R_1 is $-C(O)OR_4$ are preferred.


Compounds in which R_2 is from 1 to 3 substituents independently selected from the group consisting of hydrogen, hydroxy, trisubstituted silyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy,

-21-

cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, phenyl, substituted phenyl, pyridyloxy, thiophenoxy, substituted thiophenoxy, phenylsulfinyl, substituted phenylsulfinyl, phenylsulfonyl, substituted phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy, and substituted phenoxy are preferred, with compound in which one R_2 is selected from the group consisting of substituted alkyl, phenyl, substituted phenyl, thiophenoxy, substituted thiophenoxy, phenoxy, and substituted phenoxy being more preferred, and with benzyl, substituted benzyl, phenyl, substituted phenyl, phenoxy and substituted phenoxy being more preferred, and with benzyl, substituted benzyl, phenyl, substituted phenyl, phenoxy and substituted phenoxy being even more preferred.

When one R_2 is substituted alkyl preferred substituents are halogen, alkoxy, phenyl, substituted phenyl having from 1 to 3 substituents selected from the group consisting of hydroxy, halogen, alkoxy, carboxy, alkoxy carbonyl, amido, amino, and pyridyl, thienyl, and phenoxy.

Particularly preferred substituted alkyls are those depicted as the radical of the formula



wherein $R_{u'}$ is from selected from the group consisting of hydrogen, hydroxy, lower alkyl, and fluoro; $R_{u''}$ is from selected from the group consisting of hydrogen, lower alkyl, alkoxy, and fluoro; provided that when $R_{u'}$ is hydroxy then $R_{u''}$ is not alkoxy or fluoro, and when $R_{u'}$ is fluoro then $R_{u''}$ is not alkoxy; and R_v is from 1 to 3 groups independently selected from the group consisting of hydrogen, alkyl, alkoxy, cyano, nitro, trifluoromethyl, and halogen.

-22-

When one of R_2 is substituted phenyl preferred substituents are from 1 to 3 groups independently selected from the group consisting of hydrogen, trifluoromethyl, trifluoromethoxy, hydroxy, alkyl, alkoxy, halogen, amido, substituted amido, sulfonylamido, cyano, and nitro.

When one of R_2 is substituted thiophenoxy preferred substituents are from 1 to 3 groups independently selected from the group consisting of hydrogen, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, halogen, amido, cyano, and nitro.

When one of R_2 is substituted phenoxy preferred substituents are from 1 to 3 groups independently selected from the group consisting of hydrogen, hydroxy, alkyl, substituted alkyl having from 1 to 3 groups independently selected from the group consisting of hydroxy, alkyl, cycloalkyl, alkoxy, halogen, amido, substituted amido, sulfonylamido, cyano, nitro, phenyl, and $-S(O)_p$ alkyl (wherein p is 0, 1, or 2), cycloalkyl, alkoxy, trifluoromethoxy, halogen, acyloxy, carboxy, amido, substituted amido, amino, acylamino, sulfonylamido, sulfonamide, cyano, nitro, phenyl, substituted phenyl having from 1 to 3 groups independently selected from the group consisting of trifluoromethyl, hydroxy, alkyl, alkoxy, halogen, amido, cyano, and nitro.

Compounds in which one R_2 is sulfonylamido wherein R_p is selected from the group consisting of alkyl, phenyl, and substituted phenyl having from 1 to 3 groups independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, cyano, nitro, and trifluoromethoxy, and R_p is selected from the group consisting of hydrogen and alkyl are preferred.

Compounds in which at least one of the R_2 substituents is attached in the 3-position are preferred.

Compounds in which at least one of the R_2 substituents is attached in the 4-position are preferred.

Compounds in which R_6 is from 1 to 2 substituents independently selected from the group consisting of

-23-

hydrogen, alkyl, alkoxy, trifluoromethyl, and halogen are preferred.


Compounds in which X is selected from the group consisting of a $-\text{CH}_2-$, $-\text{CHR}_7-$, and $-\text{CH}_2\text{CH}_2-$ are preferred, with compounds in which X is $-\text{CH}_2-$ being more preferred.

Compounds in which Y is selected from the group consisting of a bond, $-\text{CH}_2-$, $-\text{CHR}_8-$, $-\text{CH}_2\text{CH}_2-$ are preferred, with compounds in which Y is a bond being more preferred.

Compounds in which X is a $-\text{CH}_2-$ and Y is bond are even most preferred.

The compounds of formula I are prepared as described in Reaction Scheme A. In Reaction Schemes below all substituents, unless otherwise indicated, are as previously defined, and all reagents are well known and appreciated in the art.

Reaction Scheme A



formula I

Reaction Scheme A, step a, depicts the reductive amination of an appropriate compound of formula (1) and an appropriate amine of formula (2) to give a compound of

formula (3). An appropriate compound of formula (1) is one in which R_6 is as desired in the final compound of formula I, X' is a bond or $-CH_2-$ and R is hydrogen, giving X to be $-CH_2-$ or $-CH_2CH_2-$, respectively, as desired for the compound

5 of formula I, or X' is a bond and R is R_7 as desired in the final compound of formula I, and the point of attachment of X' is the point of attachment of X as desired in the final compound of formula I. Compounds of formula (1) are well known in the art. An appropriate compound of formula (2) is

10 one in which R_2 is as desired in the final product of formula I or gives rise after modification or deprotection to R_2 as desired in the final compound of formula I and Y is as desired in the final product of formula I. Compounds of formula (2) are known in the art and can be obtained by

15 procedures well known in the art and those described herein. As described herein, compounds of formula (2) in which Y is a bond can be obtained by reduction of nitro groups. Compounds of formula (2) in which Y is $-CH_2-$, $-CH_2CH_2-$, $-CHR_8-$, $-CHR_9CH_2-$, or $-CH_2CHR_9-$ can be obtained by reduction

20 of a nitrile, transforming a carboxylic acid to an amine as is well known in the art, for example such transformations can be carried out by reduction of an amide, transformation to the aldehyde followed by reductive amination, or reduction to the alcohol followed by elaboration to the

25 amine (such as by Mitsunobu reaction using phthalimide followed by deprotection). All of these transformations may involve the introduction and removal of appropriate protecting groups as is well known and appreciated in the art.

30 The reductive amination depicted in Reaction Scheme A, step a, can be carried out under a variety of conditions, such as by hydrogenation using a suitable catalyst or using a suitable reducing agent. For example, an appropriate aldehyde of formula (1) is contacted with an appropriate

35 amine of formula (2) and a suitable reducing agent to give a compound of formula (3). The reaction is carried out in a suitable solvent, such as methanol, ethanol,

tetrahydrofuran, or mixtures of methanol or ethanol and tetrahydrofuran. The reaction may be carried out in the presence of a drying agent, such as sodium sulfate, cupric sulfate, or molecular sieves. The reaction is carried out in the presence of from 1.0 to 6.0 molar equivalents of a suitable reducing agent, such as, sodium borohydride or sodium cyanoborohydride. It may be advantageous to allow Schiff base formation to proceed before addition of the suitable reducing agent. When sodium cyanoborohydride is used it may be advantageous to monitor and adjust the pH during the course of the reaction as is known in the art. The reaction is generally carried out at temperatures of from 0°C to the refluxing temperature of the solvent. Generally, the reactions require 1 to 72 hours. The product can be isolated and purified by techniques well known in the art, such as filtration, extraction, evaporation, trituration, chromatography, and recrystallization.

Reaction Scheme A, step b, depicts the acylation or sulfonation, using appropriate reagents, of a compound of formula (3) to give a compound of formula (I) or a protected compound of formula I. An appropriate reagent is one that transfers a $-C(O)R_3$, $-C(O)OR_4$, or $-SO_2R_5$ group as required to give the desired R_1 group. In the case of $-C(O)R_3$ such reagents include acids, acid halides, anhydrides (including mixed anhydrides), activated amides (such as imidazolylides), and activated esters. In the case of $-C(O)OR_4$ such reagents include esters of chloroformate and pyrocarbonates (such as BOC anhydride). In the case of $-SO_2R_5$ such reagents includes halosulfonates and sulfonate anhydrides with the use of sulfonyl chlorides are preferred. Acylation and sulfonation reactions using such reagents are well known and appreciated in the art.

For example, acylation reactions to transfer $-C(O)R_3$ involve an amide formation reaction similar to those which are conventionally conducted for peptide synthesis and synthetic methods used therein can also be employed. For example, well known coupling reagents such as carbodiimides

-26-

with or without the use of well known additives such as N-hydroxysuccinimide, 1-hydroxybenzotriazole, etc. can be used to facilitate amide formation. The reaction is conventionally conducted in an inert aprotic solvent such as
5 pyridine, dimethylformamide, dichloromethane, chloroform, 1,2-dichloroethane, acetonitrile, tetrahydrofuran and the like.

Alternatively, for example an acid halide can be employed in the reaction. It may be advantageous to use a
10 suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, pyridine, sodium carbonate, potassium carbonate, sodium bicarbonate, and the like. The reaction is
15 preferably conducted at from about 0°C to about 60°C until reaction completion which typically occurs within 1 to about 24 hours. Upon reaction completion, the product of formula I or protected compound of formula I can be isolated and purified by techniques well known in the art, such as
20 filtration, extraction, evaporation, trituration, chromatography, and recrystallization.

For example, acylation reactions to transfer $-C(O)OR_4$ involve a reaction of a chloroformate ester with a compound of formula (3). For example, the reaction is conventionally
25 conducted in an inert aprotic polar diluent such as dimethylformamide, dichloromethane, chloroform, acetonitrile, 1,2-dichloroethane, pyridine, tetrahydrofuran and the like. The reaction may be carried out in the presence of a suitable base to scavenge the acid generated
30 during the reaction. Suitable bases include, by way of example, pyridine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, and the like. The reaction is preferably conducted at from about 0°C to about 80°C until reaction completion which typically occurs within 1 to about 24
35 hours. Upon reaction completion, the product of formula I or protected product of formula I can be isolated and purified by techniques well known in the art, such as

-27-

filtration, extraction, evaporation, trituration, chromatography, and recrystallization.

For example, sulfonation reactions to transfer $-SO_2R_5$ involve the reaction of halosulfonates or sulfonate anhydrides with compounds of formula (3). Such reactions are carried out in a suitable solvent, such as pyridine, tetrahydrofuran, dioxane, diethyl ether or dimethylformamide, dichloromethane, chloroform, acetonitrile, 1,2-dichloroethane, tetrahydrofuran, and the like, at a temperature from about 0°C to about ambient temperature, and are carried out in the presence of a suitable base such as pyridine, triethylamine, N,N-diisopropylethylamine, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and the like. The resultant sulfonamide is isolated by methods well known in the art, such as filtration, extraction, evaporation, trituration, chromatography, and recrystallization.

Reaction Scheme A, optional step c, not shown, a protected compound of formula I is deprotected to give a compound of formula I. Such deprotection reactions are well known and appreciated in the art. Protecting Groups in Organic Synthesis, Theodora Greene (Wiley-Interscience).


Reaction Scheme A, optional step d, not shown, an acid addition salt is formed using a pharmaceutically acceptable acid. The formation of acid addition salts is well known and appreciated in the art.

A variety of compounds of formula I and related compounds (such as compounds of formula (3) above) can be used as starting materials which upon further elaboration give rise to compounds of formula I. Some of these transformations are trivial, such as hydrolysis of a nitrile to an amide or acid, hydrolysis of an ester to an acid, formation of an amide from an acid or an ester, alkylation and acylation of hydroxy groups, oxidation, reduction, deprotection, displacements, and the like. A number other transformations, while readily apparent to the skilled

-28-

artisan, are described in detail in the Reaction Schemes below.

Reaction Scheme B



Reaction Scheme B, step a, depicts a coupling reaction of an appropriate compound of formula (4) and an appropriate aryl compound of formula (5). An appropriate compound of formula (4) is one in which X, Y, R_6 , R_2 is as defined for the compound of formula I, except one of R_2 is a bromo or iodo or triflate or $-\text{CH}_2\text{Br}$, and R_1 is a hydrogen or R_1 as desired in the final compound of formula I. Compounds of formula (4) are readily prepared as described in Reaction Scheme A. An appropriate aryl compound of formula (5) is one in which Ar is one of the R_2 groups as desired in the final product of formula I, such as phenyl, substituted phenyl, pyridyl, substituted pyridyl, thienyl, or substituted thienyl. It is appreciated in the art that boronic esters are also suitable for use in such coupling reactions. The preparation and use of such arylboronic acids (and boronic esters) is well known and appreciated in the art. W. J. Thompson and J Gaudino, J. Org. Chem., 49, 5237-5243 (1984). Arylboronic acids are frequently contaminated with their corresponding anhydrides which do not perform well in the Suzuki coupling. Material contaminated by detrimental amounts of anhydride can be converted to the corresponding acid by hydrolysis. The hydrolysis is performed, if required, by briefly boiling in water.

As will be appreciated by the skilled person, Reaction Scheme B, step a, depicts a Suzuki coupling. See for

example, A. Suzuki, Pure Appl. Chem., 66, 213-222 (1994); A. Suzuki, Pure Appl. Chem., 63, 419-422 (1991), N. Miyaura et al., J. Org. Chem., 51, 5467-5471 (1986); Y. Hoshino et al., Bull. Chem. Soc. Japan, 61, 3008-3010 (1988); N. Miyaura et al., J. Am. Chem. Soc., 111, 314-321 (1989); W. J. Thompson et al., J. Org. Chem., 53, 2052-2055 (1988); and T. I. Wallow and B. M. Novak, J. Org. Chem., 59, 5034-5037 (1994). Other coupling reactions, such as the Stille reaction, can be used.


10 It is appreciated that the coupling gives a compound of formula I when, the compound of formula (4), R_1 is R_1 as desired in the final product and when R_1 is hydrogen the product will required acylation or sulfonation, as depicted in Reaction Scheme A, step b, to give a compound of formula
15 I.

For example, an appropriate compound of formula (4) and an appropriate aryl compound of formula (5) can be coupled under Suzuki conditions to give a compound of formula I or a compound that gives rise to a compound of formula I. The
20 Suzuki coupling reaction is performed in a suitable solvent, such as toluene, dichloromethane, or tetrahydrofuran. The reaction is performed using from about 1.1 to about 3 molar equivalents of an appropriate arylboronic acid or ester. The reaction is carried out in the presence of from about 1 to
25 about 3 molar equivalents of a suitable base, such as potassium carbonate or sodium carbonate. The coupling is performed using a suitable palladium catalyst, such as tetrakis(triphenylphosphine) palladium (0), bis(acetonitrile)palladium (II) chloride, palladium (II) chloride, palladium (II) acetoacetate, and
30 tris(dibenzylideneacetone)dipalladium(0). The suitable palladium catalyst chosen may be modified by the use of ligands, such as tri(fur-2-yl)phosphine and tri(o-tolyl)phosphine: V. Farina and B. Krishnan, J. Am. Chem.
35 Soc., 113, 9586-9595 (1991). The coupling is performed at a temperature ranging from 0°C to the refluxing temperature of the solvent. The Suzuki coupling reactions depicted in

-30-

Reaction Scheme B generally require from 6 hours to 14 days. The product of the coupling reaction can be isolated and purified using techniques well known in the art. These techniques include extraction, evaporation, chromatography and recrystallization.

Reaction Scheme C.1



Reaction Scheme C.1, step a, depicts a coupling reaction of an appropriate compound of formula (4) and an appropriate phenol compound of formula (6). An appropriate compound of formula (4) is as described above in Reaction Scheme B, except that R_2 is not $-\text{CH}_2\text{Br}$. An appropriate phenol compound of formula (6) is one in which R_c is as desired in the final product of formula I or gives rise upon modification to the desired final product of formula I.


As will be appreciated by the skilled person, Reaction Scheme C, step a, depicts an Ullmann coupling. See for example, F. D. Rychnozsky and K. Hwang, J. Org. Chem., 59, 5414 (1994). It is appreciated that the coupling gives a compound of formula I when R_1 is R_1 as desired in the final product and when R_1 is hydrogen the product will required acylation or sulfonation, as depicted in Reaction Scheme A, step b, to give a compound of formula I.

For example, an appropriate compound of formula (4) and an appropriate phenol compound of formula (6) are coupled give a compound of formula I or a compound that gives rise to a compound of formula I. The Ullmann coupling reaction is performed in a suitable solvent, such as pyridine. The

-31-

reaction is performed using from about 1.1 to about 3 molar equivalents of an appropriate phenol. The reaction is carried out in the presence of from about 1 to about 3 molar equivalents of a suitable base, such as potassium carbonate or sodium carbonate. The coupling is performed using a suitable catalyst, such as copper salts. These Ullmann coupling reactions depicted in Reaction Scheme C generally require from 6 hours to 24 hours. The product of the coupling reaction can be isolated and purified using techniques well known in the art. These techniques include extraction, evaporation, chromatography and recrystallization.

Reaction Scheme C.2



Reaction Scheme C.2, step a, depicts a coupling reaction of an appropriate compound of formula (4') and an appropriate compound of formula (6'). An appropriate compound of formula (4') is one in which X, Y, R_6 , R_2 is as defined for the compound of formula I, except one of R_2 is a hydroxy, and R_1 is a hydrogen or R_1 as desired in the final compound of formula I. An appropriate compound of formula (6') is one in which R_c is one or more electron withdrawing group as desired in the final product of formula I or gives rise upon modification to the desired final product of formula I.


It is appreciated that the coupling gives a compound of formula I when R_1 is R_1 as desired in the final product and when R_1 is hydrogen the product will require acylation or sulfonation, as depicted in Reaction Scheme A, step b, to

-32-

give a compound of formula I. For the reaction depicted in Scheme C.2 it is preferred that the compound of formula (4') is one in which R_1 is hydrogen.

For example, an appropriate compound of formula (4') and an appropriate compound of formula (6') are coupled give a compound of formula I or a compound that gives rise to a compound of formula I. The reaction is performed in a suitable solvent, such as dimethylformamide, dimethylacetamide, and dimethyl sulfoxide. The reaction is performed using from about 1.1 to about 3 molar equivalents of an appropriate phenol. The reaction is carried out in the presence of from about 1 to about 3 molar equivalents of a suitable base, such as potassium hydride, sodium hydroxide, or sodium hydride. The coupling is performed using a suitable catalyst, such as copper salts. The reaction generally require from 6 hours to 48 hours. The product of the coupling reaction can be isolated and purified using techniques well known in the art. These techniques include extraction, evaporation, chromatography and recrystallization.

Reaction Scheme D




Reaction Scheme D, step a, depicts a reaction of an appropriate compound of formula (7) with appropriate organophosphorous ylid in a Wittig-type reaction to give a compound of formula I. An appropriate compound of formula (7) is one in which X, Y, R_1 , R_2 , and R_6 , are as defined for the compound of formula I. As will be appreciated by the skilled person, in addition to the aldehyde depicted in Scheme D, a variety of carbonyl compounds can be used in the reaction of Reaction Scheme D, step a, depending of the

-33-

substitution desired in the final compound of formula I. An appropriate organophosphorous ylid is one which converts the carbonyl of a compound of formula (7) to an alkenyl or substituted alkenyl as desired in the final product of formula I. Appropriate organophosphorous reagents, such as Wittig, Wittig-Horner, Horner-Emmons-Wadsworth reagents, and the use of appropriate organophosphorous reagents is well known and appreciated in the art.

For example, an appropriate compound of formula (7) is reacted with appropriate organophosphorous ylid to give a compound of formula I. An appropriate organophosphorous ylid is formed by contacting an appropriate organophosphorous reagent with a suitable base, such as lithium diisopropylamide, sodium hydride, lithium bis(trimethylsilyl)amide or potassium t-butoxide. The ylid formation is carried out in a suitable solvent, such as tetrahydrofuran, benzene, or diethyl ether. The ylid formation is generally carried out at a temperature of from -78°C to ambient temperature. An appropriate organophosphorous ylid is contacted with an appropriate compound of formula (7). The reaction is carried out in a suitable solvent, such as tetrahydrofuran, benzene, or diethyl ether. Generally, the reaction is carried out in the same solvent and temperatures used to form the appropriate organophosphorous ylid. The reaction generally requires from 1 hour to 48 hours. The product can be isolated by techniques well known in the art, such as extraction and evaporation. The product can then be purified by techniques well known in the art, such as distillation, chromatography, or recrystallization.

Reaction Scheme E




Reaction Scheme E, step a, depicts a reaction of an appropriate compound of formula (7) with appropriate organometallic reagent, such as a Grignard reagent to give a compound of formula I. An appropriate compound of formula (7) is as defined in Reaction Scheme D. An appropriate organometallic reagent is one which converts the carbonyl of a compound of formula (7) to a hydroxy substituted group as desired in the final product of formula I. Appropriate organometallic reagents and their use is well known and appreciated in the art.

For example, an appropriate compound of formula (7) is reacted with appropriate Grignard reagent to give a compound of formula I. Generally, 1 to 2 equivalents of Grignard reagent are used. The reaction is carried out in a suitable solvent, such as tetrahydrofuran, diethyl ether. The reaction is generally carried out at temperatures of from -40°C to ambient temperature. The reaction generally requires from 1 hour to 48 hours. The product can be isolated by techniques well known in the art, such as extraction and evaporation. The product can then be purified by techniques well known in the art, such as distillation, chromatography, or recrystallization.

As will be appreciated by the skilled person, the hydroxy compound thus obtained can undergo a variety of further reactions, such as halogenation, acylation, alkylation, reduction, oxidation, elimination, and the like to give further compounds of formula I.

-35-

In addition, the compounds of formula I in which R_1 is $-S(O)_2R_5$, X is $-CH_2-$, and Y is a bond can be prepared as described in Reaction Scheme F.



- 5 Reaction Scheme F, step a, depicts coupling of an appropriate compound of formula (8) with an appropriate compound of formula (9) to give a compound of formula I. An appropriate compound of formula (8) is one in which R_2 is as defined for the compound of formula I and R_1 is $-S(O)_2R_5$. An
- 10 appropriate compound of formula (9) is one in which R_6 is as defined for the compound of formula I. Compounds of formula (8) and (9) are readily prepared by methods known in the art and as described herein.
- 15 For example, where the appropriate compound of formula (9) is one substituted with $-CH_2Br$ or, preferably $-CH_2Cl$, a compound of formula (8) is treated with a suitable base, such as sodium hydride, potassium hydride, potassium t-butoxide, potassium carbonate, and cesium carbonate.
- 20 Generally, from 2 to about 5 molar equivalents of base are used and additional base may be added if the compound of formula (9) is used in the form of a salt. Generally, the reaction is carried out in a suitable solvent, such as tetrahydrofuran, diethyl ether, and dimethylformamide. The
- 25 reaction is generally carried out at temperatures of from $-10^\circ C$ to $80^\circ C$. The reaction generally requires from 1 hour to 48 hours. The product can be isolated by techniques well known in the art, such as extraction and evaporation. The product can then be purified by techniques well known in the

-36-

art, such as distillation, chromatography, or recrystallization.

For example, where the appropriate compound of formula (9) is substituted with $-CH_2OH$ the coupling is carried out under Mitsunobu conditions which are well known in the art. The reaction is carried out in a suitable solvent, such as tetrahydrofuran and diethyl ether using a phosphine, such as triphenylphosphine or a resin bound phosphine and a dialkyl azodicarboxylate, such as diethyl azodicarboxylate, di-iso-propyl azodicarboxylate or di-t-butyl azodicarboxylate. The reaction is generally carried out at temperatures of from ambient temperatures to $60^\circ C$. The reaction generally requires from 1 hour to 12 hours. The product can be isolated by techniques well known in the art, such as extraction and evaporation. The product can then be purified by techniques well known in the art, such as distillation, chromatography, or recrystallization.

The present invention is further illustrated by the following examples and preparations. These examples and preparations are illustrative only and are not intended to limit the invention in any way.

The terms used in the examples and preparations have their normal meanings unless otherwise designated. For example, $^\circ C$ refers to degrees Celsius; "N" refers to normal or normality; "M" refers to molar or molarity; "mol" refers to mole or moles; "mmol" refers to millimole or millimoles; μmol refers to micromole or micromoles; "kg" refers to kilogram or kilograms; "g" refers to gram or grams; μg refers to microgram or micrograms; "mg" refers to milligram or milligrams; μL refers to microliter or microliters; "mL" refers milliliter or milliliters; "L" refers to liter or liters; "bp" refers to boiling point; "mp" refers to melting point; "brine" refers to a saturated aqueous sodium chloride solution; "h" refers to hour or hours; "min" refers to minute or minutes; "MS" refers to mass spectrometry; "NMR" refers to nuclear magnetic resonance spectroscopy; "TFA" refers to trifluoroacetic

-37-

acid; "CH₂Cl₂" or "DCM" refers to dichloromethane; "DCE" refers to dichloroethane; "MeOH" refers to methanol; "NH₄OH" refers to a concentrated aqueous ammonia solution; "KOH" refers to potassium hydroxide; "H₂O" refers to water; "HCl" refers to hydrogen chloride; etc. Chemical shifts are given in δ and NMR spectra were obtained in CDCl₃, unless otherwise indicated.

Preparation 1

10 3-(2-Methoxyphenoxy) aniline

A solution of 3-fluoronitrobenzene (3.53g, 25mmol) and 2-methoxyphenol (3.72g, 30mmol) in anhydrous N,N-dimethylformamide (25mL) under nitrogen was treated with anhydrous potassium carbonate (7.6g, 55mmol) and heated to 15 110°C for 65h, then cooled to room temperature. The solution was diluted with dichloromethane (50mL) and treated with DOWEX® 550A OH anion exchange resin (10g) which had been washed dry with methanol. Stirring was continued for one hour, the mixture was filtered, and the filtrate 20 concentrated in vacuo (exhaustively at end to remove DMF) to give 3-(2-methoxyphenoxy)nitrobenzene as a residue.

The residue was dissolved in 2:1 hexane/dichloromethane and passed through a short column of silica gel (eluted with 1:1 hexane/dichloromethane). The concentrated product was 25 recrystallized from ethyl acetate/hexane (two crops) then placed in a Parr® bottle under nitrogen with methanol (50mL), carefully treated with Raney® nickel (one tsp.), placed on a Parr® apparatus, and hydrogenated at 40-50 psi pressure for 18h. The mixture was carefully filtered 30 through celite® under nitrogen without allowing the filter cake to dry, and the filtrate was concentrated in vacuo to afford the title compound (2.79g, 52%) as a colorless viscous oil. ¹H NMR: 7.05-7.15 (m,1H), 7.00-7.05 (m,1H), 6.95-7.00 (m,2H), 6.85-6.95 (m,1H), 6.30-6.35 (m,2H), 6.25 35 (m,1H), 3.81 (s,3H), 3.60 (br s,2H).

Preparation 2

-38-

4-(2-Benzzyloxyphenoxy)aniline


A solution of 2-benzyloxyphenol (6.01g, 30mmol) in anhydrous N,N-dimethylformamide (25mL) was treated with anhydrous potassium carbonate (7.6g, 55mmol), then with 4-fluoronitrobenzene (3.53g, 25mmol), and heated to 90°C for 5h under nitrogen. The solution was cooled to room temperature, diluted with dichloromethane (50mL), and treated with DOWEX® 550A OH anion exchange resin (10g) which had been washed dry with methanol. The mixture was stirred for 3h, filtered, and the filtrate concentrated in vacuo (exhaustively at end to remove DMF). The residue was chromatographed on silica gel (eluted with 2:1 hexane/ethyl acetate) to afford 4-(2-benzyloxyphenoxy)nitrobenzene (6.40g, 66%) as a white solid.

4-(2-Benzzyloxyphenoxy)nitrobenzene (2.57g, 8mmol) was dissolved in reagent grade ethanol (20mL) and treated with concentrated aqueous hydrochloric acid (2.5mL). The solution was heated to 55°C under nitrogen, then cautiously treated with iron powder (3.1g, 55mmol) in portions with cooling needed after initial exotherm to 75°C. After addition was complete, stirring was continued at 50-60°C for 45 minutes, then the mixture was cooled to room temperature and filtered through celite® (rinse filter cake with dichloromethane). The filtrate was concentrated in vacuo, the residue dissolved in dichloromethane and the solution washed with saturated aqueous sodium carbonate. The organic layer was separated and the aqueous layer extracted with dichloromethane. The combined organic solution was dried (sodium sulfate), concentrated in vacuo, and chromatographed on silica gel (eluted with dichloromethane, then 10% ethyl acetate/dichloromethane, then 20% ethyl acetate/dichloromethane) to afford the title compound (2.22g, 95%) as a tan solid; mp 111-112.5°C. ¹H NMR: 7.30 (m,4H), 7.20-7.30 (m,1H), 6.97 (m,2H), 6.80-6.90 (m,4H), 6.60-6.65 (m,2H), 5.12 (s,2H), 3.50 (br s, 2H).

-39-

Example 1

N-(3-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



5 A solution of 3-(2-methoxyphenoxy)aniline (269mg, 1.25mmol) and pyridine-3-carboxaldehyde (107mg, 1.00mmol) was refluxed in methanol (2.5mL) for 2h, then cooled on an ice bath to 5°C. Sodium borohydride (95mg, 2.5mmol) was added and the mixture was warmed to room temperature, stirred for 2h, concentrated *in vacuo*, and taken up in
10 dichloromethane. The resultant suspension was filtered, the filtrate concentrated *in vacuo*, and the residue chromatographed on silica gel (eluted with 2% methanol/dichloromethane) to give N-(3-(2-
15 methoxyphenoxy)phenyl)pyrid-3-ylmethylamine.


 The resultant N-(3-(2-methoxyphenoxy)phenyl)pyrid-3-ylmethylamine was dissolved in 2:1 1,2-dichloroethane/pyridine (6mL) under nitrogen, cooled (5°C), and treated with 2,2,2-trifluoroethylsulfonyl chloride
20 (300mg, 1.64mmol). After one hour at 5°C, the mixture was allowed to warm to room temperature and stirred for 18h. The product mixture was treated with anhydrous potassium carbonate (500mg), stirred 30 min, filtered, and the filtrate concentrated *in vacuo*. The residue was
25 chromatographed on silica gel (eluted with 2:1 dichloromethane/ethyl acetate) to afford the title compound (226mg, 50%) as a viscous pale amber oil. The hydrochloride salt was obtained by treatment of this material in methanol with ethereal HCl. ¹H NMR: 8.49 (d, 1H, J=4Hz), 8.29 (s, 1H),
30 7.60-7.65 (m, 1H), 7.20-7.25 (m, 2H), 7.10-7.20 (m, 1H), 6.97 (d, 1H, J=8Hz), 6.90 (m, 2H), 6.80-6.85 (m, 2H), 6.76 (m, 1H),

-40-

4.82 (s,2H), 3.70-3.85 (m,2H), 3.75 (s,3H). MS calcd. 452.4; MS (M+1) 453.3

Example 2

5 N-(3-(2-Benzyloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine




The title compound was prepared using a method similar to the method of Example 1 using 3-(2-benzyloxyphenoxy)aniline. ¹H NMR: 8.45 (m,1H), 8.28 (s,1H), 7.77 (d,1H,J=8Hz), 7.20-7.25 (m,5H), 7.10-7.15 (m,2H), 7.00-7.10 (m,3H), 6.97 (t,1H,J=8Hz), 6.85-6.90 (m,2H), 6.77 (m,1H), 4.99 (s,2H), 4.79 (s,2H), 3.55-3.65 (m,2H). MS calcd. 528.6; MS (M+1) 529.4

15

Example 3

N-(4-Phenoxy)phenyl)-N-(ethylsulfonyl)-2-(pyrid-3-yl)ethylamine



20 The title compound was prepared using a method similar to the method of Example 1 using (4-phenoxy)aniline, 2-(pyrid-3-yl)acetaldehyde, and ethylsulfonyl chloride. ¹H NMR: 8.45 (m,1H), 8.36 (s,1H), 7.50 (m,1H), 7.35-7.40 (m,2H), 7.15-7.25 (m,3H), 7.10-7.15 (m,1H), 7.03 (d,2H,J=8Hz), 6.97 (d,2H,J=8Hz), 3.91 (t,2H,J=7Hz), 2.95


25

-41-

(q, 2H, J=7Hz), 2.83 (t, 2H, J=7Hz), 1.31 (t, 3H, J=7Hz). MS calcd. 382.5; MS (M+1) 383.4

Example 4

5 N-(4-Phenoxy)phenylethyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine



A solution of pyridine-3-carboxaldehyde (322mg, 3.0mmol) and 4-phenoxyphenethylamine (747mg, 3.5mmol) in reagent grade methanol (5mL) under nitrogen was refluxed for 2h, then cooled to 5°C (ice bath), and diluted with more methanol (5mL). Sodium borohydride (0.23g, 6mmol) was added, and the mixture was slowly allowed to reach room temperature and stirred at room temperature overnight (18h).

15 The mixture was concentrated in vacuo, taken up in dichloromethane, and filtered. The filtrate was concentrated in vacuo and chromatographed on silica gel (eluted with 7% methanol/dichloromethane) to afford N-((4-phenoxy)phenylethyl)pyridine-3-methylamine (863mg, 94%).

20 A cooled (5°C) solution of N-((4-phenoxy)phenylethyl)pyridine-3-methylamine (304mg, 1.0mmol) in anhydrous 1,2-dichloroethane (4mL) with anhydrous potassium carbonate (0.50g, 3.6mmol) under nitrogen was treated dropwise with ethylsulfonyl chloride (257mg, 2.0mmol), then slowly warmed to room temperature and stirred at room temperature for 44h. The mixture was treated with tris(2-aminoethyl)amine resin (4 meq/g, 1.0g), stirred 1h, treated with DOWEX® 550A OH anion exchange resin (1.5g), stirred 30 min, then filtered and the filter cake was rinsed with dichloromethane. The filtrate was concentrated in vacuo and the residue chromatographed on silica gel (eluted

-42-


with 4:1 ethyl acetate/dichloromethane) to afford the title compound (100mg, 25%) as a pale yellow oil. The title compound was converted to the hydrochloride salt by treatment of this material in methanol with ethereal HCl. ¹H

5 NMR: 8.55 (m, 2H), 7.78 (m, 1H), 7.25-7.35 (m, 3H), 7.00-7.10 (m, 3H), 6.94 (d, 2H, J=8Hz), 6.89 (d, 2H, J=9Hz), 4.43 (s, 2H), 3.38 (t, 2H, J=8Hz), 2.88 (q, 2H, J=7Hz), 2.74 (t, 2H, J=8Hz), 1.31 (t, 3H, J=7Hz). MS calcd. 396.5; MS (M+1) 397.5

10

Example 5

N-(4-Phenoxy)phenylmethyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine




The title compound was prepared using a method similar to the method of Example 4 using 4-phenoxyphenylmethylamine.

15 ¹H NMR: 8.50 (m, 1H), 8.40 (s, 1H), 7.66 (d, 1H, J=8Hz), 7.30-7.35 (m, 2H), 7.20-7.25 (m, 1H), 7.17 (d, 2H, J=8Hz), 7.10 (m, 1H), 6.95 (d, 2H, J=8Hz), 6.90 (d, 2H, J=8Hz), 4.36 (s, 2H), 4.30 (s, 2H), 2.99 (q, 2H, J=7Hz), 1.35 (t, 3H, J=7Hz). MS
20 calcd. 382.5; MS (M+1) 383.4

Example 6

N-(4-(Phenoxy)phenyl)-N-(iso-propylsulfonyl)pyrid-3-ylmethylamine



25

The title compound was prepared using a method similar to the method of Example 1 using (4-phenoxy)aniline and iso-propylsulfonyl chloride. ¹H NMR: 8.47 (m, 1H), 8.32 (m, 1H),


-43-

7.70 (m,1H), 7.30-7.35 (m,2H), 7.20-7.25 (m,1H), 7.10-7.15 (m,3H), 6.97 (d,2H,J=8Hz), 6.85 (d,2H,J=8Hz), 4.84 (s,2H), 3.20-3.30 (m,1H), 1.42 (d,6H,J=7Hz). MS calcd. 382.5; MS (M+1) 383.4.

5

Example 7

N-(2-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethamine




10 The title compound was prepared using a method similar to the method of Example 1 using (2-phenoxy)aniline. ¹H NMR: 8.50 (m,1H), 8.31 (m,1H), 7.75 (m,1H), 7.40 (t, 2H, J=8Hz), 7.15-7.25 (m,3H), 6.95-7.05 (m,3H), 6.95 (t,1H,J=8Hz), 6.83 (d,2H,J=8Hz), 4.84 (s,2H), 3.90-4.00 (m,2H). MS calcd. 422.4; MS (M+1) 423.4.

15

Example 8

N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine



20

The title compound was prepared using a method similar to the method of Example 1 using (4-phenoxy)aniline and ethylsulfonyl chloride. ¹H NMR: 8.50 (m,1H), 8.37 (s,1H), 7.70 (d,1H,J=8Hz), 7.30-7.35 (m,2H), 7.20-7.25 (m,1H), 7.10-7.15 (m,3H), 6.98 (d,2H,J=8Hz), 6.87 (d,2H,J=9Hz), 4.83


25

-44-

(s, 2H), 3.09 (q, 2H, J=7Hz), 1.42 (t, 3H, J=7Hz). MS calcd. 368.5; MS (M+1) 369.3

Example 9


5 N-(4-(2-Methoxyphenoxy)-3-chlorophenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



The title compound was prepared using a method similar
10 to the method of Example 1 using 4-(2-methoxyphenoxy)-3-chloroaniline. The hydrochloride salt was obtained by treatment of this material in methanol with ethereal HCl. ¹H NMR: 8.51 (m, 1H), 8.32 (s, 1H), 7.66 (m, 1H), 7.25-7.30 (m, 2H), 7.15-7.20 (m, 1H), 6.85-7.00 (m, 4H), 6.55 (d, 1H, J=8.5Hz), 4.82 (s, 2H), 3.75-3.85 (m, 2H), 3.76 (s, 3H).
15 MS calcd. 486.9; MS (M+1) 487.6

Example 10

20 N-(4-(2,6-Dimethoxyphenoxy)-3-chlorophenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



The title compound was prepared using a method similar to the method of Example 1 using 4-(2,6-dimethoxyphenoxy)-3-


-45-

chloroaniline. ^1H NMR: 8.51 (m, 1H), 8.32 (s, 1H), 7.66 (m, 1H), 7.25-7.30 (m, 2H), 7.15-7.20 (m, 1H), 6.85-7.00 (m, 4H), 6.55 (d, 1H, $J=8.5\text{Hz}$), 4.82 (s, 2H), 3.75-3.85 (m, 2H), 3.76 (s, 3H). MS calcd. 486.9; MS (M+1) 487.6

5

Example 11

N-(4-(2-Benzyloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



10


The title compound was prepared using a method similar to the method of Example 1 using 4-(2-

benzyloxyphenoxy)aniline. ^1H NMR: 8.48 (m, 1H), 8.33 (s, 1H), 7.60-7.65 (m, 1H), 7.15-7.25 (m, 5H), 7.05-7.15 (m, 5H), 7.03

15 (t, 1H, $J=8\text{Hz}$), 6.94 (t, 1H, $J=8\text{Hz}$), 6.84 (d, 2H, $J=9\text{Hz}$), 5.02 (s, 2H), 4.82 (s, 2H), 3.70-3.80 (m, 2H). MS calcd. 528.6; MS (M+1) 529.4

Example 12

20 N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine




The title compound was prepared using a method similar to the method of Example 1 using 4-(2-methoxyphenoxy)aniline

-46-

and ethylsulfonyl chloride. ^1H NMR: δ 8.46 (d, 1H, $J=4.8\text{Hz}$), 8.33 (s, 1H), 7.67-7.69 (d, 1H, $J=7.7\text{Hz}$), 7.19-7.24 (m, 1H), 7.10-7.16 (m, 1H), 7.06-7.10 (d, 2H, $J=7.0$), 6.94-6.99 (d, 2H, $J=8.1\text{Hz}$), 6.89-6.92 (d, 1H, $J=7.7\text{Hz}$), 6.78-6.82 (d, 2H, $J=8.8\text{Hz}$), 4.81 (s, 2H), 3.76 (s, 3H), 3.02-3.10 (dd, 2H, $J=14.7$, 7.3Hz), 1.4 (t, 3H, $J=7.7\text{Hz}$). MS calcd. 398.5; MS (M+1) 399.2.

Example 13

10 N-(4-(2-Methoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethylamine




The title compound was prepared using a method similar to the method of Example 1 using 4-(2-methoxyphenoxy)aniline and cyclopropylsulfonyl chloride. ^1H NMR: 8.49 (d, 1H), 8.34 (s, 1H), 7.62-7.68 (m, 1H), 7.17-7.23 (m, 2H), 7.10-7.18 (m, 3H), 6.85-6.96 (m, 3H), 6.78 (m, 2H), 4.81 (s, 2H), 3.76 (s, 3H), 2.42 (m, 1H), 1.10 (m, 2H), 0.96 (m, 2H). MS calcd. 410.5; MS (M+1) 411.4.

-47-

Example 14


N-(4-(2-Methoxyphenoxy)-3-chlorophenyl)-N-ethylsulfonylpyrid-3-ylmethylamine



5 The title compound was prepared using a method similar to the method of Example 1 using 4-(2-methoxyphenoxy)-3-chloroaniline and ethylsulfonyl chloride. ^1H NMR: 8.48 (d, 1H, $J=4.8\text{Hz}$), 8.35 (s, 1H), 7.64-7.73 (d, 1H, $J=8.0\text{Hz}$),
10 7.28-7.33 (d, 1H, $J=2.5\text{Hz}$), 7.21-7.27 (m, 2H), 7.10-7.20 (m, 1H), 6.87-7.00 (m, 3H), 6.51-6.62 (d, 1H, $J=8.8\text{Hz}$), 4.81 (s, 2H), 3.76 (s, 3H), 3.01-3.15 (dd, 2H, $J=14.7, 7.3\text{Hz}$), 1.41 (t, 3H, $J=7.3\text{Hz}$). MS calcd. 432.9; MS (M+1) 433.6

Example 15

15 N-(4-(2-Methoxyphenoxy)-3-chlorophenyl)-N-cyclopropylsulfonylpyrid-3-ylmethylamine



20 The title compound was prepared using a method similar to the method of Example 1 using 4-(2-methoxyphenoxy)-3-chloroaniline and cyclopropylsulfonyl chloride. ^1H NMR: 8.55 (d, 1H, $J=8.1\text{Hz}$), 8.35 (s, 1H), 8.03 (s, 1H), 7.88 (s, 1H), 7.65 (s, 1H), 7.12-7.29 (m, 3H), 6.89-7.02 (m, 2H), 6.49-6.58


-48-

(d, 1H, $J=19.4\text{Hz}$), 5.06 (s, 2H), 3.67 (s, 3H), 2.87 (m, 1H), 1.01 (d, 2H, $J=5.5\text{Hz}$), 0.84 (m, 2H). MS calcd. 444.9; MS (M+1) 445.5

5

Example 16


N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



10 The title compound was prepared using a method similar to the method of Example 1 using 4-(2-methoxyphenoxy) aniline. The hydrochloride salt was obtained by treatment of this material in methanol with ethereal HCl. ^1H NMR: 8.49 (d, 1H), 8.29 (s, 1H), 7.62-7.68 (m, 1H), 7.20-7.28 (m, 2H),
15 7.10-7.20 (m, 1H), 7.03 (d, 1H), 6.96 (m, 2H), 6.85-6.90 (m, 1H), 6.80 (m, 2H), 4.82 (s, 2H), 3.75 (s, 3H), 1.6 (s, 2H). MS calcd. 452.5; MS (M+1) 453.3

Example 17

20 N-(4-(2-Ethoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



The title compound was prepared using a method similar to the method of Example 1 using 4-(2-ethoxyphenoxy) aniline. ^1H NMR: 8.54 (d, 2H, $J=22\text{Hz}$), 8.03 (d, 1H, $J=7.7\text{Hz}$),
25 7.63 (m, 1H), 7.20-7.25 (d, 2H, $J=6.8\text{Hz}$), 7.10-7.20 (m, 2H),


-49-

7.00 (d, 1H, J=6.6Hz), 6.92 (t, 1H, J=7.7Hz), 6.70-6.80 (d, 2H, J=8.8Hz), 4.94 (s, 2H), 4.64-4.81 (dd, 2H, J=20.2, 9.9Hz), 3.84-3.97 (dd, 2H, J=13.9, 7.0Hz), 0.99 (t, 3H, J=7.0Hz). MS calcd. 466.5; MS (M+1) 467.8

5

Example 18

N-(4-(2-Ethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethanamine




10 The title compound was prepared using a method similar to the method of Example 1 using 4-(2-ethoxyphenoxy) aniline and ethylsulfonyl chloride. ¹H NMR: 8.61 (d, 2H, J=13.2Hz), 8.13 (d, 1H, J=8.1Hz), 7.70-7.75 (m, 1H), 7.27 (d, 2H, J=8.8Hz), 7.08-7.20 (m, 2H), 7.00 (d, 1H, J=6.2Hz), 6.92 (t, 1H, J=7.7Hz), 6.72-6.76 (d, 2H, J=8.8Hz), 4.97 (s, 2H), 3.85-3.95 (dd, 2H, J=13.9, 6.7), 3.16-3.30 (dd, 2H, J=14.7, 7.3Hz), 1.25 (t, 3H, J=7.3Hz), 0.98 (t, 3H, J=7.0Hz). MS calcd. 412.4; MS (M+1) 413.6

20

Example 19

N-(4-(2-Ethoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethanamine



25


The title compound was prepared using a method similar to the method of Example 1 using 4-(2-ethoxyphenoxy) aniline

-50-

and cyclopropylsulfonyl chloride. ^1H NMR: 7.88 (d, 1H, $J=7.7\text{Hz}$), 7.26 (d, 2H, $J=8.8\text{Hz}$), 7.5-7.18 (m, 2H), 6.97-7.05 (d, 1H, $J=7.7\text{Hz}$), 6.87-6.96 (m, 1H), 6.67-6.77 (d, 2H, $J=8.8\text{Hz}$), 4.92 (s, 2H), 3.84-3.94 (dd, 2H, $J=7.0\text{Hz}$), 2.71-2.83 (m, 1H), 0.98 (m, 5H), 0.84 (m, 2H). MS calcd. 424.4; MS (M+1) 425.2

Example 20


10 N-(3-(2-Methoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethylamine



The title compound was prepared using a method similar to the method of Example 1 using 3-(2-methoxyphenoxy)aniline and cyclopropylsulfonyl chloride. ^1H NMR: 8.49 (d, 2H), 7.60 (d, 1H), 7.10-7.35 (m, 4H), 7.03-7.10 (d, 2H), 6.85-6.99 (m, 2H), 6.89 (s, 1H), 6.76 (m, 1H), 4.86 (s, 2H), 3.65 (s, 3H), 2.77 (m, 1H), 0.93 (m, 2H), 0.84 (m, 2H). MS calcd. 410.4; MS (M+1) 411.5

Example 21

20 N-(3-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine




-51-

The title compound was prepared using a method similar to the method of Example 1 using 3-(2-methoxyphenoxy)aniline and ethylsulfonyl chloride. ^1H NMR: 8.64 (d, 2H, $J=4.3\text{Hz}$), 8.00 (t, 2H, $J=6.6\text{Hz}$), 7.72-7.76 (t, 1H, $J=5.5\text{Hz}$), 7.07-7.27 (m, 4H), 6.84-6.93 (m, 3H), 6.66 (d, 1H, $J=8.1\text{Hz}$), 5.00 (s, 2H), 3.64 (s, 3H), 3.25 (dd, 2H, $J=15.0, 7.3\text{Hz}$), 1.23 (t, 3H, $J=7.7\text{Hz}$). MS calcd. 398.3; MS (M+1) 399.2.

Example 22

10 N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine




15 The title compound was prepared using a method similar to the method of Example 1 using (4-phenoxy)aniline. The hydrochloride salt was obtained by treatment of this material in methanol with ethereal HCl. ^1H NMR: 8.50 (m, 1H), 8.30 (s, 1H), 7.67 (m, 1H), 7.30-7.35 (m, 2H), 7.20-7.25 (m, 1H), 7.10-7.15 (m, 1H), 7.11 (d, 2H, $J=9\text{Hz}$), 6.99 (d, 2H, $J=8\text{Hz}$), 6.89 (d, 2H, $J=9\text{Hz}$), 4.83 (s, 2H), 3.80 (q, 2H, $J=9\text{Hz}$). MS calcd. 422.4; MS (M+1) 423.4.

-52-

Example 23


N-(3-(2-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



- 5 A solution of N-(3-(2-benzyloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine (529mg, 1.00mmol) in methanol (50mL) was carefully treated with Raney[®] nickel (one tsp.), placed on a Parr[®] apparatus, and hydrogenated at 45-50 psi pressure for 3h. The mixture was
- 10 carefully filtered through celite[®] under nitrogen without allowing the filter cake to dry, and the filtrate was concentrated in vacuo. The residual solid was triturated from petroleum ethers (30°-60°) to afford the title compound (394mg, 90%) as a white solid; mp 57.5-60.0°C. The title
- 15 compound was converted to the hydrochloride salt by treatment in methanol with ethereal HCl. ¹H NMR: 8.50 (br s, 1H), 8.25 (br s, 1H), 7.68 (d, 1H, J=8Hz), 7.25-7.30 (m, 2H), 6.95-7.10 (m, 2H), 6.90-6.95 (m, 2H), 6.70-6.85 (m, 3H), 6.05 (br s, 1H), 4.82 (s, 2H), 3.75-3.85 (m, 2H). MS calcd. 438.4;
- 20 MS(M+1) 439.3

Example 24

N-(4-(2-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine



-53-

The title compound was prepared using a method similar to the method of Example 23 using N-(4-(2-benzyloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine ¹H NMR: 8.48 (m,1H), 8.28 (s,1H), 7.70 (d,1H,J=8Hz), 7.20-7.25 (m,2H), 7.11 (d,2H,J=9Hz), 7.00-7.10 (m,2H), 6.90 (d,2H,J=9Hz), 6.80-6.85 (m,1H), 6.00 (br s,1H), 4.83 (s,2H), 3.75-3.85 (m,2H). MS calcd. 438.4; MS (M+1) 439.4

General Example A

10

General synthesis of compound of formula I

Compounds in the table below were prepared using substantially the procedure described as follows, using the corresponding reagents to provide the desired compound of formula I: Each well of a multi-well, 1.2 mL, glass, reaction plate was charged with an appropriate aryl aldehyde solution in methanol (1.0N, 100μL, 100μmol) followed by an appropriate aniline solution in methanol (0.65N, 200μL, 130μmol), and an additional 100μL of methanol was added to each well. The plate was capped and heated with shaking to 60°C for 18h, then cooled and uncapped. Sodium borohydride on alumina (10%, 60mg) was added via solid addition plate, and the reaction plate was shaken for 2h without caps and for 4h with caps. Plate contents were filtered through a filter plate into another multi-well, 1.2 mL, glass, reaction plate, and the empty plate was rinsed twice with 9:1 dichloromethane/methanol (200μL each) into the filter plate. The receiving plate was concentrated to dryness. A slurry made from polystyrene carboxaldehyde resin (1.8meq/g) and 4:1 1,2-dichloroethane/methanol (1g resin for each 10mL solvents) was added to each well (600μL/well), followed by 15% acetic acid/1,2-dichloroethane (100μL/well), and the plate was capped and shaken for 18h. The plate was uncapped, and DOWEX® 550A OH anion exchange resin (which had been washed dry with methanol) was added by solid addition plate (100mg per well). The plate was recapped and shaken for 2h, then uncapped and plate contents were filtered

-54-

through a filter plate into a multi-well, 2mL square well, plastic plate. The empty plate was rinsed twice with 9:1 dichloromethane/methanol (200µL each) into the filter plate, and the receiving plate was concentrated to dryness. The

5 plate contents were dissolved in 9:1 dichloromethane/methanol (400µL/well), and the solutions were passed through a filter plate containing a half volume of silica gel into a 96-well 1.2mL vial glass plate. The empty plate was rinsed twice with 9:1

10 dichloromethane/methanol (200µL each) into the filter plate, and the receiving plate was concentrated to dryness. In the case of sulfonation, each well is dissolved with 1:1 anhydrous 1,2-dichloroethane/pyridine (400µL), then treated with the appropriate sulfonyl chloride in anhydrous 1,2-

15 dichloroethane (1.0N, 200µL, 200µM). In the case of acylation, each well is dissolved with anhydrous 1,2-dichloroethane (400µL), then treated with the appropriate acid chloride or chloroformate ester in anhydrous 1,2-dichloroethane (1.0N, 200µL, 200µM). In either case, the

20 plate was capped and shaken for 48h, then uncapped, and each well was treated with tris(2-aminoethyl)amine resin (4meq/g, 70mg/well) by solid addition plate. Shaking with caps was continued for 3-4h, then the plate was opened, treated with dry DOWEX® 550A OH anion exchange resin (120mg/well) by


25 solid addition plate, and shaken with caps for 2-3h more. The plate contents were filtered through a filter plate into a 96-well receiving plate, the empty plate was rinsed twice with 9:1 dichloromethane/methanol (200µL each) into the filter plate, and the receiving plate was concentrated to

30 dryness to give a compound of formula I. The product plate was analyzed by whole plate mass spec and HPLC to give the compounds described in the table below. The HPLC conditions were as follows: a 4.6 x 50 mm C18 ODS_{am} column (YMC, Inc. CombiScreen™) having a 3 micron particle size and 120

35 angstrom pore size was eluted at ambient temperature at a flow rate of 3 mL/min. The fluent was a gradient from 5-100% acetonitrile/water (containing 0.1% trifluoroacetic

-55-

acid) over 4 min. The methods of detection employed included a Gilson 170 diode array detector monitoring 254 nm and a SEDEX Model 75 evaporative light scattering detector held at a 40° C. Injection volumes were held between 5-10 μ L per injection. The product can optionally be obtained as the hydrochloride salt by dissolving the free base in minimum methanol and adding 1.3eq of 2.0N HCl in ether, concentrating *in vacuo* to obtain a residue, and the residue triturated from ether. In the table below the point of attachment of the pyridyl moiety is designated with the substituent X. In the table below "M+1" refers to the mass ion, where observed, from mass spectral analysis using P.E. Sciex API 100 using was Positive APCI (Atmospheric Pressure Chemical Ionization) and heated nebulizer technique by (flow injection analysis) with a run time of 30 sec per sample. All results yielded M+1 from positive APCI. The mobile phase used was 100% MeOH with 10 mM ammonium acetate using a Gilson 215 liquid handler injector and 1 μ L injections.











formula I









20

No.	X	Y	R ₁	R ₂	R ₆	M+1
25	2-CH ₂	bond	SO ₂ CH ₃	4-phenoxy	H	355.28
26	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	H	369.34
27	2-CH ₂	bond	SO ₂ (CH ₂) ₃ CH ₃	4-phenoxy	H	383.39
28	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	H	423.39
29	2-CH ₂	bond	C(O)OCH ₃	4-phenoxy	H	335.83
30	3-CH ₂	bond	SO ₂ CH ₃	4-phenoxy	H	355.43
31	3-CH ₂	bond	SO ₂ (CH ₂) ₃ CH ₃	4-phenoxy	H	369.35
32	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	H	423.39
33	3-CH ₂	bond	C(O)OCH ₃	4-phenoxy	H	335.85
34	4-CH ₂	bond	SO ₂ CH ₃	4-phenoxy	H	355.23
35	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	H	369.34
36	4-CH ₂	bond	SO ₂ (CH ₂) ₃ CH ₃	4-phenoxy	H	397.51
37	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	H	423.41

38	4-CH ₂	bond	C(O)OCH ₃	4-phenoxy	H	335.84
39	2-CH ₂	bond	C(O)CH ₂ CH ₃	4-phenoxy	H	333.57
40	2-CH ₂	bond	C(O)-cyclopentyl	4-phenoxy	H	373.32
41	3-CH ₂	bond	C(O)CH ₂ CH ₃	4-phenoxy	H	333.58
42	3-CH ₂	bond	C(O)-cyclopentyl	4-phenoxy	H	373.53
43	4-CH ₂	bond	C(O)CH ₂ CH ₃	4-phenoxy	H	333.59
44	4-CH ₂	bond	C(O)-cyclopentyl	4-phenoxy	H	373.32
45	2-CH ₂	bond	SO ₂ CF ₃	4-phenoxy	H	423.34
46	3-CH ₂	bond	SO ₂ CF ₃	4-phenoxy	H	423.4
47	4-CH ₂	bond	SO ₂ CF ₃	4-phenoxy	H	423.4
48	2-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-phenoxy	H	383.38
49	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-phenoxy	H	383.4
50	4-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-phenoxy	H	383.4
51	2-CH ₂	bond	C(O)CH ₂ CH(CH ₃) ₂	4-phenoxy	H	361.93
52	3-CH ₂	bond	C(O)CH ₂ CH(CH ₃) ₂	4-phenoxy	H	361.93
53	4-CH ₂	bond	C(O)CH ₂ CH(CH ₃) ₂	4-phenoxy	H	361.9
54	2-CH ₂	bond	C(O)CH ₃	4-phenoxy	H	319.18
55	3-CH ₂	bond	C(O)CH ₃	4-phenoxy	H	319.23
56	4-CH ₂	bond	C(O)CH ₃	4-phenoxy	H	319.17
57	2-CH ₂	bond	C(O)-cyclopropyl	4-phenoxy	H	345.16
58	3-CH ₂	bond	C(O)-cyclopropyl	4-phenoxy	H	345.15
59	4-CH ₂	bond	C(O)-cyclopropyl	4-phenoxy	H	345.12
60	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-benzyloxy-phenoxy)	H	359.57
61	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-cyclohexyl-phenoxy)	H	335.93
62	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-benzyl-phenoxy)	H	343.41
63	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-thiophenoxy-phenoxy)	H	361.88
64	3-CH ₂	bond	SO ₂ CH ₃	4-(4-benzyloxy-phenoxy)	H	369.32
65	3-CH ₂	bond	SO ₂ CH ₃	4-(4-cyclohexyl-phenoxy)	H	345.18
66	3-CH ₂	bond	SO ₂ CH ₃	4-(4-benzyl-phenoxy)	H	353.62
67	3-CH ₂	bond	SO ₂ CH ₃	4-(4-thiophenoxy-phenoxy)	H	371.08
68	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-benzyloxy-phenoxy)	H	383.42
69	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-cyclohexyl-phenoxy)	H	359.5
70	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-benzyl-phenoxy)	H	367.55

71	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-thiophenoxy-phenoxy)	H	385.5
72	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-benzyloxy-phenoxy)	H	437.78
73	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-cyclohexyl-phenoxy)	H	413.65
74	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-benzyl-phenoxy)	H	421.19
75	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-thiophenoxy-phenoxy)	H	439.52
76	3-CH ₂	bond	SO ₂ CF ₃	4-(4-benzyloxy-phenoxy)	H	423.4
77	3-CH ₂	bond	SO ₂ CF ₃	4-(4-cyclohexyl-phenoxy)	H	399.4
78	3-CH ₂	bond	SO ₂ CF ₃	4-(4-benzyl-phenoxy)	H	407.4
79	3-CH ₂	bond	SO ₂ CF ₃	4-(4-thiophenoxy-phenoxy)	H	425.5
80	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-benzyloxy-phenoxy)	H	397.5
81	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-cyclohexyl-phenoxy)	H	373.5
82	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-benzyl-phenoxy)	H	381.63
83	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-thiophenoxy-phenoxy)	H	399.5
84	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-benzyloxy-phenoxy)	H	383.57
85	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-cyclohexyl-phenoxy)	H	359.55
86	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-benzyl-phenoxy)	H	367.5
87	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-thiophenoxy-phenoxy)	H	385.5
88	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-benzyloxy-phenoxy)	H	437.78
89	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-cyclohexyl-phenoxy)	H	413.65
90	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-benzyl-phenoxy)	H	421.16
91	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-thiophenoxy-phenoxy)	H	439.49
92	3-CH ₂	bond	C(O)-cyclopropyl	4-pentoxy	H	339.31
93	3-CH ₂	bond	C(O)-cyclopropyl	4- 	H	297.63
94	3-CH ₂	bond	C(O)-cyclopropyl	4-methoxy	H	283.69

95	3-CH ₂	bond	C(O)-cyclopropyl	4- 	H	399.33
96	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-cyclohexoxy-phenoxy)	H	351.86
97	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-pyrid-2-yloxy-phenoxy)	H	346.31
98	3-CH ₂	bond	SO ₂ CH ₃	4-pentoxy	H	349.82
99	3-CH ₂	bond	SO ₂ CH ₃	4- 	H	307.71
100	3-CH ₂	bond	SO ₂ CH ₃	4-methoxy	H	293.21
101	3-CH ₂	bond	SO ₂ CH ₃	4- 	H	409.41
102	3-CH ₂	bond	SO ₂ CH ₃	4-(4-cyclohexoxy-phenoxy)	H	361.9
103	3-CH ₂	bond	SO ₂ CH ₃	4-(4-pyrid-2-yloxy-phenoxy)	H	356.37
104	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-pentoxy	H	363.83
105	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4- 	H	321.41
106	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-methoxy	H	307.71
107	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4- 	H	423.49
108	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-cyclohexoxy-phenoxy)	H	375.65
109	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-pyrid-2-yloxy-phenoxy)	H	370.05
110	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-pentoxy	H	417.65
111	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4- 	H	375.53
112	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-methoxy	H	361.81
113	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4- 	H	477.29
114	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-cyclohexoxy-phenoxy)	H	429.83
115	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-pyrid-2-yloxy-phenoxy)	H	424.41
116	3-CH ₂	bond	SO ₂ CF ₃	4-pentoxy	H	403.4

117	3-CH ₂	bond	SO ₂ CF ₃	4- 	H	361.3
118	3-CH ₂	bond	SO ₂ CF ₃	4-methoxy	H	347.3
119	3-CH ₂	bond	SO ₂ CF ₃	4- 	H	463.5
120	3-CH ₂	bond	SO ₂ CF ₃	4-(4-cyclohexoxy-phenoxy)	H	415.4
121	3-CH ₂	bond	SO ₂ CF ₃	4-(4-pyrid-2-yloxy-phenoxy)	H	401.4
122	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-pentoxy	H	377.76
123	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4- 	H	335.85
124	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-methoxy	H	321.41
125	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4- 	H	437.87
126	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-cyclohexoxy-phenoxy)	H	389.88
127	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-pyrid-2-yloxy-phenoxy)	H	384.61
128	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-pentoxy	H	363.81
129	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4- 	H	321.4
130	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-methoxy	H	307.71
131	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4- 	H	423.47
132	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-cyclohexoxy-phenoxy)	H	375.67
133	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-pyrid-2-yloxy-phenoxy)	H	361.5
134	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-pentoxy	H	417.66
135	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4- 	H	375.52
136	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-methoxy	H	361.79
137	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4- 	H	477.5
138	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-cyclohexoxy-phenoxy)	H	429.62
139	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-pyrid-2-	H	424.36

				xyloxy-phenoxy)		
140	3-CH ₂	bond	C(O)-cyclopropyl	3-phenoxy	H	345.16
141	3-CH ₂	bond	C(O)-cyclopropyl	2-phenoxy	H	345.18
142	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-chloro-phenoxy)	H	379.4
143	3-CH ₂	bond	C(O)-cyclopropyl	4-(3-trifluoromethyl-phenoxy)	H	413.68
144	3-CH ₂	bond	C(O)-cyclopropyl	4-(2-methoxy-phenoxy)	H	375.65
145	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-cyano-phenoxy)	H	370.14
146	3-CH ₂	bond	C(O)-cyclopropyl	4-(2,4-difluoro-phenoxy)	H	381.62
147	3-CH ₂	bond	SO ₂ CH ₃	3-phenoxy	H	355.28
148	3-CH ₂	bond	SO ₂ CH ₃	2-phenoxy	H	355.4
149	3-CH ₂	bond	SO ₂ CH ₃	4-(4-chloro-phenoxy)	H	389.78
150	3-CH ₂	bond	SO ₂ CH ₃	4-(3-trifluoromethyl-phenoxy)	H	423.4
151	3-CH ₂	bond	SO ₂ CH ₃	4-(2-methoxy-phenoxy)	H	385.44
152	3-CH ₂	bond	SO ₂ CH ₃	4-(4-cyano-phenoxy)	H	380.52
153	3-CH ₂	bond	SO ₂ CH ₃	4-(2,4-difluoro-phenoxy)	H	391.63
154	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	H	369.3
155	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	2-phenoxy	H	369.3
156	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-chloro-phenoxy)	H	403.9
157	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(3-trifluoromethyl-phenoxy)	H	437.5
158	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	H	399.26
159	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-cyano-phenoxy)	H	448.44
160	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,4-difluoro-phenoxy)	H	459.37
161	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	H	423.43
162	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	2-phenoxy	H	423.39
163	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-chloro-phenoxy)	H	457.68
164	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(3-trifluoromethyl-phenoxy)	H	491.56

165	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	H	453.36
166	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-cyano-phenoxy)	H	448.44
167	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,4-difluoro-phenoxy)	H	459.37
168	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	H	369.5
169	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	2-phenoxy	H	369.5
170	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-chloro-phenoxy)	H	403.75
171	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(3-trifluoromethyl-phenoxy)	H	437.78
172	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	H	399.28
173	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-cyano-phenoxy)	H	394.5
174	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,4-difluoro-phenoxy)	H	405.5
175	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	H	423.41
176	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	2-phenoxy	H	423.4
177	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-chloro-phenoxy)	H	457.7
178	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(3-trifluoromethyl-phenoxy)	H	491.57
179	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	H	453.63
180	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-cyano-phenoxy)	H	448.45
181	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,4-difluoro-phenoxy)	H	459.37
182	3-CH ₂	bond	SO ₂ CF ₃	3-phenoxy	H	409.4
183	3-CH ₂	bond	SO ₂ CF ₃	2-phenoxy	H	409.4
184	3-CH ₂	bond	SO ₂ CF ₃	4-(4-chloro-phenoxy)	H	443.8
185	3-CH ₂	bond	SO ₂ CF ₃	4-(3-trifluoromethyl-phenoxy)	H	477.4
186	3-CH ₂	bond	SO ₂ CF ₃	4-(2-methoxy-phenoxy)	H	439.4
187	3-CH ₂	bond	SO ₂ CF ₃	4-(4-cyano-phenoxy)	H	434.4
188	3-CH ₂	bond	SO ₂ CF ₃	4-(2,4-difluoro-phenoxy)	H	445.4
189	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	3-phenoxy	H	383.5
190	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	2-phenoxy	H	383.5

191	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-chloro- phenoxy)	H	417.9
192	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(3- trifluoromethyl- phenoxy)	H	451.5
193	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(2-methoxy- phenoxy)	H	413.5
194	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-cyano- phenoxy)	H	408.5
195	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(2,4-difluoro- phenoxy)	H	419.35
196	3-CH ₂	bond	C(O)-cyclopropyl	2-chloro-5- methyl-4-phenoxy	H	393.9
197	3-CH ₂	bond	C(O)-cyclopropyl	3-chloro-4- phenoxy	H	379.33
198	3-CH ₂	bond	C(O)-cyclopropyl	2-methyl-4- phenoxy	H	359.55
199	3-CH ₂	bond	C(O)-cyclopropyl	3-trifluoromethyl- 4-phenoxy	H	413.63
200	3-CH ₂	bond	C(O)-cyclopropyl	4-(4-nitro- phenoxy)	H	390.75
201	3-CH ₂	bond	SO ₂ CH ₃	2-chloro-5- methyl-4-phenoxy	H	403.9
202	3-CH ₂	bond	SO ₂ CH ₃	3-chloro-4- phenoxy	H	389.71
203	3-CH ₂	bond	SO ₂ CH ₃	2-methyl-4- phenoxy	H	369.3
204	3-CH ₂	bond	SO ₂ CH ₃	3-trifluoromethyl- 4-phenoxy	H	423.4
205	3-CH ₂	bond	SO ₂ CH ₃	4-(4-nitro- phenoxy)	H	400.4
206	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	2-chloro-5- methyl-4-phenoxy	H	417.9
207	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-chloro-4- phenoxy	H	403.9
208	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	2-methyl-4- phenoxy	H	383.5
209	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-trifluoromethyl- 4-phenoxy	H	437.5
210	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-nitro- phenoxy)	H	414.5
211	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	2-chloro-5- methyl-4-phenoxy	H	471.9
212	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-chloro-4- phenoxy	H	457.9
213	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	2-methyl-4- phenoxy	H	437.72

214	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-trifluoromethyl-4-phenoxy	H	491.51
215	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-nitro-phenoxy)	H	468.89
216	3-CH ₂	bond	SO ₂ CF ₃	2-chloro-5-methyl-4-phenoxy	H	457.9
217	3-CH ₂	bond	SO ₂ CF ₃	3-chloro-4-phenoxy	H	443.8
218	3-CH ₂	bond	SO ₂ CF ₃	2-methyl-4-phenoxy	H	423.4
219	3-CH ₂	bond	SO ₂ CF ₃	3-trifluoromethyl-4-phenoxy	H	477.4
220	3-CH ₂	bond	SO ₂ CF ₃	4-(4-nitro-phenoxy)	H	454.4
221	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	2-chloro-5-methyl-4-phenoxy	H	432.0
222	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	3-chloro-4-phenoxy	H	417.9
223	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	2-methyl-4-phenoxy	H	397.5
224	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	3-trifluoromethyl-4-phenoxy	H	451.5
225	3-CH ₂	bond	SO ₂ (CH ₂) ₂ CH ₃	4-(4-nitro-phenoxy)	H	428.5
226	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	2-chloro-5-methyl-4-phenoxy	H	417.9
227	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-chloro-4-phenoxy	H	403.9
228	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	2-methyl-4-phenoxy	H	383.5
229	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-trifluoromethyl-4-phenoxy	H	437.5
230	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(4-nitro-phenoxy)	H	414.5
231	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	2-chloro-5-methyl-4-phenoxy	H	471.6
232	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-chloro-4-phenoxy	H	457.66
233	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	2-methyl-4-phenoxy	H	437.73
234	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-trifluoromethyl-4-phenoxy	H	491.52
235	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(4-nitro-phenoxy)	H	466.87
236	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	6-methoxy	453
237	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	6-	453

					methoxy	
238	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	6-methoxy	484
239	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	6-methoxy	399
240	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	6-methoxy	400
241	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	6-methoxy	430
242	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	6-methyl	438
243	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	6-methyl	438
244	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	6-methyl	468
245	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	6-methyl	384
246	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	6-methyl	384
247	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	6-methyl	414
248	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	6-(4-chloro-phenoxy)	550
249	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	6-(4-chloro-phenoxy)	550
250	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	6-(4-chloro-phenoxy)	580
251	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	6-(4-chloro-phenoxy)	496
252	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	6-(4-chloro-phenoxy)	496
253	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	6-(4-chloro-phenoxy)	526
254	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	2-chloro	458
255	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	2-chloro	458
256	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	2-chloro	488
257	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	2-chloro	404
258	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	2-chloro	404
259	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	2-chloro	434
260	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	2-phenoxy	516
261	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	2-phenoxy	516

262	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	2-phenoxy	546
263	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	2-phenoxy	462
264	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	2-phenoxy	462
265	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	2-phenoxy	492
266	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	6-chloro	458
267	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	6-chloro	458
268	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	6-chloro	488
269	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	6-chloro	404
270	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	6-chloro	404
271	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	6-chloro	434
272	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-phenoxy	2-chloro-6-methyl	472
273	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	3-phenoxy	2-chloro-6-methyl	471
274	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	2-chloro-6-methyl	501
275	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-phenoxy	2-chloro-6-methyl	418
276	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	3-phenoxy	2-chloro-6-methyl	418
277	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	2-chloro-6-methyl	448
278	3-CH ₂	bond	SO ₂ -cyclopropyl	4-phenoxy	H	382
279						
280	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-methoxy-phenoxy)	H	453
281	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-methoxy-phenoxy)	H	399
282	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2,6-dimethoxy-phenoxy)	H	442
283	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,6-dimethoxy-phenoxy)	H	484
284	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,6-dimethoxy-phenoxy)	H	430
285	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,6-dimethoxy-phenoxy)	H	399
286	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,6-dimethoxy-phenoxy)	H	453
287	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,6-dimethoxy-phenoxy)	H	399
288	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,6-dimethoxy-	H	453

				phenoxy)		
289	3-CH ₂	CH ₂	SO ₂ -cyclopropyl	2-phenoxy-6-chloro	H	430
290	3-CH ₂	CH ₂	SO ₂ CH ₂ CH ₃	2-phenoxy-6-chloro	H	418
291	3-CH ₂	CH ₂	SO ₂ CH ₂ CF ₃	2-phenoxy-6-chloro	H	472
292	2-CH ₂	CH ₂	SO ₂ CH ₂ CH ₃	2-phenoxy-6-chloro	H	418
293	2-CH ₂	CH ₂	SO ₂ CH ₂ CF ₃	2-phenoxy-6-chloro	H	472
294	4-CH ₂	CH ₂	SO ₂ CH ₂ CH ₃	2-phenoxy-6-chloro	H	418
295	4-CH ₂	CH ₂	SO ₂ CH ₂ CF ₃	2-phenoxy-6-chloro	H	472
296	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2,6-dichloro-phenoxy)	H	449
297	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,6-dichloro-phenoxy)	H	493
298	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,6-dichloro-phenoxy)	H	439
299	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,6-dichloro-phenoxy)	H	439
300	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,6-dichloro-phenoxy)	H	494
301	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2,6-dichloro-phenoxy)	H	439
302	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2,6-dichloro-phenoxy)	H	493
303	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2-isopropoxy-phenoxy)	H	440
304	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-isopropoxy-phenoxy)	H	482
305	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-isopropoxy-phenoxy)	H	427
306	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-isopropoxy-phenoxy)	H	427
307	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-isopropoxy-phenoxy)	H	481
308	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-isopropoxy-phenoxy)	H	427
309	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-isopropoxy-phenoxy)	H	481
310	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2-fluoro-6-methoxy-phenoxy)	H	430
311	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-fluoro-6-	H	472

				methoxy- phenoxy)		
312	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-fluoro-6-methoxy- phenoxy)	H	418
313	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-fluoro-6-methoxy- phenoxy)	H	418
314	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-fluoro-6-methoxy- phenoxy)	H	472
315	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-fluoro-6-methoxy- phenoxy)	H	418
316	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-fluoro-6-methoxy- phenoxy)	H	471
317	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2-trifluoromethyl- phenoxy)	H	449
318	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-trifluoromethyl- phenoxy)	H	492
319	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-trifluoromethyl- phenoxy)	H	438
320	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-trifluoromethyl- phenoxy)	H	437
321	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-trifluoromethyl- phenoxy)	H	492
322	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-trifluoromethyl- phenoxy)	H	437
323	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-trifluoromethyl- phenoxy)	H	492
324	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2-isopropyl-5-methyl- phenoxy)	H	438
325	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-isopropyl-5-methyl- phenoxy)	H	479
326	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-isopropyl-5-methyl- phenoxy)	H	425
327	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-isopropyl-5-methyl- phenoxy)	H	426
328	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-isopropyl-5-	H	479

-68-

				methyl-phenoxy)		
329	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-isopropyl-5-methyl-phenoxy)	H	425
330	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-isopropyl-5-methyl-phenoxy)	H	479
331	3-CH ₂	bond	SO ₂ -cyclopropyl	4-(2-cyclopentyl-phenoxy)	H	450
332	3-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-cyclopentyl-phenoxy)	H	492
333	3-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-cyclopentyl-phenoxy)	H	438
334	2-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-cyclopentyl-phenoxy)	H	438
335	2-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-cyclopentyl-phenoxy)	H	492
336	4-CH ₂	bond	SO ₂ CH ₂ CH ₃	4-(2-cyclopentyl-phenoxy)	H	438
337	4-CH ₂	bond	SO ₂ CH ₂ CF ₃	4-(2-cyclopentyl-phenoxy)	H	492

Preparation 3

4-(4-Benzyloxyphenoxy) aniline

A solution of 4-benzyloxyphenol (6.01g, 30mmol) in anhydrous dimethylformamide (50ml) under a nitrogen cover was treated with sodium hydride (1.2g of 60% oil dispersion, 30mmol) in one portion at room temperature. A moderate gas evolution ensued, and the reaction temperature rose to 41°C. After stirring an additional 35 minutes,

4-Fluoronitrobenzene was added rapidly dropwise, neat via syringe. A mild exotherm brought the reaction temperature to 32°C, after which the reaction was stirred for 18 hours at room temperature. The reaction mixture was poured over ice/water (250ml), stirred for thirty minutes and the yellow solid collected by suction filtration. Silica gel chromatography (Waters® LC2000; two Pre-Pak® columns, eluting with 3/1 hexanes/methylene chloride) afforded 4-(4-benzyloxyphenoxy)-1-nitrobenzene (5.9g, 73%) as a white solid. ¹H NMR(400MHz): 5.08(2H,s), 6.94-6.99(2H,m),

-69-


7.02 (4H, s), 7.32-7.47 (5H, m), 8.15-8.20 (2H, m); MS (ESI) m/z 320.2 ([M⁻H] -, 100).

A mechanically-stirred solution of 4-(4-benzyloxyphenoxy)-1-nitrobenzene (5.6g, 17mmol) in absolute
5 ethanol (50ml) was treated with concentrated hydrochloric acid (6ml). The solution was warmed to 55-60°C under a nitrogen cover. Iron powder (6.5g, 115mmol) was added in several portions. A mild exotherm (while still being heated) brought the reaction temperature to 68°C. After
10 completing the iron addition the reaction temperature was brought to 70°C and maintained at that temperature for 1.5 hours. The mixture was then cooled to room temperature and filtered through a pad of Celite®. The filter cake was washed with ethanol (100ml) and methylene chloride (50ml),
15 and the filtrate partitioned between methylene chloride and 1M potassium carbonate. The green aqueous layer was extracted a second time with methylene chloride and then dried over anhydrous magnesium sulfate. Filtration and concentration in vacuo afforded crude product (5.4g),
20 contaminated with unreacted starting material. Silica gel chromatography (Waters® LC2000 with 2 PrePak® columns, eluting with methylene chloride) provided the title compound (3.75g, 76%), as well as unreacted starting material (1.2g).
25 ¹H NMR (400MHz): 3.53 (2H, br s), 5.02 (2H, s), 6.62-6.67 (2H, m), 6.79-6.84 (2H, m), 6.86-6.93 (4H, m), 7.29-7.44 (5H, m); MS (ESI) m/z 291.9 ([M+H]⁺, 100).

-70-

Example 338

N-(4-(4-Benzyloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



5 4-(4-Benzyloxyphenoxy)aniline (3.4g, 11.67mmol) was suspended in methanol (100ml) and treated with pyridine-3-carboxaldehyde (1.25g, 11.67mmol) in one portion via syringe. This solution was heated to reflux for two hours, and then cooled to -5°C. Solid sodium borohydride (0.88g, 10 23mmol) was added in one portion. A mild gas evolution ensued, and the reaction temperature rose to -2°C. The mixture was then stirred at room temperature for two hours, after which TLC analysis of an aliquot showed incomplete reduction. An additional quantity of sodium borohydride was 15 added (0.45g, 12mmol) was added and the mixture stirred another two hours. The solvent was removed in vacuo and the residue slurried in methylene chloride. After filtration to remove insolubles and concentration in vacuo, the crude oil thereby obtained was purified via silica gel chromatography 20 (Waters® LC2000 using two PrePak® columns, eluting with 99/1 methylene chloride/methanol). N-4-(4-Benzyloxyphenoxy)phenylpyrid-3-ylmethylamine was obtained as a white solid (3.6g, 81%). ¹H NMR(400MHz): 4.33(2H,s), 5.02(2H,s), 6.56-6.62(2H,m), 6.83-6.92(6H,m), 7.24- 25 7.44(6H,m), 7.70(1H,ddd,J=7.8,~2.0,~2.0), 8.53(1H,dd,J=4.9,1.5), 8.63(1H,d,J=1.5); MS(ESI)m/z 382.9([M+H]⁺,100).


N-4-(4-Benzyloxyphenoxy)phenylpyrid-3-ylmethylamine (3.55g, 9.3mmol) was dissolved in 1,2-dichloroethane (46ml) in a flame-dried, serum-capped round bottom flask under a

-71-

nitrogen cover. Anhydrous pyridine (24ml) was added via syringe, the solution cooled to -5°C , and trifluoroethanesulfonyl chloride was added neat, dropwise via syringe. After stirring thirty minutes at 0°C the solution was stirred at room temperature for 18 hours. Potassium carbonate (6.0g) was added to the mixture and it was stirred another hour. The mixture was then filtered and the filtrate concentrated in vacuo to a dark oil. Silica gel chromatography (Waters® LC2000 using two PrePak® columns, eluting with 99/1 methylene chloride/methanol). Product-containing fractions were combined and concentrated, and the resulting mixture chromatographed a second time using a 90/10 to 84/16 methylene chloride/ethyl acetate gradient. The title compound was obtained (4.36g, 89%) as an off-white solid. ^1H NMR(400MHz): 3.81(2H,q,J=9.3), 4.84(2H,s), 5.05(2H,s), 6.83-6.88(2H,m), 6.96(4H,s), 7.07-7.12(2H,m), 7.26(1H,dd,J=4.9,3.9), 7.30-7.46(4H,m), 7.71(1H,ddd,J=7.8,2.0,2.0), 8.32(1H,d,J=1.9), 8.52(1H,dd,J=4.9,1.4); MS(ESI)m/z 529.0([M+H]⁺,100); Anal. Calcd. for $\text{C}_{27}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_4\text{S}$ C,61.36; H,4.39; N,5.30. Found: C,61.32; H,4.44; N,5.31.

Example 339

N-(4-(4-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



N-4-(4-Benzyloxyphenoxy)phenyl-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine (3.0g, 5.68mmol) was dissolved in absolute ethanol/ethyl acetate

-72-

(100ml, 1/1) in a Parr® bottle. Raney nickel (approximately 1-1.5 tsp.) was added and the mixture hydrogenated at 40psi on a shaker for twenty-two hours. After filtering to remove the catalyst, the filtrate was concentrated in vacuo to provide crude product as a white solid. Recrystallization from hot ethyl acetate/methanol (6/1) provided the title compound (1.9g, 76%). ¹H NMR(400MHz, DMSO-d₆): 4.73(2H,q,J=10.3), 4.88(2H,s), 6.75-6.84(4H,m), 6.85-6.91(2H,m), 7.23-7.29(2H,m), 7.34(1H,dd,J=7.8,4.9), 7.67(1H,m), 8.38(1H,d,J=2.0), 8.45(1H,dd,J=4.9,1.5), 9.4(1H,s); MS(ESI)m/z 439.1([M+H]⁺,100); Anal. Calcd. for C₂₀H₁₇F₃N₂O₄s C,54.79; H,3.91; N,6.39. Found: C,54.72; H,3.85; N,6.32.

15

Preparation 43-(2-Methoxyphenylsulfinyl)aniline

A solution of 3-fluoronitrobenzene (9.50g, 67.3mmol) and 2-methoxythiophenol (7.50g, 53.5mmol) in anhydrous DMF (40mL) under nitrogen was treated with anhydrous potassium carbonate (14g, 101mmol), and heated to 115°C for 18h. The solution was cooled, filtered (solid rinsed with methylene chloride), and the filtrate concentrated exhaustively in vacuo under high vacuum to remove all DMF. The residue was taken up in water and extracted with ether (2X75mL). The combined ether solution was dried (MgSO₄), filtered, the filtrate concentrated in vacuo and the residue chromatographed on silica gel (eluted with 2:1 hexane/methylene chloride) to afford 4.01g (29%) of 2-methoxy-3'-nitrodiphenylsulfide as a viscous orange oil. ¹H NMR: 3.82(3H,s), 6.95-7.00(2H,m), 7.35-7.45(4H,m), 7.95-8.00(2H,m).

30

2-Methoxy-3'-nitrodiphenylsulfide (332mg, 1.27mmol) was taken up in chloroform (1.5ml) and treated with trichloroacetone (250μl, 2.8mmol), followed immediately by

-73-


the addition of aqueous hydrogen peroxide (250 μ l of 30%, 2.4mmol). The reaction was stirred at room temperature for twenty-four hours and then partitioned between methylene chloride and aqueous sodium bisulfite. The organic layer was washed once with brine, dried over magnesium sulfate, filtered and concentrated to an oil. Purification by radial silica gel chromatography (4mm Chromatotron[®] plate, eluting with 2/1 hexanes/ethyl acetate) afforded 1-methoxy-2-(3-nitrophenylsulfinyl)benzene (272mg, 77%) as an oil which crystallized on standing. ¹H NMR(400MHz): 3.89(3H,s), 6.90(1H,d,J=7.3), 7.18(1H,dt,J=7.8,1.0), 7.41-7.47(1H,m), 7.63(1H,t, J=7.8), 7.89(1H,dd,J=7.8,1.4), 8.07-8.12(1H,m), 8.22-8.28(1H,m), 8.61(1H,m,); MS(ESI)m/z 276.8([M-H]⁻,70); Anal. Calcd. for C₁₃H₁₁NO₄S C,56.31; H,4.00; N,5.05. Found: C,56.34; H,4.01; N,5.05.

1-Methoxy-2-(3-nitrophenylsulfinyl)benzene (217mg, 0.78mmol) was dissolved in ethyl alcohol (5.0ml) and water (1.75ml), to which was added iron powder (488mg, 8.7mmol) and ammonium chloride (77mg, 1.4mmol). This mixture was heated to reflux for four hours, cooled to room temperature and the supernatant decanted. The insoluble material was rinsed with methylene chloride, followed by aqueous 1M potassium carbonate. All decanted solutions were combined and the organic layer separated. The aqueous layer was extracted again with methylene chloride, and the combined organics washed once with brine. After drying over magnesium sulfate and concentration in vacuo, the title compound was obtained as a white solid (145mg, 75%). ¹H NMR(400MHz): 3.89(3H,s), 6.69-6.74(1H,m), 6.86(1H,d,J=8.4), 7.03-7.09(2H,m), 7.10-7.20(2H,m), 7.38(1H,dt,J=8.3,1.5), 7.86(1H,dd,J=7.8,1.5).

-74-

Example 340

N-(3-(2-Methoxyphenylsulfinyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylamine



- 5 3-(1-Methoxyphenylsulfinyl)aniline (145mg, 0.59mmol)
and pyridine-3-carboxaldehyde (63mg, 0.59mmol) were reacted
in anhydrous methanol (3.0ml), followed by treatment with
sodium borohydride (44mg, 1.17mmol) as previously described
(Intermediate 3). Silica gel chromatography (2mm
10 Chromatotron® plate, eluting with 20/1 ethyl
acetate/hexanes) afforded N-(3-(2-
methoxyphenylsulfinyl)phenyl)pyrid-3-ylmethylamine (162mg,
82%) as an oil. ¹H NMR(400MHz): 3.77(3H,s), 4.35(2H,br s),
6.61(1H,m), 6.83(1H,d,J=8.0), 6.96(1H,br t), 7.01-
15 7.04(1H,m), 7.11(1H,dt,J=7.8,1.0), 7.18(1H,t,J=7.8), 7.21-
7.28(1H,br s), 7.35-7.41(1H,m), 7.63(1H,br d),
7.82(2H,dd,J=7.8,1.5), 8.40-8.80(2H,br s); MS(ESI)m/z
339.1([M+H]⁺,100)
- 20 N-(3-(2-Methoxyphenylsulfinyl)phenyl)pyrid-3-
ylmethylamine (159mg, 0.44mmol) was taken up in 1,2-
dichloroethane (2.0ml) and anhydrous pyridine (1.0ml) and
cooled under nitrogen to 0°C. Ethanesulfonyl chloride
(103mg, 0.80mmol) is added dropwise via syringe and the
reaction allowed to stir at 0°C for thirty minutes. The ice
25 bath is removed and the mixture stirred 88 hours at room
temperature, as a matter of convenience. Solid potassium
carbonate was added, the reaction stirred an additional
hour, and then filtered and concentrated to a dark oil.
Radial silica gel chromatography (2mm Chromatotron® plate,

-75-

eluting with 20/1 methylene chloride/methanol) afforded the title compound (16mg, 8%). ^1H NMR(400MHz): 1.39(3H,t,J=7.3), 3.04(2H,q,J=7.3), 3.78(3H,s), 4.88(2H,s), 6.86(1H,d,J=7.8), 7.11-7.21(2H,m), 7.25-7.30(1H,m), 7.35(1H,t,J=7.8), 7.42(1H,dt,J=7.3,2.0), 7.56-7.62(2H,m), 7.68(1H,m), 7.81(1H,dd,J=7.3,1.5), 8.31(1H,br s), 8.46(1H,br s); MS(HRMS)m/z 431.1116([M+H]⁺ calcd for C₂₁H₂₃N₂O₄S 431.1099).

Preparation 5

4-(2,4-Difluorophenoxy)aniline

10 1-(2,4-Difluorophenoxy)-4-nitrobenzene

A biphasic mixture of potassium carbonate (304 g, 2.20mol), 1-fluoro-4-nitrobenzene (148mL, 1.40mol) and 2,4-difluorophenol (200g, 1.54mol) in N,N-dimethylformamide (1.0 L) was heated at 90°C under nitrogen for 22 h, after which the mixture was cooled to room temperature. The mixture was poured into water (1.0 L) and was extracted with ethyl acetate (2 x 1.5 L). The combined organic extracts were washed with water (1 x 1.0 L), dried over MgSO₄, filtered and the solvent was removed under reduced pressure to afford the crude product as a yellow semi-solid. This residue was triturated with hexanes (500mL) and gravity filtered, washing with hexanes (2 x 100mL) to provide 1-(2,4-difluorophenoxy)-4-nitrobenzene as off-white crystals (209 g, 60%), mp 58-62°C. ^1H NMR(300 MHz, DMSO-d₆): 7.15(2H,d,J=9.4), 7.27-7.20(1H,m), 7.62-7.48(2H,m), 8.25(2H,d,J=9.4).

A suspension of 1-(2,4-difluorophenoxy)-4-nitrobenzene (209g, 1.17mol) and 10% palladium-on-carbon (20g, 50% wet) in methanol (1.0 L) was shaken under an atmosphere of hydrogen (60psi) at room temperature for 5 h. The mixture was filtered through a plug of Celite® (150g), washing with methanol (2 x 300mL) and the solvent was removed under reduced pressure to afford the crude product as a dark red oil. This residue was triturated with hexanes (500mL) and


-76-

filtered to provide the title compound as a gray solid (175 g, 95%). ^1H NMR (300 MHz, DMSO- d_6): 6.55 (2H, d, $J=8.8$), 6.73 (2H, d, $J=8.8$), 7.02-6.95 (2H, m), 7.40 (1H, t, $J=11.4$).

5

Example 341

N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline



4-(2,4-Difluorophenoxy)aniline (2.21g, 10.0mmol) and
10 pyridine-3-carboxaldehyde (1.12g, 10.5mmol) were dissolved
in anhydrous methanol (35ml) and the solution was heated at
55°C for three hours. The solution was cooled and
concentrated in vacuo to a residual oil, which was
maintained under a 90 μ m Hg vacuum for twenty-four hours. N-
15 (4-(2,4-Difluorophenoxy)phenyl)pyrid-3-ylmethylaniline was
obtained in quantitative yield. ^1H NMR (400MHz): 6.83-
6.90 (1H, m), 6.93-7.00 (3H, m), 7.05-7.13 (1H, m), 7.21-
7.27 (2H, m), 7.40 (1H, dd, $J=8.1, 4.9$), 8.27 (1H, dd, $J=8.1, 1.7$),
8.50 (1H, s), 8.69 (1H, dd, $J=4.9, 1.7$), 9.00 (1H, d, $J=1.7$);
20 MS (ESI) m/z 311.1 ($[M+H]^+$, 100); Anal. Calcd. for $\text{C}_{18}\text{H}_{12}\text{F}_2\text{N}_2\text{O}$
C, 69.67; H, 3.90; N, 9.03. Found: C, 69.28; H, 3.99; N, 8.91.

N-(4-(2,4-Difluorophenoxy)phenyl)pyrid-3-
ylmethylaniline (205mg, 0.66mmol) was taken up in anhydrous
methanol (3.0ml) and was treated, at room temperature, with
25 solid sodium borohydride (50mg, 1.32mmol) in one portion.
There was an initial foaming and mild exotherm to 29 C,
after which the mixture was stirred under ambient conditions
for four hours. Aqueous 1N sodium hydroxide was added and
the mixture extracted four times with methylene chloride.

-77-

The combined organics were washed once with brine, dried over magnesium sulfate and the solvent removed in vacuo to provide N-4-(2,4-difluorophenoxy)phenylpyrid-3-ylmethanamine (200mg, 97%) as a colorless oil which crystallized on standing. ¹H NMR(400MHz): 4.34(2H,s), 6.56-6.62(2H,m), 6.73-6.80(1H,m), 6.82-6.87(2H,m), 6.87-6.94(2H,m), 7.28(1H,dd,J=7.8,2.9), 7.70(1H,ddd,J=7.8,1.5,1.5).

N-4-(2,4-Difluorophenoxy)phenylpyrid-3-ylmethanamine (184mg, 0.59mmol) was stirred in anhydrous acetonitrile (2.0ml) under a nitrogen cover. The solution was treated, via syringe, with anhydrous triethylamine (99μl, 0.71mmol) and then cooled to -8°C. Trifluoroethanesulfonyl chloride (87μl, 0.71mmol) was added neat, dropwise via syringe, at such a rate that the reaction temperature did not exceed -3°C. The mixture was stirred for two hours at -8-(-2)°C and then quenched with 1M potassium carbonate (3.0ml). The upper layer was separated and the aqueous portion extracted three times with ethyl acetate. The combined organics were washed once with saturated sodium chloride, dried over magnesium sulfate and concentrated in vacuo to provide the crude product as a yellow solid. Radial silica gel chromatography (2mm Chromatotron® plate, eluting with 1/1 hexanes/ethyl acetate) provided the title compound (193mg, 71%) as an off-white solid. ¹H NMR(400MHz): 3.81(2H,q,J=9.0), 4.85(2H,s), 6.83-6.92(3H,m), 6.92-6.99(1H,m), 7.06-7.16(3H,m), 7.24-7.31(1H,m), 7.70(1H,ddd,J=9.5,1.7,1.7), 8.33(1H,br s), 8.53(1H,br s); MS(ESI)m/z 454.1([M+H]⁺,100); Anal. Calcd. for C₂₀H₁₅F₅N₂O₃S C,52.40; H,3.30; N,6.11. Found: C,52.13; H,3.28; N,5.99.


-78-

Preparation 6(4-Bromophenyl)pyridin-3-ylmethylamine

A solution of 4-bromoaniline (Aldrich; 1.3 equiv.) in methanol (0.4 M) was treated with 3-pyridinecarboxaldehyde (Aldrich; 1.0 equiv.). The solution was heated to reflux for 2 hours. The reaction was cooled to 0°C and treated slowly with sodium borohydride (3.4 equiv.). After 1 hour the cooling bath was removed and stirring continued overnight. The reaction was concentrated in vacuo. The residue was partitioned between DCM and water. The aqueous phase was back-extracted once with DCM. The combined organics were washed with water and brine. The organic layer was concentrated to a white solid, which was purified via recrystallization from 1.2:4 ethyl acetate/hexanes to give the title compound. Anal Calcd for $C_{12}H_{11}BrN_2 \cdot 0.1H_2O$: C, 54.40; H, 4.26; N, 10.57. Found: C, 54.30; H, 4.12; N, 10.44. MS found 262.84, 264.83 $[M+H]^+$.

Example 342

20 N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



A solution of N-N-(4-bromophenyl)pyridin-3-ylmethylamine the (1.0 equiv.) in pyridine (0.9 M) was treated with the guaiacol (Aldrich) (3.0 (equiv.) and anhydrous potassium carbonate (1.5 equiv.). The reaction was warmed to 90°C then treated with cupric oxide. The mixture was heated to reflux for 48 hours. The reaction was cooled


-79-

and diluted with ethyl acetate. The mixture was extracted with 10% aqueous ethylenediamine (3-6 times), 0.1 M potassium carbonate, and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated. The reaction mixture was purified via preparative HPLC eluting with 70:30 to 60:40 DCM/ethyl acetate to give N-(4-(2-methoxyphenoxy)phenyl)pyridin-3-ylmethylamine. ¹H NMR (400 MHz) 3.88 (3H, s), 4.33 (2H, s), 6.60 (2H, m), 6.79-6.89 (4H, m), 6.95-7.04 (2H, m), 7.23-7.29 (1H, m), 7.70 (1H, m), 8.53 (1H, m), 8.64 (1H, bs). MS found 307.0 [M+H]⁺

A solution of N-(4-(2-methoxyphenoxy)phenyl)pyridin-3-ylmethylamine (1.0 equiv.) in 2:1 DCE/Pyridine (0.15 M) was cooled to 0°C and treated with 2,2,2-trifluoroethanesulfonyl chloride (1.8 equiv.). The mixture was allowed to warm to ambient temperature and stir overnight. The reaction was treated with anhydrous potassium carbonate, stirred for 40 min, and filtered. The filtrate was purified via preparative HPLC eluting with 98:2 to 96:4 DCM/MeOH to give the title compound. Anal Calcd for C₂₁H₁₉F₃N₂O₄S: C, 55.75; H, 4.23; N, 6.19. Found: C, 55.65; H, 4.27; N, 6.19. MS found 453.0 [M+H]⁺

Example 343

N-(4-(3-Benzyloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



A solution of an 3-benzyloxyaniline (1.2 equiv.) in methanol (0.4 M) was treated with 3-pyridinecarboxaldehyde (1.0 equiv.). The solution was heated to reflux for 2.5

-80-


hours. The reaction was cooled to 0°C and treated with sodium borohydride (2.5 equiv.) in 3 portions. The cooling bath was removed and stirring continued for 2 hours. The reaction was concentrated in vacuo. The residue was taken up in DCM and filtered through celite. The filtrate was concentrated in vacuo and purified via preparative HPLC eluting with 85:15 to 70:30 DCM/ethyl acetate to give N-(4-(3-benzyloxyphenyl)pyridin-3-yl)methylamine. Anal Calcd for $C_{19}H_{18}N_2O \cdot 0.1H_2O$: C, 78.11; H, 6.28; N, 9.59. Found: C, 77.86; H, 6.21; N, 9.56. MS found 291.1 (M + H)⁺

A solution of N-(4-(3-benzyloxyphenyl)pyridin-3-yl)methylamine (1.0 equiv.) in 2:1 DCE/Pyridine (0.15 M) was cooled to 0°C and treated with 2,2,2-trifluoroethanesulfonyl chloride (1.8 equiv.). The mixture was allowed to warm to ambient temperature and stir overnight. The reaction was treated with anhydrous potassium carbonate, stirred for 40 min, and filtered. The filtrate was purified via preparative HPLC eluting with 70:30 to 60:40 DCM/ethyl acetate, evaporated, and then triturated with diethyl ether to give the title compound. Anal Calcd for $C_{21}H_{19}F_3N_2O_3S$: C, 57.79; H, 4.39; N, 6.42. Found: C, 57.60; H, 4.47; N, 6.41. ¹H NMR (400 MHz) 3.77 (2H, q, J=9.0 Hz), 4.86 (2H, d), 4.99 (2H, d), 6.82 (2H, m), 6.95 (1H, m), 7.25 (2H, m), 7.34-7.40 (5H, m), 7.67 (1H, td, J=2.0, 8.0 Hz), 8.32 (1H, bs), 8.50 (1H, d, J=4.0 Hz). MS found 437.1 [M+H]⁺

-81-

Example 344


N-(4-(3-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



- 5 To a mixture of 2 N-4-(3-benzyloxyphenoxy)phenyl-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine in ethanol (0.1 M) in a well-purged par bottle was added Raney® Nickel. The catalyst was rinsed into the mixture with ethyl acetate. The reaction was placed under 37 psi of
- 10 hydrogen gas for 5 hours. The contents were filtered through celite and concentrated in vacuo to give the title compound. Anal Calcd for $C_{14}H_{13}F_3N_2O_3S \cdot 0.3H_2O$: C, 47.81; H, 3.90; N, 7.96. Found: C, 47.81; H, 3.80; N, 7.86. 1H NMR (400 MHz) 3.84 (2H, q, $J=9.1$ Hz), 4.88 (2H, s), 6.68 (1H, m), 6.72-6.78 (2H, m), 7.19 (1H, t, $J=8.2$ Hz), 7.34 (1H, dd, $J=5.1, 7.9$ Hz), 7.75 (1H, d, $J=7.6$ Hz), 8.30 (1H, s), 8.46 (1H, d, $J=3.9$ Hz). MS found 347 $[M]^+$
- 15

Example 345

20 N-(4-t-Butyldimethylsilyloxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



To a mixture of 4-aminophenol (Aldrich; 1.0 equiv.) in benzene (1 M) was added 3-pyridenecarboxaldehyde (Aldrich;

-82-

1.0 equiv.). The flask was fitted with a Dean-Stark trap and heated to reflux overnight. (A solid mass formed on the bottom of the flask, which was difficult to break up). The reaction was cooled to ambient and concentrated in vacuo.

5 The solid was taken up in methanol (0.2 M), cooled to 0°C, and treated with sodium borohydride (1.5 equiv.) in 4 portions. The cooling bath was removed and stirring continued for 2 hours. A small amount of was added to quench unreacted hydride. The reaction was concentrated in

10 vacuo. The residue was partitioned between ethyl acetate and water. The aqueous layer was back-extracted with ethyl acetate. The combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude solid was recrystallized from hexanes/ethyl acetate to

15 give N-(4-hydroxyphenyl)pyridin-3-ylmethanamine. ¹H NMR (400 MHz, DMSO d₆) 4.16 (2H, s), 6.41 (2H, m), 6.48 (2H, m), 7.28 (1H, ddd, J=0.73, 4.8, 7.7 Hz), 7.7 (1H, td, J=2.2, 7.3 Hz), 8.38 (1H, m), 8.39 (1H, s), 8.52 (1H, d, J=1.5 Hz).

Alternately, a solution of 4-aminophenol (1.0 equiv.)

20 (Aldrich) in 2:1 methanol/ethanol was treated with 3-pyridinecarboxaldehyde (1.05 equiv.). The solution was allowed to stir for 1 hour. The reaction was cooled to 0°C and treated with sodium borohydride (4.2 equiv.) in 5 portions. The cooling bath was removed and stirring

25 continued for 20 hours. The reaction mixture was concentrated in vacuo. The residue was mixed with 1M HCl, warmed, and partitioned between ethyl acetate and 0.1M K₂CO₃. The pH of the aqueous phase was adjusted to pH=7 (using 1M HCl and 1M K₂CO₃) and the product extracted 4-6

30 times with ethyl acetate. The organic phases were combined, washed with brine, dried over anhydrous MgSO₄, and concentrated to afford N-(4-hydroxyphenyl)pyridin-3-ylmethanamine. ¹H NMR (400 MHz, DMSO-d₆): d 4.18 (2H, s),


-83-

5.65 (1H, s), 6.41-6.53 (4H, m), 7.29-7.32 (1H, m), 7.70-7.72 (1H, m), 8.39-8.40 (2H, m), 8.53-8.54 (1H, m).
MS Found 201.2 [M+H]⁺.

A solution of N-(4-hydroxyphenyl)pyridin-3-ylmethanamine (1.0 equiv.) in THF (0.1 M) was cooled to 0°C and treated with imidazole (1.0 equiv.) and t-butyldimethylsilyl chloride (1.1 equiv.). The reaction was warmed to ambient temperature and stirred overnight. The THF was removed in vacuo. The residue was dissolved in ethyl acetate and washed with 0.1 N HCl, saturated aqueous NaHCO₃, water, and brine. The residue was purified via preparative HPLC eluting with 80:20 to 68:32 DCM/ethyl acetate to give N-(4-(t-butyldimethylsilyloxy)phenyl)pyridin-3-ylmethanamine. Anal Calcd for C₁₈H₂₆N₂OSi: C, 68.74; H, 8.33; N, 8.91. Found: C, 68.62; H, 8.28; N, 8.74. ¹H NMR (400 MHz) 0.15 (6H, s), 0.96 (9H, s), 3.77 (1H, bs), 4.30 (2H, s), 6.53 (2H, m), 6.70 (2H, m), 7.26 (1H, m), 7.70 (1H, td, J=1.9, 7.7 Hz), 8.53 (1H, dd, J=1.4, 4.6 Hz), 8.62 (1H, d, J=1.6 Hz). MS found 315.2 [M+H]⁺.

Following the procedure of Example 342 using N-(4-(t-butyldimethylsilyloxy)phenyl)pyridin-3-ylmethanamine and ethanesulfonyl chloride (Aldrich) and purifying via preparative HPLC eluting with 90:10 to 82:18 DCM/ethyl acetate gave the title compound. Anal Calcd for C₂₀H₃₀N₂O₃SSi: C, 59.08; H, 7.43; N, 6.89. Found: C, 58.87; H, 7.11; N, 6.85. MS found 407.2 [M+H]⁺.


-84-

Example 346N-(4-Hydroxyphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

A mixture of N-((4-t-butyldimethylsilyloxy)phenyl)-N-
5 (ethanesulfonyl)pyrid-3-ylmethylamine 4-aminophenol was
added THF (0.5 M), water (0.5 M), and acetic acid (0.16 M)
was heated to reflux for 3 days. The reaction was cooled to
ambient temperature and concentrated in vacuo. The
resultant solid was recrystallized from ethyl acetate to
10 give the title compound. Anal Calcd for $C_{14}H_{16}N_2O_3S$: C, 57.52;
H, 5.52; N, 9.58. Found: C, 57.25; H, 5.50; N, 9.48. MS
found 293.1 $[M+H]^+$

Example 347

15 N-(4-t-Butyldimethylsilyloxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



Following the procedure of Example 342 using N-(4-(t-
butyldimethylsilyloxy)phenyl)pyridin-3-ylmethylamine and
20 2,2,2-trifluoroethanesulfonyl chloride (Aldrich) and
purifying via preparative HPLC eluting with 92:8 to 86:14
DCM/ethyl acetate gave the title compound. Anal Calcd for
 $C_{20}H_{27}F_3N_2O_3SSi$: C, 52.15; H, 5.91; N, 6.08. Found: C, 52.10;
H, 5.80; N, 6.01. 1H NMR (400 MHz) 0.18 (6H, s), 0.96 (9H,


-85-

s), 3.80 (2H, q, J=9.2 Hz), 4.83, (2H, s), 6.77 (2H, m), 7.04 (2H, m), 7.24 (1H, dd, J=4.5, 7.4 Hz), 7.66 (1H, td, J=1.8, 8.0 Hz), 8.33 (1H, d, J=1.8 Hz), 8.51 (1H, dd, J=1.5, 4.8 Hz). MS found 461.1 [M+H]⁺

5

Example 348

N-(4-Hydroxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine




10 To N-(4-t-butyldimethylsilyloxy)phenyl-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine was added THF (0.5 M), water (0.5 M), and acetic acid (0.16 M). The solution was heated to reflux for 3 days. The reaction was cooled to ambient temperature and concentrated in vacuo.

15 The resultant solid was recrystallized from ethyl acetate to give the title compound. ¹H NMR (400 MHz) 3.82 (2H, q, J=8.8 Hz), 4.84 (2H, s), 6.73 (2H, m), 6.99 (2H, m), 7.43 (1H, dd, J=5.4, 7.3 Hz), 7.91 (1H, m), 8.22 (1H, bs), 8.52 (1H, m).

20

Example 349

N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine




-86-

- Using the method of Example 343 using 4-phenoxyaniline (Aldrich) and 3-pyridinecarboxaldehyde (Aldrich) and purifying via preparative HPLC eluting with 95:5 to 60:40 DCM/ethyl acetate gave N-(4-phenoxyphenyl)pyridin-3-ylmethylamine. Anal Calcd for $C_{18}H_{16}N_2O$: C, 78.24; H, 5.84; N, 10.14. Found: C, 78.19; H, 5.67; N, 10.03. 1H NMR (400 MHz, DMSO) 4.00 (1H, bt), 4.35 (2H, d, $J=5.1$ Hz), 6.62 (2H, m), 6.89-6.93 (4H, m), 6.99-7.03 (1H, m), 7.25-7.30 (3H, m), 7.71 (1H, m), 8.54 (1H, dd, $J=1.8, 4.8$ Hz), 8.64 (1H, d, $J=1.8$ Hz). MS found 277.0 $[M+H]^+$

- Using the method of Example 343 using N-(4-phenoxyphenyl)pyridin-3-ylmethylamine and 2,2,2-trifluoroethanesulfonyl chloride (Aldrich) and purifying via preparative HPLC eluting with 90:10 to 70:30 DCM/ethyl acetate gave the title compound. Anal Calcd for $C_{20}H_{17}F_3N_2O_3S$: C, 56.87; H, 4.06; N, 6.63. Found: C, 56.76; H, 4.09; N, 6.69. MS found 423.1 $[M+H]^+$

Example 350

- 20 N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-1-oxypyrid-3-ylmethylamine



- A solution of N-(4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-1-oxypyrid-3-ylmethylamine (1.0 equiv.) in DCM (0.1 M) was treated with mCPBA (55%; 1.1 equiv.; Lancaster). The resulting mixture was stirred at ambient temperature for 3 hours. The reaction was diluted with DCM, washed with saturated aqueous $NaHCO_3$, and brine. The organic layer was dried over sodium sulfate, filtered,


-87-

and concentrated. The residue was purified via preparative HPLC eluting with 96:4 DCM/MeOH to give the title compound. Anal Calcd for $C_{20}H_{17}F_3N_2O_4S$: C, 54.79; H, 3.91; N, 6.39. Found: C, 54.68; H, 3.78; N, 6.30. MS found 439.0 $[M+H]^+$

5

Example 351

N-(4-(2-Cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine




- 10 A solution of N-(4-hydroxyphenoxyphenyl)pyridin-3-ylmethylamine (1.0 equiv.) in DMF (0.15 M) was treated with sodium hydride (1.2 equiv.; as a 60% dispersion in oil). After stirring for 40 min., 2-fluorobenzonitrile (Aldrich; 1.7 equiv.) was added. After 2 hours the reddish reaction
- 15 was diluted with ethyl acetate and washed with 0.25 M phosphate buffer, water, and brine. The organic phase was dried over Na_2SO_4 , filtered, and concentrated. The oil was purified via radial chromatography eluting with 70:30 to
- 20 50:50 DCM/ethyl acetate to give N-(4-(2-cyanophenoxy)phenyl)pyridin-3-ylmethylamine. Anal Calcd for $C_{19}H_{15}N_3O \cdot 0.2H_2O$: C, 74.83; H, 5.09; N, 13.78. Found: C, 74.86; H, 4.99; N, 13.97. 1H NMR (400 MHz) 4.10 (1H, bs), 4.38 (2H, s), 6.64 (2H, m), 6.77 (1H, d, $J=8.3$ Hz), 6.94 (2H, m), 7.04 (1H, t, $J=7.3$ Hz), 7.30 (1H, dd, $J=4.9$, 7.8 Hz), 7.41 (1H, m), 7.61 (1H, dd, $J=1.5$, 7.3 Hz), 7.72 (1H, d, $J=7.8$ Hz), 8.55 (1H, d, $J=3.4$ Hz), 8.65 (1H, d, $J=1.5$ Hz). MS found 302.1 $[M+H]^+$
- 25

-88-

Using the method of Example 342 using N-(4-(2-cyanophenoxy)phenyl)pyridin-3-ylmethanamine and 2,2,2-trifluoroethanesulfonyl chloride (Aldrich) and purifying via preparative HPLC eluting with 90:10 to 78:22 DCM/ethyl acetate gave the title compound. Anal Calcd for $C_{21}H_{16}F_3N_3O_3S$ • 0.2H₂O: C, 55.92; H, 3.67; N, 9.32. Found: C, 55.77; H, 3.51; N, 9.18. MS found 447.8 [M+H]⁺

Example 352

10 N-(4-(2-Cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyridin-3-ylmethanamine




Using the method of Example 342 using N-(4-(2-cyanophenoxy)phenyl)pyridin-3-ylmethanamine and ethanesulfonyl chloride (Aldrich) and purifying via preparative HPLC eluting with 98:2 to 96:4 DCM/MeOH. Anal Calcd for $C_{21}H_{19}N_3O_3S$ • 0.2H₂O: C, 63.52; H, 4.92; N, 10.58. Found: C, 63.51; H, 4.79; N, 10.55. MS found 394.0 [M+H]⁺

-89-

Example 353

N-(3-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine



5 A solution of 3-bromoaniline (Aldrich; 1.3 equiv.) in methanol (0.4 M) was treated with 3-pyridinecarboxaldehyde (Aldrich; 1.0 equiv.). The solution was heated to reflux for 2 hours. The reaction was cooled to 0°C and treated slowly with sodium borohydride (3.4 equiv.). After 1 hour
10 the cooling bath was removed and stirring continued overnight. The reaction was concentrated in vacuo. The residue was partitioned between DCM and water. The aqueous phase was back-extracted once with DCM. The combined organics were washed with water and brine. The organic
15 layer was concentrated to a white solid, which was purified via column chromatography eluting with 90:10 DCM/ethyl acetate to give N-(3-bromophenyl)pyridin-3-ylmethylamine. Anal Calcd for $C_{12}H_{11}BrN_2$: C, 54.77; H, 4.21; N, 10.64. Found: C, 54.67; H, 4.19; N, 10.57. MS found 262.99, 264.99
20 $[M+H]^+$

Using the method of Example 342 using N-(3-bromophenyl)pyridin-3-ylmethylamine and guaiacol (Aldrich) and purifying via preparative HPLC eluting with 1:1 DCM/ethyl acetate gave N-(3-(2-Methoxyphenoxy)phenyl)pyrid-
25 3-ylmethylamine. Anal Calcd for $C_{19}H_{18}N_2O_2 \cdot 0.5H_2O$: C, 72.36; H, 6.07; N, 8.88. Found: C, 72.43; H, 5.80; N, 8.96. MS found 307.2 $[M+H]^+$

Using the method of Example 342 using N-(3-(2-methoxyphenoxy)phenyl)pyridin-3-ylmethylamine and ethanesulfonyl


-90-

chloride (Aldrich) and purifying via preparative HPLC eluting with 98:2 to 96:4 DCM/MeOH gave the title compound. Anal Calcd for $C_{21}H_{22}N_2O_4S$: C, 63.30; H, 5.56; N, 7.03. Found: C, 63.16; H, 5.51; N, 6.64. MS found 398.9 $[M+H]^+$

5

Example 354

N-(3-(2-phenylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine




10 Using the procedure of Example 342 using N-(3-bromophenyl)pyridin-3-ylmethylamine and 2-phenylphenol (Aldrich) and purifying via preparative HPLC eluting with 90:10 to 80:20 DCM/ethyl acetate gave N-(3-(2-phenylphenoxy)phenyl)pyrid-3-ylmethylamine. Anal Calcd for

15 $C_{24}H_{20}N_2O \cdot 0.2H_2O$: C, 80.96; H, 5.78; N, 7.87. Found: C, 81.07; H, 5.73; N, 7.63. MS found 353.1 $[M+H]^+$


Using the procedure of Example 342 using N-(3-(2-phenylphenoxy)phenyl)pyrid-3-ylmethylamine and ethanesulfonyl chloride (Aldrich) and purifying via

20 preparative HPLC eluting with 99:1 to 97:3 DCM/MeOH gave the title compound. Anal Calcd for $C_{26}H_{24}N_2O_3S$: C, 70.25; H, 5.44; N, 6.30. Found: C, 70.13; H, 5.39; N, 6.26. MS found 445.1 $[M+H]^+$

-91-

Example 355N-(4-Bromophenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine

Using the procedure of Example 343 using N-(4-bromophenyl)pyridin-3-ylmethanamine and ethanesulfonyl chloride (Aldrich) and purifying via preparative HPLC eluting with 90:10 to 70:30 DCM/ethyl acetate gave the title compound. Anal Calcd for $C_{14}H_{15}BrN_2O_2S$: C, 47.33; H, 4.26; N, 7.88. Found: C, 47.24; H, 4.23; N, 7.79. MS found 354.0, 355.9 FD.

Example 356N-(4-(2-Fluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine

15

Using the method of Example 342 using N-(4-bromophenyl)pyridin-3-ylmethanamine and 2-fluorophenol (Aldrich) and purifying via preparative HPLC eluting with 90:10 to 80:20 DCM/ethyl acetate gave N-(4-(2-fluorophenoxy)phenyl)pyrid-3-ylmethanamine. Anal Calcd for $C_{18}H_{15}FN_2O$: C, 73.45; H, 5.14; N, 9.52. Found: C, 73.36; H, 5.22; N, 9.35. MS found 295.1 $[M+H]^+$


-92-

Using the method of Example 342 using N-(4-(2-fluorophenoxy)phenyl)pyrid-3-ylmethylamine and ethanesulfonyl chloride (Aldrich) and purifying via preparative HPLC eluting with 99:1 to 97:3 DCM/MeOH gave the


5 title compound. Anal Calcd for $C_{20}H_{19}FN_2O_3S \cdot 0.2H_2O$: C, 61.59; H, 5.01; N, 7.18. Found: C, 61.65; H, 4.85; N, 7.14. MS found 387.1 [M+H]⁺

By the method of Example 356 the following compounds

10 were prepared and purified by preparative HPLC:




No.	R _{1'}	R ₂	Data
357	H	3-fluoro	Anal Calcd for $C_{18}H_{15}FN_2O \cdot 0.4H_2O$: C, 71.70; H, 5.28; N, 9.29. Found: C, 71.87; H, 5.04; N, 9.47. MS found 295.1 [M+H] ⁺
358	SO ₂ CH ₂ CH ₃	3-fluoro	Anal Calcd for $C_{20}H_{19}FN_2O_3S$: C, 62.16; H, 4.96; N, 7.25. Found: C, 61.91; H, 4.95; N, 7.24. MS found 387.1 [M+H] ⁺
359	H	4-fluoro	Anal Calcd for $C_{18}H_{15}FN_2O$: C, 73.45; H, 5.14; N, 9.52. Found: C, 73.23; H, 5.10; N, 9.32. MS found 295.1 [M+H] ⁺
360	SO ₂ CH ₂ CH ₃	4-fluoro	Anal Calcd for $C_{20}H_{19}FN_2O_3S$: C, 62.16; H, 4.96; N, 7.25. Found: C, 62.18; H, 4.98; N, 7.15. MS found 387.2 [M+H] ⁺

Example 361N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

- 5 Using the method of Example 342 using N-(4-Bromophenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine and 2,4-difluorophenol and purifying via reverse phase chromatography affording the HCl salt. Anal Calcd for $C_{20}H_{18}F_2N_2O_3S \cdot 1.2HCl$: C, 53.60; H, 4.32; N, 6.25. Found: C, 53.55; H, 4.18; N, 6.23. MS found 405.1 [M+H]⁺

By the method of Example 342 the following compounds were prepared and purified via reverse phase chromatography affording the HCl salt, except where noted:



No.	Rc	Data
362	2-trifluoromethoxy	Anal Calcd for $C_{21}H_{19}F_3N_2O_4S \cdot 1.2HCl$: C, 50.83; H, 4.10; N, 5.65. Found: C, 50.66; H, 3.79; N, 5.62. MS found 453.0 [M+H] ⁺
363	4-trifluoromethoxy	Anal Calcd for $C_{21}H_{19}F_3N_2O_4S$: C, 55.75; H, 4.23; N, 6.19. Found: C, 55.60; H, 4.26; N, 6.16. MS found 453.1 [M+H] ⁺ (analysis on free-base)
364	4-fluoro-2-methyl	Anal Calcd for $C_{21}H_{21}FN_2O_3S$: C, 62.98; H, 5.28; N, 7.00. Found: C, 62.76; H, 5.28; N, 6.95. MS found 401.1 [M+H] ⁺ (analysis on free-base)
365	2,4-dimethyl	Anal Calcd for $C_{22}H_{24}N_2O_3S \cdot H_2O \cdot HCl$: C, 58.59; H, 6.03; N, 6.21. Found: C, 58.34; H, 5.67; N, 6.23. MS found


		397.0 [M+H] ⁺
366	4-methyl	Anal Calcd for C ₂₁ H ₂₂ N ₂ O ₃ S•0.5H ₂ O: C, 64.43; H, 5.92; N, 7.16. Found: C, 64.19; H, 5.52; N, 7.03. HRMS calculated 383.1429 [M+H] ⁺ Found 383.1428 (analysis on free-base)
367	4-isopropyl	Anal Calcd for C ₂₃ H ₂₆ N ₂ O ₃ S•0.1H ₂ O: C, 67.00; H, 6.40; N, 6.79. Found: C, 66.87; H, 6.27; N, 6.78. MS found 411.1 [M+H] ⁺ (analysis on free-base)
368	4-t-butyl	Anal Calcd for C ₂₄ H ₂₈ N ₂ O ₃ S: C, 67.90; H, 6.65; N, 6.60. Found: C, 68.02; H, 6.63; N, 6.57. MS found 425.1 [M+H] ⁺ (analysis on free-base)
369	2-methyl	Anal Calcd for C ₂₁ H ₂₂ N ₂ O ₃ S•0.3H ₂ O: C, 65.03; H, 5.87; N, 7.22. Found: C, 64.94; H, 5.73; N, 7.14. MS found 383.1 [M+H] ⁺ (analysis on free-base)
370	2-C(O)NH ₂	Anal Calcd for C ₂₁ H ₂₁ N ₃ O ₄ S: C, 61.30; H, 5.14; N, 10.21. Found: C, 61.16; H, 4.89; N, 9.95. MS found 412.1 [M+H] ⁺ (analysis on free-base)
372	2-S(O)CH ₃	Anal Calcd for C ₂₁ H ₂₂ N ₂ O ₄ S ₂ •0.5H ₂ O: C, 57.38; H, 5.27; N, 6.37. Found: C, 57.31; H, 5.32; N, 5.98. MS found 431.1 [M+H] ⁺ (purified by radial chromatography eluting with 60:40 to 90:10 THF/hexanes)
373	4-t-butyl-2-fluoro	Anal Calcd for C ₂₄ H ₂₇ FN ₂ O ₃ S•0.2H ₂ O: C, 64.61; H, 6.19; N, 6.28. Found: C, 64.28; H, 5.83; N, 6.19. MS found 443.3 [M+H] ⁺ (purified via radial chromatography eluting with 50:50 to 70:30 THF/hexanes)
374	4-fluoro-2-n-propyl	¹ H NMR (400 MHz) 0.89 (3H, t, J=7.3 Hz), 1.44 (3H, t, J=7.3 Hz), 1.56 (2H, sextet, J=7.8 Hz), 2.48 (2H, t, J=7.8 Hz), 3.10 (2H, q, J=7.3 Hz), 4.85 (2H, s), 6.78 (2H, m), 6.85 (2H, m), 6.94 (1H, m), 7.13 (2H, m), 7.32 (1H, bs), 7.79 (1H, d, J=7.8 Hz), 8.4 (1H, bs), 8.55 (1H, bs). HRMS calculated 429.1648 [M+H] ⁺ Found 429.1656 (analysis of free-base)
375	4-C(O)OCH ₃	¹ H NMR (400 MHz, DMSO-d ₆) 1.28 (3H, t, J=7.3 Hz), 3.26 (2H, q, J=7.3 Hz), 3.80 (3H, s), 4.96 (2H, s), 7.00-7.05 (4H, m), 7.40 (2H, m), 7.56 (1H, bs), 7.86 (1H, d, J=7.8 Hz), 7.93 (2H, m), 2 protons alpha to the pyridyl N broadened into the baseline. HRMS calculated 427.1328 [M+H] ⁺ Found 427.1338
376	4-CH ₂ C(O)NH ₂	Anal Calcd for C ₂₂ H ₂₃ N ₃ O ₄ S: C, 53.40; H, 5.07; N, 8.49. Found: C, 53.50; H, 4.90; N, 8.46. MS found 426.0 [M+H] ⁺ (analysis on free-base)
377	3-t-butyl	Anal Calcd for C ₂₄ H ₂₈ N ₂ O ₃ S: C, 67.90; H, 6.65; N, 6.60. Found: C, 68.02; H, 6.34; N, 6.49. MS found 425.1 [M+H] ⁺ purified by radial chromatography eluting with 50:50 hexanes/THF)
378	2-methoxy	Anal Calcd for C ₂₁ H ₂₂ N ₂ O ₄ S: C, 63.30; H, 5.56; N, 7.03. Found: C, 63.25; H, 5.59; N, 7.02. MS found 399.1 [M+H] ⁺ (purified via radial chromatography eluting with 50:50

-95-

		hexanes/THF)
379	3-methyl	Anal Calcd for $C_{21}H_{22}N_2O_3S$: C, 65.95; H, 5.80; N, 7.32. Found: C, 65.55; H, 5.64; N, 7.21. MS found 383.1 [M+H] ⁺ (analysis on free-base)
380	2-chloro	Anal Calcd for $C_{20}H_{19}ClN_2O_3S$: C, 59.62; H, 4.75; N, 6.95. Found: C, 59.63; H, 4.61; N, 6.88. MS found 403.1 [M+H] ⁺ (purified via radial chromatography eluting with 60:40 to 50:50 hexanes/THF)
381	4-C(O)HN ₂	Anal Calcd for $C_{21}H_{21}N_3O_4S \cdot 1.1HCl \cdot 1H_2O$: C, 53.71; H, 5.17; N, 8.95. Found: C, 53.65; H, 4.79; N, 8.39. MS found 412.1 [M+H] ⁺
382	2-methyl	Anal Calcd for $C_{21}H_{22}N_2O_3S \cdot 0.3H_2O$: C, 65.03; H, 5.87; N, 7.22. Found: C, 64.94; H, 5.73; N, 7.14. MS found 383.1 [M+H] ⁺ . (isolated as the free-base)
383	4-S(O) ₂ CH ₃	Anal Calcd for $C_{21}H_{22}N_2O_5S_2$: C, 56.48; H, 4.96; N, 6.27. Found: C, 56.33; H, 5.03; N, 6.20. MS found 447.1 [M+H] ⁺ (purified via radial chromatography eluting with 50:50 to 70:30 THF/hexanes)
384	2-(prop-2-yl)	Anal Calcd for $C_{23}H_{26}N_2O_3S$: C, 67.29; H, 6.38; N, 6.82. Found: C, 66.91; H, 6.30; N, 6.68. MS found 411.2 [M+H] ⁺ (purified via normal phase radial chromatography eluting with 1:1 THF/hexanes)
385	2-ethyl	Anal Calcd for $C_{22}H_{24}N_2O_3S$: C, 66.64; H, 6.10; N, 7.07. Found: C, 66.49; H, 6.02; N, 6.87. MS found 397.2 [M+H] ⁺ (purified via flash chromatography eluting with 1:1 ethyl acetate/hexanes to 100% ethyl acetate)
386	4-S(O) ₂ NH ₂	Anal Calcd for $C_{20}H_{21}N_3O_5S_2$: C, 53.68; H, 4.73; N, 9.39. Found: C, 53.29; H, 4.70; N, 9.29. MS found 448.1 [M+H] ⁺ (purified via normal phase radial chromatography eluting with 5% (methanol/7M ammonia)/dichloromethane)

Example 387

N- (4- (2,4-Difluorophenoxy) phenyl) -N- (ethanesulfonyl) -1-
pyrid-3-ylethylamine



-96-


A solution of N-(4-(2,4-difluorophenoxy)phenyl)amine (1.0 equiv.) in dichloromethane (0.2 M) was cooled to 0°C and treated with 3-acetylpyridine (Aldrich; 1.4 equiv.), acetic acid (5.0 equiv.), and sodium triacetoxyborohydride (2.5 equiv.). The reaction was allowed to warm to ambient temperature and stirred an additional 22 hours. The reaction was cautiously quenched with saturated aqueous NaHCO₃ then adjusted to pH=10 with 1 N NaOH. The mixture was stirred for 4 hours then the layers were separated. The aqueous layer was extracted twice with DCM. The combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude material was purified via radial chromatography eluting with 50:50 to 60:40 ethyl acetate/hexanes to give N-(4-(2,4-difluorophenoxy)phenyl)-1-pyrid-3-ylethylamine. ¹H NMR (400 MHz) 1.54 (3H, d, J=6.7 Hz), 3.96 (1H, bs), 4.48 (1H, q, J=6.7 Hz), 6.44 (2H, m), 6.76 (2H, m), 6.83-6.93 (2H, m), 7.24 (1H, m), 7.44 (1H, m), 7.68 (1H, td, J=1.8, 7.9 Hz), 8.50 (1H, d, J=3.8 Hz), 8.64 (1H, bs). HRMS calcd 327.1309. Found 327.1308.

Using the method of Example 342 using N-(4-(2,4-difluorophenoxy)phenyl)-1-pyrid-3-ylethylamine and 2,2,2-trifluoroethanesulfonyl chloride and purifying via radial chromatography eluting with 95:5 to 85:15 CHCl₃/ethyl acetate gave the title compound. Anal Calcd for C₂₁H₁₇F₅N₂O₃S•0.2H₂O: C, 52.98; H, 3.68; N, 5.89. Found: C, 52.88; H, 3.73; N, 5.67. MS found 473.1 [M+H]⁺

-97-

Example 388

N-((3-Benzyloxyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




5 Using the method of Example 342 using (3-benzyloxy-phenyl)pyridin-3-ylmethylamine and ethanesulfonyl chloride and purifying via preparative HPLC eluting with 90:10 to 75:25 DCM/ethyl acetate gave, after trituration with diethyl ether, the title compound. Anal Calcd for $C_{21}H_{22}N_2O_3S$: C, 10 65.95; H, 5.80; N, 7.32. Found: C, 65.85; H, 5.75; N, 7.38. MS found 383.1 [M+H]⁺

Preparation 7

2-(3-Hydroxy-3-methyl)butyl-4-fluorophenol


15 A solution of 6-fluoro-2,2-dimethyl-chroman-4-one (EP 193493; 1 equiv.) in ethanol (0.24 M) was treated with copper chromite (0.6 equiv.). The reaction was heated to 200°C for 6 hours at 3000 psi of hydrogen gas. The reaction was filtered and concentrated to a solid. The crude 20 material was recrystallized from hot hexanes to give the title compound. MS found 198 [M+H]⁺

-98-

Example 389N-(3-(Bromophenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine

Using the method of Example 342 using (3-bromophenyl)pyridin-3-ylmethylamine and ethanesulfonyl chloride and purifying via preparative HPLC eluting with 90:10 to 70:30 DCM/ethyl acetate gave the title compound. Anal Calcd for $C_{14}H_{15}BrN_2O_2S$: C, 47.33; H, 4.26; N, 7.88. Found: C, 47.07; H, 4.05; N, 7.67. MS found 354.9, 356.9 [M+H]⁺.

By the method of Example 342 using N-(3-(bromophenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine the following compounds were prepared and purified via reverse phase chromatography and isolated as the free-base, except where noted:



No.	Rc	Data
390	2-fluoro	Anal Calcd for $C_{20}H_{19}FN_2O_3S$: C, 62.16; H, 4.96; N, 7.25. Found: C, 61.85; H, 4.92; N, 7.02. MS found 387.1 [M+H] ⁺
391	3-fluoro	Anal Calcd for $C_{20}H_{19}FN_2O_3S$: C, 62.16; H, 4.96; N, 7.25. Found: C, 61.84; H, 5.00; N, 7.13. MS found 387.1 [M+H] ⁺
392	4-fluoro	Anal Calcd for $C_{20}H_{19}FN_2O_3S$: C, 62.16; H, 4.96; N, 7.25. Found: C, 62.02; H, 4.70; N, 7.23. MS found 387.1 [M+H] ⁺
393	2, 4-difluoro	Anal Calcd for $C_{20}H_{17}F_3N_2O_3S$: C, 56.87; H, 4.06; N, 6.63. Found: C, 56.93; H, 4.00; N, 6.43. MS found 423.0 [M+H] ⁺
394	2-ethoxy	Anal Calcd for $C_{22}H_{24}N_2O_4S$: C, 64.06; H, 5.86; N, 6.79. Found: C, 64.10; H, 5.61; N, 6.75. MS found 413.0 [M+H] ⁺

395	2-phenyl	Anal Calcd for $C_{26}H_{24}N_2O_3S$: C, 70.25; H, 5.44; N, 6.30. Found: C, 70.43; H, 5.35; N, 6.18. MS found 445.1 [M+H] ⁺
396	4-trifluoro methoxy	Anal Calcd for $C_{21}H_{19}F_3N_2O_4S$: C, 55.75; H, 4.23; N, 6.19. Found: C, 55.46; H, 4.20; N, 6.10. MS found 453.0 [M+H] ⁺
397	4-methyl	¹ H NMR (400 MHz) 1.42 (3H, t, J=7.3 Hz), 2.34 (3H, s), 3.10 (2H, q, J=7.3 Hz), 4.85 (2H, s), 6.83 (4H, m), 6.95 (1H, m), 7.13 (2H, m), 7.23 (2H, m), 7.70 (1H, d, J=7.8 Hz), 8.37 (1H, bs), 8.51 (1H, bs). HRMS calculated 383.1429 [M+H] ⁺ Found 383.1426.
398	2-methyl-4-fluoro	¹ H NMR (400 MHz) 1.42 (3H, t, J=7.3 Hz), 2.09 (3H, s), 3.11 (2H, q, J=7.3 Hz), 4.84 (2H, s), 6.68-6.95 (6H, m), 7.22 (2H, m), 7.69 (1H, d, J=7.8 Hz), 8.33 (1H, bs), 8.51 (1H, bs). HRMS calculated 401.1335 [M+H] ⁺ Found 401.1327.
399	2-trifluoro methoxy	Anal Calcd for $C_{21}H_{19}F_3N_2O_4S$: C, 55.75; H, 4.23; N, 6.19. Found: C, 55.60; H, 4.12; N, 6.05. MS found 453.1 [M+H] ⁺
400	4-CH ₂ C(O)NH ₂	Anal Calcd for $C_{22}H_{23}N_3O_4S \cdot 0.5H_2O$: C, 60.81; H, 5.27; N, 9.67. Found: C, 60.69; H, 5.27; N, 9.48. MS found 426.1 [M+H] ⁺
401	4-C(O)NH ₂	Anal Calcd for $C_{21}H_{21}N_3O_4S \cdot 2.1HCl \cdot 1.1H_2O$: C, 49.66; H, 5.02; N, 8.27. Found: C, 49.67; H, 4.92; N, 8.11. MS found 412.1 [M+H] ⁺ (isolated as the HCl salt)
402	4-S(O) ₂ CH ₃	Anal Calcd for $C_{21}H_{22}N_2O_5S_2 \cdot 0.2H_2O$: C, 56.03; H, 5.02; N, 6.22. Found: C, 56.02; H, 4.78; N, 6.12. MS found 447.1 [M+H] ⁺ (purified via radial chromatography eluting with 50:50 to 70:30 THF/hexanes)
403	2-S(O)CH ₃	Anal Calcd for $C_{21}H_{22}N_2O_4S_2 \cdot 0.4H_2O$: C, 57.62; H, 5.25; N, 6.40. Found: C, 57.62; H, 5.25; N, 6.24. HRMS calculated 431.1099 [M+H] ⁺ Found 431.1114 (purified via radial chromatography eluting with 50:50 to 70:30 THF/hexanes)
404	4-t-butyl	¹ H NMR (400 MHz) 1.33 (9H, s), 1.42 (3H, t, J=7.8 Hz), 3.11 (2H, q, J=7.8 Hz), 4.87 (2H, s), 6.83-6.97 (5H, m), 7.22-7.36 (4H, m), 7.76 (1H, d, J=7.8 Hz), 8.38 (1H, bs), 8.53 (1H, bs). HRMS calculated 425.1899 [M+H] ⁺ Found 425.1906 (purified via radial chromatography eluting with 50:50 hexanes/THF)
405	3-methyl	Anal Calcd for $C_{21}H_{22}N_2O_3S$: C, 65.95; H, 5.80; N, 7.32. Found: C, 66.09; H, 5.86; N, 7.29. MS found 383.1 [M+H] ⁺
406	2-n-propyl-4-fluoro	Anal Calcd for $C_{23}H_{25}FN_2O_3S$: C, 64.47; H, 5.88; N, 6.54. Found: C, 64.31; H, 5.79; N, 6.45. MS found 429.1 [M+H] ⁺
407	2-chloro	¹ H NMR (400 MHz) 1.42 (3H, t, J=7.3 Hz), 3.11 (2H, q, J=7.3 Hz), 4.86 (2H, s), 6.8-6.92 (3H, m), 7.00 (1H, dd, J=2.0, 7.8 Hz), 7.12 (1H, dt, J=2.0, 7.8 Hz), 7.21-7.28 (3H, m), 7.45 (1H, dd, J=2.0, 8.3 Hz), 7.68 (1H, d, J=7.8 Hz), 8.36 (1H, bs), 8.50 (1H, bs). HRMS calculated 403.0883 [M+H] ⁺ Found 403.0896 (purified via radial


		chromatography eluting with 60:40 to 50:50 hexanes/THF)
408	2-methyl	¹ H NMR (400 MHz) 1.42 (3H, t, J=7.3 Hz), 2.13 (3H, s), 3.11 (2H, q, J=7.3 Hz), 4.84 (2H, s), 6.74-6.80 (3H, m), 6.93-6.95 (1H, m), 7.07-7.24 (5H, m), 7.68 (1H, td, J=2.0, 7.8 Hz), 8.34 (1H, bs), 8.50 (1H, d, J=3.4 Hz). HRMS calculated 383.1429 [M+H] ⁺ Found 383.1429 (purified via radial chromatography eluting with 60:40 to 50:50 hexanes/THF)
409	H	Anal Calcd for C ₂₀ H ₂₀ N ₂ O ₃ S: C, 65.20; H, 5.47; N, 7.60. Found: C, 64.86; H, 5.25; N, 7.26. MS found 369.1 [M+H] ⁺ (purified via radial chromatography eluting with 60:40 to 50:50 hexanes/THF)
410	4-C(O)OCH ₃	Anal Calcd for C ₂₂ H ₂₂ N ₂ O ₅ S•1HCl: C, 57.07; H, 5.01; N, 6.05. Found: C, 56.73; H, 5.01; N, 6.01. MS found 427.1 [M+H] ⁺ (isolated as the HCl salt)
411	3-t-butyl	Anal Calcd for C ₂₄ H ₂₈ N ₂ O ₃ S: C, 67.90; H, 6.65; N, 6.60. Found: C, 68.17; H, 6.45; N, 6.51. MS found 425.2 [M+H] ⁺ (purified via radial chromatography eluting with 60:40 to 50:50 hexanes/THF)
412	4-fluoro-2-(3-hydroxy-3-methylbutyl	Anal Calcd for C ₂₅ H ₂₉ FN ₂ O ₄ S: C, 63.54; H, 6.18; N, 5.93. Found: C, 63.16; H, 6.05; N, 5.84. MS found 473.2 [M+H] ⁺
413	2-fluoro-4-t-butyl	Anal Calcd for C ₂₄ H ₂₇ FN ₂ O ₃ S: C, 65.14; H, 6.15; N, 6.33. Found: C, 65.28; H, 6.24; N, 6.30. MS found 442.1 (FD). (purified via radial chromatography eluting with 50:50 to 70:30 THF/hexanes)
414	4-CH ₂ CO ₂ CH ₃	Anal Calcd for C ₂₃ H ₂₄ N ₂ O ₅ S•0.5H ₂ O: C, 61.45; H, 5.61; N, 6.23. Found: C, 61.43; H, 5.43; N, 6.45. MS found 441.1 [M+H] ⁺ (purified via radial chromatography eluting with 50:50 to 75:25 THF/hexanes)
415	3-C(O)NH ₂	¹ H NMR (400 MHz) 1.44 (3H, t, J=7.3 Hz), 3.13 (2H, q, J=7.8 Hz), 4.87 (2H, s), 5.7 (1H, bs), 6.74 (1H, bs), 6.86 (1H, t, J=2.0 Hz), 6.96 (1H, m), 7.06 (1H, m), 7.12 (1H, ddd, J=0.98, 2.4, 8.3 Hz), 7.28 (2H, m), 7.33 (1H, t, J=7.8 Hz), 7.43 (1H, t, J=7.8 Hz), 7.60 (1H, m), 7.72 (1H, d, J=7.8 Hz), 8.32 (1H, bs), 8.48 (1H, bs). HRMS calculated 412.1331 [M+H] ⁺ Found 412.1329 (purified via radial chromatography eluting with 60:40 to 70:30 THF/hexanes)
416	2,4-difluoro	Anal Calcd for C ₂₀ H ₁₈ F ₂ N ₂ O ₃ S•0.1DCM: C, 58.46; H, 4.44; N, 6.78. Found: C, 58.65; H, 4.19; N, 6.59. HRMS calcd 405.1084. Found 405.1083 [M+H] ⁺
417	4-CH ₂ CO ₂ CH ₃	Anal Calcd for C ₂₃ H ₂₄ N ₂ O ₅ S•0.5H ₂ O: C, 61.45; H, 5.61; N, 6.23. Found: C, 61.43; H, 5.43; N, 6.45. MS found 441.1 [M+H] ⁺ (purified via radial chromatography eluting with 50:50 to 75:25 THF/hexanes)
418	2,4,6-trifluoro	Anal Calcd for C ₂₀ H ₁₇ F ₃ N ₂ O ₃ S: C, 56.87; H, 4.06; N, 6.63. Found: C, 56.93; H, 4.00; N, 6.43. MS found 423.0 [M+H] ⁺

-101-

419	2-(prop-2-yl)	Anal Calcd for $C_{23}H_{26}N_2O_3S$: C, 67.29; H, 6.38; N, 6.82. Found: C, 67.37; H, 6.25; N, 6.66. MS found 411.2 $[M+H]^+$ (purified via normal phase radial chromatography eluting with 1:1 THF/hexanes)
420	2-ethyl	Anal Calcd for $C_{22}H_{24}N_2O_3S$: C, 66.64; H, 6.10; N, 7.07. Found: C, 66.72; H, 6.09; N, 6.88. MS found 397.2 $[M+H]^+$ (purified via flash chromatography eluting with 1:1 ethyl acetate/hexanes to 100% ethyl acetate)
421	4-S(O) ₂ NH ₂	Anal Calcd for $C_{20}H_{21}N_3O_5S_2 \cdot HCl$: C, 49.63; H, 4.58; N, 8.68. Found: C, 49.58; H, 4.42; N, 8.43. MS found 448.1 $[M+H]^+$ (isolate as the HCl salt from reverse phase chromatography)

Example 422

N-(4-(3-Methoxybenzyloxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline



5


A solution of N-(4-(4-hydroxyphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline (1.0 equiv.) in DMSO (0.15 M) was cooled to 0°C. Sodium hydride (1.1 equiv.; 60% dispersion in oil) was added; after 20 minutes at 0°C 3-methoxybenzyl bromide (Aldrich; 1.3 equiv.) was added and the reaction warmed to ambient temperature. After stirring overnight the reaction was diluted with ethyl acetate and washed with 0.1 M potassium carbonate, and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified via preparative HPLC eluting with 90:10 to 70:30 DCM/ethyl acetate to give the title compound. Anal Calcd for $C_{22}H_{24}N_2O_4S \cdot 0.1H_2O$: C, 64.06; H, 5.86; N, 6.79. Found: C, 63.78; H, 5.89; N, 6.76. MS found 413.0 $[M+H]^+$.

20

-102-

Example 443


N-(3-(2-Fluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



5 Using the method of Example 342 using N-(3-(2-fluorophenoxy)phenyl)pyridin-3-ylmethylamine and 2,2,2-trifluoroethanesulfonyl chloride and purifying via radial chromatography eluting with 40:60 to 50:50 THF/hexanes gave the title compound. Anal Calcd for $C_{20}H_{16}F_4N_2O_3S$: C, 54.54; H, 3.66; N, 6.36. Found: C, 54.23; H, 3.40; N, 6.31. MS found 441.2 $[M+H]^+$

Example 444

15 N-(3-(2-Methylphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine




20 Using the method of Example 342 using N-(3-(2-methylphenoxy)phenyl)pyridin-3-ylmethylamine and 2,2,2-trifluoroethanesulfonyl chloride and purifying via radial chromatography eluting with 40:60 to 50:50 THF/hexanes gave the title compound. Anal Calcd for $C_{21}H_{19}F_3N_2O_3S \cdot 0.1H_2O$: C, 57.55; H, 4.42; N, 6.39. Found: C, 57.28; H, 4.15; N, 6.33. MS found 437.2 $[M+H]^+$

-103-

Example 445

N-(3-(4-Carboxymethylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




5 N-(3-(4-Carbomethoxymethylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (1.0 equiv.) was dissolved in THF (3.3 M) and treated with 1N NaOH (3 equiv.). The reaction was stirred overnight then concentrated in vacuo to remove THF. The pH was adjusted to
10 4 with HCl, which caused the title compound to precipitate. The solid was collected via filtration washing with pH=4 water to give the title compound. Anal Calcd for $C_{22}H_{22}N_2O_5S \cdot 0.2H_2O$: C, 61.44; H, 5.25; N, 6.51. Found: C, 61.39; H, 5.12; N, 6.59. MS found 427.0 [M+H]⁺

15

Example 446

N-(4-(2-Fluoro-4-methylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




20 Using the method of Example 342 using N-(4-hydroxyphenyl)-N-(ethanesulfonyl)pyridin-3-ylmethylamine and 4-bromo-2-fluorotoluene (Strem) and purifying via preparative HPLC eluting with 90:10 to 70:30 DCM/ethyl

-104-

acetate) gave the title compound. Anal Calcd for $C_{21}H_{21}FN_2O_3S \cdot 0.2H_2O$: C, 62.42; H, 5.34; N, 6.93. Found: C, 62.48; H, 5.33; N, 6.72. 1H NMR (400 MHz) 1.42 (3H, t, $J=7.3$ Hz), 2.35 (3H, s), 3.10 (2H, q, $J=7.3$ Hz), 4.82 (2H, s), 6.82-7.00 (5H, m), 7.12 (2H, m), 7.30 (1H, bs), 7.78 (1H, d, $J=7.8$ Hz), 8.40 (1H, bs), 8.55 (1H, bs).

By a method similar to the method of Example 1 the following compounds were prepared:



10

No.	R1	R2	Data
447	$SO_2CH_2CH_3$	3-(2-methoxy-phenylsulfanyl)	1H NMR: 8.30 (d, 1H, $J=3$ Hz), 7.62 (s, 1H), 7.30 (d, 1H, $J=7$ Hz), 7.20 (m, 1H), 7.05-7.18 (m, 6H), 4.79 (s, 2H), 3.79 (s, 3H), 3.00-3.05 (m, 2H), 1.35 (t, 3H, $J=7$ Hz). MS calcd. 414.5; MS (M+1) 416.1.
448	$SO_2CH_2CF_3$	3-(2-methoxy-phenylsulfanyl)	1H NMR: 8.48 (d, 1H, $J=4$ Hz), 8.26 (s, 1H), 7.60 (m, 1H), 7.32-7.36 (m, 1H), 7.15-7.22 (m, 6H), 6.90-7.00 (m, 2H), 4.78 (s, 2H), 3.69-3.79 (m, 5H). MS calcd. 468.5; MS (M+1) 469.9.
449	$SO_2CH_2CF_3$	3-(2-methoxy-phenoxy)-	1H NMR: 8.50 (d, 1H, $J=4$ Hz), 8.30 (s, 1H), 7.64 (d, 1H, $J=8$ Hz), 7.14-7.24 (m, 4H), 6.99 (d, 1H, $J=8$ Hz), 6.93 (s, 1H), 6.84-6.86 (m, 2H), 6.76 (s, 1H), 4.82 (s, 2H), 3.75-3.82 (m, 5H). MS calcd. 452.5; MS (M+1) 453.3.
450	$SO_2CH_2CF_3$	4-(2-benzyloxy-phenoxy)	1H NMR: 8.5 (s, 1H), 8.28 (s, 1H), 7.69 (d, 1H, $J=8$ Hz), 7.26 (m, 2H), 7.02-7.12 (m, 4H), 6.84-6.91 (m, 4H), 4.83 (s, 2H), 3.76-3.83 (dd, 2H). MS calcd. 438.4; MS (M+1) 439.4.
451	$SO_2CH_2CH_3$	3-(4-fluoro-2-methoxy-phenoxy)	1H NMR: 8.5 (dd, 1H), 8.32 (d, 1H, $J=1$ Hz), 7.67 (d, 1H, $J=8$ Hz), 7.16-7.22 (m, 3H), 6.87 (m, 2H), 6.75 (m, 2H), 6.62 (m, 1H), 4.83 (s, 2H), 3.73 (s, 3H), 3.08 (dd, 2H), 1.37-1.41 (t, 3H). MS calcd. 416.5; MS (M+1) 417.6.
452	$SO_2CH_2CF_3$	3-(4-fluoro-2-methoxy-	1H NMR: 8.49 (d, 1H, $J=4$ Hz), 8.28 (s, 1H), 7.65 (d, 1H, $J=8$ Hz), 7.20-7.22 (m, 3H), 6.80-

		phenoxy)	6.90 (m,2H), 6.70 (m,1H), 6.60 (m,1H), 4.82 (s, 2h), 3.72-3.82 (m,4H). MS calcd. 470.5; MS (M+1)471.6
453	SO ₂ CH ₂ CH ₃	3-(2-bromo - phenoxy)	¹ H NMR: 8.47 (dd,1H), 8.33(d,1H,J=2Hz), 7.65(m,1H), 7.61 (m,1H), 7.19-7.27 (m,4H), 6.96-7.05 (m,3H), 6.78-6.86 (m,3H), 4.84 (s,2H), 3.06-3.10 (m,2H), 1.37-1.41 (t,3H). MS calcd. 447.4, MS (M+1)449.0
454	SO ₂ CH ₂ CH ₃	3-(2,3-dimethoxy-phenoxy)	¹ H NMR: 8.47 (dd,1H), 8.35 (d,1H,J=1Hz), 7.65 (dd,1H), 7.17-7.22 (m,3H), 6.81-7.00 (m,3H), 6.84 (m,2H), 6.72 (dd,1H), 6.47 (dd,1H), 4.83(s, 2H), 3.87 (s,3H), 3.71 (s,3H), 3.05-3.11 (dd,2H), 1.38 (t,3H). MS calcd. 428.5; MS (M+1)429.6
455	SO ₂ CH ₂ CH ₃	3-(2-chloro-phenoxy)	¹ H NMR: 8.47 (dd,1H), 8.33 (d,1H,J=2Hz), 7.65 (d,1H,J=8Hz), 7.42 (dd,1H), 7.19-7.25 (m,4H), 7.11 (dd,1H), 6.97 (dd,1H), 6.86-6.89 (m,1H), 6.82 (d,2H,J=2Hz), 6.78-6.80 (m,2H), 4.84 (s,3H), 3.11 (dd,3H), 1.39 (t,2H). MS calcd. 402.9; MS (M+1)403.8.
456	SO ₂ CH ₂ CH ₃	3-(2-chloro-6-methyl-phenoxy)	¹ H NMR: 8.45 (m,1H), 8.31 (d,1H,J=1Hz), 7.61 (d,1H,J=8Hz), 7.06-7.26 (m,5H), 6.90 (dd,1H), 6.69 (dd,1H), 6.58 (t,1H), 4.81 (s,2H), 3.05-3.10 (dd,2H), 2.07 (s,3H), 1.37 (t,3H). MS calcd. 416.9; MS (M+1)417.7
457	SO ₂ CH ₂ CH ₃	3-(2-isopropoxy-phenoxy)	¹ H NMR: 8.47 (dd,1H), 8.35 (d,1H,J=2Hz), 7.68 (d,1H,J=8Hz), 7.21 (dd,1H), 7.09-7.22 (m,3H), 6.84-6.98 (m,4H), 6.82 (s,1H), 6.74 (dd,1H), 4.84 (s,2H), 4.39 (m,1H), 3.08 (dd,2H), 1.38 (t,3H), 1.12 (d,6H,J=7Hz). MS calcd. 426.5; MS (M+1)427.6
458	SO ₂ CH ₂ CF ₃	3-fluoro-5-(2-methoxy-phenoxy)	¹ H NMR (CD ₃ OD): 8.79 (m,2H), 8.56 (d,1H,J=8Hz), 8.05 (dd,1H), 7.22 (t,1H), 7.11 (d,J=7Hz), 6.90-7.03 (m,3H), 6.68 (s,1H), 6.49-6.53 (m,1H), 5.14 (s,2H), 4.41 (dd,2H), 3.70 (s,3H). MS calcd. 470.45; MS (M+1) 471.6
459	SO ₂ CH ₂ CH ₃	3-fluoro-5-(2-methoxy-phenoxy)	¹ H NMR (CD ₃ OD): 8.77 (s,2H), 8.57 (s, 1H), 8.04 (s,1H), 7.21 (s,1H), 7.09 (s,1H), 6.95 (m,3H), 6.71 (s,1H), 6.42 (d,1H,J=9Hz), 5.15 (s,2H), 3.69 (s,3H), 3.27 (m,2H), 1.34 (m,3H). MS calcd. 416.48; MS (M+1)417.7
460	SO ₂ CH ₂ CH ₂ CF ₃	3-(2-methoxy-phenoxy)	¹ H NMR (CD ₃ OD): 8.53-8.83 (m,3H), 7.90-8.08 (m,1H), 6.74-7.26 (m,8H), 5.13 (s,2H), 3.66 (s,3H), 3.25 (m,2H), 2.65 (m,2H). MS calcd. 466.38; MS (M+1) 467.6
461	SO ₂ CH ₂ CF ₃	3-(2-bromo-	¹ H NMR: 7.63 (m,2H), 7.37 (m,3H), 7.04-

		phenoxy)	7.19 (m,4H), 6.91 (s,2H), 6.77 (br,1H), 4.10 (dd,1H), 3.85 (s, NH), 2.02 (s,1H), 1.24 (t,2H). MS calcd. 501.1; MS (M+1)501.4 (502.4, due to Br).
462	SO ₂ CH ₂ CF ₃	3-(2,3-dimethoxy-phenoxy)	¹ H NMR (CD ₃ OD): 8.69-8.77 (m,2H), 8.51 (s,1H), 8.00 (s,1H), 7.33 (s,1H), 7.03-7.11 (m,2H), 6.89 (m,2H), 6.69 (s,1H), 6.56 (m,1H), 5.10 (s,2H), 4.35 (m,2H), 3.85 (s,3H), 3.58 (s,3H). MS calcd. 482.18; MS (M+1)483.8
463	SO ₂ CH ₂ CH ₃	3-(2-chloro-phenoxy)	¹ H NMR: 8.47 (dd,1H), 8.33 (d,1H,J=2Hz), 7.65 (d,1H,J=8Hz), 7.42 (dd,1H), 7.19-7.25 (m,4H), 7.11 (dd,1H), 6.97 (dd,1H), 6.86-6.89 (m,1H), 6.82 (d,2H,J=2Hz), 6.78-6.80 (m,2H), 4.84 (s,3H), 3.11 (dd,3H), 1.39 (t,2H). MS calcd. 402.9; MS (M+1)403.8.
464	SO ₂ CH ₂ CF ₃	3-(2-chloro-phenoxy)	¹ H NMR: 7.34-7.50 (m,5H), 7.19 (m,3H), 6.91 (m,4H), 4.10 (dd,1H), 3.85 (br, NH), 2.02 (s,1H), 1.24 (t,1H). MS calcd. 456.87; MS (M+1)457.
465	SO ₂ CH ₂ CF ₃	3-(2-chloro-6-methyl-phenoxy)	¹ H NMR: 6.65-7.90 (m,11H), 3.70 (br, NH), 3.43 (m,1H), 2.13 (s,3H), 1.95 (m,2H), 1.20 (m,1H). MS calcd. 470.9; MS (M+1)471.6
466	SO ₂ CH ₂ CF ₃	3-(2-isopropoxy-phenoxy)	¹ H NMR: 8.73 (m,2H), 8.50 (s,1H), 7.98 (s,1H), 7.27 (s,1H), 6.94-7.12 (m,6H), 6.77 (s,2H), 5.10 (br, NH), 4.29-4.36 (m,4H), 1.02 (s,3H). MS calcd. 480.51; MS (M+1)481.4

-107-

Preparation 8N-(4-Methoxycarbonylphenyl)pyrid-3-ylmethylaniline

A mixture of 3-pyridinecarboxaldehyde (4.72 mL, 50 mmol) and methyl 4-aminobenzoate (9.83 g, 65 mmol) in 140 mL of methanol was heated to reflux for 2.5 h then cooled to 0 °C. Solid NaBH₄ was added slowly and the reaction mixture was warmed to ambient temperature and stirred for 14 h. The mixture was concentrated and partitioned between DCM and H₂O. The aqueous layer was extracted with DCM and the combined organic layers were washed with H₂O and brine and concentrated. The residue was chromatographed on silica gel with DCM to 2% MeOH in DCM to give 8.08 g of a white solid (67% yield). ¹H NMR (DMSO-d₆): 8.57 (d, J=1.8Hz, 1H), 8.46 (dd, J=4.7, 1.8Hz, 1H), 7.73 (dt, J=8.4, 2.2Hz, 1H), 7.68 (d, J=8.8Hz, 2H), 7.35 (ddd, J=8.1, 4.8, 0.7Hz, 1H), 7.13 (br t, J=5.9Hz, 1H), 6.64 (d, J=8.8Hz, 2H), 4.38 (d, J=6.2Hz, 2H), 2.75 (s, 3H). MS calcd. 242.1; MS (M+1) 243.2.

Alternately, 3-pyridinecarboxaldehyde ((61.6 g, 0.575 moles, 1 eq) and methyl 4-aminobenzoate (103.87 g, 0.687 moles, 1.2 eq) with p-toluenesulfonic acid (2.19 g, .012 moles, 0.02 eq) were refluxed in methanol (25 volumes) for 2 hours. The reaction mixture was cooled to 0°C and sodium borohydride (67.6 g, 1.787 moles, 3.5 eq) added slowly then it was allowed to warm to ambient overnight. The reaction was concentrated, dissolved with dichloromethane and washed with water then brine, and evaporated to give the title compound.

Preparation 9N-(3-Methoxycarbonylphenyl)pyrid-3-ylmethylaniline

The title compound was prepared using a method similar to Preparation 8 using 3-aminobenzoate. ¹H NMR: 8.64 (d, J=2.4Hz, 1H), 8.54 (dd, J=4.9, 1.5Hz, 1H), 7.69 (dt, J=7.8, 2.0Hz, 1H), 7.41 (dt, J=7.8, 1.3Hz, 2H), 7.32 (dd, J=2.5, 1.5, Hz, 1H), 7.27 (dd, J=7.8, 3.9Hz, 1H), 7.23

-108-

(t, J=8.3Hz, 1H), 6.79 (ddd, J=7.8, 2.5, 1.0Hz, 1H), 4.40 (d, J=5.9Hz, 2H), 4.19 (br t, J=5.9Hz, 1H) 3.88 (s, 3H).


Preparation 10

5 N-(4-Benzylphenyl)pyrid-3-ylmethanamine

The title compound was prepared using a method similar to Preparation 8 using 4-aminodiphenylmethane (purchased from TCI). ¹H NMR: 8.63 (br s, 1H), 8.53 (br d, J=4.4Hz, 1H), 7.50 (br d, J=7.8Hz, 1H), 7.26 (m, 3H), 7.18 (m, 3H), 7.00 (m, 2H), 6.57 (m, 2H), 4.34 (s, 2H), 3.99 (br s, 1H), 3.88 (s, 2H).


Example 467

15 N-(4-(Benzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine




To a solution of N-(4-benzylphenyl)pyrid-3-ylmethanamine (0.517 g, 1.88 mmol) dissolved in 8 mL dichloroethane and 4 mL pyridine at 0 °C was added 2,2,2-trifluoroethylsulfonyl chloride (0.313 mL, 2.83 mmol). The reaction was stirred at ambient temperature overnight. The mixture was treated with 1.5 g anhydrous K₂CO₃ and stirred for 2 h. Then the mixture was filtered and concentrated. The residue was chromatographed on silica gel with 3:1 to 2:1 DCM/EtOAc to give an amorphous white solid. ¹H NMR: 8.52 (br d, J=3.3Hz, 1H), 8.32 (br s, 1H), 7.71 (dt, J=6.8, 1.4Hz, 1H), 7.33-7.20 (m, 4H), 7.18-7.10 (m, 6H), 4.88 (s, 2H), 3.95 (s, 2H), 3.79 (q, J=9.3Hz, 2H).

-109-

Example 468N-(4-(Benzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

The title compound was prepared using a method similar
5 to the method of Example 467 using ethanesulfonyl chloride.
¹H NMR: 8.50 (br d, J=3.4Hz, 1H), 8.36 (br s, 1H), 7.77
(dd, J=7.8, 1.5Hz, 1H), 7.31-7.19 (m, 4H), 7.17-7.09 (m, 6H),
4.87 (s, 2H), 3.92 (s, 2H), 3.08 (q, J=7.3Hz, 2H), 1.42
(t, J=7.3Hz, 3H). MS calcd. 366.1; MS (M+1) 367.1.

10

Example 469N-(4-Methoxycarbonylphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine


15 The title compound was prepared using a method similar
to the method of Example 467 using N-(4-methoxycarbonyl-
phenyl)pyrid-3-ylmethylamine. ¹H NMR: 8.52 (br s, 1H), 8.37
(br s, 1H), 8.02 (m, 2H), 7.68 (d, J=7.8Hz, 1H), 7.33 (m, 2H),
7.27 (m, 1H), 4.95 (s, 2H), 3.90 (s, 3H), 3.82 (q, J=9.3Hz, 2H).

20

-110-

Example 470

N-(3-Methoxycarbonylphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



5


The title compound was prepared using a method similar to the method of Example 467 using N-(3-methoxycarbonylphenyl)pyrid-3-ylmethylamine. ¹H NMR: 8.51

(dd, J=4.8, 1.8 Hz, 1H), 8.33 (d, J=1.8 Hz, 1H), 8.00
10 (dt, J=7.3, 1.5 Hz, 1H), 7.93 (t, J=1.5 Hz, 1H), 7.68
(dt, J=7.7, 2.2 Hz, 1H), 7.43 (t, J=7.7 Hz, 1H), 7.39
(dt, J=7.7, 1.5 Hz, 1H), 7.25 (ddd, J=7.3, 4.8, 1.5 Hz, 1H), 4.93
(s, 2H), 3.92 (s, 2H), 3.82 (q, J=9.3 Hz, 2H).

15

Example 471

N-(4-(Hydroxymethyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine




To a solution of N-(4-hydroxymethyl-phenyl)pyrid-3-ylmethylamine (0.472 g, 1.22 mmol) dissolved in 15 mL THF at,
20 -78 °C was DIBAL (1.0 M in toluene, 3.04 mL, 3.04 mmol).
The reaction was stirred for 1h and then warmed to 0 °C for
1 h. It was quenched with 0.5 mL methanol and stirred
overnight with 60 mL ether and 30 mL saturated Rochelle's

-111-

salt. The mixture was extracted with ether, dried over MgSO_4 , filtered and concentrated. The residue was chromatographed on silica gel with 1:1 DCM/EtOAc to give the title compound as an amorphous white solid. ^1H NMR: 8.43 (d, $J=3.8\text{Hz}$, 1H), 8.27 (s, 1H), 7.68 (d, $J=7.8\text{Hz}$, 1H), 7.32 (m, 2H), 7.23 (m, 1H), 7.19 (m, 2H), 4.88 (s, 2H), 4.63 (s, 2H), 3.80 (q, $J=9.3\text{Hz}$, 2H), 3.10 (br s, 1H).

Example 472

10 N-(3-(Hydroxymethyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine




The title compound was prepared using a method similar to the method of Example 471 using N-(3-methoxycarbonylphenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. ^1H NMR: 8.50 (dd, $J=4.9, 1.5\text{Hz}$, 1H), 8.31 ($J=2.0\text{Hz}$, 1H), 7.70 (dt, $J=7.8, 2.0\text{Hz}$, 1H), 7.34 (m, 2H), 7.25 (m, 2H), 7.14 (dt, $J=7.3, 2.5\text{Hz}$, 1H), 4.90 (s, 2H), 4.67 (d, $J=5.4\text{Hz}$, 2H), 3.81 (q, $J=9.3\text{Hz}$, 1H), 1.92 (br t, $J=5.4\text{Hz}$, 1H).

20

Example 473

N-(4-Formylphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine




-112-

To a solution of DMSO (0.190 mL, 2.68 mmol) in 4 mL DCM at -78 °C was added oxalyl chloride (0.146 mL, 1.67 mmol) dropwise. After 15 min a solution of N-(4-(hydroxymethyl)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine (0.241 g, 0.669 mmol) was added via cannula. The reaction was stirred for 30 min and triethylamine (0.932 mL, 6.69 mmol) was added and warmed to 0 °C over 1 h. The mixture was poured into saturated NaHCO₃ solution and diluted with ether. The organic layer was washed with H₂O and brine, dried over MgSO₄, filtered, and concentrated. The residue was chromatographed on silica gel with 5:1 DCM/EtOAc to give 173 mg of a clear oil (72%). ¹H NMR: 9.97 (s, 1H), 8.50 (dd, J=4.9, 1.5 Hz, 1H), 8.35 (d, J=2.0 Hz, 1H), 7.87 (m, 2H), 7.66 (dt, J=7.8, 2.0 Hz, 1H), 7.44 (m, 2H), 7.24 (ddd, J=7.8, 4.9, 1.0 Hz, 1H), 4.97 (s, 2H), 3.84 (q, J=9.3 Hz, 2H).

Example 474

N-(3-Formylphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



-113-


The title compound was prepared using a method similar to the method of Example 473 using N-(3-hydroxymethylphenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. ¹H NMR: 9.97 (s, 1H), 8.51

5 (dd, J=4.9, 1.5 Hz, 1H), 8.33 (d, J=2.0 Hz, 1H), 7.85 (dt, J=7.8, 2.0 Hz, 1H), 7.77 (t, J=2.0 Hz, 1H), 7.69 (dt, J=7.8, 2.0 Hz, 1H), 7.54 (t, J=7.8 Hz, 1H), 7.48 (dt, J=7.8, 2.0 Hz, 1H), 7.26 (dd, J=7.8, 4.9 Hz, 1H), 4.95 (s, 2H), 3.83 (q, J=9.3 Hz, 2H).

10

Example 475

N-(3-(α-Hydroxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine




15 To a solution of N-(3-formylphenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine (0.174 g, 0.486 mmol) in 4 mL THF at 0 °C was added phenyl magnesium chloride (2.0 M in THF, 0.364 mL, 0.728 mmol). After 1 h at ambient temperature, the reaction was poured in to saturated

20 NaHCO₃ solution and extracted with DCM. The extracts were dried over MgSO₄, filtered and concentrated. The residue was chromatographed on silica gel with 1:1 DCM/EtOAc to give a clear oil. ¹H NMR: 8.41 (dd, J=4.9, 1.5 Hz, 1H), 8.24 (d, J=2.0 Hz, 1H), 7.67 (dt, J=7.8, 2.0 Hz, 1H), 7.40=7.15 (m, 10H),

25 5.78 (s, 1H), 4.86 (s, 2H), 3.77 (q, J=9.3 Hz, 2H), 3.21 (br s, 1H). MS calcd. 436.1; MS (M+1) 437.1. The HCl salt was prepared by adding 1.0 M HCl in ether solution to the free base in ether suspension, stirring for 10 min then collecting the ppt by filtration.

Optionally, the HCl salt can be prepared by adding 1.0 M HCl in ether solution to the free base in ether suspension, stirring for 10 min then collecting the ppt by filtration.

- 5 By a method similar to the method of Example 475 the following compounds were prepared:




No.	R2	Data
476	4-(α -hydroxybenzyl)	$^1\text{H NMR}$: 8.38 (dd, $J=4.9, 2.0\text{Hz}$, 1H), 8.21 (d, $J=1.5\text{Hz}$, 1H), 7.61 (dt, $J=7.8, 1.5\text{Hz}$, 1H), 7.33–7.09 (m, 10H), 5.72 (d, $J=2.5\text{Hz}$, 1H), 4.79 (s, 2H), 3.71 (q, $J=9.3\text{Hz}$, 2H), 2.71 (d, $J=3.4\text{Hz}$, 1H)
477	4-(α -hydroxy-2-methylsulfanyl benzyl)	$^1\text{H NMR}$: 8.39 (dd, $J=4.9, 2.0\text{Hz}$, 1H), 8.24 (d, $J=1.5\text{Hz}$, 1H), 7.65 (dt, $J=7.8, 1.5\text{Hz}$, 1H), 7.43–7.38 (m, 3H), 7.27–7.13 (m, 6H), 6.20 (d, $J=1.5\text{Hz}$, 1H), 4.85 (s, 2H), 3.78 (q, $J=9.3\text{Hz}$, 2H), 3.60 (br s, 1H), 2.38 (s, 3H). MS calcd. 482.1; MS (M+1) 483.1
478	3-(α -hydroxy-2-methylsulfanyl benzyl)	$^1\text{H NMR}$: 8.40 (dd, $J=4.9, 2.0\text{Hz}$, 1H), 8.22 (d, $J=2.0\text{Hz}$, 1H), 7.62 (dt, $J=7.8, 1.5\text{Hz}$, 1H), 7.39–7.33 (m, 2H), 7.32–7.15 (m, 6H), 7.06 (d, $J=7.8\text{Hz}$, 1H), 6.14 (d, $J=3.4\text{Hz}$, 1H), 4.85 (A of AB, d, $J=14.8\text{Hz}$, 1H), 4.80 (B of AB, d, $J=14.8\text{Hz}$, 1H), 3.84–3.70 (m, 2H), 3.53 (d, $J=4.3\text{Hz}$, 1H), 2.39 (s, 3H). MS calcd. 482.1; MS (M+1) 483.1
479	4-(α -hydroxy-2-methoxybenzyl)	$^1\text{H NMR}$: 8.45 (dd, $J=4.9, 1.5\text{Hz}$, 1H), 8.29 (d, $J=2.0\text{Hz}$, 1H), 7.67 (dd, $J=8.3\text{Hz}$, 1H), 7.38 (d, $J=8.3\text{Hz}$, 2H), 7.29–7.20 (m, 3H), 7.16 (d, $J=8.6\text{Hz}$, 2H), 6.94 (dt, $J=1.0, 7.8\text{Hz}$, 1H), 6.88 (d, $J=8.3\text{Hz}$, 1H), 6.01 (d, $J=4.9\text{Hz}$, 1H), 4.87 (s, 2H), 3.78 (q, $J=9.3\text{Hz}$, 2H), 3.77 (s, 3H)
480	3-(α -hydroxy-2-methoxybenzyl)	$^1\text{H NMR}$: 8.42 (dd, $J=4.9, 1.5\text{Hz}$, 1H), 8.24 (d, $J=2.0\text{Hz}$, 1H), 7.63 (dt, $J=7.8, 2.0\text{Hz}$, 1H), 7.37 (d, $J=7.3\text{Hz}$, 1H), 7.34–7.24 (m, 3H), 7.22–7.17 (m, 2H), 7.09 (br d, $J=9.0\text{Hz}$, 1H), 6.96 (dt, $J=1.0, 7.3\text{Hz}$, 1H), 6.88 (d, $J=8.3\text{Hz}$, 1H), 6.03 (s, 1H), 4.87 (s, 2H), 3.80 (br s, 1H), 3.79 (q, $J=9.3\text{Hz}$, 2H), 3.77 (s, 3H).
481	4-(α -hydroxy-3,4-	$^1\text{H NMR}$: 8.41 (dd, $J=4.9, 2.0\text{Hz}$, 1H), 8.23

-115-

	difluorobenzyl)	(d,J=1.5Hz,1H), 7.69 (dt,J=7.8,2.0Hz,1H), 7.34 (d,J=7.3Hz,2H), 7.24 (dd,J=4.9,4.0Hz,1H), 7.21-7.07 (m,4H), 7.03 (m,1H), 5.73 (s,1H), 4.87 (s,2H), 3.79 (q,J=9.3Hz,2H), 3.34 (br s,1H). MS calcd. 472.1; MS (M+1) 473.1
482	3-(α -hydroxy-3,4-difluorobenzyl)	¹ H NMR: 8.29 (d,J=3.9Hz,1H), 8.12 (d,J=1.5Hz,1H), 7.57 (dt,J=7.8,2.0Hz,1H), 7.34-7.24 (m,2H), 7.18-7.11 (m,3H), 7.09-6.96 (m,2H), 6.89 (m,1H), 5.63 (s,1H), 4.82 (s,2H), 4.67 (br s,1H), 3.77 (q,J=9.3Hz,2H). MS calcd. 472.1; MS (M+1) 473.1
483	4-(α -hydroxy-2-phenylbenzyl)	¹ H NMR: 8.46 (d,1H,J=3.4Hz), 8.26 (s,1H), 7.76-7.60 (m,1H), 7.56-7.45 (m,1H), 7.42-7.30 (m,5H), 7.44-7.15 (m,4H), 7.15-7.00 (m,5H), 5.89 (d,1H,J=3.4Hz), 4.85 (s,2H), 3.76 (q,2H,J=9.8Hz)
484	3-(α -hydroxy-2-phenylbenzyl)	¹ H NMR: 8.45 (m,1H), 8.22 (d,1H), 7.62-7.57 (m,1H), 7.43-7.30 (m,6H), 7.28-7.14 (m,5H), 7.10-6.98 (m,3H), 5.90 (s,1H), 4.80 (q,2H), 3.82-3.62 (q,2H)
485	4-(1-hydroxy-1-(5-methylpyrid-2-yl)methyl)	¹ H NMR: 8.50 (d,1H), 8.37 (s,1H), 8.31 (s,1H), 7.63 (d,1H), 7.15 (m,6H), 7.00 (d,1H), 5.68 (d,1H), 4.84 (s,2H), 3.78 (q,2H), 2.32 (s,3H).
486	3-(1-hydroxy-1-(5-methylpyrid-2-yl)methyl)	¹ H NMR: 8.49 (m,1H), 8.35 (d,1H,J=1.5Hz), 7.70-7.65 (d,2H,7.8Hz), 7.57-7.52 (m,1H), 7.46-7.16 (m,7H), 6.26 (d,1H), 4.87(s,1H), 3.88 (q,2H)
487	4-(α -hydroxy-2-trifluoromethylbenzyl)	¹ H NMR: 8.47 (q,1H,J=2.0, 2.93), 8.24 (s,1H,J=2.0Hz), 7.70-7.52 (m,3H), 7.46-7.08 (m,8H), 6.24 (d,1H), 4.83 (s,2H), 3.75 (q,2H)
488	3-(α -hydroxy-2-fluorobenzyl)	¹ H NMR: 8.43 (d,1H), 8.24 (s,1H), 7.68 (m,1H), 7.42-6.88 (m,9H), 5.78 (s,1H), 4.87 (s,2H), 3.86 (q,2H)
489	4-(α -hydroxy-2-fluorobenzyl)	¹ H NMR: 8.46 (d,1H,J=3.4), 8.30 (s,1H), 7.65 (m,1H), 7.47-7.38 (m,3H), 7.30-6.82 (m,6H), 6.12 (d,1H), 4.87 (s,2H), 3.75 (q,2H,J=8.8Hz)
490	4-(α -hydroxy-3-fluorobenzyl)	¹ H NMR: 8.43 (d,1H), 8.24 (s,1H), 7.68 (m,1H), 7.42-6.88 (m,9H), 5.78 (s,1H), 4.87 (s,2H), 3.86 (q,2H).

Example 491


N-(3-(Benzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine



-116-

To a solution of N-3-(α -hydroxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine (0.050 g, 0.115 mmol) in 2 mL DCM and 0.5 mL triethylsilane was added trifluoroacetic acid (0.3 mL). The reaction was stirred at ambient temperature overnight and poured into saturated NaHCO₃ solution and extracted with EtOAc. The combined extracts were dried over MgSO₄, filtered and concentrated. The residue was chromatographed on silica gel with 4:1 to 2:1 DCM/EtOAc to give 0.025 g of a clear oil (52% yield). ¹H NMR: 8.51 (dd, J=4.9, 1.5 Hz, 1H), 8.22 (d, J=2.0 Hz, 1H), 7.69 (dt, J=7.8, 2.0 Hz, 1H), 7.32-7.20 (m, 4H), 7.18-7.11 (m, 6H), 4.86 (s, 2H), 3.94 (s, 2H), 3.79 (q, J=9.3 Hz, 2H). MS calcd. 420.1; MS (M+1) 421.1. Optionally, the HCl salt can be prepared by adding 1.0 M HCl in ether solution to the free base in ether suspension, stirring for 10 min then collecting the ppt by filtration.

By a method similar to the method of Example 491 the following compounds were prepared:




No.	R ₂	Data
492	4-(2-methylsulfonyl benzyl)	¹ H NMR: 8.50 (vbr s, 2H), 7.71 (br d, J=7.8 Hz, 1H), 7.29 (br s, 1H), 7.23 (m, 2H), 7.17 (br d, J=8.3 Hz, 2H), 7.11 (m, 2H), 7.05 (br d, 8.3 Hz, 2H), 3.87 (s, 2H), 4.04 (s, 2H), 3.79 (q, J=9.3 Hz, 2H), 2.41 (s, 3H). MS calcd. 466.1; MS (M+1) 467.0.
493	3-(2-methylsulfonyl benzyl)	¹ H NMR: 8.50 (br s, 1H), 8.31 (br s, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.28-7.15 (m, 5H), 7.11 (dt, J=1.5, 6.8 Hz, 1H), 7.02 (m, 3H), 4.73 (s, 2H), 4.03 (s, 2H), 3.78 (q, J=9.3 Hz, 2H), 2.42 (s, 3H). MS calcd. 466.1; MS (M+1) 467.0.
494	4-(2-methoxybenzyl)	¹ H NMR: 8.50 (br d, J=3.9 Hz, 1H), 8.33 (br d, J=7.8 Hz, 1H), 7.68 (br d, J=7.8 Hz, 1H), 7.28-7.16

-117-

		(m,4H), 7.12–7.20 (m,3H), 6.92–6.85 (m,2H), 4.86 (s,2H), 3.93 (s,2H), 3.79 (q,J=9.3Hz,2H), 3.78 (s,3H)
495	3-(2-methoxybenzyl)	¹ H NMR: 8.48 (d,J=3.4Hz,1H), 8.30 (d,J=1.5Hz,1H), 7.61 (dt,J=7.8,2.0Hz,1H), 7.24–7.15 (m,4H), 7.06 (br s,1H), 7.03–6.95 (m,2H), 6.91–6.84 (m,2H), 4.84 (s,2H), 3.91 (s,2H), 3.77 (s,3H), 3.75 (q,J=9.3Hz,2H)
496	4-(3,4-difluorobenzyl)	¹ H NMR: 8.51 (dd,J=4.9,1.5Hz,1H), 8.31 (d,J=2.0Hz,1H), 7.69 (dt,J=7.8,2.0Hz,1H), 7.25 (dd,J=7.8,4.9Hz,1H), 7.17–7.04 (m,5H), 6.93 (m,1H), 6.86 (m,1H), 4.87 (s,2H), 3.89 (s,2H), 3.80 (q,J=9.3Hz,2H)
497	3-(3,4-difluorobenzyl)	¹ H NMR: 8.50 (dd,J=4.9,1.5Hz,1H), 8.29 (d,J=1.5Hz,1H), 7.62 (dt,J=7.8,2.0Hz,1H), 7.31 (t,J=7.8Hz,1H), 7.21 (dd,J=7.8,4.9Hz,1H), 7.15–7.02 (m,3H), 6.91 (s,1H), 6.82–6.71 (m,2H), 4.85 (s,2H), 3.85 (s,2H), 3.79 (q,J=9.3Hz,2H). MS calcd. 456.1; MS (M+1) 457.1
498	4-(2-phenylbenzyl)	¹ H NMR: 8.52 (br s,1H), 8.31 (br s,1H), 7.66 (d,1H,J=7.8Hz), 7.30 (m,4H), 7.27–7.17 (m,4H), 7.13 (m,2H), 7.01 (d,2H,J=8.4Hz), 6.88 (d,2H,J=8.4Hz), 4.84 (s,2H), 3.92 (s,2H), 3.76 (q,2H,J=9.3Hz). MS calcd 496.1; MS (M+1) 497.1
499	3-(2-phenylbenzyl)	¹ H NMR: 8.42 (br s,1H), 7.19 (br s,1H), 7.51 (d,1H,J=7.8Hz), 7.28–7.09 (m,7H), 7.06 (m,3H), 6.99 (m,1H), 6.88 (d,1H,J=8.3Hz), 6.82 (d,1H,J=7.8Hz), 6.67 (s,1H), 4.70 (s,2H), 3.83 (s,2H), 3.62 (q,2H,J=9.3Hz). MS calcd 496.1; MS (M+1) 497.1

Example 500

N-(3-Methoxycarbonylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5

Into a 0°C solution of N-(3-methoxycarbonylphenyl) pyrid-3-ylmethylamine (204 g, 0.842 mole, 1 eq) in dichloroethane (3610 mL) and pyridine (1775 mL) was added ethanesulfonyl chloride (114 mL, 1.2 mole, 1.43 eq). The reaction was allowed to warm to room temperature overnight.


10

-118-

The dark red reaction was stirred with potassium carbonate (204 g) for 30 minutes and then filtered and concentrated to dryness. The residue was purified by Biotage, eluting with 3:1 to 2:1 DCM/ EtOAc mixture to give the title compound as
5 a white solid (137.0 g, 49% yield).

Example 501


N-(3-(Hydroxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



10

Into a -78°C solution of N-(3-methoxycarbonylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (75 g, 0.224 mole, 1eq) in THF was added slowly DIBAL-H (561 mL, 1M in toluene, 2.5 eq). The mixture was stirred for 1 hour and then was
15 warmed to 0°C with an ice water bath and stirred for 2 h. The reaction was carefully quenched with methanol (18.50 mL, 0.396 mole, 1.8 eq). It was then diluted with ether (4650 mL) and Saturated Rochelle's salt (2775 mL) and stirred vigorously overnight. The layers were separated and the
20 aqueous extracted with EtOAc (2000 mL). The combined organics were washed with brine, dried with MgSO₄, filtered and concentrated. The residue was chromatographed, eluting with 1:1 DCM/EtOAc to give the title compound as a white solid (51.4 g, 43% Yield).

-119-


Example 502N-(3-Formylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline

Into a -78°C solution of DMSO (20.8 mL, 0.269 mole, 3.1
5 eq) in DCM (460 mL) was added oxalyl chloride (16 mL, 0.109
mole, 1.25 eq) dropwise and stirred for 15 minutes. N-(3-
(Hydroxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline (26.4 g, 0.86 mole, 1 eq) was added dropwise
via addition funnel as a solution in DCM (146 mL). The
10 reaction mixture was stirred for 30 min. then TEA (102 mL, 1
mole, 11.7 eq) was added via addition funnel. The reaction
mixture was allowed to warmed to 0°C with an ice bath and
stirred for 1 hour with a N_2 sweep through a bleach/caustic
scrubber. The reaction mixture was poured into saturated
15 NaHCO_3 and diluted with diethyl ether (2000 mL). The layers
were separated and the aqueous layer backextracted with
diethyl ether (1000 mL). The combined organics were washed
with brine (1000 mL), dried with MgSO_4 , filtered and
concentrated. The residue was purified by flash
20 chromatography, eluting with 1:1 DCM/EtOAc to give the title
compound as a white solid (15.0 g, 57.2).

-120-

Example 503

N-(4-(Hydoxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5 To a -78°C solution of N-(4-methoxycarbonylphenyl)pyrid-3-ylmethylamine (105 g, 0.433 moles, 1eq) in THF (17 volumes) was added slowly DIBAL-H (1M in toluene, 1084 mL, 1.084 moles, 2.5 eq,) and held cold for 1 hour. The reaction was then allowed to warm to 0°C for 2 h. The
10 reaction was carefully quenched with methanol (1.8 eq). It was then diluted with ether (62 volumes) and Saturated Rochelle's salt (37 volumes) and stirred vigorously overnight. The layers were separated and the aqueous extracted with EtOAc. The combined organics were washed
15 with brine, dried with MgSO_4 , filtered, and concentrated to give N-(4-hydroxymethylphenyl)pyrid-3-ylmethylamine (88.2 g, 95 % Yield).

To a 0°C solution of give N-(4-hydroxymethylphenyl)pyrid-3-ylmethylamine (75 g, 0.35 moles, 1eq) and imidazole
20 (26.21 g, 0.384 moles, 1.1 eq) in DCM was added slowly t-butyldimethylsilyl chloride (85.09 g, 564.5 moles, 1.6 eq) and held cold for 1/4 hour. The reaction was then allowed to warm to 0°C overnight. The reaction was partitioned with water and DCM. The organic layer was stripped to give N-(4-
25 t-butyldimeythsilyloxymethylphenyl) pyrid-3-ylmethylamine a yellow solid (115 g, 100% yield)


To a 0°C solution of N-(4-t-butyldimeythsilyloxy methylphenyl)pyrid-3-ylmethylamine (115.25 g, 0.351 moles, 1 eq) in dichloromethane (DCM, 17.7volumes) and pyridine

-121-

(8.7volumes) was added ethanesulfonyl chloride (50.26 g, 0.391 moles, 1.1 eq). The reaction was allowed to warm to room temperature overnight. The dark red reaction was stirred with K_2CO_3 (1 wt eq) for 30 minutes and then
5 filtered and concentrated to dryness. The residue was purified by Biotage with 3:1 to 2:1 DCM/ EtOAc to give N-(4-t-butyl dimeythsilyloxymethylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine a yellow solid (91.24 g, 62% yield).

To a 0°C solution of N-(4-t-butyl dimeythsilyloxymethylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine (90.61 g, 0.215 moles, 1 eq) in DCM (10 volumes) was added tetrabutylammonium fluoride (1.0 M in THF, 252.4 mL, 1.17 eq) dropwise and stirred for 15 minutes. The bath was removed and the reaction allowed to stir
15 overnight. Washed with sat. Na_2CO_3 solution, water, and then brine. Dried the organics with Na_2SO_4 . Stripped to yellow oil. Combined lots and prepped clean with 50/50 EtOAc/DCM on Biotage 75. Triturated solid product to give the title compound (30.0 g, 46% yield).

20

Example 504N-(4-Formylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

To a solution of DMSO (0.190 mL, 2.68 mmol) in 4 mL DCM
25 at -78 °C was added oxalyl chloride (0.146 mL, 1.67 mmol) dropwise. After 15 min a solution of N-(4-(hydroxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (0.241 g, 0.669 mmol) was added via cannula. The reaction was stirred for 30 min and triethylamine (0.932

-122-

mL, 6.69 mmol) was added and warmed to 0 °C over 1 h. The mixture was poured into saturated NaHCO₃ solution and diluted with ether. The organic layer was washed with H₂O and brine, dried over MgSO₄, filtered, and concentrated.


5. The residue was chromatographed on silica gel with 5:1 DCM/EtOAc to give 173 mg of a clear oil (72%). ¹H NMR: 9.97 (s, 1H), 8.50 (dd, J=4.9, 1.5 Hz, 1H), 8.35 (d, J=2.0 Hz, 1H), 7.87 (m, 2H), 7.66 (dt, J=7.8, 2.0 Hz, 1H), 7.44 (m, 2H), 7.24 (ddd, J=7.8, 4.9, 1.0 Hz, 1H), 4.97 (s, 2H), 3.84 (q, J=9.3 Hz, 2H).

10

Example 505

N-(3-(Phenoxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine

-123-




To a solution of triphenylphosphine (0.141 g, 0.539 mmol) in 3.5 mL THF was added diethylazodicarboxylate (0.165 g, 0.539 mmol). After 5 min phenol (0.061 g, 0.646 mmol) was added as a solution in 2 mL THF. After 5 min N-(3-(hydroxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (0.165 g, 0.539 mmol) was added as a solution in 2 mL THF and the reaction was stirred for 3 days. The mixture was diluted with EtOAc, washed with 1 N NaOH and brine, dried over MgSO₄, filtered and concentrated. The residue was chromatographed on silica gel with 4:1 to 2:1 DCM/EtOAc to give the title compounds as a clear oil. ¹H NMR: 8.48 (d, J=1.5Hz, 1H), 8.36 (s, 1H), 7.64 (d, J=7.8Hz, 1H), 7.36-7.23 (m, 5H), 7.19 (m, 2H), 6.95 (t, J=7.8Hz, 1H), 6.91 (d, J=7.8Hz, 1H), 5.01 (s, 2H), 4.84 (s, 2H), 3.03 (q, J=7.6Hz, 2H), 1.39 (t, J=7.6Hz, 3H). MS calcd. 382.1; MS (M+1) 383.1.

-124-


Example 506

N-(4-(Phenoxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5 The title compound was prepared using a method similar to the method of Example 505 using N-(4-hydroxymethyl-phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine. ^1H NMR: 8.41 (d, 1H, $J=3.4\text{Hz}$), 8.29 (d, 1H, $J=1.5\text{Hz}$), 7.63 (d, 1H, $J=7.8\text{Hz}$), 7.00-7.40 (m, 7H), 6.86 (m, 3H), 4.92 (s, 2H), 10 4.81 (s, 2H), 3.00 (q, 2H, $J=7.3\text{Hz}$), 1.34 (t, 3H, $J=7.3\text{Hz}$). MS calcd 382.1; MS (M+1) 383.1.

By a method similar to the method of Example 475 the following compounds were prepared:



15


No.	R2	Data
507	3-(α -hydroxybenzyl)	^1H NMR: 8.43 (dd, $J=4.9, 1.5\text{Hz}$, 1H), 8.29 (d, $J=2.0\text{Hz}$, 1H), 7.63 (dt, $J=8.3, 1.5\text{Hz}$, 1H), 7.36-7.21 (m, 8H), 7.19-7.12 (m, 2H), 5.77 (s, 1H), 4.84 (s, 2H), 3.06 (q, $J=7.3\text{Hz}$, 2H), 2.68 (br s, 1H), 1.39 (t, $J=7.3\text{Hz}$, 3H)
508	4-(α -hydroxybenzyl)	^1H NMR: 8.48 (d, 1H, $J=3.9\text{Hz}$), 8.35 (br s, 1H), 7.73 (d, 1H, $J=7.8\text{Hz}$), 7.34 (m, 5H), 7.30-7.23 (m, 3H), 7.21 (d, 2H, $J=8.3\text{Hz}$), 5.80 (s, 2H), 4.88 (s, 2H), 3.07 (q, 2H, $J=7.3\text{Hz}$), 1.41 (t, 3H, $J=7.3\text{Hz}$). MS calcd

-125-

		382.1; MS (M+1) 383.1
509	3-(α -hydroxy-2-fluorobenzyl)	¹ H NMR: 8.46 (d,1H,J=3.4Hz), 8.32 (s,1H), 7.62 (m,1H), 7.42-6.92 (m,9H), 6.00 (s,1H), 4.85 (s,2H), 3.06 (m,2H), 1.38 (m,3H). MS calcd 400.1; MS (M+1) 401.1
510	3-(α -hydroxy-3-fluorobenzyl)	¹ H NMR: 8.46 (d,1H), 8.34 (s,1H), 7.62 (d,1H), 7.40-7.15 (m,6H), 7.04-6.88 (m,3H), 5.75 (s,1H), 4.85 (s,2H), 3.07 (q,2H,J=7.3Hz), 1.40 (t,3H,7.3Hz). MS calcd 400.1; MS (M+1) 401.1

Example 511

N-(3-(α -Hydroxy-4-ethoxycarbonylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5


A solution of ethoxycarbonylphenylzinc iodide in THF (Rieke Metals, Inc.) (0.5 M, 2.8 ml) was evaporated to dryness under nitrogen. To the residue was added chromium(III) chloride (0.210 g, 1.33 mmole), N-(3-formylphenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine (0.210 g, 0.7 mmole), and tetramethylurea (0.5 + 1.5 ml), followed by chlorotrimethylsilane (0.7 ml, 0.55 mmole) dropwise. The mixture was stirred overnight at room temperature. A few pieces of ice, 1 ml of saturated NaHCO₃ and 1 ml of ethylene diamine were added to the reaction mixture, which was filtered. The organic layer was washed with brine, after extraction with ethyl acetate. Evaporation afforded the crude product, that was chromatographed on a silica-gel column eluted with ethyl acetate and chloroform to give the title compound. ¹H NMR: 8.44 (d,1H, J=4.1Hz), 8.29 (s,1H), 7.99 (d,2H,J=8Hz), 7.62 (d,1H), 7.34-7.14 (m,7H), 5.80 (s,1H), 4.85 (s,2H), 4.36 (q,2H, J=7.1Hz), 3.05

-126-

(q, 2H, J=7.4Hz), 1.41 (m, 6H). MS calcd. 454.2; MS (M+1) 455.2.


Example 512

N- (3- (α-Hydroxy-3-ethoxycarbonylbenzyl)phenyl) -N-
 5 (ethanesulfonyl)pyrid-3-ylmethylaniline



The title compound was prepared using a method similar to the method of Example 511 using 3-ethoxycarbonylphenylzinc chloride (Rieke Metals Inc.) as
 10 starting materials. ¹H NMR: 8.43-8.29 (m, 2H), 7.63 (d, 1H), 7.40-7.00 (m, 9H), 5.80 (s, 1H), 4.85 (s, 2H), 4.36 (q, 2H), 3.08 (m, 4H), 1.38 (m, 6H). MS calcd 454.2; MS (M+1) 455.2.

By a method similar to the method of Example 491 the
 15 following compounds were prepared:




No.	R2	Data
513	3-(4-ethoxycarbonyl benzyl)	¹ H NMR: 8.48 (d, 1H, J=4.3Hz), 8.33 (s, 1H), 7.95 (d, 1H, J=8.2Hz), 7.62 (d, 1H, J=7.8Hz), 7.27-6.94 (m, 7H), 4.85 (s, 2H), 4.36 (q, 2H, J=7.3Hz), 3.95 (s, 2H), 3.10 (q, 2H, J=7.0Hz), 2.04 (1H), 1.38 (m, 6H). MS calcd 438.2; MS (M+1) 439.1
514	3-(2-fluorobenzyl)	¹ H NMR: 8.47 (m, 1H), 8.36 (d, 1H, J=2.0Hz), 7.64 (m, 1H), 7.26-6.96 (m, 9H), 4.85 (s, 2H), 3.93 (s, 2H), 3.08 (q, 2H). MS calcd 384.1; MS (M+1) 385.2

-127-

Example 515


N-(3-(α -Fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



- 5 To a solution of N-(3-(α -hydroxybenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (0.106 g, 2.77 mmol) in DCM was added DAST (0.040 mL, 3.05 mmol). The reaction was stirred overnight and poured into saturated NaHCO₃ solution and extracted with EtOAc, dried over MgSO₄, filtered, and
- 10 concentrated. The residue was chromatographed on silica gel with 2:1 DCM/EtOAc to give the title compound as a clear oil. ¹H NMR: 8.47 (dd, J=4.9, 1.5 Hz, 1H), 8.33 (d, J=2.0 Hz, 1H), 7.63 (dt, J=7.8, 2.0 Hz, 1H), 7.38-7.28 (m, 4H), 7.24-7.16 (m, 6H), 4.89 (AofAB, d, J=14.8 Hz, 1H), 4.83
- 15 (BofABd, J=14.8 Hz, 1H), 3.07 (q, J=7.3 Hz, 2H), 1.40 (t, J=7.3 Hz, 3H). MS calcd. 384.1; MS (M+1) 385.1.

Example 516

20 N-(4-(α -Fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




-128-

By the method of Example 515 using N-(4-(α -hydroxybenzyl)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline gave the title compound. ^1H NMR: 8.49 (d, 1H, $J=3.9\text{Hz}$), 8.37 (br s, 1H), 7.72 (d, 1H, $J=7.8\text{Hz}$), 7.37 (m, 3H), 7.31-7.23 (m, 7H), 6.41 (d, 1H, $J=49.9\text{Hz}$), 4.90 (s, 2H), 3.08 (q, 2H, $J=7.3\text{Hz}$), 1.43 (t, 3H, $J=7.3\text{Hz}$). MS calcd 384.1; MS (M+1) 385.2.


Example 517

10 N-(3-Benzoylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline




To a solution of N-(3-(α -hydroxybenzyl)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline (0.717 g, 1.87 mmol) in 10 mL DCM was added activated MnO_2 (0.489 g, 5.62 mmol).
15 The reaction was gently heated and sonicated for 5 min then stirred overnight. Another portion of MnO_2 (0.489 g, 5.62 mmol) was added and it was sonicated and stirred overnight again. The mixture was filtered through Celite and concentrated to give a pure white solid. ^1H NMR: 8.52
20 (dd, $J=4.9, 1.5\text{Hz}$, 1H), 8.40 (d, $J=2.0\text{Hz}$, 1H), 7.74-7.66 (m, 5H), 7.61 (m, 1H), 7.51-7.42 (m, 4H), 7.25 (dd, $J=7.8, 4.9\text{Hz}$, 1H), 4.93 (s, 2H), 3.14 (q, $J=7.3\text{Hz}$, 2H), 1.45 (t, $J=7.3\text{Hz}$, 3H). MS calcd. 380.1; MS (M+1) 381.1.

-129-

Example 518N-(4-Benzoylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

By the method of Example 517 using N-(4-(α -
5 hydroxybenzyl)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine
the title compound was obtained. ^1H NMR: 8.51
(d, 1H, $J=3.9\text{Hz}$), 8.44 (br s, 1H), 7.79-7.71 (m, 4H), 7.59
(m, 1H), 7.48 (m, 2H), 7.41 (d, 2H, $J=8.3\text{Hz}$), 7.26 (m, 2H), 4.99
(s, 2H), 3.15 (q, 2H, $J=7.3\text{Hz}$), 1.46 (t, 3H, $J=7.3\text{Hz}$). MS calcd
10 380.1; MS (M+1) 381.1.

Example 519N-(3-(1-Phenylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

15


To a suspension of methyltriphenylphosphonium bromide
(0.269 g, 0.752) in 3 mL THF at 0 °C was added KHMDS (0.5 M
in toluene, 1.5 mL, 0.752 mmol). The mixture was warmed to
ambient temperature for 1 h and N-(3-benzoylphenyl)-N-
20 (ethylsulfonyl)pyrid-3-ylmethylamine (0.143 g, 0.376 mmol)
as a solution in 3 mL THF was added via cannula. After 3 h
the mixture was poured into saturated NaHCO_3 solution and
Extracted with EtOAc, dried over MgSO_4 , filtered and

-130-

concentrated. The residue was chromatographed with 10:1 to 5:1 DCM/EtOAc to give the title compound as a clear oil. ^1H NMR: 8.50 (dd, $J=4.9, 1.5\text{Hz}$, 1H), 8.35 (d, $J=2.0\text{Hz}$, 1H), 7.70 (dt, $J=7.8, 2.0\text{Hz}$, 1H), 7.37-7.19 (m, 9H), 7.14 (m, 1H), 5.48 (d, $J=1.0\text{Hz}$, 1H), 5.39 (d, $J=1.0\text{Hz}$, 1H), 4.85 (s, 2H), 3.09 (q, $J=7.3\text{Hz}$, 2H), 1.41 (t, $J=7.3\text{Hz}$, 3H). MS calcd. 378.1; MS (M+1) 379.1.

Example 520


10 N-(4-(1-Phenylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



By the method of Example 519 using N-(4-benzoylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine the title compound was obtained. ^1H NMR: 8.51 (d, 1H, $J=3.9\text{Hz}$), 8.44 (br s, 1H), 7.79-7.71 (m, 4H), 7.59 (m, 1H), 7.48 (m, 2H), 7.41 (d, 2H, $J=8.3\text{Hz}$), 7.26 (m, 2H), 4.99 (s, 2H), 3.15 (q, 2H, $J=7.3\text{Hz}$), 1.46 (t, 3H, $J=7.3\text{Hz}$). MS calcd 380.1; MS (M+1) 381.1.

Example 521

20 N-(3-(α -Methylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



-131-

The title compound was prepared using a method similar to the method of Example 491 using N-[3-(1-

phenylvinyl)phenyl]-N-(ethylsulfonyl)pyrid-3-ylmethylamine.

¹H NMR: 8.47 (dd, J=4.9, 1.5 Hz, 1H), 8.32 (d, J=2.0 Hz, 1H), 7.61

5 (dt, J=7.8, 2.0 Hz, 1H), 7.30-7.05 (m, 9H), 6.99 (m, 1H), 4.82

(s, 2H), 4.08 (q, J=7.3 Hz, 1H), 3.04 (q, J=7.3 Hz, 2H), 1.56


(d, J=7.3 Hz, 3H), 1.38 (t, J=7.3 Hz, 3H). MS calcd. 380.2; MS

(M+1) 381.2.

10

Example 522

N-(4-(α-Methylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylamine



The title compound was prepared using a method similar to the method of Example 491 using N-[3-(1-

15 phenylvinyl)phenyl]-N-(ethylsulfonyl)pyrid-3-ylmethylamine.

¹H NMR: 8.49 (dd, 1H, J=4.4, 1.0 Hz), 8.35 (d, 1H, J=1.5 Hz), 7.72

(d, 1H, J=7.8 Hz), 7.31-7.11 (m, 10H), 4.86 (s, 2H), 4.10

(q, 1H, J=7.3 Hz), 3.07 (q, 2H, J=7.3 Hz), 1.59 (d, 3H, J=7.3 Hz),


20 1.41 (q, 3H, J=7.3 Hz). MS calcd 380.2; MS (M+1) 381.3.

-132-

Preparation 11N-(3-Iodo-4-methylphenyl)pyrid-3-ylmethanamine

The title compound was prepared using a method similar to the method of Preparation 8 with 3-iodo-4-methylaniline as starting material. ^1H NMR: 8.61 (d, $J=1.5\text{Hz}$, 1H), 8.53 (dd, $J=4.9, 2.0\text{Hz}$, 1H), 7.67 (dt, $J=7.8, 1.5\text{Hz}$, 1H), 7.27 (ddd, $J=7.8, 4.9, 1.0\text{Hz}$, 1H), 7.15 (d, $J=2.5\text{Hz}$, 1H), 7.00 (d, $J=8.3\text{Hz}$, 1H), 6.52 (dd, $J=7.8, 2.5\text{Hz}$, 1H), 4.30 (d, $J=5.4\text{Hz}$, 2H), 3.97 (br s, 1H), 2.31 (s, 3H).

10

Example 523N-(3-Iodo-4-methylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine


The title compound was prepared using a method similar to the method of Example 467 using N-(3-iodo-4-methylphenyl)pyrid-3-ylmethanamine. ^1H NMR: 8.50 (d, $J=3.4\text{Hz}$, 1H), 8.36 (d, $J=1.6\text{Hz}$, 1H), 7.69 (m, 2H), 7.26 (t, $J=5.9\text{Hz}$, 1H), 7.14 (d, $J=7.8\text{Hz}$, 1H), 7.08 (dd, $J=7.8, 2.0\text{Hz}$, 1H), 4.84 (s, 2H), 3.08 (q, $J=7.3\text{Hz}$, 2H), 1.42 (t, $J=7.3\text{Hz}$, 1H).

20

-133-

Example 524

N-(3-Formyl-4-methylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




- 5 A mixture of N-(3-iodo-4-methylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine (0.415 g, 0.997 mmol), sodium formate (0.102 g, 1.50 mmol), and dichloro-bis(triphenylphosphine)palladium (0.014 g, 0.020 mmol) were combined in 1.0 mL DMF and purged with anhydrous CO gas.
- 10 The mixture was heated to 100 °C for 1.5 h. The reaction was poured into saturated NaHCO₃ solution and extracted with EtOAc. The combined fractions were washed with H₂O and brine, dried over MgSO₄, filtered and concentrated. The mixture was chromatographed on silica gel with 1:1 EtOAc/DCM
- 15 to give the title compound as a clear oil. ¹H NMR: 10.11 (s,1H), 8.38 (br s,1H), 8.26 (br s,1H), 7.60 (m,2H), 7.13 (m,1H), 7.00 (s,2H), 4.80 (s,2H), 3.00 (q,J=7.3Hz,2H), 2.52 (s,3H), 2.35 (t,J=7.3Hz,3H).

20

Example 525

N-(3-(α-Hydroxybenzyl)-4-methylphenyl)-N-ethanesulfonylpyrid-3-ylmethylamine




-134-

The title compound was prepared using a method similar to the method of Example 475 using N-(3-formyl-4-methylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine. ¹H NMR: 8.46 (br s, 1H), 8.30 (br s, 1H), 7.69 (br d, J=7.8Hz, 1H), 7.45 (s, 1H), 7.36-7.19 (m, 4H), 7.13 (d, J=6.3Hz, 2H), 7.06 (m, 2H), 5.87 (s, 1H), 4.91 (AofAB, d, J=14.7Hz, 1H), 4.82 (BofAB, d, J=14.7Hz, 1H), 3.08 (q, J=7.3Hz, 2H), 2.54 (br s, 1H), 2.13 (s, 3H), 1.41 (t, J=7.3Hz, 3H). MS calcd. 396.2; MS (M+1) 397.2.

10

Example 526

N-(3-Benzyl-4-methylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




15 The title compound was prepared using a method similar to the method of Example 491 using N-(3-(α -hydroxybenzyl)-4-methylphenyl)-N-ethanesulfonylpyrid-3-ylmethylamine. ¹H NMR: 8.49 (d, J=3.9, 1H), 8.32 (br s, 1H), 7.67 (br d, J=7.8Hz, 1H), 7.28-7.17 (m, 4H), 7.09 (d, J=7.8Hz, 1H), 7.02 (dd, J=7.8, 2.0Hz, 1H), 6.97 (d, J=7.4Hz, 2H), 6.88 (d, J=2.3Hz, 1H), 4.81 (s, 2H), 3.88 (s, 2H), 3.06 (q, J=7.3Hz, 2H), 2.18 (s, 3H), 1.39 (t, J=7.3Hz, 3H). MS calcd. 380.2; MS (M+1) 381.2.

20

-135-

Example 527

N-(3-(4-t-Butylphenoxy)-4-methylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




5 The title compound was prepared following Example 342 using N-(3-iodo-4-methylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine and 4-tert-butylphenol and purifying via radial chromatography eluting with 50:50 to 53:47

THF/hexanes gave the title compound. ¹H NMR (400 MHz) 1.32
10 (9H, s), 1.39 (3H, t, J=7.8 Hz), 2.19 (3H, s), 3.07 (2H, q, J=7.8 Hz), 4.79 (2H, s), 6.70 (3H, m), 6.92 (1H, dd, J=2.0, 7.8 Hz), 7.16 (1H, d, J=7.8 Hz), 7.20-7.31 (3H, m), 7.67 (1H, d, J=8.3 Hz), 8.31 (1H, bs), 8.50 (1H, bs). HRMS calculated 439.2055 [M+H]⁺ Found 439.2073.

15

Example 528

N-(3-(2-Methoxyphenoxy)benzyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



20 The title compound was prepared following Example 1 using 3-(2-benzyloxyphenoxy)benzyl amine gave the title compound which was isolated as its HCl salt. ¹H NMR: 8.53 (s, 1H), 8.40 (s, 1H), 7.62 (d, 1H, J=8Hz), 7.14-7.24 (m, 4H),


-136-

6.85-7.00 (m, 4H), 6.77 (s, 1H), 4.39 (s, 2H), 4.30 (s, 2H),
3.80 (s, 3H), 3.56-3.58 (m, 3H). MS calcd. 466.48; MS (M+1)
467.9.

5

Example 529


N-(3-(2-Methoxyphenoxy)benzyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



The title compound was prepared following Example 1
10 using 3-(2-benzyloxyphenoxy)benzyl amine gave the title
compound which was isolated as its HCl salt. ¹H NMR:
8.51 (d, 1H, J=4Hz), 8.39 (s, 1H), 7.65 (d, 1H, J=8Hz), 7.13-7.24
(m, 4H), 6.84-7.02 (m, 4H), 6.78 (s, 1H), 4.34 (s, 2H), 4.25
(s, 2H), 3.81 (s, 3H), 2.92-2.96 (m, 2H), 1.28 (t, 3H, J=8Hz). MS
15 calcd. 412.5; MS (M+1) 413.6.

Example 530

N-(3-(2-Phenylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



20

Benzyltriphenylphosphonium bromide (0.765 g, 1.77
mmol) was dispersed into THF (12 ml) and cooled at 0°C. To
the cooled suspension was added dropwise a solution of
potassium bis(trimethylsilyl)amide (0.5 M, 3.5ml, 1.75
25 mmol). After stirring at 0 °C for 1 h, a solution of). N-


-137-

(3-formyl-phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine
(0.304 g, 1.0 mmol) in THF was added. The reaction mixture
was stirred at ambient temperature for 2 h. Evaporation and
chromatography on silica-gel eluting with toluene-EtOAc to
5 give the title compound. ^1H NMR: 8.48 (d, 1H, $J=3.4\text{Hz}$), 8.30
(d, 1H, $J=2.0\text{Hz}$), 7.65 (d, 1H, $J=7.8\text{Hz}$), 7.30-6.74 (m, 8H), 6.60
(q, 2H, $J=12.2, 37.1\text{Hz}$), 4.68 (s, 2H), 2.87 (q, 2H, $J=7.3\text{Hz}$), 1.28
(t, 3H, $J=7.4\text{Hz}$). MS calcd 378.1; MS (M+1) 379.1.

10

Example 531

N-(3-(2-Phenylethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylamine




N-(2-phenylvinylphenyl)-N-(ethylsulfonyl)pyrid-3-
15 ylmethylamine (0.50 g, 0.13 mmol) was dissolved in ethanol
(5 ml), followed by addition of 5% platinum-on-carbon (0.38
g). After flushing with hydrogen, the mixture was stirred
under hydrogen-ballon at ambient temperature overnight and
filtered. Upon evaporation, it underwent chromatography on
20 silica-gel with eluent of toluene and EtOAc and gave 0.32 g
(64% yield). ^1H NMR: 8.48 (d, 1H, $J=3.4$), 8.34 (s, 1H), 7.68
(s, 1H), 7.30-6.86 (m, 10H), 4.81 (s, 2H), 3.04-2.82 (m, 6H),
1.38 (t, 3H, $J=7.3\text{Hz}$). MS calcd 380.2; MS (M+1) 381.1.

-138-

Example 532


N-(3-(Prop-1-en-1-yl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5 The title compound was prepared using a method similar to the method of Example 530 using N-(3-formylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine. ^1H NMR: 8.39 (d, 1H, $J=1.5\text{Hz}$), 8.30 (s, 1H), 7.62 (d, 1H, $J=8.3\text{Hz}$), 7.22-6.80 (m, 5H), 6.25 (d, 1H, $J=10.3$), 5.70 (m, 1H), 4.80 (s, 1H), 3.01 (q, 2H, $J=7.4\text{Hz}$), 1.72 (d, 3H, $J=6.4\text{Hz}$), 1.34 (t, 3H, $J=7.3\text{Hz}$). MS calcd 316.1; MS (M+1) 317.1.

Example 533

15 N-(3-(2-N,N-Diethylamidovinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




The title compound was prepared using a method similar to the method of Example 530 using N-(3-formylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine. ^1H NMR: 8.41 (d, 1H, $J=3.4\text{Hz}$), 8.32 (s, 1H), 7.70-7.03 (m, 9H), 6.61 (d, 1H, $J=15.1\text{Hz}$), 4.83 (s, 1H), 3.39 (m, 2H), 3.05 (m, 2H), 1.36 (t, 3H, $J=7.3\text{Hz}$), 1.26-1.04 (m, 6H). MS calcd 401.2; MS (M+1) 402.2.

-139-

Example 534


N-(3-(2-Ethoxycarbonylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



- 5 The title compound was prepared using a method similar to the method of Example 530 using N-(3-formylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine. ¹H NMR: 8.50 (d, 1H, J=1.5Hz), 8.37 (s, 1H), 7.80-7.50 (m, 2H), 7.30-7.10 (m, 4H), 4.90 (s, 2H), 4.25 (q, 2H, J=7.3Hz), 3.10 (q, 2H, 7.3Hz), 1.50-1.28 (m, 6H). MS calcd 374.1; MS (M+1) 375.1.

Example 535

N-(3-Propylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




- 15 The title compound was prepared using a method similar to the method of Example 431. ¹H NMR: 8.48 (d, 1H, J=3.4Hz), 8.35 (d, 1H, J=1.5Hz), 7.70 (d, 1H, 7.8Hz), 7.21 (m, 2H), 7.05 (m, 3H), 4.87 (s, 2H), 3.10 (q, 2H, J=7.8Hz), 2.50 (t, 2H, J=7.3Hz), 1.75-1.20 (m, 6H), 0.85 (t, 3H, J=7.3Hz). MS calcd 318.1; MS (M+1) 319.1.

-140-

Example 536

N-(3-Trifluoromethoxyphenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethamine




5 3-(Trifluoromethoxy)aniline (0.602 g, 3.4 mmol) and
pyridine-3-carboxaldehyde (0.400g, 3.7 mmol) were dissolved
in methanol (10 ml). The solution was refluxed for 3 h and
then cooled in an ice-bath. To the solution was added
sodium borohydride (0.212 g, 5.5 mmol) in portions. The
10 reaction mixture was stirred at ambient temperature
overnight. After addition of small pieces of ice, the
solvent was evaporated to near dryness. The residue was
dissolved in cold water and extracted with ethyl acetate. The
organic phase was washed with brine and dried over MgSO_4 .
15 Filtration and evaporation afforded N-(3-
trifluoromethoxyphenyl)pyrid-3-ylmethamine. ^1H NMR: 8.43-
8.44 (m, 2H), 7.60 (d, 1H), 7.00-7.30 (m, 3H), 6.20-6.40 (m, 2H),
4.27 (d, 5.4 Hz). MS calcd 268.1; MS (M+1) 269.0.

N-(3-trifluoromethoxyphenyl)pyrid-3-ylmethamine (0.270
20 g, 1 mmol) and pyridine were dissolved in dichloroethane (2
ml). The solution was cooled in an ice-bath. To the
solution was added 2,2,2-trifluoroethylsulfonyl chloride
(0.274 g, 1.5 mmol). The mixture was stirred at room
temperature overnight. Upon removing solvent, the residue
25 was dissolved in water and extracted with EtOAc. The
organic phase was washed with brine concentrated. The
residue was chromatographed to afford the title compound.
 ^1H NMR: 8.42 (d, 1H, $J=6.4\text{ Hz}$), 8.20 (d, 1H, $J=2.0\text{ Hz}$), 7.57

-141-

(d, 1H, J=9.8Hz), 7.40-6.85 (m, 5H), 4.81 (s, 2H), 3.72 (q, 2H, J=7.8Hz). MS calcd 414.1; MS (M+1) 415.1.

By a method similar to the method of Example 536 the following compounds were prepared:




No.	R1	R2	Data
537	SO ₂ CH ₂ CH ₃	3-trifluoromethoxy	¹ H NMR: 8.42 (s, 1H), 8.29 (s, 1H), 7.60 (d, 1H), 7.00-7.30 (m, 5H), 4.81 (s, 2H), 3.01 (q, 2H, J=7.3Hz), 1.35 (t, 3H, J=7.3). MS calcd 360.1; MS (M+1) 361.2.
538	SO ₂ CH ₂ CF ₃	4-trifluoromethyl	¹ H NMR: 8.43 (d, 1H, J=3.9Hz), 8.26 (s, 1H), 7.56 (m, 3H), 7.00-7.30 (m, 3H), 4.85 (s, 2H), 3.72 (q, 2H, J=8.3Hz). MS calcd 398.05; MS (M+1) 399.1
539	SO ₂ CH ₂ CF ₃	4-trifluoromethoxy	¹ H NMR: 8.44 (d, 1H, J=3.9Hz), 8.25 (d, 1.5Hz), 7.59 (d, 1H, J=7.8Hz), 5.00-7.30 (m, 5H), 4.80 (s, 2H), 3.72 (q, 2H, J=8.8Hz). MS calcd 414.1; MS (M+1) 415.1
540	SO ₂ CH ₂ CH ₃	4-trifluoromethoxy	¹ H NMR: 8.42 (d, 1H, J=3.4Hz), 8.29 (d, 1H, J=2.0Hz), 7.61 (d, 1H, J=7.8Hz), 7.00-7.25 (m, 5H), 4.79 (s, 2H), 3.01 (q, 2H, J=7.3Hz), 1.35 (t, 3H, J=7.3Hz). MS calcd 360.1; MS (M+1) 361.2
541	SO ₂ CH ₂ CF ₃	3-methoxy	¹ H NMR: 8.41 (d, 1H, J=3.4Hz), 8.26 (s, 1H), 7.59 (d, 1H, J=7.8Hz), 7.17 (m, 2H), 6.60-6.86 (m, 3H), 4.79 (s, 2H), 3.50-3.82 (m, 5H). MS calcd 360.1; MS (M+1) 361.1
542	SO ₂ CH ₂ CF ₃	4-(prop-2-yl)	¹ H NMR: 8.42 (d, 1H, J=3.9Hz), 8.23 (1H), 7.62 (d, 1H, J=7.8Hz), 6.96-7.26 (m, 5H), 4.78 (s, 2H), 3.71 (q, 2H, J=9.3Hz), 2.79 (quint, 1H, J=7.3Hz), 1.13 (d, 6H, J=7.8Hz). MS calcd 372.1; MS (M+1) 373.2.
543	SO ₂ CH ₂ CF ₃	2-trifluoromethoxy	¹ H NMR: 8.44 (m, 1H), 8.18 (d, 1H, J=2.0Hz), 7.62 (d, 1H, J=7.8Hz), 6.80-7.40 (m, 5H), 3.80 (q, 2H, J=9.3Hz).

-142-

			MS calcd 414.1; MS (M+1) 415.1
544	SO ₂ CH ₂ CF ₃	3-(prop-2-yloxy)	¹ H NMR: 8.41 (d, 1H, J=3.4Hz), 8.26 (d, 1H, J=1.5Hz), 7.59 (d, 1H, J=7.8Hz), 7.10-7.22 (m, 2H), 6.56-6.80 (m, 3H), 4.79 (s, 2H), 4.34 (m, 1H, J=5.9Hz), 3.73 (q, 2H, J=9.2Hz), 1.17 (d, 6H, J=5.9Hz). MS calcd 388.1; MS (M+1) 389.2

Example 545

N- (3-Benzyl-4-chlorophenyl) -N- (2,2,2-
 5 trifluoroethanesulfonyl)pyrid-3-ylmethylamine



2-Chloro-5-nitrobenzophenone (1.3 g, 5.0 mmol), tin(II) chloride (4.5 g, 20 mmol), and ethanol (20 ml) were mixed and heated at 70 °C for 1 h. After cooling to room temperature, to the reaction mixture were added ice, EtOAc and aqueous NaHCO₃ and it was stirred for 30 min. The organic layer was washed with brine and dried over MgSO₄. Filtration and evaporation afforded 5-amino-2-chlorobenzophenone. ¹H NMR, 7.85 (m, 2H), 7.30-7.66 (m, 3H), 7.20 (d, 1H, J=8.8Hz), 6.60-6.80 (m, 2H). MS calcd 231.1; MS (M+1) 232.0.

5-Amino-2-chlorobenzophenone (1.2 g, 5.2 mmol) and pyridine-3-carboxaldehyde (0.642 g, 6 mmol) were dissolved in methanol. The solution was refluxed for 2 h and then cooled in ice-bath. To the cold solution was added sodium borohydride (0.741 g, 19.5 mmol) in portions. The reaction mixture was stirred at ambient temperature overnight. After addition of small pieces of ice, most of the solvent was evaporated. The residue was dissolved in water and

-143-

extracted with EtOAc. The combined organic layer was washed with brine and dried over MgSO_4 . Upon filtering and evaporation, solid precipitated, when chloroform was added to the oil. After cooling for a while, filtration and
5 drying gave N-(3-(α -hydroxybenzyl)-4-chlorophenyl)pyrid-3-methylamine. ^1H NMR, 8.40-8.70 (m, 2H), 7.65 (d, 1H), 7.00-7.50 (m, 7H), 6.83 (d, 1H, $J=2.5\text{Hz}$), 6.43 (d, 1H), 6.14 (s, 1H). MS calcd 324.1; MS (M+1) 325.1.


N-(3-(α -hydroxybenzyl)-4-chlorophenyl)pyrid-3-
10 methylamine (0.105 g, 0.32 mmol) was dispersed into methylene chloride (5 ml) and triethylsilane (1 ml). The mixture was cooled in an ice-bath. To the cooled suspension was added trifluoroacetic acid (0.6 ml) and then stirred overnight. The reaction mixture was cooled at 0 °C, to which
15 was added ice, aqueous NaHCO_3 and chloroform. The organic phase was washed with brine and evaporated to dryness. Chromatography afforded N-(3-benzyl-4-chlorophenyl)pyrid-3-ylmethylamine. ^1H NMR: 8.53 (d, 2H, $J=14\text{Hz}$), 7.19 (d, 1H, $J=8\text{Hz}$), 7.00-7.40 (m, 8H), 6.20-6.40 (m, 2H), 4.27
20 (s, 2H), 3.99 (s, 2H). MS calcd 308.1; MS (M+1) 309.1.

N-(3-benzyl-4-chlorophenyl)pyrid-3-ylmethylamine (0.04 g, 0.13 mmol) and pyridine (1 ml) was dissolved in DCM. The reaction was cooled in an ice-bath to which was added dropwise 2,2,2-trifluoroethylsulfonyl chloride (0.59 g, 0.32
25 mmol). The mixture was stirred at room temperature overnight. After evaporation of solvent, the residue was dissolved in EtOAc and washed with cold NaHCO_3 and brine, and evaporated to dryness. Chromatography gave the title compound. ^1H NMR: 8.51 (d, 1H, $J=3.9\text{Hz}$), 8.27 (s, 1H), 7.59
30 (d, 1H, $J=7.8\text{Hz}$), 7.34 (t, 1H, $J=8.3\text{Hz}$), 7.28 (d, 2H, $J=7.8\text{Hz}$), 7.21 (m, 2H), 8.03 (m, 3H), 6.89 (d, 1H, $J=2.4\text{Hz}$), 4.78 (s, 2H), 4.01 (s, 2H), 3.73 (q, 2H, $J=9.3\text{Hz}$). MS calcd 454.1; MS (M+1) 455.0.

-144-

Preparation 12N-(4-(3-Hydroxyphenyl)pyrid-3-ylmethylamine

3-Pyridinecarboxaldehyde (0.550 g, 5 mmol) and 3-aminophenol (0.540 g, 5 mmol) were dissolved into methanol (15 ml). To the solution was added a mixture of sodium cyanoborohydride (0.378 g, 6 mmol) and zinc chloride (0.408 g, 3.0 mmol) in methanol at room temperature. The reaction mixture was stirred for 2.5 h. Most of the methanol was evaporated under reduced pressure. Ice water was added to the residue. It was filtered and the layers were separated. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over MgSO_4 , filtered, and concentrated to give the title compound. ^1H NMR: 8.53 (s, 1H), 8.45 (d, 1H, $J=3.9\text{Hz}$), 7.72 (d, 1H, $J=7.8\text{Hz}$), 7.24-7.30 (m, 2H), 6.95-7.01 (m, 1H), 4.27 (s, 2H). MS calcd. 200.1; MS (M+1) 201.1.

Example 546N-(4-(3-Cyclobutyloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine


Sodium hydride (60% in mineral oil, 0.072 g, 1.8 mmol) was suspended in DMF at 0 °C. To the dispersion was added dropwise N-(3-hydroxyphenyl)pyrid-3-ylmethylamine (0.250 g, 1.24 mmol) as a solution in DMF. The reaction mixture was stirred at room temperature for 30 min. Then bromocyclobutane (0.25 g, 1.84 mmol) was added as a solution in DMF. The reaction was concentrated and the residue was diluted with water, extracted with EtOAc, washed with brine,

-145-

dried over MgSO_4 , filtered and concentrated. The residue was purified by silica-gel chromatography to give N-(4-(3-Cyclobutyloxyphenyl)pyrid-3-yl)methylamine. ^1H NMR: , 8.61 (d, 1H, $J=2.3\text{Hz}$), 8.51 (q, 1H, $J=1.6, 3.13$), 7.68 (m, 1H), 7.25 (m, 1H), 7.04 (t, 1H, $J=1.7\text{Hz}$), 6.18-6.24 (m, 2H), 6.09 (t, 1H, $J=2.3\text{Hz}$), 4.6 (quint, 1H, $J=6.7\text{Hz}$), 2.33-2.42 (m, 2H), 2.06-2.18 (m, 2H), 1.76-1.88 (m, 1H), 1.57-1.70 (m, 1H). MS calcd. 254.1; MS (M+1) 255.1.

To a solution of give N-(4-(3-Cyclobutyloxyphenyl)pyrid-3-yl)methylamine (0.180 g, 0.71 mmol) in DCM (5 ml) and pyridine (1 ml) was dropped a solution of 2,2,2-trifluoroethylsulfonyl chloride (0.156 g, 0.85 mmol) in DCM (1ml) at 0°C . The reaction mixture was stirred overnight ambient temperature. After evaporation of solvent, the residue was diluted with ice water and extracted with EtOAc. The organic layer was washed with brine, evaporated and chromatographed on silica gel eluting with chloroform / ethyl acetate to give the title compound. ^1H NMR: 8.50 (d, 1H, $J=4.7\text{Hz}$), 8.34 (s, 1H), 7.65-7.69 (m, 1H), 7.21-7.26 (m, 2H), 6.74-6.80 (m, 2H), 6.63 (t, 1H, $J=2.0\text{Hz}$), 4.53 (q, 1H, $J=7.0\text{Hz}$), 3.80 (q, 2H, $J=8.0\text{Hz}$), 2.82-2.90 (m, 2H), 2.03-2.15 (m, 2H), 1.77-1.89 (m, 1H), 1.60-1.73 (m, 2H). MS calcd. 400.1; MS (M+1) 401.2.

By a method similar to the method of Example 546 the following compounds were prepared:



No.	R2	Data
547	3-isobutyloxy	^1H NMR: 8.51 (m, 1H), 8.35 (d, 1H, $J=2.0\text{Hz}$), 7.68


		(m,1H), 7.25 (m,2H), 6.66-6.90 (m,3H), 4.88 (s,2H), 3.80 (q,2H,J=9.0Hz), 3.61 (d,2H,J=5.7Hz), 2.01 (m,1H,J=6.6Hz), 1.00 (d,6H,J=6.5Hz). MS calcd ; MS (M+1)
548	3-sec-butoxyl	¹ H NMR: 8.48 (d,1H,J=3.5Hz), 8.35 (s,1H), 7.67 (m,1H), 7.20-7.28 (m,2H), 6.60-6.90 (m,3H), 4.87 (s,2H), 4.17 (m,1H,J=6.2Hz), 3.82 (q,2H,J=9.0Hz), 1.45-1.75 (m, 2H), 1.20 (d,3H,J=5.9Hz), 0.92 (t,3H,J=7.4Hz). MS calcd 402.1; MS (M+1) 403.2
549	3-cyclopentyloxy	¹ H NMR: 8.52 (d,1H,J=4.3Hz), 8.35 (s,1H), 7.68 (m,1H), 7.26 (m, 2H), 6.60-6.90 (m, 3H), 4.87 (s,2H), 4.62 (m,2H), 3.82 (q,2H,J=9.0Hz), 1.40-2.00 (m,8H). MS calcd 414.1; MS (M+1) 415.2
550	3-cyclohexyloxy	¹ H NMR: 8.20-8.40 (m,2H), 7.69 (m,1H), 7.25 (m,2H), 6.60-6.94 (m,3H), 4.87 (s,2H), 4.11 (m,1H), 3.83 (q,2H,J=8.8Hz), 1.10-2.00 (m,10H). MS calcd 428.1; MS (M+1) 429.1
551	3-(1-ethoxycarbonyl-1,1-dimethyl methoxy)	¹ H NMR: 8.49 (m,1H), 8.33 (d,1H,J=1.9Hz), 7.66 (m,1H), 7.24 (m,2H), 6.60-6.90 (m,3H), 4.85 (s,2H), 4.17 (q,2H,J=7.5Hz), 3.80 (q,2H,J=9.4Hz), 1.52 (s,6H), 1.20 (t,3H,J=7.0Hz). MS calcd 460.1; MS (M+1) 461.1.
552	3-(1-ethoxycarbonyl-1-methylmethoxy)	¹ H NMR: 8.51 (m,1H), 8.35 (d,1H,J=1.9Hz), 7.66 (m,1H), 7.24 (m,2H), 6.82 (m,3H), 4.87 (s,2H), 4.64 (q,1H,J=6.6Hz), 4.18 (q,2H,J=7.0Hz), 3.80 (q,2H,J=9.0Hz), 1.60 (s,6H), 1.23 (t,3H,J=8.9Hz). MS calcd 446.1; MS (M+1) 447.0.
553	3-(1-(ethoxycarbonyl)-cyclobut-1-yloxy	¹ H NMR: 8.50 (m,1H), 8.32 (d,1H,J=2.0Hz), 7.66 (m,1H), 7.25 (m,2H), 6.50-6.90 (m,3H), 4.85 (s,2H), 3.88 (q,2H,J=7.3Hz), 3.78 (q,2H,J=9.0Hz), 2.68 (m,2H), 2.36 (m,2H), 2.00 (m,2H), 1.13 (t,3H,J=7.0Hz). MS calcd 472.1; MS (M+1) 473.1.
554	3-pent-3-yloxy	¹ H NMR: 8.51 (m,1H), 8.35 (d,1H,J=2.0Hz), 7.67 (m,1H), 7.24 (m,2H), 6.60-6.90 (m,3H), 4.87 (s,2H), 3.98 (m,1H,J=5.5Hz), 3.82 (q,2H,J=9.3Hz), 1.59 (m,4H), 0.89 (t,6H,J=7.4Hz). MS calcd 416.1; MS (M+1) 417.1
555	3-pent-2-yloxy	¹ H NMR: 8.50 (m,1H), 8.35 (d,1H,J=2.0Hz), 7.67 (m,1H), 7.23 (m,2H), 6.60-6.90 (m,3H), 4.87 (s,2H), 4.24 (m, 1H,J=5.9Hz), 3.82 (q,2H,J=9.0Hz), 1.27-1.80 (m,4H), 1.21 (d,3H,J=5.9Hz), 0.90 (t,3H,J=7.1Hz). MS calcd 416.1; MS (M+1) 417.2
556	3-(2,2,2-trifluoroethoxy)-	¹ H NMR: 8.52 (m,1H), 8.35 (d,1H,J=1.6Hz), 7.67 (m,1H), 7.26 (m,2H), 6.70-6.98 (m,3H), 4.89 (s,2H), 4.26 (q,2H,J=7.8Hz), 3.81 (q,2H,J=8.4Hz). MS calcd 428.1; MS (M+1) 429.1
557	3-(2-methyl-	¹ H NMR: 8.51 (s,1H), 8.35 (d,1H,J=2.4Hz), 7.67

-147-

	butyloxy)	(m,1H), 7.24 (m,2H), 6.60-6.90 (m,3H), 4.88 (s,2H), 3.80 (q,2H,J=9.0Hz), 3.62 (m,2H), 1.78 (m,1H), 1.52 (m,1H), 1.23 (m,1H), 0.95 (m,6H). MS calcd 416.1; MS (M+1) 417.2
558	3-(ethoxycarbonyl methoxy)	¹ H NMR: 8.50 (d,1H,J=4.9Hz), 8.35 (d,1H,J=2.0Hz), 7.65 (m,1H), 7.26 (m, 2H), 6.60-6.90 (m,3H), 4.87 (s,2H), 4.53 (s,2H), 4.24 (q,2H,J=7.3Hz), 3.80 (q,2H,J=8.8Hz), 1.27 (t,3H,J=7.3Hz). MS calcd 432.1; MS (M+1) 433.0

Example 559

N-(3-(2-Fluoro-4-cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline




5

Prepare by the method of Example 342 using 3,4-difluoro-4-cyanobenzene and N-(3-hydroxyphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, purifying via radial chromatography eluting with 50:50 to 60:40 THF/hexanes, to give the title compound. Anal Calcd for C₂₁H₁₈FN₃O₃S: C, 61.30; H, 4.41; N, 10.21. Found: C, 61.32; H, 4.50; N, 10.07. MS found 412.0 [M+H]⁺.

-148-

Example 560

N-(4-(2-Fluoro-4-amidophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



5 A solution of N-(4-hydroxyphenyl)-3-pyridylmethylamine (1.0 equiv.) in DMF (0.1-0.3M) was treated with sodium hydride (1.0-1.5 equiv.) (60% dispersion in mineral oil). The reaction mixture was allowed to stir at room temperature for 30 minutes. The solution was then treated with 3,4-
10 difluorobenzonitrile (1.6 equiv.) and allowed to stir. When complete (about 3 hours) the reaction mixture was partitioned between ethyl acetate/0.1M K₂CO₃, the organic layer separated, and the aqueous layer extracted 3 times with ethyl acetate. The organic layers were combined,
15 washed with brine, and dried over MgSO₄. The organic phase was concentrated in vacuo and purified by recrystallization from ethyl acetate/hexanes to give N-(4-(2-fluoro-4-cyanophenoxy)phenyl)-3-pyridylmethyl-amine ¹H NMR (400 MHz, DMSO-d₆): 4.29 (2H, d, J=5.9 Hz), 6.40 (1H, t, J=5.5 Hz),
20 6.63-6.65 (2H, m), 6.83 (1H, t, J=8.6 Hz), 6.90-6.92 (2H, m), 7.33-7.36 (1H, m), 7.55-7.57 (1H, m), 7.74-7.76 (1H, m), 7.93-7.97 (1H, m), 8.43-8.44 (1H, m), 8.58 (1H, s). MS Found 320.1 [M+H]⁺.

25 A solution (0.1M) of N-(4-(2-fluoro-4-cyanophenoxy)phenyl)-3-pyridylmethylamine (1.0 equiv.) in 85% v/v H₂SO₄ was allowed to stir at room temperature for 18 to 24 hours. The reaction mixture was poured over ice and neutralized with an appropriate amount of concentrated NaOH.

-149-

The mixture was extracted 3 times with ethyl acetate, washed with brine, dried over MgSO_4 , and concentrated in vacuo to give N-(4-(2-fluoro-4-amidophenoxy)phenyl)-3-pyridylmethylamine as a crystalline solid. ^1H NMR (400MHz, DMSO-d_6):

5 4.28 (2H, d, $J=5.9$ Hz), 6.31 (1H, t, $J=6.1$ Hz), 6.61-6.64 (2H, m), 6.81 (1H, t, $J=8.6$ Hz), 6.84-6.87 (2H, m), 7.33-7.36 (1H, m), 7.38 (1H, s), 7.60-7.63 (1H, m), 7.73-7.80 (2H, m), 7.93 (1H, s), 8.43-8.44 (1H, m), 8.58 (1H, d, $J=2.0$ Hz).
MS Found 338.1 $[\text{M}+\text{H}]^+$.

10 A solution of N-(4-(2-fluoro-4-amidophenoxy)phenyl)-3-pyridylmethylamine (1.0 equiv.) in DCM / pyridine (1/1 v/v) (0.2M) was cooled to 0°C and treated with 2,2,2-trifluoroethanesulfonyl chloride (1.2 equiv.). The mixture was allowed to stir while the temperature was maintained at
15 $0-2^\circ\text{C}$. The reaction was complete in approximately 5 minutes. The reaction mixture was partitioned between ethyl acetate/0.1 M K_2CO_3 , the organic layer separated, and the aqueous layer extracted 2-4 times with ethyl acetate. The organic layers were combined, washed with brine, and dried.
20 over MgSO_4 . The organic phase was concentrated in vacuo and purified via preparative HPLC eluting with methanol (2%) / ethyl acetate. The title compound was afforded by recrystallization from ethyl acetate/hexanes. Anal Calcd for $\text{C}_{21}\text{H}_{17}\text{F}_4\text{N}_3\text{O}_4\text{S}$: C, 52.17; H, 3.54; N, 8.69. Found: C, 51.78; H, 3.47; N, 8.45. MS found 484.1 $[\text{M}+\text{H}]^+$.
25


The HCl salt was obtained by combining N-(4-(2-fluoro-4-amidophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine (1 equiv.) in acetonitrile (0.4M) and adding 1.1 equiv. of HCl (0.27M), the solution was cooled to
30 -78°C , and lyophilized over a 72 hour period to afford the HCl salt. Anal Calcd for $\text{C}_{21}\text{H}_{17}\text{F}_4\text{N}_3\text{O}_4\text{S}\cdot\text{HCl}\cdot 0.8\text{H}_2\text{O}$: C, 47.21; H, 3.70; N, 7.86; Cl, 6.64. Found: C, 46.97; H, 3.56; N, 7.74; Cl, 7.03.

-150-

¹H NMR (400 MHz, DMSO-d₆): 4.83 (2H, q, J=9.8 Hz), 5.05 (2H, s), 7.00-7.02 (2H, m), 7.20 (1H, t, J=8.6 Hz), 7.38-7.40 (2H, m), 7.51 (1H, s), 7.73-7.75 (1H, m), 7.80-7.84 (1H, m), 7.85-7.88 (1H, m), 8.06 (1H, s), 8.24 (1H, d, J=8.1 Hz), 8.67 (1H, s), 8.71 (1H, d, J=4.8 Hz). MS found 484.1 [M+H]⁺.

Example 561

N-(3-(2-Fluoro-4-cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



10

Prepare by the method of Example 342 using N-(3-hydroxyphenyl)-3-pyridylmethylamine and 3,4-difluor-4-cyanobenzene gave N-(3-(2-fluoro-4-cyanophenoxy)phenyl)pyrid-3-ylmethylamine which was purified by recrystallization from ethyl acetate/hexanes. ¹H NMR (400 MHz): 4.25 (1H, s), 4.36 (2H, d, J=5.5 Hz), 6.30 (1H, t, J=2.0 Hz), 6.38 (1H, m), 6.48 (1H, m), 6.96 (1H, t, J=8.2 Hz), 7.17 (1H, t, J=8.20 Hz), 7.28 (1H, m), 7.33 (1H, d, J=8.6 Hz), 7.44 (1H, m), 7.67 (1H, d, J=7.8 Hz), 8.55 (1H, s), 8.61 (1H, s). MS Found 320.2 [M+H]⁺.

20

Sulfonation by the method of Example 526 in 1.8:1 dichloroethane/pyridine (0.25M) and raising the temperature after addition of to 45°C for 1 hour and 15 minutes after addition of the 2,2,2-trifluoroethanesulfonyl chloride. Next, 50 mg of anhydrous K₂CO₃ was added to the reaction mixture and it was allowed to stir for 45 minutes. The mixture was next filtered through Celite® (521) and concentrated in vacuo. The crude material was


25

-151-

chromatographed via normal phase radial chromatography eluting with 1:1 to 0:1 hexanes/THF. The material was chromatographed a second time via normal phase radial chromatography eluting with 30:70 acetone/hexanes to give
5 the title compound. Anal Calcd for $C_{21}H_{15}F_4N_3O_3S$: C, 54.19; H, 3.25; N, 9.03. Found: C, 54.28; H, 3.30; N, 8.97. MS found 466.1 $[M+H]^+$.

Example 562

10 N-(3-(2,4-Difluoro-4-cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



Prepare by the method of Example 351 using N-(3-hydroxyphenyl)-3-pyridylmethylamine and 3,4,5-difluoro-4-cyanobenzene gave N-(3-(2,4-difluoro-4-cyanophenoxy)phenyl)pyrid-3-ylmethylamine which was purified by
15 recrystallization from ethyl acetate/hexanes. 1H NMR(400 MHz, DMSO): 4.24(2H, d, $J=5.9$ Hz), 6.11(1H, m), 6.15(1H, t, $J=2.2$ Hz), 6.35(1H, m), 6.50(1H, t, $J=5.9$ Hz), 7.00(1H, t, $J=8.1$ Hz), 7.32(1H, m), 7.67(1H, m), 8.00(2H, m), 8.43(1H, d, $J=3.4$ Hz), 8.51(1H, s). MS Found 338.2 $[M+H]^+$.
20

The title compound was prepared following the procedure Example 526 using N-(3-(2,5-difluoro-4-cyanophenoxy)phenyl)-3-pyridylmethylamine and 2,2,2-trifluoroethanesulfonyl
25 chloride in 2:1 dichloroethane/pyridine (0.23M) and the temperature was raised to 40°C for 4 hours after addition of 2,2,2-trifluoroethanesulfonyl chloride. Next, 50 mg of anhydrous K_2CO_3 was added to the reaction mixture and it was


-152-

allowed to stir for 40 minutes. The mixture was next filtered through Celite® (521) and concentrated in vacuo. The crude material was chromatographed via normal phase radial chromatography eluting with 20:80 ethyl

- 5 acetate/dichloromethane gave the title compound. Anal Calcd for $C_{21}H_{14}F_5N_3O_3S$: C, 52.18; H, 2.92; N, 8.69. Found: C, 52.12; H, 2.84; N, 8.61. MS found 484.0 $[M+H]^+$.

Example 563

- 10 N-(4-(2-Fluoro-4-cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




- Prepare by the method of Example 351 using N-(4-hydroxyphenyl)-N-(ethanesulfonyl)-3- and 3,4-difluorobenzonitrile and purifying via radial chromatography eluting with 50:50 to 60:40 THF/hexanes. Anal Calcd for $C_{21}H_{18}FN_3O_3S$: C, 61.30; H, 4.41; N, 10.21. Found: C, 61.32; H, 4.50; N, 10.07.
- 15

-153-

Example 564


N-(4-(2-Fluoro-4-amidophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine



- 5 Prepare by the method of Example 560 using N-(4-(2-fluoro-4-cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine and 85% aqueous H₂SO₄ (0.1M). The resultant solution was stirred for 3 days. (The reaction does not take 3 days and can be monitored by TLC). The pH of the
- 10 reaction was adjusted to 10 with 5 N NaOH followed by saturated aqueous NaHCO₃ and extracted twice with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product was purified via reverse-phase
- 15 chromatography affording the HCl salt. Anal Calcd for C₂₁H₂₀FN₃O₄S•0.9HCl: C, 54.56; H, 4.56; N, 9.09. Found: C, 54.72; H, 4.55; N, 8.95. MS found 430.4 [M+H]⁺

Example 565

- 20 N-(3-(Bromomethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine




-154-

Resin-supported triphenylphosphine (1.6 g, 3 mmol per gram resin) was dispersed on dichloromethane. At 0 °C, bromine (0.850 g, 5.3 mmol) solution was added dropwise to the resin. And the mixture was stirred for 15 min, followed
5 by dropping a solution of N-(3-hydroxymethylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline (0.930 g, 3 mmol). After 1 h, the resin was filtered and washed with CHCl₃. Evaporation afforded the title compound. ¹H NMR: , 8.81 (s,1H), 8.68 (d,1H, J=5.4Hz), 8.47 (d,1H,J=8.3Hz), 7.91 (m,1H), 7.26-7.39 (m,1H), 5.16 (s,2H), 4.40 (s,2H), 3.12
10 (q,2H,J=7.3Hz), 1.40 (t,3H,J=7.3Hz). MS calcd. 370.0; MS (M+1) 371.1.

Example 566

15 N-(3-(2-Methoxybenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline




-155-

The flask was charged with N-(3-bromomethylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine (0.180 g, 0.500 mmol), 2-methoxyphenylboronic acid (0.113 g, 0.75 mmol), 4.5 ml of DME, 1.5 ml of 2 M Na₂CO₃, and tetrakis(triphenylphosphine) palladium(0) (0.018 g, 0.016 mmol). After N₂-flushing, the mixture was heated at 50 °C overnight. The reaction mixture was concentrated, diluted with water, and extracted with EtOAc. The organic layer was washed with brine and concentrated. The residue was chromatographed on a silica-gel column with 1:1 to 1:3 toluene/EtOAc to afford the title compound. ¹H NMR: , 8.37 (d, 1H, J=3.9Hz), 8.24 (s, 1H), 7.55 (d, 1H, J=7.8Hz), 6.74-7.17 (m, 9H), 4.76 (s, 2H), 3.80 (s, 2H), 3.69 (s, 2H), 2.94 (q, 2H, J=7.3Hz), 1.32 (t, 3H, J=7.3Hz). MS calcd. 396.2; MS (M+1) 397.2.

15

By a method similar to the method of Example 566 the following compounds were prepared:



No.	R ₂	Data
567	3-(2-trifluoromethylbenzyl)	¹ H NMR: 8.47 (d, 1H, J=4.9Hz), 8.31 (br s, 1H), 7.65 (m, 2H), 7.44 (m, 1H), 7.33 (m, 1H), 7.25 (d, 1H, J=7.8Hz), 7.21 (dd, 1H, J=7.8, 4.9Hz), 7.11 (br dd, 2H, J=7.8Hz), 7.06 (br d, 1H, J=7.3Hz), 7.01 (br d, 1H, J=7.8Hz), 6.95 (br s, 1H), 4.12 (s, 2H), 3.06 (q, 2H, J=7.3Hz), 1.40 (t, 3H, J=7.3Hz). MS calcd 434.1; MS (M+1) 435.2
568	3-(4-cyanobenzyl)	¹ H NMR: 8.48 (d, 1H, J=3.9Hz), 8.31 (s, 1H), 7.66 (d, 1H, J=7.8Hz), 7.55 (d, 2H, J=7.8Hz), 7.27 (m, 2H), 7.20 (m, 1H), 7.13 (m, 2H), 7.04 (d, 1H, J=7.3Hz), 6.97 (s, 1H), 4.85 (s, 2H), 3.95 (s, 2H), 3.08 (q, 2H, J=7.3Hz), 1.41 (t, 3H, J=7.3Hz). MS calcd 391.1; MS (M+1) 392.3
569	3-(2-chlorobenzyl)	¹ H NMR: 8.48 (br s, 1H), 8.33 (br s, 1H), 7.66 (br d, 1H, J=7.8Hz), 7.36 (m, 1H), 7.28-7.17 (m, 4H), 7.09 (br d, 2H, J=7.8Hz), 7.02 (m, 2H), 4.04 (d, 2H), 3.07

-156-

		(q,2H,J=7.3Hz), 1.40 (m,3H,J=7.3Hz). MS calcd 400.1; MS (M+1) 401.0
570	3-(4-fluorobenzyl)	¹ H NMR: 8.56 (d,1H,J=4.4Hz), 8.42 (s,1H), 7.95 (t,1H,J=7.4Hz), 7.72 (d,1H,J=7.6Hz), 7.27 (m,1H), 7.21 (t,1H,J=7.6Hz), 7.05 (m, 3H), 6.94 (m,3H), 4.86 (s,2H), 3.84 (s,2H), 3.06 (q,2H,J=7.3Hz), 1.40 (t,3H,J=7.3Hz). MS calcd 384.1; MS (M+1) 385.2.
571	3-(thien-2-yl methyl)	¹ H NMR: 8.47 (d,1H,J=4.9Hz), 8.34 (d,1H,J=1.5Hz), 7.66 (d,1H,J=8.3Hz), 7.25 (t,1H,J=7.3Hz), 7.20 (dd,1H,J=7.8,4.9Hz), 7.17-6.17 (m,4H), 6.91 (dd,1H,J=4.9,3.4Hz), 6.69 (d,1H,J=2.5Hz), 4.86 (s,2H), 4.10 (s,2H), 3.08 (q,2H,J=7.3Hz), 1.43 (t,3H,J=7.3Hz). MS calcd 372.1; MS (M+1) 373.1
572	3-(thien-3-yl methyl)	¹ H NMR: 8.48 (d,1H,J=3.9Hz), 8.33 (s,1H), 7.67 (d,1H,J=7.8Hz), 7.26-7.20 (m,3H), 7.10 (d,2H,J=7.3Hz), 7.02 (s,1H), 6.78 (m,2H), 3.91 (s,2H), 3.08 (q,2H,J=7.3Hz), 1.41 (t,3H,J=7.3Hz). MS calcd 372.1; MS (M+1) 373.1
573	3-(2-bromobenzyl)	¹ H NMR: 8.38 (d,1H,J=3.4Hz), 8.24 (d,1H,J=1.5Hz), 7.56 (d,1H,J=8.3Hz), 7.46 (d,1H,J=7.3Hz), 7.12 (m,3H), 7.01 (m,3H), 6.93 (m,2H), 4.75 (s,2H), 3.95 (s,2H), 2.98 (q,2H,J=7.3Hz), 1.30 (t,3H,J=7.3Hz). MS calcd 446.1; MS (M+1) 447.1
574	3-(5-methyl-thiophen-2-yl)methyl	¹ H NMR: 8.47 (dd,1H,J=4.9,1.6Hz), 8.35 (d,1H,J=1.6Hz), 7.66 (dt,1H,J=7.8,2.0Hz), 7.26-7.18 (m,2H), 7.15-7.07 (m,3H), 6.54 (m,1H), 6.46 (d,1H,J=3.1Hz), 4.84 (s,2H), 4.00 (s,2H), 3.07 (q,2H,J=7.3Hz), 2.41 (s,3H), 1.41 (t,3H,J=7.3Hz). MS calcd 386.1; MS (M+1) 387.1
575	3-(2,4-difluorobenzyl)	¹ H NMR: 8.8.49 (dd,1H,J=4.7,1.1Hz), 8.34 (d,1H,J=1.5Hz), 7.67 (d,1H,J=7.8Hz), 7.22 (m,2H), 7.08 (m,2H), 7.01 (s,1H), 6.94 (m,1H), 6.78 (m,2H), 4.84 (s,2H), 3.85 (s,2H), 3.08 (q,2H,J=7.3Hz), 1.41 (t,3H,J=7.3Hz). MS calcd 402.1; MS (M+1) 403.1
576	3-(2,4-dichloro benzyl)	

Preparation 13

N-(4-(4-Cyanophenyl)phenyl)-N-ethylsulfonylamine

4-Amino-4'-cyanobiphenyl (1.03g, 5.3mmol) (TCI) was dissolved in a mixture of 8ml dichloromethane / 2ml pyridine was treated with ethanesulfonyl chloride (0.61g, 5.3mmol) and stirred for 18h at room temperature. The solution was diluted with dichloromethane and washed twice with 1N HCl. The organic phase was separated, dried over sodium sulfate,

-157-

filtered, and concentrated *in vacuo* to afford the title compound. ^1H NMR: 7.75 (d, 2H, J=8Hz), 7.67 (d, 2H, J=8Hz), 7.60 (d, 2H, J=8Hz), 7.37 (d, 2H, J=8Hz), 6.90 (s, 1H), 3.22 (q, 2H, J=8Hz), 1.45 (t, 3H, J=8Hz).

5

Preparation 14

N-(2-Methoxy-5-phenyl)phenyl)-N-ethanesulfonylamine

The title compound was prepared using a method similar to the method of Preparation 13 using 5-phenyl-O-anisidine.

10 MS calcd. 291.3; MS ($M^+ - 1$) 290.2.

Preparation 15

N-(1-(4-Bromophenyl)ethyl)pyrid-3-ylmethylamine

A solution of 4-bromo- α -methylbenzylamine (1.5g, 7.7mmol), 3-pyridinecarboxaldehyde (0.8g, 7.5mmol), and sodium triacetoxyborohydride (2.25g, 10.5mmol) in 60ml of 1,2-dichloroethane was stirred at room temperature for 18h. The solution was diluted with dichloromethane and washed twice with a saturated sodium bicarbonate solution, once with water, and once with brine. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated *in vacuo* to afford the title compound. ^1H NMR: 8.70 (m, 2H), 7.85 (m, 1H), 7.67 (d, 2H, J=8Hz), 7.45 (d, 2H, J=8Hz), 7.43 (m, 1H), 3.95 (q, 1H, J=8Hz), 3.83 (q, ABX, 2H), 1.57 (d, 3H, J=8Hz). MS calcd. 291.2; MS ($M+1$) 292.1.

20

25

Preparation 16

N-(1-(4-Bromophenyl)ethyl)-N-ethylsulfonylamine


30 4-Bromo- α -methylbenzylamine (8.15g, 40.73mmol) and (4.15g, 41.00mmol) triethylamine dissolved in 150ml dichloromethane was treated slowly with ethanesulfonyl chloride (5.27g, 41.00mmol) and stirred for 15 minutes. The reaction mixture was extracted with 50ml 1N HCl / 15ml

-158-

brine. The organic layer was separated, dried sodium sulfate, filtered, and concentrated in vacuo to afford the title compound. ^1H NMR: 7.52 (d, 2H, $J=12\text{Hz}$), 7.25 (d, 2H, $J=12\text{Hz}$), 4.77 (m, 1H), 4.63 (m, 1H), 2.77 (m, 2H), 1.56 (d, 3H, $J=8\text{Hz}$), 1.27 (t, 3H, $J=8\text{Hz}$). MS calcd. 292.2; MS ($M+ -1$) 291.1.

Example 577

N-(1-(4-Bromophenyl)ethyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



N-(1-(4-Bromophenyl)ethyl)-N-ethylsulfonylamine (1.25g, 4.28mmol), and (0.75g, 4.6mmol) of 3-picolyl chloride hydrochloride, and (5.1g, 37mmol) of potassium carbonate were dissolved in 40ml DMF. Additional 3-picolyl chloride hydrochloride (0.75g, 4.6mmol) was added after 30 minutes and the mixture stirred 20h at room temperature. The mixture was diluted with 120ml ethyl acetate and 60ml of water and transferred to a separatory funnel. The organic layer was separated and washed twice with water. The organic layer was again separated and dried over sodium sulfate, filtered, and concentrated in vacuo to afford a dark oil. The oil was purified by radial chromatography on a 6 micron silica plate eluting with 1 to 4% methanol / dichloromethane to afford after concentration of fractions the title compound. MS calcd. 383.2; MS ($M+1$) 384.1.

-159-

Preparation 17N-(Ethylsulfonyl)pyrid-3-ylmethylaniline

3-Aminomethyl pyridine (2.15g, 19.88mmol) was dissolved in 40ml dichloromethane. Ethanesulfonyl chloride (2.56g, 19.9mmol) was added to the mixture and stirred for 18h. To the resultant precipitate was added 40ml diethyl ether and decanted from the solid. The solid was partitioned between a mixture of 100ml dichloromethane / 20ml isopropyl alcohol and 20ml of a saturated sodium bicarbonate solution. The organic layer was separated and the aqueous phase extracted twice with the 80/20 mixture of dichloromethane / isopropyl alcohol. The organic layers were combined, dried over sodium sulfate, filtered, and concentrated *in vacuo* to afford the title compound. ¹H NMR: 8.67 (s, 1H), 8.60 (d, 1H, J=4Hz), 7.90 (m, 1H), 7.42 (m, 1H), 5.77 (t, 1H, J=6Hz), 4.38 (d, 2H, J=6Hz), 3.07 (t, 2H, J=8Hz), 1.38 (t, 3H, J=8Hz). MS calcd. 200.2; MS (M+1) 201.1.

Preparation 184-Cyanophenylboronic acid.

A solution of 4-bromobenzonitrile (91 g, 0.50 mole) in THF (1.1 L) was dried in the presence of activated 3 Å molecular sieves at room temp. This solution was filtered and cooled to -100°C. A 1.6 M solution of *n*-butyllithium in hexanes (355 mL, 0.567 mol) was added to the cold solution over 15 min while maintaining the internal temperature between -105 and -93°C. To the resulting orange reaction mixture was added trimethylborate (81 g, 0.78 mol) over 3 min, briefly increasing the reaction temperature to -72°C. The reaction mixture was recooled to -100°C over 5 minutes and then was allowed to warm slowly to room temperature over 2.3 h. The reaction mixture was acidified with 4N HCl to pH 2.2, and was diluted with CH₂Cl₂ (200 mL). The aqueous layer was separated and the organic layer was washed with brine (2

-160-

x 200 mL), dried over anhydrous MgSO_4 , filtered, and the solvent removed under reduced pressure to a pale yellow solid. This solid was additionally purified by dissolution in 1N NaOH and extraction into CH_2Cl_2 / THF (1:1, 2 x 200 mL). The aqueous phase was acidified with 4N HCl to pH 2.2 and was extracted into CH_2Cl_2 / THF (1:1, 500 mL). The combined organic extracts were concentrated to a crude solid (64.6 g) that was triturated with diethyl ether (160 mL) and dried under vacuum to afford the intermediate title compound (44.0 g, 59.9%) as a white powder. ^1H NMR (d_6 -acetone, 300 MHz): δ 8.03 (d, 2H, $J = 8.1$), 7.75 (d, 2H, $J = 8.4$), 7.54 (s, 2H).

Preparation 19

N-(3-(4-Cyanophenyl)phenyl)pyrid-3-ylmethylaniline

A solution of N-(3-bromophenyl)pyridin-3-ylmethylaniline (364mg, 1.38mmol), 4-cyanophenylboronic acid (305mg, 2.08mmol), sodium carbonate (2.15ml of a 2M aqueous solution, 4.3mmol), and tetrakis(triphenylphosphine)palladium(0) (70mg, 0.061mmol), under a nitrogen atmosphere was refluxed in dioxane (15ml) for 6h, then cooled to room temperature. The mixture was diluted with dichloromethane (70ml) and water (15ml). The organics were separated, dried over sodium sulfate, filtered, and concentrated to a brown solid. The solid was purified by radial chromatography eluting with 2 to 4% methanol / dichloromethane to afford the title compound. MS calcd. 285.3; MS (M+1) 286.3.

Preparation 20

N-(3-(4-(N'-Methanesulfonyl-N'-t-butoxycarbonylaminoethyl)phenyl)pyrid-3-ylmethylaniline

To a 10 °C solution of phenethylamine (12.1 g, 0.100 mol) and triethylamine (11.1 g, 0.110 mol) in CH_2Cl_2 (50 mL)

-161-

- was added methanesulfonyl chloride (12.6 g, 0.110 mol) dropwise over 10 min. The solution was stirred at room temperature for 1.5 h and was then washed with 1 N HCl (5 x 20 mL). The organic phase was directly concentrated to provide the intermediate title compound, N-(methysulfonyl) (2-phenylethyl)amine, (21.2 g, 93.3%) as an oil. ¹H NMR (300 MHz) 7.32 (m, 2H), 7.23 (m, 3H), 4.30 (br s, 1H), 3.40 (t, 2H, J=3.9), 2.88 (t, 2H, J=4.2), 2.81 (s, 3H).
- 10 To a stirring room temperature solution of N-(methysulfonyl)-N-(2-phenylethyl)amine (205 g, 1.03 moles), water (200 mL), 95% sulfuric acid (111 g, 1.08 moles) in acetic acid (1 L), was added iodine (111 g, 0.438 mol) and periodic acid (45.6 g, 0.206 mol). The reaction mixture was
- 15 warmed to 70-75 °C for 3 h. The heat was removed and the dark violet reaction mixture was allowed to proceed overnight at room temperature. Potassium hydroxide pellets (85%, 143 g, 2.16 moles) were added to neutralized the sulfuric acid and then enough saturated aqueous sodium
- 20 sulfite was added to decolorize the mixture to afford a white suspension. The suspension was cooled to 15 °C and filtered. The filter cake was triturated thoroughly with water and was then dissolved in CH₂Cl₂ (1 L) and extracted with additional water (2 x 200 mL). The organic phase was
- 25 concentrated under reduced pressure to provide N-(2-(4-iodophenyl)ethyl)-N-(methysulfonyl)amine, (201 g, 60.2%) as a white powder. ¹H NMR (300 MHz) 7.64 (d, 2H, J=4.8), 6.97 (d, 2H, J=5.1), 4.37 (br t, 1H, J=4), 3.36 (app. q, 2H, J=3.9), 2.85 (s, 3H), 2.82 (t, 2H, J=3.9).
- 30 A room temperature solution of N-(2-(4-iodophenyl)ethyl)-N-(methysulfonyl)amine (201 g, 0.618 mol), 4-dimethylaminopyridine (3.8 g, 0.031 mol) and di-*t*-butyl dicarbonate (162 g, 0.744 mol) in DCM (1 L) was allowed to stir overnight. The reaction mixture was washed

-162-

with water (2 x 400 mL) and the organic phase was concentrated to about 600 mL and hexanes (400 mL) was added. This combined solution was washed again with water (400 mL) and was concentrated to a solid that was suspended in hexanes (600 mL) and filtered. The collected solids were dried under reduced pressure to afford the intermediate title compound, N-(t-butoxycarbonyl)-N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine (241.5 g, 91.5%) as a white solid. ¹H NMR (300 MHz) 7.63 (d, 2H, J=7.8), 6.98 (d, 2H, J=7.8), 3.88 (t, 2H, J=6.9), 3.10 (s, 3H), 2.88 (t, 2H, J=6.9), 1.51 (s, 9H).

To a degassed solution of N-(t-butoxycarbonyl)-N-(2-(4-iodophenyl)ethyl)-N-(methylsulfonyl)amine (128 g, 0.300 mol), triethylamine (91.1 g, 0.900 mol), and 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium (II)-CH₂Cl₂ complex (2.9 g, 0.0035 mol) in acetonitrile (600 mL) was added pinacolborane (50 g, 0.391 mol) dropwise. The mixture was stirred at 70-74 °C for 8 h and then was cooled to room temperature. The reaction mixture was concentrated to a fluid oil that was partitioned between MTBE (500 mL) and water (500 mL). The organic phase was separated and washed with water (2 x 200 mL) and concentrated to a residue that was partially dissolved with heptane (1 L). The heptane soluble fraction was filtered through Celite® 521 and concentrated to an oil (95 g). The residue was dissolved in acetone (600 mL) and heptane (600 mL) and filtered through Celite® 521. The combined filtrates were concentrated to 95 g of a mixture of a 3:1 molar ratio (¹H NMR, 81.0% by weight) of intermediate title compound, N-(t-butoxycarbonyl)-N-(methylsulfonyl)-N-(2-(4-(4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl))phenyl)ethyl)amine and its protio derivative. ¹H NMR (300 MHz) 7.75 (d, 2H, J=7.8), 7.23 (d, 2H, J=8.1), 3.87 (t, 2H, J=8.1), 2.99 (s, 3H), 2.90 (t, 2H, J=7.5), 1.53 (s, 9H), 1.33 (s, 6H), 1.27 (s, 6H).

-163-

To a room temperature solution of N-(t-butoxycarbonyl)-N-(methylsulfonyl)-N-(2-(4-(4,4,5,5-tetramethyl(1,3,2-dioxaborolan-2-yl))phenyl)ethyl)amine (81.0% potent, 95 g, 0.18 mol) in acetone (2 L) was added 1N ammonium acetate (1L) and sodium periodate (145 g, 0.678 mol) with stirring. The reaction was allowed to proceed overnight. The reaction mixture was concentrated to remove the acetone, and the aqueous phase was decanted away from the oily product. The aqueous phase was extracted with DCM (100 mL) and MTBE (2 x 100 mL). The combined oily product and organic phases were adjusted to pH 12.5 with the addition of 1 N NaOH. The phases were separated, and the organic phase was extracted with 1 N NaOH (100 mL) and water (2 x 100 mL). HPLC analysis (60% CH₃CN / 40% H₂O, 2 mL / min, Zorbax C-18, 205 nm) of the organic phase indicated that the product had been removed from this phase. The aqueous phases (containing product) were finally combined and washed with CH₂Cl₂ (100 mL) and MTBE (2 x 100 mL). The aqueous phase was added to CH₂Cl₂ (450 mL) and 1 N H₂SO₄ was added until the aqueous phase was at pH 3.05. The phases were separated and the aqueous phase was extracted with CH₂Cl₂ (100 mL). The combined organic extracts (containing product) were concentrated to an oil (58.5 g) that crystallized overnight. The resulting solid mass was triturated with 10% MTBE in heptane (100 mL) to afford, after filtration and drying under reduced pressure, N-(t-butoxycarbonyl)-N-(methylsulfonyl)-N-(2-(4-boronic acid)phenyl)ethyl)amine (47.7 g, 77.2%) as a white powder. ¹H NMR (d₆-DMSO, 300 MHz) δ 7.83 (d, 2H, J= 4.8), 7.24 (d, 2H, J=5.1), 7.12 (s, 2H), 3.90 (t, 2H, J=3.9), 3.12 (s, 3H), 2.95 (t, 2H, J=4.5), 1.52 (s, 9H).

A solution of N-(3-bromophenyl)pyridin-3-ylmethylamine (180mg, 0.68mmol), N-(t-butoxycarbonyl)-N-(methylsulfonyl)-N-(2-(4-boronic acid)phenyl)ethyl)amine (350mg, 1.0mmol),

-164-

and dioxane (12ml) stirring under nitrogen was treated with 2M sodium carbonate (1.36ml, 2.7mmol) and tetrakis(triphenylphosphine) palladium(0) (35mg, 0.030mmol). This was heated to reflux for four hours, after which the reaction was concentrated in vacuo. The concentrated reaction mixture was then purified on a Chromatotron using a 4000 micron plate and 3% methanol/dichloromethane as the solvent system. The product containing fractions were collected and concentrated in vacuo to yield an oil, which was dissolved into ether/hexanes and concentrated in vacuo to give the title compound as an off-white foam. ¹H NMR: 8.60-8.70 (s, 1H), 8.50-8.60 (s, 1H), 7.75-7.80 (d, 1H, J=12Hz), 7.60-7.70 (m, 1H), 7.45-7.55 (m, 2H), 7.20-7.35 (m, 3H), 7.00-7.10 (m, 1H), 6.75-6.80 (d, 2H, 10Hz), 4.40-4.45 (s, 1H), 3.85-4.00 (m, 2H), 3.40-3.50 (q, 2H, 16Hz), 2.90-3.00 (m, 3H), 1.50-1.60 (s, 9H), 1.20-1.30 (m, 2H). MS calcd. 481.6; MS (M+1) 482.1.

Preparation 21

20 N-Methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide

4-Carboxyphenylboronic acid (10.0 g, 60.3 mmol) was suspended in 100 mL of toluene and pinacol added (7.1 g, 60.3 mmol). The reaction was heated to reflux with a Dean-Stark trap attached. The reaction became homogenous upon heating. After 2 h reflux the reaction was allowed to stand overnight and white needles were collected by filtration, rinsed with toluene, and vacuum dried to 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid 12.2 g (81%). MS (FD MS): M = 248. Analysis calculated for C₁₃H₁₇BO₄: C, 62.94; H, 6.91 Found: C, 62.71; H, 6.91.

4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid (6.0 g, 24.2 mmol) was suspended in 20 mL of thionyl chloride, 3 drops of DMF added and the reaction

-165-


heated to reflux under nitrogen. The solid dissolved upon warming. After refluxing 2 h the reaction was concentrated in vacuo and dried to a white solid under vacuum. The acid chloride was dissolved in 30 mL of THF and cooled to 0°C.

5 40% aqueous methylamine (10.4 mL) was added dropwise. After the addition was complete the ice bath was removed and stirring continued for 30 min. The reaction was concentrated in vacuo (3 x 1:1 EtOAc:toluene) then extracted with ether / water. The organic layer was dried over sodium

10 sulfate, filtered and concentrated to 5.2 g (83%) of the title compound as a white solid. MS (FD MS): M = 261. Analysis calculated for $C_{14}H_{20}BNO_3$: C, 64.40; H, 7.72; N, 5.36. Found: C, 64.09; H, 7.70; N, 5.28.

15 Example 578

N-(4-(4-Cyanophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



A solution of N-(4-(4-cyanophenyl)phenyl)-N-

20 ethylsulfonylamine (200mg, 0.7mmol), 3-picolyl chloride hydrochloride (123mg, 0.75mmol), and cesium carbonate (2.3g, 7.0mmol) was dissolved in 10ml DMF and stirred for 18h at room temperature. The mixture was diluted with 80ml ethyl acetate, 20ml water. The organic phase was separated and


25 washed twice with 25ml of water. The organic phase was then dried over sodium sulfate, filtered, and concentrated in vacuo to an oily residue. The residue was flushed through a

-166-

20g mega bond elut silica column with 0 to 5% methanol / ethyl acetate. The desired fractions were concentrated in vacuo to afford the title compound. ^1H NMR: 8.55 (bs, 1H), 8.41 (bs, 1H), 7.78 (d, 1H, $J=8\text{Hz}$), 7.72 (d, 2H, $J=12\text{Hz}$), 7.6 (d, 2H, $J=12\text{Hz}$), 7.52 (d, 2H, $J=12\text{Hz}$), 7.35 (d, 2H, $J=12\text{Hz}$), 7.29 (m, 1H), 4.95 (s, 1H), 3.15 (q, 2H, $J=8\text{Hz}$), 1.45 (t, 3H, $J=8\text{Hz}$). MS calcd. 377.5; MS (M+1) 378.2.

Example 579

10 N-((2-Methoxy-5-phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine




The title compound was prepared using a method similar to the method of Example 545 using N-(2-methoxy-5-phenyl)phenyl)-N-ethanesulfonylamine. ^1H NMR: 8.5 (d, 1H, $J=4\text{Hz}$), 8.41 (s, 1H), 7.88 (m, 1H), 7.51 (dd, 1H, $J=4, 8\text{Hz}$), 7.28-7.45 (m, 7H), 7.0 (d, 1H, $J=8\text{Hz}$), 4.9 (s, 2H), 3.98 (s, 1H), 3.16 (q, 2H, $J=8\text{Hz}$), 1.45 (t, 3H, $J=8\text{Hz}$). MS calcd. 382.5; MS (M+1) 383.1.

20

Example 580

N-(1-(4-Bromophenyl)ethyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine




-167-

A solution of N-(1-(4-bromophenyl)ethyl)pyrid-3-ylmethanamine (630mg, 2.16mmol) and 4-(dimethylamino)pyridine (263mg, 2.16mmol) in 18ml of dichloromethane was treated with 2,2,2-trifluoroethylsulfonyl chloride (420mg, 2.3mmol) with stirring for 15 minutes at room temperature. The solution was concentrated to approximately 2ml and directly purified by radial chromatography on a 1 micron silica plate, eluting with 3% methanol / dichloromethane. The fractions were concentrated to afford the title compound. ¹H NMR: 8.52 (bs,1H), 8.42 (bs,1H), (d,1H,J=8Hz), 7.45 (d,2H,J=8Hz), 7.22 (d,2H,J=8Hz), 5.25 (q,1H,J=8Hz), 4.38 (q,2H,ABX), 3.6 (q,2H,J=12Hz), 1.68 (d,3H,J=8Hz). MS calcd. 437.3; MS (M+1), (M+2), 438.0, 439.0.

Example 581

N-(3-(4-Cyanophenyl)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethanamine



A solution of N-(3-(4-cyanophenyl)phenyl)pyrid-3-ylmethanamine (255mg, 0.894mmol) in 8ml dichloromethane / 2ml pyridine was treated with 2,2,2-trifluoroethylsulfonyl chloride in 3 portions of 171mg (0.94mmol) over 1h at 45°C. The solution was cooled and diluted with 60ml diethyl ether and washed successively with water and saturated sodium bicarbonate solution. The organics were separated, dried over sodium sulfate, filtered, and concentrated to an oil. The oil was purified by radial chromatography on a 2 micron silica plate eluting with 2 to 4% methanol / dichloromethane


-168-

to afford the title compound. ^1H NMR: 8.65 (bs, 1H), 8.42 (bs, 1H), 7.85 (m, 1H), 7.75 (d, 2H, $J=8\text{Hz}$), 7.58 (d, 2H, $J=8\text{Hz}$), 7.30-7.55 (m, 5H), 5.02 (s, 2H), 3.78 (q, 2H, $J=8\text{Hz}$). MS calcd. 431.44; MS (M+1) 432.1.

5

Example 582

N-((3-Iodophenyl)methyl)-N-(ethanesulfonyl)pyrid-3-ylamine




A solution of 3-aminopyridine (2.15g, 22.84mmol) and
10 ethanesulfonyl chloride (2.18ml, 22.84mmol) in
dichloromethane (150ml) was stirred for 20h at room
temperature. The mixture was washed with 30ml saturated
sodium bicarbonate solution and extracted with 15%
isopropanol / dichloromethane. The organics were combined,
15 dried over sodium sulfate, filtered, and concentrated in
vacuo to give N-(ethanesulfonyl)-3-aminopyridine (2.15g, as
a crude solid. The solid was dissolved in N,N-
dimethylformamide (50ml) and treated with potassium
carbonate (6.37g, 22.8mmol) and 3-iodobenzyl bromide (6.80g,
20 22.8mmol) with stirring at room temperature for 3h. The
mixture was diluted with ethyl acetate (150ml) and washed
four times with water (100ml). The organics were separated,
dried over sodium sulfate, filtered, and concentrated in
vacuo to afford a crude residue. The residue was purified
25 on a 200g pad of silica eluting with 3% methanol /
dichloromethane to afford the title compound. MS calcd.
402.3; MS (M+1) 403.1.

-169-

Example 583

N-((3-Iodophenyl)methyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine




5 A solution of N-(ethylsulfonyl)pyrid-3-ylmethylamine (1.1g, 5.5mmol), cesium carbonate (1.79g, 5.5mmol), and 3-iodobenzyl bromide (1.64g, 5.5mmol) was stirred in N,N-dimethylformamide (25ml) for 5h at room temperature. The
10 mixture was diluted with ethyl acetate (100ml) and washed four times with water (50ml). The organics were separated, dried over sodium sulfate, filtered, and concentrated in vacuo to a crude residue. The residue was purified by
15 radial chromatography on a 4 micron silica plate eluting with 3% methanol / dichloromethane to afford the title compound. ¹H NMR: 8.6 (d, 1H, J=4Hz), 8.41 (s, 1H), 7.75 (m, 1H), 7.65 (m, 1H), 7.60 (s, 1H), 7.25-7.40 (m, 2H), 7.08 (m, 1H), 4.43 (s, 2H), 4.33 (s, 2H), 3.08 (q, 2H, J=8Hz), 1.43 (t, 3H, J=8Hz). MS calcd. 416.3; MS (M+1) 417.1.

20

Example 584

N-(1-(4-(2,4-Difluorophenyl)phenyl)ethyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine




25

A solution of N-(1-(4-bromophenyl)ethyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (200mg, 0.52mmol),

-170-

2,4-difluorophenylboronic acid (124mg, 0.78mmol), sodium carbonate (0.78ml of a 2M aqueous solution, 1.56mmol), and tetrakis(triphenylphosphine)palladium(0) (26mg, 0.023mmol), under a nitrogen atmosphere was refluxed in dioxane (8ml) for 6h, then cooled to room temperature. The mixture was concentrated to a tan residue and resuspended in 2ml dichloromethane. The suspension was subjected to purification by radial chromatography on a 2 micron silica plate eluting with 2 to 4% methanol / dichloromethane to afford the title compound. ¹H NMR: 8.45 (bs, 1H), 8.37 (bs, 1H), 7.62 (d, 1H, J=8Hz), 7.45 (m, 5H), 7.15 (m, 1H), 6.95 (m, 2H), 5.30 (q, 1H, J=8Hz), 4.35 (s, 2H), 2.92 (q, 2H, J=8Hz), 1.67 (d, 3H, J=8Hz), 1.37 (t, 3H, J=8Hz). MS calcd. 416.5; MS (M+1) 417.1.


By a method similar to the method of Example 584 the following compounds were prepared:



No.	Y	R ₂	Data
585	CH(CH ₃)	4-(4-cyano phenyl)	¹ H NMR: 8.42 (bs, 1H), 8.35 (bs, 1H), 7.45-7.80 (m, 9H), 7.21 (m, 1H), 5.33 (q, 1H, J=8Hz), 4.37 (s, 2H), 2.95 (q, 2H, J=8Hz), 1.70 (d, 3H, J=8Hz), 1.40 (t, 3H, J=8Hz). MS calcd. 405.5; MS (M+1) 406.2
586	CH ₂	3-(2,4-difluoro phenyl)	¹ H NMR : 8.57 (bs, 1H), 8.45 (bs, 1H), 7.58 (d, 1H, J=8Hz), 7.15-7.35 (m, 6H), 6.75-6.85 (m, 2H), 4.87 (s, 2H), 3.07 (q, 2H, J=8Hz), 1.36 (t, 3H, J=8Hz). MS calcd. 388.4; MS (M+1) 389.2
587	CH ₂	3-(4-cyano phenyl)	¹ H NMR: 8.53 (bs, 1H), 8.42 (bs, 1H), 7.78 (m, 1H), 7.75 (d, 2H, J=8Hz), 7.63 (d, 2H, J=8Hz), 7.3-7.55 (m, 5H), 4.49 (s, 3H), 4.47 (s, 3H), 3.12 (q, 2H, J=8Hz), 1.45 (t, 3H, J=8Hz). MS calcd. 391.5; MS (M+1) 392.2
588	CH ₂	3-(3-methane sulfonyl aminophenyl)	¹ H NMR: 8.65 (bs, 1H), 8.58 (bs, 1H), 7.9 (d, 1H, J=8Hz), 7.70 (m, 1H), 7.30-7.5 (m, 9H), 4.54 (s, 2H), 4.48 (s, 2H), 3.13 (q, 2H, J=8Hz), 3.09 (s, 3H), 1.45 (t, 3H, J=8Hz). MS calcd. 459.6; MS

			(M+1) 460.2
589	CH ₂	3-(4-N-methylamido phenyl)	¹ H NMR: 8.48 (bs,2H), 7.88 (d,2H,J=8Hz), 7.78 (m,1H), 7.60 (d,2H,J=8Hz), 7.54 (m,1H), 7.25-7.45 (m,4H), 6.35 (m,1H), 4.48 (s,2H), 3.10 (q,2H,J=8Hz), 3.07 (d,3H,J=4Hz), 1.45 (t,3H,J=8Hz). MS calcd. 423.5; MS (M+1) 423.2

By a method similar to the method of Example 584 the following compounds were prepared:



No.	R ₂	Data
590	3-(4-cyano phenyl)	¹ H NMR: 8.45 (bs,2H), 7.90 (d,1H,J=8Hz), 7.58 (d,2H,J=8Hz), 7.42 (d,2H,J=8Hz), 7.28-7.4 (m,5H), 4.90 (s,2H), 2.95 (q,2H,J=8Hz), 1.32 (t,3H,J=8Hz). MS calcd. 377.5; MS (M+1) 378.2
591	3-(2,4-difluoro phenyl)	¹ H NMR: 8.65 (bs,1H), 8.47 (bs,1H), 7.95 (m,1H), 7.25-7.45 (m,6H), 6.85-7.0 (m,2H), 5.0 (s,2H), 3.15 (q,2H,J=8Hz), 1.47 (t,3H,J=8Hz). MS calcd. 388.4; MS (M+1) 389.1
592	3-(3-methane sulfonyl aminophenyl)	¹ H NMR: 8.63 (s,1H), 8.58 (bs,1H), 7.9 (m,1H), 7.56 (s,1H), 7.25-7.5 (m,9H), 5.05 (s,2H), 3.3 (q,2H,J=8Hz), 3.08 (s,3H), 1.45 (t,3H,J=8Hz). MS calcd. 445.6; MS (M+1) 446.2
593	3-((3,5-bis-trifluoromethyl) phenyl)	¹ H NMR: 8.60 (bs,1H), 8.45 (bs,1H), 7.90 (m,3H), 7.35-7.55 (m,5H), 5.05 (s,2H), 3.20 (q,2H,J=8Hz), 1.52 (t,3H,J=8Hz). MS calcd. 488.5; MS (M+1) 489.1
594	3-phenyl	¹ H NMR: 8.49 (bs,1H), 8.41 (bs,1H), 7.90 (m,1H), 7.80 (m,1H), 7.15-7.45 (m,9H), 4.90 (s,2H), 3.07 (q,2H,J=8Hz), 1.38 (t,3H,J=8Hz). MS calcd. 352.5; MS (M+1) 353.2
595	3-((4-(2-trifluoroacetyl amino) ethyl)phenyl)	¹ H NMR: 8.65 (bs,1H), 8.57 (bs,1H), 7.92 (m,1H), 7.40-7.55 (m,4H), 7.20-7.30 (m,5H), 6.35 (m,1H), 5.15 (s,2H), 3.7 (m,2H), 3.20 (q,2H,J=8Hz), 2.95 (m,2H), 1.50 (t,3H,J=8Hz). MS calcd. 491.5; MS (M+1) 492.1
596	3-(4-acetylaminophenyl)	¹ H NMR: 8.55 (bs,1H), 8.50 (bs,1H), 7.95 (m,1H), 7.60 (m,3H), 7.35-7.55 (m,6H), 7.22 (m,1H), 5.03 (s,2H), 3.17 (q,2H,J=8Hz), 2.25 (s,3H), 1.45


		(t,3H,J=8Hz). MS calcd. 409.5; MS (M+1) 410.1
597	3-(4-methanesulfonylphenyl)	¹ H NMR: 8.57 (bs,1H), 8.43 (bs,1H), 8.03 (d,2H,J=16Hz), 7.85 (m,1H), 7.70 (d,2H,J=16Hz), 7.45-7.55 (m,3H), 7.35 (m,2H), 5.0 (s,2H), 3.18 (q,2H,J=8Hz), 3.12 (s,3H), 1.50 (t,3H,J=8Hz). MS calcd. 430.6; MS (M+1) 431.1
598	3-(4-trifluoromethoxyphenyl)	¹ H NMR: 8.57 (bs,1H), 8.45 (bs,1H), 7.85 (m,1H), 7.40-7.55 (m,5H), 7.35 (m,1H), 7.25-7.30 (m,3H), 5.0 (s,2H), 3.15 (q,2H,J=8Hz), 1.50 (t,3H,J=8Hz). MS calcd. 436.5; MS (M+1) 437.0
599	3-(pyrid-4-yl)	¹ H NMR: 8.68 (bs,2H), 8.55 (bs,1H), 8.45 (bs,1H), 7.82 (m,1H), 7.40-7.60 (m,6H), 7.32 (m,1H), 5.0 (s,2H), 3.17 (q,2H,J=8Hz), 1.50 (t,3H,J=8Hz). MS calcd. 353.4; MS (M+1) 354.2
600	3-(3-trifluoromethylphenyl)	¹ H NMR: 8.55 (bs,1H), 8.47 (bs,1H), 7.92 (m,1H), 7.45-7.70 (m,7H), 7.40 (m,1H), 7.32 (m,1H), 5.03 (s,2H), 3.17 (q,2H,J=8Hz), 1.50 (t,3H,J=8Hz). MS calcd. 420.5; MS (M+1) 421.1
601	3-(4-carboxyphenyl)	¹ H NMR: 8.70 (bs,1H), 8.62 (bs,1H), 8.15 (m,3H), 7.20-7.70 (m,7H), 5.12 (s,2H), 3.20 (q,2H,J=8Hz), 1.52 (t,3H,J=8Hz). MS calcd. 396.5; MS (M+1) 397.1
602	3-(4-(N'-methanesulfonyl-N'-t-butoxycarbonyl aminoethyl)phenyl)	MS calcd. 573.7; MS (M+1) 574.2
603	3-(2-methylphenyl)	¹ H NMR (Methanol d ₄): 8.40-8.60 (br s, 2H), 8.00-8.10 (m, 1H), 7.50-7.65 (br s, 1H), 7.35-7.50 (br s, 2H), 7.15-7.30 (m, 5H), 7.05-7.15 (br s, 1H), 5.00-5.15 (s, 2H), 3.20-3.35 (m, 2H), 2.05-2.20 (s, 3H), 1.40-1.50 (m, 3H). MS calcd. 480.51; MS (M+1) 367.2 (isolated as the trifluoroacetic acid salt)
604	3-(2-methoxyphenyl)	¹ H NMR (Methanol d ₄): 8.40-8.50 (br s, 2H), 7.90-8.00 (d, 1H, J=10Hz), 7.50-7.55 (s, 1H), 7.40-7.50 (m, 1H), 7.25-7.40 (m, 4H), 7.20-7.25 (d, 1H, J=16Hz), 6.95-7.10 (m, 2H), 5.00-5.05 (s, 2H), 3.70-3.80 (s, 3H), 3.20-3.30 (m, 2H), 1.40-1.50 (m, 3H). MS calcd. 496.5; MS (M+1) 383.2 (isolated as the trifluoroacetic acid salt)
605	3-(2-trifluoromethylphenyl)	¹ H NMR (Methanol d ₄): 8.50-8.60 (br s, 2H), 8.05-8.15 (d, 1H, J=8Hz), 7.70-7.80 (d, 1H, J=16Hz), 7.50-7.70 (m, 3H), 7.40-7.50 (m, 2H), 7.30-7.35 (m, 2H), 7.20-7.30 (m, 1H), 5.05-5.15 (s, 2H), 3.20-3.35 (m, 2H), 1.35-1.45 (m, 3H). MS calcd. 534.5; MS (M+1) 421.2 (isolated as the trifluoroacetic acid salt)

-173-

606	3-(2-chlorophenyl)	¹ H NMR: 8.45-8.55 (s, 1H), 8.35-8.45 (s, 1H), 7.70-7.80 (d, 1H, J=10Hz), 7.40-7.50 (m, 1H), 7.35-7.40 (m, 2H), 7.25-7.35 (m, 3H), 7.20-7.35 (m, 3H), 4.90-4.95 (s, 2H), 3.10-3.20 (m, 2H), 1.40-1.50 (t, 3H, J=8Hz). MS calcd. 386.9; MS (M+1) 387.2
607	3-(2-fluorophenyl)	¹ H NMR (Methanol d ₄) : 8.40-8.50 (br s, 2H), 7.85-7.95 (d, 1H, J=10Hz), 7.50-7.55 (s, 1H), 7.30-7.50 (m, 6H), 7.15-7.30 (m, 2H), 5.00-5.10 (s, 2H), 3.20-3.35 (m, 2H), 1.40-1.50 (t, 3H, J=8Hz). MS calcd. 484.5; MS (M+1) 371.1 (isolated as the trifluoroacetic acid salt)
608	3-(3,5-difluorophenyl)	¹ H NMR (Methanol d ₄) : 8.55-8.40 (br s, 2H), 7.90-8.00 (d, 1H, J=10Hz), 7.50-7.60 (m, 2H), 7.40-7.50 (m, 3H), 7.15-7.25 (d, 2H, J=16Hz), 6.90-7.00 (m, 1H), 5.00-5.10 (s, 2H), 3.20-3.35 (m, 2H), 1.40-1.50 (m, 3H). MS calcd. 502.4; MS (M+1) 389.2 (isolated as the trifluoroacetic acid salt)
609	3-(3-acetylaminophenyl)	¹ H NMR: 8.45-8.50 (d, 1H, J=8Hz), 8.40-8.45 (s, 1H), 7.70-7.75 (d, 1H, J=16Hz), 7.50-7.60 (m, 2H), 7.45-7.50 (d, 1H, J=16Hz), 7.40-7.45 (s, 1H), 7.35-7.40 (m, 2H), 7.20-7.30 (m, 3H), 4.90-4.95 (s, 2H), 3.45-3.50 (q, 1H, 12Hz), 3.10-3.20 (q, 2H, J=16Hz), 2.20-2.25 (s, 3H), 1.40-1.50 (t, 3H, J=8Hz). MS calcd. 446.0; MS (M+1) 410.2 (isolated as the hydrochloric acid salt)

Example 610

N-((4-Methyl-3-(4-cyanophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5

A solution of N-(3-iodo-4-methylphenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine (103mg, 0.247mmol) and 4-cyanophenylboronic acid (55mg, 0.371mmol) in 4ml of 1,4-dioxane stirring under nitrogen was treated with 2M sodium


-174-

carbonate (0.37mL, 0.741mmol) and tetrakis(triphenylphosphine)palladium (0) (12.6mg, 0.011mmol). This was refluxed for three hours and then allowed to stir at room temperature for 16 hours. The reaction had not completed after this time so the reaction was treated with an additional 5.7mg (0.005mmol) of tetrakis(triphenylphosphine)palladium (0) and refluxed for two hours. The reaction was then cooled to room temperature and concentrated in vacuo. This was then dissolved in a minimal amount of dichloromethane and purified on a Chromatotron (2000micron plate) with 3% methanol/dichloromethane to give a residue which was recrystallized using ether/hexanes to give the title compound. ¹H NMR: 8.45-8.55 (d, 1H, J=4Hz), 8.35-8.40 (s, 1H), 7.75-7.80 (d, 1H, J=12Hz), 7.65-7.70 (d, 1H, J=12Hz), 7.20-7.35 (m, 5H), 7.15-7.20 (m, 1H), 7.00-7.05 (s, 1H), 4.85-4.95 (s, 2H), 3.05-3.15 (q, 2H, J=10Hz), 2.15-2.20 (s, 3H), 1.40-1.50 (t, 3H, J=8Hz) ; MS calcd. 391.5; MS (M+1) = 392.1.

20

Example 611

N-(3-(4-(2-Methanesulfonylaminoethyl)phenyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylamine



25

A solution of N-(3-(4-(N'-methanesulfonyl-N'-t-butoxycarbonylaminoethyl)phenyl)pyrid-3-ylmethylamine and 2,2,2-trifluoroethanesulfonyl chloride (134mg, 0.735mmol) in 3:1 dichloromethane/pyridine (4mL) was stirred for 16 hours after which the reaction had not completed yet. Another


-175-

67mg (0.368mmol) of 2,2,2-trifluoroethanesulfonyl chloride was added and the reaction was heated to 45°C for 30 minutes. The reaction was then allowed to cool to room temperature. Ether was used to extract the organic material, which was washed four times with deionized water. The organic layer was then dried with sodium carbonate, filtered, and concentrated in vacuo. The concentrated mixture was then dissolved in a minimal amount of dichloromethane and purified on a Chromatotron (6000micron plate) using 3% methanol/dichloromethane. The proper fractions were collected and concentrated in vacuo and treated with 3mL of 2:1 trifluoroacetic acid:dichloromethane and stirred for 1 hour to take off the Boc protecting group. Acetonitrile was then added and the reaction was concentrated in vacuo in order to remove any water. This step was repeated two additional times, which left an oil. The oil was treated with 0.64mL (0.64mmol) of 1M hydrochloric acid, 5mL of ether, and 5mL hexanes, which caused the title compound to precipitate out of solution. The solid was filtered and collected. This yielded the title compound as the HCl salt. ¹H NMR (Methanol d₄) : 8.35-8.45 (br s, 2H), 7.80-7.90 (d, 1H, J=12Hz), 7.55-7.60 (d, 1H, J=16Hz), 7.40-7.55 (m, 4H), 7.30-7.40 (m, 4H), 5.00-5.05 (s, 2H), 4.30-4.40 (q, 4H, J=16Hz), 3.25-3.35 (s, 4H), 2.80-2.90 (m, 4H). MS calcd. 564.0; MS (M+1) = 528.3.

-176-

Example 612

N-((3-(4-Amidophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



5


N-((3-(4-Cyanophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (147mg, 0.36mmol) was treated with concentrated sulfuric acid (2.5ml) for 22h at room temperature. The reaction was neutralized with 50 weight % aqueous sodium hydroxide to pH 7.0. This milky solution was extracted three times with 15% isopropanol / dichloromethane and the organics were combined and concentrated in vacuo to a tan solid. The solid was purified by radial chromatography on a 1 micron silica plate eluting with 3 to 10% methanol / dichloromethane to afford the title compound (49mg, 35%). ¹H NMR: 8.56 (s, 1H), 8.5 (s, 1H), 7.95 (m, 1H), 7.90 (d, 2H, J=8Hz), 7.72 (d, 2H, J=8Hz), 7.3-7.58 (m, 5H), 6.20 (bs, 1H), 5.75 (bs, 1H), 5.05 (s, 2H), 3.17 (q, 2H, J=8Hz), 1.5 (t, 3H, J=8Hz). MS calcd. 395.5; MS (M+1) 396.1.

20

Example 613

N-(3-(4-(2-Methanesulfonylaminoethyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine

-177-




A solution of N-(3-(4-(N'-methanesulfonyl-N'-t-butoxycarbonylaminoethyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (78mg, 0.136mmol) in
 5 2ml dichloromethane / 3ml trifluoroacetic acid was stirred for 40 minutes at room temperature. The mixture was diluted with acetonitrile and concentrated to an oil. The oil was dissolved in 0.5ml dichloromethane and treated with ethereal HCl to afford the title compound as the HCl salt. ¹H NMR (d₄
 10 methanol): 8.80 (bs, 1H), 8.73 (bs, 1H), 8.60 (m, 1H), 8.0 (m, 1H), 7.66 (m, 1H), 7.57 (m, 1H), 7.52 (d, 2H, J=8Hz), 7.43 (m, 2H), 7.35 (d, 2H, J=8Hz), 5.23 (s, 2H), 3.32 (m, 4H), 2.87 (t, 2H, J=8Hz), 2.82 (s, 3H), 1.40 (t, 3H, J=8Hz). MS calcd. 510.1; MS (M+1-HCl) 474.1.

15

Example 614

N-((3-(2-Methyl-4-cyanophenyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine



20 In a one pot reaction, a solution of 4-bromo-3-methylbenzonitrile (166mg, 0.845mmol), bis(pinacolato)diboron (236mg, 0.93mmol), potassium acetate (249mg, 2.5mmol), and DMSO (7mL) was stirred under nitrogen until all the materials present were dissolved. Then 55mg

-178-

(0.068mmol) palladium(II) chloride (dppf) complex with dichloromethane (1:1) was introduced to the solution, which was then heated to 80°C for three hours. During this time the solution turned a dark brown color.

5 The reaction was allowed to cool to room temperature after the three hours had passed N-(3-bromophenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine (300mg, 0.845mmol), 2M sodium carbonate (1.25mL, 2.5mmol) and another equivalent of palladium(II) chloride (dppf) complex with dichloromethane
10 (1:1) (55mg, 0.068mmol) were added to the reaction. The reaction was then stirred under nitrogen while being heated to 120°C for 16 hours.

After 16 hours, the reaction was allowed to cool again. Dichloromethane was used for the extraction and the crude
15 was washed with water and brine. After the washing, the organic layer was dried with sodium sulfate, filtered, and concentrated in vacuo. This was then purified using a Chromatotron (4000 micron plate) and 2% methanol/dichloromethane. The fractions containing the
20 product were collected and concentrated in vacuo and recrystallized from ether/hexanes to give the title compound. ¹H NMR: 8.45-8.55 (d, 1H, J=8Hz), 8.30-8.40 (s, 1H), 7.70-7.80 (d, 1H, J=16Hz), 7.45-7.55 (m, 1H), 7.40-7.50 (t, 2H, J=16Hz), 7.25-7.35 (m, 3H), 7.15-7.20 (m, 1H), 7.10-
25 7.15 (s, 1H), 4.90-5.00 (s, 2H), 3.05-3.10 (q, 2H, J=10Hz), 2.05-2.10 (s, 3H), 1.4-1.5 (t, 3H, J=16Hz). MS calcd. 391.5; MS (M+1) 392.2.

Preparation 22

30 N-(4-(2,4-Difluorophenoxy)phenyl)-N-ethylsulfonylamine
Ethanesulfonyl chloride (9.4 mL, 99 mmol) was added dropwise over 5 min to a dark gray solution of 4-(2,4-difluorophenoxy)aniline (20.0 g, 90 mmol) and 4-dimethylaminopyridine (16.6 g, 136 mmol) in methylene

-179-

chloride (180 mL) at room temperature under nitrogen, after which the mixture was stirred at room temperature for 26 h. The mixture was washed with saturated aqueous sodium bicarbonate solution (200 mL), brine (100 mL), dried over 5 MgSO₄, filtered and the solvent was removed under reduced pressure to afford the crude product as an amber oil. This residue was triturated with diethyl ether (300 mL) and filtered to provide an amber solid. This material was further purified by flash column chromatography on silica 10 gel, eluting with ethyl acetate/chloroform (1:9), to provide the title compound as an off-white powder: ¹H NMR (300 MHz, DMSO-d₆) 9.69 (s, 1H), 7.52-7.44 (m, 1H), 7.28-7.09 (m, 2H), 7.20 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 3.03 (q, J = 7.6 Hz, 2H), 2.50 (t, J = 1.6 Hz, 3H).

15

Preparation 23

N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)amine

2,2,2-Trifluoroethanesulfonyl chloride (10.0 g, 54.8 20 mmol) was added dropwise to a solution of 4-(2,4-difluorophenoxy)aniline (11.0 g, 50.0 mmol) and 4-dimethylaminopyridine (9.1 g, 74.6 mmol) in methylene chloride (100 mL) at 0 °C under nitrogen. The mixture was slowly warmed to room temperature, stirring for a total of 25 72 h. The mixture was washed with saturated aqueous sodium bicarbonate solution (200 mL), dried over MgSO₄, filtered and the solvent was removed under reduced pressure to afford the crude product as an orange oil. This residue was purified by flash column chromatography on silica gel, 30 eluting with ethyl acetate/chloroform (1:4), to provide the title compound as a yellow solid: mp 105-108 °C; TLC R_f (1:9 ethyl acetate/chloroform) = 0.75; ¹H NMR (300 MHz, CDCl₃) 7.23 (d, J = 8.9 Hz, 2H), 7.14-6.87 (m, 3H), 6.93

-180-

(d, $J = 8.9$ Hz, 2H), 3.76 (q, $J = 8.8$ Hz, 2H) ppm; APCI MS m/z 366 $[C_{14}H_{10}F_5NO_3S-H]^-$.

Preparation 24

5 (2-Fluoropyridin-3-yl)methanol

Thionyl chloride (0.43 mL, 5.87 mmol) was added to a slurry of 2-fluoronicotinic acid (9, 0.69 g, 4.89 mmol) and N,N-dimethylformamide (0.1 mL, catalytic amount) in benzene (60 mL) at room temperature under nitrogen, after which the mixture was heated at reflux for 3 h. The solvent was removed under reduced pressure to provide an amber oil that was dissolved in 1,4-dioxane (40 mL) under nitrogen. The solution was treated with sodium borohydride (0.38 g, 10.0 mmol) and the mixture was stirred at room temperature for 24 h. The suspension was diluted with saturated $NaHCO_3$ solution (200 mL) and extracted with diethyl ether (3 x 200 mL). The combined organic extracts were dried over Na_2SO_4 , filtered and the solvents were removed under reduced pressure to provide the title compound: 1H NMR (300 MHz) 8.13 (d, $J = 3.7$ Hz, 1H), 7.93-7.88 (m, 1H), 7.24-7.19 (m, 1H), 4.78 (s, 2H), 2.14 (bs, 1H) ppm.

Preparation 25

(2-Methylpyridin-3-yl)methanol

25 To a slurry of lithium aluminum hydride (500 mg, 13.2 mmol) in anhydrous tetrahydrofuran (45 mL) at 0 °C under nitrogen was added dropwise a solution of methyl 2-methylnicotinate (17, 1.0 g, 6.6 mmol) in anhydrous tetrahydrofuran (5 mL). After 1 h the suspension was diluted with water (1 mL) and 6 N NaOH solution (5 mL). The precipitate was removed by vacuum filtration and the filtrate was dried over Na_2SO_4 , filtered, and the solvent was removed under reduced pressure to provide the title compound as a light yellow oil: 1H NMR (300 MHz) 8.37 (d,

-181-

J = 4.9 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.14 (dd, J = 7.6 Hz, 4.9 Hz, 1H), 4.72 (s, 2H), 2.95-2.74 (bs, 1H), 2.53 (s, 3H) ppm.

5

Preparation 26(6-Methylpyridin-3-yl)methanol

To a slurry of lithium aluminum hydride (500 mg, 13.2 mmol) in anhydrous tetrahydrofuran (45 mL) at 0 °C under nitrogen was added dropwise a solution of methyl 4-methylnicotinate (15, 1.0 g, 6.6 mmol) in anhydrous tetrahydrofuran (5 mL). After 1.5 h the suspension was diluted with water (1 mL) and 6 N NaOH solution (5 mL). The precipitate was removed by vacuum filtration and the filtrate was dried over Na₂SO₄, filtered, and the solvent was removed under reduced pressure to provide the title compound as a light yellow oil: ¹H NMR (300 MHz) 8.34 (s, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 7.9 Hz, 1H), 4.65 (s, 2H), 4.18-4.10 (bs, 1H), 2.51 (s, 3H) ppm.

20

Preparation 27(6-Fluoropyridin-3-yl)methanol

Thionyl chloride (0.29 mL, 4.08 mmol) was added to a slurry of 6-fluoronicotinic acid (13, 0.48 g, 3.40 mmol) and N,N-dimethylformamide (0.1 mL, catalytic amount) in benzene (40 mL) at room temperature under nitrogen, after which the mixture was heated at reflux for 3 h. The solvent was removed under reduced pressure to provide an amber oil that was dissolved in 1,4-dioxane (25 mL) under nitrogen. The solution was treated with sodium borohydride (0.26 g, 6.80 mmol) and the mixture was stirred at room temperature for 24 h. The suspension was diluted with sat. NaHCO₃ solution (200 mL) and extracted with diethyl ether (3 x 200 mL). The combined organic extracts were dried over Na₂SO₄, filtered and the solvents were removed under reduced pressure to


-182-

provide the title compound as a colorless oil: ^1H NMR (300 MHz) 8.20 (s, 1H), 7.87-7.81 (dt, $J = 8.0, 2.3$ Hz, 1H), 6.97-6.93 (dd, $J = 8.4, 2.8$ Hz, 1H), 4.73 (s, 2H), 2.04 (bs, 1H) ppm.

5

Example 615

N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)-2-fluoropyrid-3-ylmethylamine




10 Di-tert-butyl azodicarboxylate (0.36 g, 1.57 mmol) was added to a suspension of (2-fluoropyridin-3-yl)methanol (10, 0.20 g, 1.57 mmol), N-(4-(2,4-difluorophenoxy)phenyl)-N-ethylsulfonylamine (0.49 g, 1.56 mmol) and polystyrene resin-bound triphenylphosphine (0.52 g, 1.57 mmol, ~3
15 mmol/g) in anhydrous tetrahydrofuran (5 mL) at 0 °C under nitrogen. The resulting yellow suspension was warmed to room temperature and stirred for 19 h, after which additional polystyrene resin bound triphenylphosphine (0.52 g, 1.57 mmol, ~3mmol/g) and di-tert-butyl azodicarboxylate
20 (0.36 g, 1.57 mmol) were added. This solution was stirred for 24 h after which the suspension was diluted with anhydrous tetrahydrofuran (100 mL) and the solids were removed by vacuum filtration. The filtrate solvent was removed under reduced pressure to provide the crude product
25 as a yellow oil. This oil was purified by medium pressure liquid chromatography on silica gel, eluting with hexanes/ethyl acetate (7:3), to provide a colorless oil. This oil was triturated with hexanes/ethyl acetate (4-5 mL) to give the title compound as a white powder (0.28 g, 53%):

-183-

mp 110-112 °C; TLC R_f (3:2 hexanes/ethyl acetate) = 0.44; ¹H NMR (300 MHz) 8.11 (m, 1H), 7.90 (m, 1H), 7.24-7.15 (m, 3H), 7.11-7.03 (m, 1H), 6.98-6.86 (m, 2H), 6.84 (d, J = 6.8 Hz, 2H), 4.91 (s, 2H), 3.15-3.07 (q, J = 7.4 Hz, 2H), 1.43 (t, J = 7.4 Hz, 1H) ppm; ¹³C NMR (75 MHz) 163.3, 161.3, 160.1, 157.8, 156.5, 153.1, 147.5 (d, J = 14.9 Hz), 141.7, 139.1, 133.6, 130.5, 123.8 (d, J = 9.7 Hz), 122.1, 119.1 (d, J = 29.2 Hz), 117.5, 112.0 (d, J = 22.9 Hz), 106.0 (t, J = 24.3 Hz), 49.1, 46.0, 8.44 ppm; APCI MS m/z 423 [C₂₀H₁₇F₃N₂O₃S+H]⁺.
 10 Anal. Calcd. for C₂₀H₁₇F₃N₂O₃S: C, 56.87; H, 4.06; N, 6.63. Found: C, 56.90; H, 4.10; N, 6.45.

By a method similar to the method of Example 615 the following compounds were prepared:



15

No.	R ₁	R ₆	Data
616	SO ₂ CH ₂ CF ₃	2-fluoro	mp 114-115 °C; TLC R _f (7:3 hexanes/ethyl acetate) = 0.45; ¹ H NMR (300 MHz) 8.13 (m, 1H), 7.90 (m, 1H), 7.22-7.11 (m, 3H), 7.10-7.05 (m, 1H), 6.99-6.90 (m, 2H), 6.87 (d, J = 8.9 Hz, 2H), 4.92 (s, 2H), 3.86-3.77 (q, J = 9.1 Hz, 2H) ppm; ¹³ C NMR (75 MHz) 163.3, 161.4, 160.1, 158.5, 158.1, 156.5, 153.2, 147.9 (d, J = 14.9 Hz), 141.7, 138.9, 131.9, 130.8, 123.9 (d, J = 9.7 Hz), 122.2, 118.3 (d, J = 29.3 Hz), 117.7, 112.2 (d, J = 22.9 Hz), 106.0 (t, J = 21.9 Hz), 52.6 (q, J = 31.9 Hz), 49.8 ppm; APCI MS m/z 477 [C ₂₀ H ₁₄ F ₆ N ₂ O ₃ S+H] ⁺ . Anal. Calcd. for C ₂₀ H ₁₄ F ₆ N ₂ O ₃ S: C, 50.42; H, 2.96; N, 5.88. Found: C, 50.05; H, 2.79; N, 5.72
617	SO ₂ CH ₂ CH ₃	6-fluoro	mp 103-105 °C; TLC R _f (1:1 hexanes/ethyl acetate) = 0.38; ¹ H NMR (300 MHz) 7.92 (d, J = 2.2 Hz, 1H), 7.86-7.80 (dt, J = 8.0, 2.4 Hz, 1H), 7.13 (d, J = 9.0 Hz, 2H), 7.10-7.04 (m, 1H), 6.98-6.87 (m, 2H), 6.84 (d, J = 8.9 Hz, 2H), 4.81 (s, 2H), 3.12-3.05 (q, J = 7.4 Hz, 2H), 1.43 (t, J = 7.4 Hz, 1H) ppm; ¹³ C NMR (75 MHz)

			165.3, 162.1, 161.3 (d, $J = 10.2$ Hz), 158.0, 156.5 (d, $J = 12.5$ Hz), 153.2 (d, $J = 12.2$ Hz), 147.9 (d, $J = 15.0$ Hz), 142.2, 139.1 (d, $J = 12.1$ Hz), 133.3, 130.9, 130.3, 124.0 (d, $J = 9.8$ Hz), 117.5, 112.0 (d, $J = 22.9$ Hz), 110.1 (d, $J = 37.5$ Hz), 106.0 (t, $J = 22.0$ Hz), 52.6, 46.1, 8.50 ppm; APCI MS m/z 423 [C ₂₀ H ₁₇ F ₃ N ₂ O ₃ S+H] ⁺ . Anal. Calcd. for C ₂₀ H ₁₇ F ₃ N ₂ O ₃ S: C, 56.87; H, 4.06; N, 6.63. Found: C, 56.78; H, 3.97; N, 6.53
618	SO ₂ CH ₂ CF ₃	6-fluoro	mp 107-109 °C; TLC R_f (3:2 hexanes/ethyl acetate) = 0.54; ¹ H NMR (300 MHz) 7.90 (d, $J = 2.3$ Hz, 1H), 7.84-7.78 (dt, $J = 2.4, 8.0$ Hz, 1H), 7.11 (d, $J = 9.0$ Hz, 2H), 7.15-7.06 (m, 2H), 7.00-6.90 (m, 2H), 6.87 (d, $J = 8.9$ Hz, 2H), 4.83 (s, 2H), 3.83-3.76 (q, $J = 9.1$ Hz, 2H) ppm; ¹³ C NMR (75 MHz) 165.5, 162.3, 161.4 (d, $J = 10.3$ Hz), 158.6, 156.6 (d, $J = 12.4$ Hz), 153.2 (d, $J = 12.2$ Hz), 148.1 (d, $J = 15.1$ Hz), 142.1 (d, $J = 8.2$ Hz), 138.8, 131.5, 131.0, 129.5, 124.1 (d, $J = 9.7$ Hz), 120.2, 117.7, 112.3 (d, $J = 23.0$ Hz), 110.3 (d, $J = 37.6$ Hz), 106.0 (t, $J = 21.9$ Hz), 53.4, 52.7 (q, $J = 31.7$ Hz) ppm; APCI MS m/z 477 [C ₂₀ H ₁₄ F ₆ N ₂ O ₃ S+H] ⁺ . Anal. Calcd. for C ₂₀ H ₁₄ F ₆ N ₂ O ₃ S: C, 50.42; H, 2.96; N, 5.88. Found: C, 50.40; H, 2.87; N, 5.77
619	SO ₂ CH ₂ CH ₃	6-methyl	mp 108-111 °C; TLC R_f (9:1 methylene chloride/methanol) = 0.52; ¹ H NMR (300 MHz) 8.20 (d, $J = 2.0$ Hz, 1H), 7.59 (dd, $J = 2.3$ Hz, 8.0 Hz, 1H), 7.13 (d, $J = 9.0$ Hz, 1H), 7.15-7.06 (m, 3H), 6.86-6.83 (m, 3H), 6.84 (d, $J = 8.9$ Hz, 1H), 4.79 (s, 2H), 3.11-3.04 (q, $J = 7.4$ Hz, 2H), 2.51 (s, 3H), 1.72 (s, H), 1.43 (t, $J = 7.4$ Hz, 1H) ppm; ¹³ C NMR (75 MHz) 161.2 (d, $J = 10.2$ Hz), 158.6, 158.0 (d, $J = 10.2$ Hz), 157.8, 156.5 (d, $J = 12.2$ Hz), 153.2 (d, $J = 12.2$ Hz), 149.5, 139.2 (d, $J = 11.9$ Hz), 137.2, 133.6, 131.0, 129.3, 123.9 (d, $J = 9.7$ Hz), 123.6, 117.5, 112.0 (d, $J = 22.9$ Hz), 106.0 (t, $J = 22.0$ Hz), 53.3, 46.1, 24.5, 8.5 ppm; APCI MS m/z 419 [C ₂₁ H ₂₀ F ₂ N ₂ O ₃ S+H] ⁺ . Anal. Calcd. for C ₂₁ H ₂₀ F ₂ N ₂ O ₃ S: C, 60.27; H, 4.82; N, 6.69. Found: C, 59.94; H, 4.76; N, 6.58
620	SO ₂ CH ₂ CF ₃	6-methyl	mp 94-96 °C; TLC R_f (4:6 hexanes/ethyl acetate) = 0.58; ¹ H NMR (300 MHz) 8.16 (d, $J = 2.1$ Hz, 1H), 7.59 (dd, $J = 2.3$ Hz, 7.9 Hz, 2H), 7.13 (d, $J = 9.0$ Hz, 1H), 7.09-7.06 (m, 2H), 6.99-6.86 (m, 3H), 6.86 (d, $J = 8.9$ Hz, 1H), 4.81 (s, 2H), 3.85-3.76 (q, $J = 9.1$ Hz, 2H), 2.52 (s, 3H), 1.61 (s, 2H) ppm; ¹³ C NMR (75 MHz) 161.4 (d, $J = 10.2$ Hz), 159.0, 158.4, 158.1 (d, $J = 10.2$ Hz), 157.8, 156.6 (d, $J = 12.2$ Hz), 153.2 (d, $J = 12.2$ Hz), 149.5, 139.0 (d, $J = 12.0$ Hz), 137.1, 131.9, 131.1, 128.4, 124.0 (d, $J = 9.8$ Hz), 123.7, 120.3,

			117.6, 112.1 (d, $J = 22.9$ Hz), 106.0 (t, $J = 22.0$ Hz), 54.1, 53.4-52.1 (q, $J = 31.7$ Hz), 24.6 ppm; APCI MS m/z 473 $[C_{21}H_{17}F_5N_2O_3S+H]^+$. Anal. Calcd. for $C_{21}H_{17}F_5N_2O_3S$: C, 53.39; H, 3.63; N, 5.93. Found: C, 53.34; H, 3.44; N, 5.82
621	$SO_2CH_2CH_3$	2-methyl	TLC R_f (9:1 methylene chloride/methanol) = 0.47; 1H NMR (300 MHz) 8.37 (d, $J = 4.9$ Hz, 1H), 7.55 (d, $J = 7.7$ Hz, 1H), 7.17 (d, $J = 9.2$ Hz, 2H), 7.10-7.02 (m, 3H), 6.98-6.88 (m, 3H), 6.83 (d, $J = 8.9$ Hz, 2H), 4.88 (s, 2H), 3.14-3.07 (q, $J = 7.4$ Hz, 2H), 2.46 (s, 3H), 1.45 (t, $J = 7.3$ Hz, 1H) ppm; ^{13}C NMR (75 MHz) 161.4, 157.9, 157.3, 156.8, 154.1, 148.5, 139.4, 137.5, 134.2, 131.0, 130.0, 124.3, 122.2, 117.5, 112.3 (d, $J = 22.9$ Hz), 106.3 (t, $J = 22.0$ Hz), 52.5, 45.6, 28.8, 23.7, 8.7 ppm; APCI MS m/z 419 $[C_{21}H_{20}F_2N_2O_3S+H]^+$. Anal. Calcd. for $C_{21}H_{20}F_2N_2O_3S \cdot 0.10H_2O$: C, 60.02; H, 4.84; N, 6.67. Found: C, 59.86; H, 4.91; N, 6.74
622	$SO_2CH_2CF_3$	2-methyl	TLC R_f (7:3 ethyl acetate/hexanes) = 0.46; 1H NMR (300 MHz) 8.38 (d, $J = 4.8$ Hz, 1H), 7.54 (d, $J = 7.7$ Hz, 1H), 7.15 (d, $J = 9.0$ Hz, 1H), 7.12-7.04 (m, 3H), 6.99-6.88 (m, 3H), 6.85 (d, $J = 9.0$ Hz, 1H), 4.90 (s, 2H), 3.85-3.76 (q, $J = 9.1$ Hz, 2H), 2.41 (s, 3H) ppm; ^{13}C NMR (75 MHz) 161.4 (d, $J = 10.3$ Hz), 158.5, 158.0 (d, $J = 9.9$ Hz), 157.4, 156.6 (d, $J = 10.2$ Hz), 153.2 (d, $J = 10.2$ Hz), 149.2, 138.9 (d, $J = 10.3$ Hz), 137.8, 132.0, 130.9, 129.3, 123.9 (t, $J = 3.9$ Hz), 121.8, 120.3, 117.6, 112.1 (d, $J = 22.9$ Hz), 106.0 (t, $J = 22.0$ Hz), 53.5, 53.1-52.0 (q, $J = 31.8$ Hz), 22.3 ppm; APCI MS m/z 473 $[C_{21}H_{17}F_5N_2O_3S+H]^+$. Anal. Calcd. for $C_{21}H_{17}F_5N_2O_3S$: C, 53.39; H, 3.63; N, 5.93. Found: C, 53.73; H, 3.76; N, 6.07

Preparation 28

N-(Ethylsulfonyl)-N-(3-(N'-(2-chlorophenyl)-N'-methylsulfonamide)aniline

- 5 To a solution of 2-chloro-N-methylaniline (4.96 mmol, 1.1 eq., 702 mg) and pyridine (5.86 mmol, 464 mg) in 20 mL of methylene chloride was added 3-nitrobenzenesulfonyl chloride (4.51 mmol, 1.0 g) in one portion. The reaction mixture was stirred 16 hr and diluted with methylene
- 10 chloride and water. The aqueous layer was separated and extracted once with methylene chloride. The combined organic layers were extracted once with a saturated solution

-186-

of aqueous sodium carbonate, once with water, and then dried over sodium sulfate. The crude product was purified using flash chromatography (10-60% ethyl acetate / hexane) to give N-(2-chlorophenyl)-N-methyl-(3-nitrophenyl)sulfonamide which
5 solidifies on standing. ^1H NMR (300 MHz) 3.29 (s, 3H), 7.25-7.45 (m, 4H), 7.71 (t, $J = 7.82$ Hz, 1H), 8.06 (d, $J = 7.82$ Hz, 1H), 8.40-8.50 (m, 1H), 8.60-8.65 (m, 1H). MS (ESI): m/e 327.13, 329.13 (M+1).

A solution of N-(2-chlorophenyl)-N-methyl-(3-nitrophenyl)sulfonamide (2.6 mmol, 848 mg) and tin (II) chloride dihydrate (10.4 mmol, 2.35 g) were heated for 4 hr at reflux in 15 mL of methanol. The reaction mixture was cooled to room temperature and diluted with 20 mL of ethyl acetate and 10 mL of a saturated solution of aqueous sodium
15 carbonate. Heavy gas evolution was observed upon addition of aqueous sodium carbonate to the reaction mixture. The reaction mixture was stirred 1 hr and then filtered through a plug of Celite[®]. The layers were separated and the organic layer was extracted once with a saturated solution
20 of aqueous sodium carbonate, once with brine, and then dried with sodium sulfate. The crude product was purified using flash chromatography (0-5% ethyl acetate / methylene chloride) to give N-(2-chlorophenyl)-N-methyl-(3-aminophenyl)sulfonamide as an off white foam. ^1H NMR (300
25 MHz) 3.13 (s, 3H), 3.80 (br s, 2H), 6.80-6.87 (m, 1H), 7.02-7.25 (m, 6H), 7.30-7.38 (m, 1 H). MS (ESI): m/e 297.2, 299.2 (M+1).

To a solution of

N-(2-Chlorophenyl)-N-methyl-(3-aminophenyl)sulfonamide
30 (3.38 mmol, 1.0 g), DMAP (0.83 mmol, 120 mg) and pyridine (16.9 mol, 1.33 mL) in 20 mL methylene chloride was added ethanesulfonyl chloride (12.2 mmol, 3.6 eq., 1.56 g) in two portions. The reaction mixture was stirred 10 hr and diluted with then methylene chloride and water. The layers


-187-

were separated and the aqueous layer was extracted once with methylene chloride. The combined organic layers were extracted once with a saturated solution of aqueous sodium carbonate and then dried with sodium sulfate. The crude product was purified using flash chromatography (0-30% ethyl acetate / methylene chloride) to give the title compound. ¹H NMR (300 MHz) 1.36 (t, J = 5.87 Hz, 3H), 3.10-3.16 (m, 2H), 3.23 (s, 3H), 7.04 (s, 1H), 7.22-7.60 (m, 8 H). MS (ESI): m/e 389.01, 390.88 (M+1).

10

Example 623

N-(3-(N'-Methyl-N'-(2-chlorophenylsulfonamido)phenyl))-N-(ethanesulfonyl)pyrid-3-ylmethanamine



15 To a solution of (0.48 mmol, 186.6 mg) dissolved in 5 mL of anhydrous DMF was added a 1.0 M solution of lithium bis(trimethylsilyl)amide in hexane (1.2 mmol, 2.5 eq., 1.2 mL). The solution was stirred 5 min. and 3-picolyl chloride hydrochloride (0.50 mmol, 82 mg) was added in one portion.

20 After overnight stirring, the reaction mixture was concentrated to dryness under vacuum. The residue was dissolved in methanol and loaded onto a 2 g SCX ion exchange cartridge (Varian Sample Preparation, 0.75 meq / g loading). After washing with additional methanol the crude product was

25 eluted from the column using 10 mL of a 2.0 M solution of ammonia in methanol. The crude produce was purified using mass guided reverse phase semi-preparative chromatography (ESI detection; ACN with 0.1% TFA / water with 0.1% TFA;

-188-

Flow rate 25 mL/min.; 10% organic for 1 min. then a gradient over 12 min. to 95% organic then 95% organic for 1 min.) to give the TFA salt of the product as an oil after solvent evaporation. The purified sample was desalted using
5 a 1 g SCX ion exchange column as previously described (methanol washing solvent and 2.0 M ammonia in methanol the eluting solvent) to give the title compound. ¹H NMR (300 MHz) 1.40 (t, J = 7.43 Hz, 3H), 3.04 (q, J = 7.43 Hz, 2H),
3.18 (s, 3H), 4.89 (s, 2H), 7.20-7.30 (m, 3H), 7.32-7.37 (m,
10 1H), 7.44-7.52 (m, 3H), 7.65-7.75 (m, 3H), 8.39 (br s, 1H), 8.51 (br s, 1H). MS (ESI): m/e 480.2, 482.2 (M+1).

The compounds of the present invention can be
15 administered alone or in the form of a pharmaceutical composition, that is, combined with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and chemical properties of the compound selected, the chosen route of
20 administration, and standard pharmaceutical practice. The compounds of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable salts, for purposes of stability, convenience of crystallization, increased
25 solubility, and the like.

In practice, the compounds of formula I are usually administered in the form of pharmaceutical compositions, that is, in admixture with pharmaceutically acceptable carriers or diluents, the proportion and nature of which are
30 determined by the chemical properties of the selected compound of formula I, the chosen route of administration, and standard pharmaceutical practice.

Thus, the present invention provides pharmaceutical compositions comprising a compound of the formula I and a
35 pharmaceutically acceptable diluent. .

-189-

The compounds of formula I can be administered by a variety of routes. In effecting treatment of a patient afflicted with disorders described above, a compound of formula I can be administered in any form or mode which makes the compound bioavailable in an effective amount, including oral and parenteral routes. For example, compounds of formula I can be administered orally, by inhalation, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, occularly, topically, sublingually, buccally, and the like. Oral administration is generally preferred for treatment of the neurological and psychiatric disorders described herein.

One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disorder or condition to be treated, the stage of the disorder or condition, and other relevant circumstances. (*Remington's Pharmaceutical Sciences*, 18th Edition, Mack Publishing Co. (1990)).

The pharmaceutical compositions of the present invention are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art. The pharmaceutical composition may be adapted for oral, inhalation, parenteral, or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solution, suspensions, or the like.

The compounds of the present invention may be administered orally, for example, with an inert diluent or capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% of the compound of the present

-190-

invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the compound present in compositions is such that
5 a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention may be determined by a person skilled in the art.

The tablets, pills, capsules, troches, and the like may also contain one or more of the following adjuvants: binders
10 such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and
15 sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.
20 Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other coating agents. A syrup may contain, in addition to the present compounds, sucrose as a
25 sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

For the purpose of parenteral therapeutic
30 administration, the compounds of the present invention may be incorporated into a solution or suspension. These preparations typically contain at least 0.1% of a compound of the invention, but may be varied to be between 0.1 and about 90% of the weight thereof. The amount of the compound
35 of formula I present in such compositions is such that a suitable dosage will be obtained. The solutions or suspensions may also include one or more of the following

-191-

adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Preferred compositions and preparations are able to be determined by one skilled in the art.

The compounds of the present invention may also be administered topically, and when done so the carrier may suitably comprise a solution, ointment, or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bees wax, mineral oil, diluents such as water and alcohol, and emulsifiers, and stabilizers. Topical formulations may contain a concentration of the formula I or its pharmaceutical salt from about 0.1 to about 10% w/v (weight per unit volume).

In order to more fully illustrate the operation of this invention, typical pharmaceutical compositions are described below. The examples are illustrative only, and are not intended to limit the scope of the invention in any way.

-192-

FORMULATION 1

A typical tablet, appropriate for use in this method, may be prepared using conventional techniques and may contain:

	Amount per Tablet	Concentration by Weight (%)
5		
Compound of formula I	5.0 mg	4.7
Lactosum	67.8 mg Ph. Eur.	64.2
10 Avicel®	31.4 mg	29.8
Amberlite®	1.0 mg	1.0
magnesium stearate	0.25 mg Ph. Eur.	0.3
TOTAL	105.45 mg	100

FORMULATION 2

15 Hard gelatin capsules may be prepared using the following ingredients:

	Amount per Tablet	Concentration by Weight (%)
20		
Compound of formula I	0.1 mg	0.05
starch dried	200 mg	95.2
magnesium stearate	10 mg	4.8
TOTAL	210.1 mg	100

25 The above ingredients are mixed and filled into hard gelatin capsules in 210.1 mg quantities.

FORMULATION 3

30 Suspensions each containing 1 mg of medicament per 5 mL dose are as follows:

	Amount per 5mL of suspension
Compound of formula I	1 mg
sodium carboxymethyl cellulose	50 mg
35 syrup	1.25 mL
benzoic acid solution	0.10 mL
flavor	q.v.

-193-

color

q.v.

water

q.s. to 5 mL

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color is diluted with some of the water and added to the paste with stirring. Sufficient water is then added to produce the required volume.

10 The compounds of formula I are potentiators of metabotropic glutamate (mGlu) receptor function, in particular they are potentiators of mGlu₂ and/or mGlu₃ receptors. That is, the compounds of formula I do not appear to bind at the glutamate recognition site on the mGlu
15 receptor, but in the presence of glutamate or a glutamate agonist, the compounds of formula I increase mGlu receptor response. The present potentiators are expected to have their effect at mGlu receptors by virtue of their ability to increase the response of such receptors to glutamate or
20 glutamate agonists, enhancing the function of the receptors. The behavior of the potentiators of formula I at mGlu₂ receptors is shown in Example A which is suitable to identify potentiators useful for carrying out the present invention.

25

Example A

[³H]-2S-2-Amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid Receptor Binding

[³H]-2S-2-Amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid (17.5 Ci/mmol) was tritiated by
30 Chemsyn Laboratories. Membranes from mGlu₂ receptor expressing RGT cells were prepared by harvesting adherent cells from confluent T-150 flasks with a cell scraper. Cells and media were then placed in 50 ml conical tubes and
35 centrifuged at 4° C at 1000g for 5 minutes. The supernatant was removed and the pellet was frozen at -10° C until use. Washed cell membranes were prepared by adding 20 ml of 10 mM

-194-

potassium phosphate buffer pH 7.6 @ 5° C + 100 mM potassium bromide and homogenizing with an Ultra-Turrax tissuemizer for 15 seconds at 90% output. The homogenate was centrifuged at 48,000 x g for 10 minutes at 5°C. This last
5 step was repeated two times, and the final pellet was resuspended in 10 ml of the same buffer and reserved on ice until initiating the binding assay.

[³H]-2S-2-Amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid can be assayed by the method
10 described by Johnson et al. *Neuropharmacology* 38: 1519-1529 (1999). Accordingly, [³H]-2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid binding was assayed in a reaction mixture containing 10 mM potassium phosphate (pH 7.6), 100 mM potassium bromide and
15 generally 1 nM [³H]-2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid, (final volume 500 µl). The incubation was initiated by the addition of the membrane suspension, (about 15 µg membrane protein), and allowed to continue on ice for 30 min.
20 Incubation was terminated by rapid filtration with a Brandel cell harvester through glass fiber Whatman GF/B filters pre-wet with the same potassium phosphate buffer assay buffer (at 4° C). The filters were washed five times with 1 ml of buffer. Filter sections were transferred to minivials and 5
25 ml of Fisher Scientific ScintiSafe liquid scintillation cocktail was added to each vial. Vials were allowed to set for several hours prior to counting on a Beckman LS6000 liquid scintillation counter.

Displacement of 1 nM [³H]-2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid
30 binding was assayed in homogenates derived from a mGlu₂ receptor expressing cell line. At concentrations up to 100 µM, the potentiator of formula I did not significantly displace [³H]-2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid binding. Displacement of
35 1 nM [³H]-2S-2-Amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid is presented in the table below.

-195-

Treatment	K _I (μM)	(95% Confidence Interval)
Glutamate	7.8	(1.1-15.7)
Compound of Example 16	>100	

Potentiation of Glutamate-Induced Increase in Intracellular Calcium with a mGluR₂ Expressing Cell Line.

5 Cell lines expressing human mGlu₂ receptors were derived as previously described (Desai, Burnett, Mayne, Schoepp, *Mol. Pharmacol.* 48, 648-657, 1995) and cultured in DMEM with 5% dialyzed fetal bovine serum, 1 mM glutamine, 1 mM sodium pyruvate, 50 μg/ml Geneticin G418, and 0.2 mg/ml
10 hygromycin B. Confluent cultures were passaged weekly. These cells are referred to as RGT cells for Rat Glutamate Transporter, and have been co-transfected with the glutamate/aspartate transporter GLAST. The RGT cell line
15 expressing the mGluR₂ receptors was stably transfected with the promiscuous G-protein, Galpha15 to change the signaling pathway to the mGlu₂ receptor to one that could be easily measured through release of intracellular calcium. Thus, intracellular calcium levels were monitored before and after
20 the addition of drugs on a Fluorometric Imaging Plate Reader (i.e. FLIPR, Molecular Devices). The following buffer was used throughout as an assay buffer: 10 mM KCl, 138 mM NaCl, 5 mM Ca Cl₂, 1 mM MgCl₂, 4 mM NaH₂PO₄, 10 mM Glucose, 10 mM HEPES, pH 7.4. Cells that had been plated 48 h prior at a
25 density of 30-40,000 cells per well in a 96-well plate were loaded with a calcium-sensitive dye for 90 min at 25°C. Fluo-3 (2 mM in DMSO, Molecular Probes) were mixed with a equal volume of 10% pluronic acid in DMSO, and diluted to 8 μM into the buffer described above containing 10% fetal
30 bovine serum to make the loading buffer. Following loading of the cells, the loading buffer was removed and replaced with assay buffer prior to drug addition and monitoring on

-196-

the FLIPR. Results are analyzed by taking the difference of the peak height minus the background fluorescence and expressing the results as a percent of the maximal glutamate response (30 μ M glutamate, typically about 30-50,000

5 Relative Fluorescent Units).

Data from such an experiment using a representative compound of the present invention is presented in the table below.

Treatment	% Maximal Glutamate Response (as defined by 30 μ M Glutamate) mean \pm SD
20 μ M Compound of Example 1	2.3 \pm 0.8 %
0.5 μ M L-glutamate	1.9 \pm 1.0 %
20 μ M Compound of Example 1 + 0.5 μ M L-glutamate	85.5 \pm 5.8 %*

10 * p < 0.05, ANOVA followed by contrast analysis

As seen from the results above the compounds of formula I potentiate the response of the mGlu₂ receptor to glutamate. This response can be blocked by pretreatment of
 15 the cells with the mGlu_{2/3} antagonists 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid. Taken together with the inability of these compounds to displace [³H]-2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid-labeled receptors, these
 20 results show that the compounds of formula I act at a site other than the glutamate recognition site to potentiate the effects of glutamate at mGlu receptors.

Using the procedure of Example A, the effect of representative compounds of the present invention on the
 25 response of different mGlu₂ glutamate-site agonists (such as glutamate, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid (APDC), and 2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)

-197-

glycine (DCG IV), (Schoepp, D.D., Jane, D.E., Monn, J.A., *Neuropharmacology* 38: 1431-1476, (1999)) is presented in the tables below.

5

	Buffer	3 μ M Compound of Example 22
	% Maximal Response (mean \pm SD, n=2)	
Buffer	0.0 \pm 3.2%	4.7 \pm 0.4%
30 μ M APDC	100.7 \pm 1.6%	120.3 \pm 10.0%
10 μ M APDC	107.2 \pm 3.6%	119.1 \pm 4.0%
3 μ M APDC	80.3 \pm 9.3%	114.0 \pm 0.8%*
1 μ M APDC	16.8 \pm 1.5%	92.0 \pm 3.4%*
300 nM APDC	1.7 \pm 0.4%	28.4 \pm 1.7%*
100 nM APDC	-0.8 \pm 0.5%	0.2 \pm 0.6%
30 nM APDC	1.3 \pm 0.1%	0.5 \pm 1.5%
1 nM APDC	0.3 \pm 1.2%	0.1 \pm 0.7%

* p < 0.05, t-test vs. agonists alone

	Buffer	3 μ M Compound of Example 22
	% Maximal Response (mean \pm SD, n=2)	
Buffer	0.0 \pm 0.7%	3.7 \pm 1.4%
30 μ M DCG IV	68.5 \pm 0.14%	138.2 \pm 7.1%

-198-

10 μ M DCG IV	79.3 \pm 10.8%	147.9 \pm 1.5%
3 μ M DCG IV	68.3 \pm 5.1%	153.0 \pm 2.8%
1 μ M DCG IV	67.9 \pm 15.0%	141.1 \pm 5.9%
300 nM DCG IV	34.3 \pm 6.3%	132.9 \pm 5.5%
100 nM DCG IV	4.2 \pm 0.8%	83.3 \pm 10.5%
30 nM DCG IV	4.5 \pm 4.3%	11.1 \pm 6.1%
1 nM DCG IV	4.3 \pm 3.5%	-0.1 \pm 0.6%

	Buffer	1 μ M Compound of Example 16
	% Maximal Response (mean \pm SD, n=2)	
Buffer	0.0 \pm 0.3%	1.6 \pm 1.0%
24 μ M Glutamate	100.0 \pm 5.8%	95.4 \pm 2.4%
8 μ M Glutamate	96.7 \pm 3.2%	98.4 \pm 6.4%
2.4 μ M Glutamate	83.5 \pm 4.6%	92.5 \pm 4.4%
800 nM Glutamate	16.9 \pm 8.2%	62.9 \pm 0.1%
240 nM Glutamate	-0.1 \pm 0.4%	17.4 \pm 2.8%
80 nM Glutamate	0.1 \pm 0.1%	0.3 \pm 1.1%
24 nM Glutamate	0.2 \pm 0.2%	0.1 \pm 0.8%
8 nM Glutamate	-0.7 \pm 0.3%	2.8 \pm 1.9%

-199-

	Buffer +	1 μ M Compound of Example 1	1 μ M Compound of Example 9
	% Maximal Response (mean \pm SD, n=2)		
	0.0 \pm 2.6%	0.1 \pm 0.1%	4.2 \pm 2.7%
30 μ M Glutamate	107.2 \pm 11.7%	116.7 \pm 4.3%	108.0 \pm 12.3%
10 μ M Glutamate	108.2 \pm 4.8%	107.6 \pm 10.7%	102.9 \pm 6.2%
3 μ M Glutamate	84.2 \pm 4.3%	112.1 \pm 10.3%	101.6 \pm 8.1%
1 μ M Glutamate	22.6% (N=1)	79.2 \pm 14.6%	93.1 \pm 2.5%
300 nM Glutamate	-1.1 \pm 0.6%	42.5 \pm 4.3%	60.0 \pm 10.6%
100 nM Glutamate	-1.0 \pm 1.2%	1.5 \pm 1.2%	20.5 \pm 4.3%
30 nM Glutamate	-1.6 \pm 0.4%	2.2 \pm 1.3%	4.7 \pm 0.4%
10 nM Glutamate	-1.1 \pm 0.6%	-0.3 \pm 0.2%	2.4 \pm 0.3%

The results in the tables above demonstrate the ability of compounds of the present invention to potentiate the effects of mGlu₂ receptor agonists such as glutamate, APDC, and DCG IV. It is recognized that the compounds of the present invention would be expected to increase the effectiveness of glutamate and glutamate agonists of the mGlu₂ receptor. Thus, the potentiators of the present invention are expected to be useful in the treatment of various neurological and psychiatric disorders associated with glutamate dysfunction described to be treated herein and others that can be treated by such potentiators as are appreciated by those skilled in the art.

In one embodiment of the present invention provides methods of treating neurological and psychiatric disorders

-200-

associated with glutamate dysfunction, comprising:
administering to a patient in need thereof an effective
amount of a potentiator of metabotropic glutamate receptors.

Specifically, the present invention provides a method
5 of treating neurological and psychiatric disorders
associated with glutamate dysfunction, comprising:
administering to a patient in need thereof an effective
amount of a potentiator of mGlu₂ and/or mGlu₃ receptors,
that is, the present invention provides methods using an
10 effective amount of a potentiator of mGlu₂ receptors, an
effective amount of a potentiator of mGlu₃ receptor, or an
effective amount of a potentiator of mGlu₂ and mGlu₃
receptors.

In a preferred embodiment the present invention
15 provides a method for treating migraine, comprising:
administering to a patient in need thereof an effective
amount of a metabotropic glutamate potentiator, in
particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

In another preferred embodiment the present invention
20 provides a method for treating anxiety, comprising:
administering to a patient in need thereof an effective
amount of a metabotropic glutamate potentiator, in
particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

Particularly preferred anxiety disorders are
25 generalized anxiety disorder, panic disorder, and obsessive
compulsive disorder.

In another preferred embodiment the present invention
provides a method for treating schizophrenia, comprising:
administering to a patient in need thereof an effective
30 amount of a metabotropic glutamate potentiator, in
particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

In yet another preferred embodiment the present
invention provides a method for treating epilepsy,
comprising: administering to a patient in need thereof an
35 effective amount of a metabotropic glutamate potentiator, in
particular a potentiator of mGlu₂ and/or mGlu₃ receptors.

-201-

Because the compounds of formula I enhance the normal physiological function of the mGlu receptors, the compounds of formula I are useful for the treatment of a variety of neurological and psychiatric disorders associated with glutamate dysfunction, including: acute neurological and psychiatric disorders such as cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia (including AIDS-induced dementia), Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity (including tremors) seizures, epilepsy, convulsions, migraine (including migraine headache), urinary incontinence, substance tolerance, substance withdrawal (including, substances such as opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, hypnotics, etc.), psychosis, schizophrenia, anxiety (including generalized anxiety disorder, panic disorder, and obsessive compulsive disorder), mood disorders (including depression, mania, bipolar disorders), trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain (including acute and chronic pain states, severe pain, intractable pain, neuropathic pain, and post-traumatic pain), tardive dyskinesia, sleep disorders (including narcolepsy), attention deficit/hyperactivity disorder, and conduct disorder.

At present, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV™) (1994, American Psychiatric Association, Washington, D.C.), provides a diagnostic tool for identifying many of the disorders described herein. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for neurological and

-202-

psychiatric disorders described herein and that these systems evolve with medical scientific progress.

Because the compounds of formula I potentiate mGlu receptor response, in particular mGlu₂ and/or mGlu₃ receptor response, to glutamate and glutamate agonists. Such agonists are easily recognized and some are available in the art. Schoepp, D.D., Jane, D.E., Monn, J.A., *Neuropharmacology* 38: 1431-1476, (1999).

Thus, a more particular embodiment, it is understood that the present invention extends to a method of potentiating the action of a glutamate receptor agonist at the Group II mGlu receptors, comprising administering to a patient in need thereof an effective amount of a mGluR_{2/3} potentiator, in particular a compound of formula I, in combination with a potentiated amount of an mGlu receptor agonist. Such a combination may be advantageous in that it may augment the activity and selectivity of mGlu agonist.

As used herein, the term "patient" refers to a warm blooded animal such as a mammal which is afflicted with one or more neurological and psychiatric disorders associated with glutamate dysfunction. It is understood that guinea pigs, dogs, cats, rats, mice, horses, cattle, sheep, and humans are examples of animals within the scope of the meaning of the term. It is also understood that this invention relates specifically to the potentiation of mammalian metabotropic glutamate receptors.

It is also recognized that one skilled in the art may affect the neurological and psychiatric disorders by treating a patient presently afflicted with the disorders or by prophylactically treating a patient afflicted with the disorders with an effective amount of the compound of formula I. Thus, the terms "treatment" and "treating" are intended to refer to all processes wherein there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of the neurological and psychiatric disorders described herein, but does not necessarily indicate a total elimination of all disorder symptoms, and

-203-

is intended to include prophylactic treatment of such neurological and psychiatric disorders.

As used herein, the term "effective amount" of a compound of formula I refers to an amount, that is, the dosage which is effective in treating the neurological and psychiatric disorders described herein.

An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining an effective amount, the dose of a compound of formula I, a number of factors are considered by the attending diagnostician, including, but not limited to: the compound of formula I to be administered; the co-administration of an mGlu agonist, if used; the species of mammal; its size, age, and general health; the specific disorder involved; the degree of involvement or the severity of the disorder; the response of the individual patient; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of other concomitant medication; and other relevant circumstances.

An effective amount of a compound of formula I is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day. Preferred amounts are able to be determined by one skilled in the art.

As used herein, the term "potentiated amount" refers to an amount of an mGlu agonist, that is, the dosage of agonist which is effective in treating the neurological and psychiatric disorders described herein when administered in combination with an effective amount of a compound of formula I. A potentiated amount is expected to be less than the amount that is required to provided the same effect when the mGlu agonist is administered without an effective amount of a compound of formula I.

-204-

A potentiated amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining a potentiated amount, the dose of an mGlu agonist to be administered in combination with a compound of formula I, a number of factors are considered by the attending diagnostician, including, but not limited to: the mGlu agonist selected to be administered, including its potency and selectivity; the compound of formula I to be co-administered; the species of mammal; its size, age, and general health; the specific disorder involved; the degree of involvement or the severity of the disorder; the response of the individual patient; the modes of administration; the bioavailability characteristics of the preparations administered; the dose regimens selected; the use of other concomitant medication; and other relevant circumstances.

A potentiated amount of an mGlu agonist to be administered in combination with an effective amount of a compound of formula I is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day and is expected to be less than the amount that is required to provided the same effect when administered without an effective amount of a compound of formula I. Preferred amounts of a co-administered mGlu agonist are able to be determined by one skilled in the art.

Of the neurological and psychiatric disorders associated with glutamate dysfunction which are treated according to the present invention, the treatment of migraine, anxiety, schizophrenia, and epilepsy are particularly preferred. Particularly preferred anxiety disorders are generalized anxiety disorder, panic disorder, and obsessive compulsive disorder.

Thus, in a preferred embodiment the present invention provides a method for treating migraine, comprising: administering to a patient in need thereof an effective

-205-

amount of a compound of formula I or a pharmaceutical composition thereof.

In one of the available sources of diagnostic tools, *Dorland's Medical Dictionary* (23rd Ed., 1982, W. B. Saunders Company, Philadelphia, PA), migraine is defined as a symptom
5 complex of periodic headaches, usually temporal and unilateral, often with irritability, nausea, vomiting, constipation or diarrhea, and photophobia. As used herein the term "migraine" includes these periodic headaches, both
10 temporal and unilateral, the associated irritability, nausea, vomiting, constipation or diarrhea, photophobia, and other associated symptoms. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for neurological and
15 psychiatric disorders, including migraine, and that these systems evolve with medical scientific progress.

In another preferred embodiment the present invention provides a method for treating anxiety, comprising:
administering to a patient in need thereof an effective
20 amount of a compound of formula I or a pharmaceutical composition thereof.

At present, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IVTM) (1994, American Psychiatric Association, Washington, D.C.),
25 provides a diagnostic tool including anxiety and related disorders. These include: panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress
30 disorder, generalized anxiety disorder, anxiety disorder due to a general medical condition, substance-induced anxiety disorder and anxiety disorder not otherwise specified. As used herein the term "anxiety" includes treatment of those anxiety disorders and related disorder as described in the
35 DSM-IV. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for neurological and psychiatric disorders, and

-206-

particular anxiety, and that these systems evolve with medical scientific progress. Thus, the term "anxiety" is intended to include like disorders that are described in other diagnostic sources.

5 A number of preclinical laboratory animal models for migraine and anxiety have been described. One commonly used model of migraine is the dural extravasation model that has been described by Phebus et al., Life Sci., 61(21), 2117-2126 (1997) which can be used to evaluate the present
10 compounds.

Example B

Animal Model of Dural Protein Extravasation

15 Harlan Sprague-Dawley rats (250-350 g) were anesthetized with sodium pentobarbital intraperitoneally (65 mg/kg) and placed in a stereotaxic frame (David Kopf Instruments) with the incisor bar set at -3.5 mm. Following a midline sagittal scalp incision, two
20 pairs of bilateral holes were drilled through the skull (6 mm posteriorly, 2.0 and 4.0 mm laterally, all coordinates referenced to bregma). Pairs of stainless steel stimulating electrodes, insulated except at the tips (Rhodes Medical Systems, Inc.), were lowered through the holes in both
25 hemispheres to a depth of 9 mm.

25 The femoral vein was exposed and a dose of the test compound was injected intravenously (i.v.) at a dosing volume of 1 ml/kg or, in the alternative, test compound was administered orally (p.o.) via gavage at a volume of 2 ml/kg. Approximately 8 minutes post i.v. injection, a 50
30 mg/kg dose of Evans Blue, a fluorescent dye, was also injected intravenously. The Evans Blue complexed with proteins in the blood and functioned as a marker for protein extravasation. Exactly 10 minutes post-injection of the
35 test compound, the left trigeminal ganglion was stimulated for 3 minutes at a current intensity of 1.0 mA (5 Hz, 4 msec duration) with a Model 273 potentiostat/ galvanostat (EG&G Princeton Applied Research).

-207-

Fifteen minutes following stimulation, the animals were killed and exsanguinated with 40 mL of saline. The top of the skull was removed to facilitate the collection of the dural membranes. The membrane samples were removed from both hemispheres, rinsed with water, and spread flat on microscopic slides. Once dried, the tissues were coverslipped with a 70% glycerol/water solution.

A fluorescence microscope (Zeiss) equipped with a grating monochromator and a spectrophotometer was used to quantify the amount of Evans Blue dye in each sample. An excitation wavelength of approximately 535 nm was utilized and the emission intensity at 600 nm was determined. The microscope was equipped with a motorized stage and also interfaced with a personal computer. This facilitated the computer-controlled movement of the stage with fluorescence measurements at 25 points (500 nm steps) on each dural sample. The mean and standard deviation of the measurements were determined by the computer.

The extravasation induced by the electrical stimulation of the trigeminal ganglion was an ipsilateral effect (i.e. occurs only on the side of the dura in which the trigeminal ganglion was stimulated). This allows the other (unstimulated) half of the dura to be used as a control. The ratio of the amount of extravasation in the dura from the stimulated side, over the amount of extravasation in the unstimulated side, was calculated. Control animals dosed only with saline, yielded a ratio of approximately 1.9. In contrast, a compound which effectively prevented the extravasation in the dura from the stimulated side would yield a ratio of approximately 1.0.

Data from such an experiment using a representative compound of the present invention is presented in the table below.

Inhibition of Dural Protein Extravasation

Compound	Dose	Route of Admin	Extrav. Ratio	n
----------	------	----------------	---------------	---

-208-

			+ s.e.m.	
vehicle	1 mL/kg	i.v.	1.89+0.08	9
Example 16	10 pg/kg	i.v.	1.87+0.07	4
Example 16	100 pg/kg	i.v.	1.37+0.07	3
Example 16	1 ng/kg	i.v.	1.04+0.05	3
Example 16	100 ng/kg	i.v.	0.99+0.004	3

The fear potentiated startle response model has been extensively used as a model of anxiety and can be used to evaluate the present compounds. Davis, *Psychopharmacol.*, 62, 1 (1979); Davis, *Behav. Neurosci.*, 100, 814 (1986); Davis, *Tr. Pharmacol. Sci.*, 13, 35 (1992).

Example C

Fear Potentiated Startle Paradigm

Male Sprague-Dawley rats weighing 325-400 g were purchased from Harlan Sprague-Dawley, Inc. (Cumberland, IN) and given a one week acclimation period before testing. Rats were individually housed with food and water ad libitum in an animal room on a 12-hour light/dark cycle with lights on between 6:00 A.M. and 6:00 P.M. The compound of Example 16 was prepared in a suspension of 5% ethanol, 0.5% CMC, 0.5% Tween 80 and 99% water. 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl) propionic acid was prepared in sterile water. Control rats were given the respective vehicle.

The fear potentiated startle paradigm is conducted over three consecutive days. All three days begin with a 5-minute adaptation period before the trial starts. On day one (baseline startle) after the adaptation period, the animal receives 30 trials of 120dB auditory noise. The mean startle amplitude (V_{max}) is used to assign animals to groups with similar means before conditioning begins. Day two consists of conditioning the animals. Each animal receives 0.5 mA of shock for 500 msec preceded by a 5 second presentation of light which remains on for the duration of the shock. Ten presentations of the light and shock are administered. Day three is the testing trial where drug administration occurs

-209-

prior to testing. Twenty-four hours after conditioning, startle testing sessions are conducted. Ten trials of acoustic startle (120 dB), non-light paired, are presented at the beginning of the session. This is followed by 20
5 random trials of the noise alone and 20 random trials of noise preceded by light. Excluding the first 10 trials, the startle response amplitudes for each trial type are averaged for each animal. Data is presented as the difference between
10 light + noise and noise-alone. Differences in startle response amplitudes were analyzed by JMP statistical software using a One-way Anova (analysis of variance, t-test). Group differences were considered to be significant at $p < 0.05$.

Data from such an experiment using a representative
15 compound of the present invention is presented in the table below. In the experiment shown below the compound of Example 16 was given i.p. 30 minutes prior to testing.

Dose Response Experiment

20

Compound of Example 16 (mg/kg)	Difference in Startle Amplitude (V_{max}) + S.E.
Exp. 1 Control	188 + 47
0.03	108 + 41
0.3	154 + 38
3.0	21 + 24*
Exp. 2 Control	455 + 106
1.0	120 + 87*
3.0	148 + 86*
10.0	105 + 91*

* $P < 0.05$

In another preferred embodiment the present invention provides a method for treating epilepsy, comprising:
25 administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutical composition thereof.

At present, there are several types and subtypes of seizures associated with epilepsy, including idiopathic,

-210-

symptomatic, and cryptogenic. These epileptic seizures can be focal (partial) or generalized. They can also be simple or complex. Epilepsy is described in the art, such as Epilepsy: A comprehensive textbook. Ed. by Jerome Engel, Jr. and Timothy A. Pedley. (Lippincott-Raven, Philadelphia, 1997). At present, the International Classification of Diseases, Ninth Revision, (ICD-9) provides a diagnostic tool including epilepsy and related disorders. These include: generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with impairment of consciousness, partial epilepsy without impairment of consciousness, infantile spasms, epilepsy partialis continua, other forms of epilepsy, epilepsy, unspecified, NOS. As used herein the term "epilepsy" includes these all types and subtypes. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for neurological and psychiatric disorders, including epilepsy, and that these systems evolve with medical scientific progress.

Various electroshock-induces models has been extensively used as a model of seizure disorders.

Example D

25 Electroshock-induced seizures

Application of electrical stimulation by corneal electrodes to mice can induce tonic hindlimb-extensor seizures. Blockade of tonic extensor seizures induced by electroshock is considered predictive for drugs which block seizure propagation and may be effective in preventing various seizures in humans, including epileptic seizures.

Vehicle or a dose of a test drug are administered to groups of 5 to 10 mice each. Thirty minutes later, electroshock (10 mA, 0.2 sec duration) is administered by transcorneal electrodes. The number of mice exhibiting tonic extensor seizures in each group is recorded. The data

-211-

are reported as the percentage of mice which are protected from seizures.


Data from such an experiment using a representative compound of the present invention is presented in the table
5 below.

Compound of Example 590 (mg/kg, ip)	Percent Protection
vehicle	0%
30	60 %
100	100 %

-212-

WHAT IS CLAIMED IS:

1. A compound of the formula



wherein

R_1 is selected from the group consisting of $-C(O)R_3$, $-C(O)OR_4$, and $-SO_2R_5$

wherein R_3 is selected from the group consisting of alkyl and cycloalkyl, R_4 is selected from the group consisting of alkyl and cycloalkyl, R_5 is selected from the group consisting of alkyl, cycloalkyl, and fluorinated alkyl;

R_2 is from 1 to 3 substituents independently selected from the group consisting of hydrogen, hydroxy, trisubstituted silyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, phenyl, substituted phenyl, pyridyloxy, thiophenoxy, substituted thiophenoxy, phenylsulfinyl, substituted phenylsulfinyl, phenylsulfonyl, substituted phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy, and substituted phenoxy;

or

two R_2 substituents are taken together, on adjacent positions, to form a fused cycloalkyl or a methylenedioxy ring, and one R_2 substituent is selected

-213-

from the group consisting of hydrogen, hydroxy,
trisubstituted silyloxy, alkyl, substituted alkyl,
alkenyl, substituted alkenyl, alkoxy, substituted
alkoxy, cycloalkoxy, substituted cycloalkoxy,
5 cycloalkyl, substituted cycloalkyl, halogen, cyano,
nitro, phenyl, substituted phenyl, pyridyloxy,
thiophenoxy, substituted thiophenoxy, phenylsulfinyl,
substituted phenylsulfinyl, phenylsulfonyl, substituted
phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy,
10 and substituted phenoxy;

R_6 is from 1 to 2 substituents independently selected
from the group consisting of hydrogen, alkyl, alkoxy,
trifluoromethyl, halogen, phenoxy, and substituted
15 phenoxy;

X is selected from the group consisting of a bond,
-CH₂-, -CHR₇-, and -CH₂CH₂- wherein R₇ is lower alkyl;

20 Y is selected from the group consisting of a bond,
-CH₂-, -CHR₈-, -CH₂CH₂-, -CHR₉CH₂-, and -CH₂CHR₉, wherein
R₈ is lower alkyl and R₉ is lower alkyl;

25 and the pharmaceutically acceptable salts thereof and
the pyridyl N-oxides thereof.

2. A compound according to Claim 1 wherein the
pyridyl moiety is attached to X at the 3-position.

3. A compound according to Claim 2 wherein R₁ is
-SO₂R₅.

30 4. A compound according to Claim 1 wherein the
pyridyl moiety is attached to X at the 4-position.

5. A compound according to Claim 2 wherein R₁ is
-C(O)OR₄.

-214-

6. A compound according to Claim 3 or 5 wherein R_2 is from 1 to 3 substituents independently selected from the group consisting of hydrogen, hydroxy, trisubstituted silyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, phenyl, substituted phenyl, pyridyloxy, thiophenoxy, substituted thiophenoxy, phenylsulfinyl, substituted phenylsulfinyl, phenylsulfonyl, substituted phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy, and substituted phenoxy.
7. A compound according to Claim 6 wherein R_2 is selected from group consisting of substituted alkyl, phenyl, substituted phenyl, thiophenoxy, substituted thiophenoxy, phenoxy, and substituted phenoxy.
8. A compound according to Claim 7 wherein the substituted alkyl is selected from the group consisting of benzyl and substituted benzyl
9. A compound according to Claim 7 wherein R_2 is selected from group consisting of phenyl and substituted phenyl.
10. A compound according to Claim 7 wherein R_2 is selected from group consisting of phenoxy and substituted phenoxy.
11. A compound according to any of Claims 1-10 wherein at least one of the R_2 substituents is attached in the 3-position.
12. A compound according to any of Claims 1-10 wherein at least one of the R_2 substituents is attached in the 4-position.
13. A compound according to Claim 1 wherein at least 1 R_2 is substituted benzyl, substituted phenyl, or substituted phenoxy and one of the substituents is

-215-

selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, halogen, cyano, amido, and substituted amido.

14. A compound according to any one of Claims 1-13
5 wherein X is a $-\text{CH}_2-$.
15. A compound according to any one of Claims 1-13
wherein Y is a bond.
16. A compound according to any one of Claims 1-13
wherein X is a $-\text{CH}_2-$ and Y is bond.
- 10 17. A compound of Claim 1 selected from the group
consisting of N-(3-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-
Benzyloxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-
15 Phenoxy)phenyl)-N-(ethylsulfonyl)-2-(pyrid-3-
yl)ethylamine, N-(4-Phenoxy)phenylethyl)-N-
(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-
Phenoxy)phenylmethyl)-N-(ethylsulfonyl)pyrid-3-
ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(iso-
20 propylsulfonyl)pyrid-3-ylmethylamine, N-(2-
(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-
3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-
(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-
Methoxyphenoxy)-3-chlorophenyl)-N-(2,2,2-
25 trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-
(2,6-Dimethoxyphenoxy)-3-chlorophenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-
Benzyloxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-
30 Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-
ylmethylamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-
(cyclopropylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-
Methoxyphenoxy)-3-chlorophenyl)-N-ethylsulfonyl)pyrid-
3-ylmethylamine, N-(4-(2-Methoxyphenoxy)-3-

-216-

chlorophenyl)-N-cyclopropylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-Ethoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-Ethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-Ethoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-Methoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(2-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(methylsulfonyl)pyrid-2-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(butylsulfonyl)pyrid-2-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(methoxycarbonyl)pyrid-2-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(butylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(methoxycarbonyl)pyrid-3-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(methylsulfonyl)pyrid-4-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-ylmethylamine, N-(4-(Phenoxy)phenyl)-N-(butylsulfonyl)pyrid-4-ylmethylamine, N-(4-

-217-

(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(methoxycarbonyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(propionyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(cyclopentylcarbonyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(propionyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(cyclopentylcarbonyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(propionyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(cyclopentylcarbonyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(propylsulfonyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(propylsulfonyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(2-methylpropionyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(2-methylpropionyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(2-methylpropionyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(acetyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(acetyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(acetyl)pyrid-4-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-4-ylmethanamine, N-(4-(4-Benzyloxyphenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(4-

-218-

Cyclohexylphenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-
3-ylmethanamine, N-(4-(4-Benzylphenoxy)phenyl)-N-
(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(4-
Thiophenoxyphenoxy)phenyl)-N-
5 (cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(4-
Benzyloxyphenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-
ylmethanamine, N-(4-(4-Cyclohexylphenoxy)phenyl)-N-
(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
Benzylphenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-
10 ylmethanamine, N-(4-(4-Thiophenoxyphenoxy)phenyl)-N-
(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
Benzyloxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-
ylmethanamine, N-(4-(4-Cyclohexylphenoxy)phenyl)-N-
(ethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
15 Benzylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-
ylmethanamine, N-(4-(4-Thiophenoxyphenoxy)phenyl)-N-
(ethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
Benzyloxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
20 Cyclohexylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
Benzylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
Thiophenoxyphenoxy)phenyl)-N-(2,2,2-
25 trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-
Benzyloxyphenoxy)phenyl)-N-
(trifluoromethylsulfonyl)pyrid-3-ylmethanamine, N-(4-
(4-Cyclohexylphenoxy)phenyl)-N-
(trifluoromethylsulfonyl)pyrid-3-ylmethanamine, N-(4-
30 (4-Benzylphenoxy)phenyl)-N-
(trifluoromethylsulfonyl)pyrid-3-ylmethanamine, N-(4-
(4-Thiophenoxyphenoxy)phenyl)-N-
(trifluoromethylsulfonyl)pyrid-3-ylmethanamine, N-(4-
(4-Benzyloxyphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-

-219-

- ylmethyllamine, N-(4-(4-Cyclohexylphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-Benzylphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-Thiophenoxyphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-Benzylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Cyclohexylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Benzylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Thiophenoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Benzylphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Cyclohexylphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Benzylphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Thiophenoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethyllamine, N-(4-(4-Pentoxyl)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethyllamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethyllamine, N-(4-(4-Methoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethyllamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethyllamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethyllamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethyllamine, N-(4-(4-Pentoxyl)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethyllamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethyllamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-

-220-

5 yloxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Pentoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Methoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Pentoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Methoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Pentoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(Methoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-

-221-

- (trifluoromethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(Pentoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(Methoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(Pentoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(Methoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(Pentoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(3,4-Methylenedioxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(Methoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(5,6,7,8-Tetrahydronaphth-2-yloxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Cyclohexyloxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Pyrid-2-yloxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(2-(Phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(4-

-222-

Chlorophenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(4-Cyanophenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(2-(Phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-Chlorophenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-Cyanophenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(2-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Chlorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Cyanophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(2-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Chlorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(2,2,2-

-223-

- trifluoroethylsulfonyl)pyrid-2-ylmethylaniline, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylaniline, N-(4-(4-Cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylaniline, N-(3-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(2-(Phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Chlorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Cyanophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(2-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Chlorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-(3-(Phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(2-(Phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Chlorophenoxy)phenyl)-N-

-224-

- (trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2-Methoxyphenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Cyanophenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylaniline, N-(3-(Phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(2-(Phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Chlorophenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(3-Trifluoromethylphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2-Methoxyphenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-Cyanophenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylaniline, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethylaniline, N-(3-Chloro-4-(phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethylaniline, N-(2-Methyl-4-(phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethylaniline, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethylaniline, N-(4-(4-Nitrophenoxy)phenyl)-N-(cyclopropylcarbonyl)pyrid-3-ylmethylaniline, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylaniline, N-(3-Chloro-4-(phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylaniline, N-(2-Methyl-4-(phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylaniline, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-

-225-

Nitrophenoxy)phenyl)-N-(methylsulfonyl)pyrid-3-ylmethylamine, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-Chloro-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(2-Methyl-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Nitrophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(3-Chloro-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(2-Methyl-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Nitrophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(3-Chloro-4-(phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(2-Methyl-4-(phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Nitrophenoxy)phenyl)-N-(trifluoromethylsulfonyl)pyrid-3-ylmethylamine, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylamine, N-(3-Chloro-4-(phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylamine, N-(2-Methyl-4-(phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethylamine, N-(3-

-226-

- Trifluoromethyl-4-(phenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(4-(4-Nitrophenoxy)phenyl)-N-(propylsulfonyl)pyrid-3-ylmethanamine, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(3-Chloro-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(2-Methyl-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Nitrophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(2-Chloro-5-methyl-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(3-Chloro-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(2-Methyl-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(3-Trifluoromethyl-4-(phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(4-Nitrophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-methoxypyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-methoxypyrid-3-ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-methoxypyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-6-methoxypyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(ethylsulfonyl)-6-methoxypyrid-3-ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-6-methoxypyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-methylpyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-methylpyrid-3-

-227-

- ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-methylpyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-6-methylpyrid-3-ylmethyllamine, N-(3-(Phenoxy)phenyl)-N-(ethylsulfonyl)-6-methylpyrid-3-ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-6-methylpyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-(4-chlorophenoxy)pyrid-3-ylmethyllamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-(4-chlorophenoxy)pyrid-3-ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-6-(4-chlorophenoxy)pyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-6-(4-chlorophenoxy)pyrid-3-ylmethyllamine, N-(3-(Phenoxy)phenyl)-N-(ethylsulfonyl)-6-(4-chlorophenoxy)pyrid-3-ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-6-(4-chlorophenoxy)pyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-chloropyrid-3-ylmethyllamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-chloropyrid-3-ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-chloropyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-2-chloropyrid-3-ylmethyllamine, N-(3-(Phenoxy)phenyl)-N-(ethylsulfonyl)-2-chloropyrid-3-ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-2-chloropyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-phenoxy-pyrid-3-ylmethyllamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-phenoxy-pyrid-3-ylmethyllamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-phenoxy-pyrid-3-ylmethyllamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-

-228-

- 2-phenoxy)pyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-
N-(ethylsulfonyl)-2-phenoxy)pyrid-3-ylmethanamine, N-(4-
(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-2-
phenoxy)pyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-
5 (2,2,2-trifluoroethylsulfonyl)-6-chloropyrid-3-
ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)-6-chloropyrid-3-
ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)-6-chloropyrid-3-
10 ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-
6-chloropyrid-3-ylmethanamine, N-(3-(Phenoxy)phenyl)-N-
(ethylsulfonyl)-6-chloropyrid-3-ylmethanamine, N-(4-(2-
Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-6-chloropyrid-
3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-
15 trifluoroethylsulfonyl)-2-chloro-6-methylpyrid-3-
ylmethanamine, N-(3-(Phenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)-2-chloro-6-methylpyrid-3-
ylmethanamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)-2-chloro-6-methylpyrid-3-
20 ylmethanamine, N-(4-(Phenoxy)phenyl)-N-(ethylsulfonyl)-
2-chloro-6-methylpyrid-3-ylmethanamine, N-(3-
(Phenoxy)phenyl)-N-(ethylsulfonyl)-2-chloro-6-
methylpyrid-3-ylmethanamine, N-(4-(2-
Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)-2-chloro-6-
25 methylpyrid-3-ylmethanamine, N-(4-(Phenoxy)phenyl)-N-
(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Methoxyphenoxy)phenyl)phenyl)-N-
(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Methoxyphenoxy)phenyl)-N-(2,2,2-
30 trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-
Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-
ylmethanamine, N-(4-(2,6-Dimethoxyphenoxy)phenyl)-N-
(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2,6-
Dimethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-

-229-

ylmethylanine, N-(4-(2,6-Dimethoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2,6-Dimethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethylanine, N-(4-(2,6-Dimethoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylanine, N-(4-(2,6-Dimethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-ylmethylanine, N-(4-(2,6-Dimethoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(ethylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(ethylsulfonyl)pyrid-2-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(ethylsulfonyl)pyrid-4-ylmethylanine, N-(4-(2-Phenoxy-6-chloro)phenylmethyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-ylmethylanine, N-(4-(2,6-Dichlorophenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethylanine, N-

-230-

(4-(2-Isopropoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-Trifluoromethylphenoxy)phenyl)-N-(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Trifluoromethylphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Trifluoromethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Trifluoromethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-Trifluoromethylphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-

-231-

- Trifluoromethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-
4-ylmethanamine, N-(4-(2-
Trifluoromethylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-
5 Isopropyl-5-methylphenoxy)phenyl)-N-
(cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Isopropyl-5-methylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Isopropyl-5-methylphenoxy)phenyl)-N-
10 (ethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Isopropyl-5-methylphenoxy)phenyl)-N-
(ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-
Isopropyl-5-methylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-
15 Isopropyl-5-methylphenoxy)phenyl)-N-
(ethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-
Isopropyl-5-methylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-(4-(2-
Cyclopentylphenoxy)phenyl)-N-
20 (cyclopropylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Cyclopentylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethanamine, N-(4-(2-
Cyclopentylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-
ylmethanamine, N-(4-(2-Cyclopentylphenoxy)phenyl)-N-
25 (ethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-
Cyclopentylphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-2-ylmethanamine, N-(4-(2-
Cyclopentylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-4-
ylmethanamine, N-(4-(2-Cyclopentylphenoxy)phenyl)-N-
30 (2,2,2-trifluoroethylsulfonyl)pyrid-4-ylmethanamine, N-
(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-
(2,2,2-trifluoroethoxy)pyrid-3-ylmethanamine, N-(4-(2-
Methoxyphenoxy)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)-2-(2,2,2-trifluoroethoxy)pyrid-

-232-

3-ylmethamine, N-(4-(2-Isopropoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-(2,2,2-trifluoroethoxy)pyrid-3-ylmethamine, N-(4-(2-Fluoro-6-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-2-(2,2,2-trifluoroethoxy)pyrid-3-ylmethamine, , N-(4-(4-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(3-(2-Methoxyphenylsulfinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-(3-Benzyloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-(3-Hydroxyphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-t-Butyldimethylsilyloxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine, N-(4-Hydroxyphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine, N-(4-t-Butyldimethylsilyloxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-Hydroxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-(Phenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-1-oxypyrid-3-ylmethamine, N-(4-(2-Cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(4-(2-Cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine, N-(3-(2-Methoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-phenylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(4-Bromophenyl)-N-(ethanesulfonyl)pyrid-3-

-233-

ylmethyllamine, N-(4-(2-Fluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(3-Fluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-Fluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2-trifluoromethoxyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-fluoro-2-methyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-trifluoromethoxyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2,4-dimethylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-methylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-isopropylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-t-butylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2-methylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2-Amidophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(3-Methylsulfinylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-t-butyl-2-fluorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-fluoro-2-n-propylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-Carbonylmethoxyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(4-amidomethylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(3-t-butylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2-methoxyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(3-methylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethyllamine, N-(4-(2-

-234-

chlorophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Amidophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(2-methylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Methylsulfonylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(2-(prop-2-yl)phenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(2-ethylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(4-Sulfonylamidophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)-1-pyrid-3-ylethylamine, N-(3-Benzyloxyphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylamine, N-(3-(Bromophenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-fluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(3-fluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(4-fluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2,4-difluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-ethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-phenyl phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(4-trifluoromethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(4-methylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-methyl-4-fluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(2-trifluoromethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(4-Amidomethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(4-Amidophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethylamine, N-(3-(4-Methylsulfonylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-

-235-

ylmethamine, N-(3-(4-Methylsulfinylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(4-t-butylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(3-methylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-n-propyl-4-fluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-chlorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-methylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(4-carbonylmethoxyphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(3-t-butylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(4-fluoro-2-(3-hydroxy-3-methylbutyl)phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-fluoro-4-t-butylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(4-Carbonylmethoxymethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(3-Amidophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2,4-difluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2,4,6-trifluorophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-(prop-2-yl)phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(2-ethylphenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(4-Sulfonylamidophenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(3-(phenoxy)phenyl)-N-(ethylsulfonyl)pyrid-3-ylmethamine, N-(4-(3-Methoxybenzyloxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethamine, N-(3-(2-Fluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethamine, N-(3-(2-

-236-

Methylphenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(4-Carboxymethylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(4-(2-Fluoro-4-methylphenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-methoxy-phenylsulfanyl))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-methoxy-phenylsulfanyl))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-methoxy-phenylsulfanyl))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(4-(2-benzyloxy-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(4-fluoro-2-methoxy-phenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(4-fluoro-2-methoxy-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-bromo-phenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2,3-dimethoxy-phenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-chlorophenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-chloro-6-methylphenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-isopropoxy-phenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-fluoro-5-(2-methoxy-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(3-fluoro-5-(2-methoxy-phenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-methoxy-phenoxy))phenyl)-N-(3,3,3-trifluoropropanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2-bromo-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethanamine, N-(3-(2,3-dimethoxy-phenoxy))phenyl)-N-(2,2,2-

trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-chloro-phenoxy))phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-chloro-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-chloro-6-methyl-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-isopropoxy-phenoxy))phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(Benzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(Benzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-Methoxycarbonylphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-Methoxycarbonylphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(Hydoxymethyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(Hydroxymethyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -Hydroxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-2-methylsulfanylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -hydroxy-4-methylsulfanylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-2-methoxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -hydroxy-2-methoxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-3,4-difluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -

-238-

hydroxy-3,4-difluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-2-phenylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -hydroxy-2-phenylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(1-hydroxy-1-(5-methylpyrid-2-yl)methyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-2-trifluoromethylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -hydroxy-2-fluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-2-fluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxy-3-fluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(Benzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(2-methylsulfonyl benzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-methylsulfonylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-methoxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-methoxybenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(3,4-difluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(3,4-difluorobenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(2-phenylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-phenylbenzyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-

-239-

Methoxycarbonylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(Hydroxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(Hydroxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(Phenoxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(Phenoxymethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -hydroxybenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -hydroxybenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -hydroxy-2-fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -Hydroxy-3-ethoxycarbonylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-ethoxycarbonylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -Fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -Fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-Benzoylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-Benzoylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(1-Phenylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(1-Phenylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -Methylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(α -Methylbenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-Iodo-4-methylphenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(α -

-240-

Hydroxybenzyl)-4-methylphenyl)-N-ethanesulfonyl)pyrid-
3-ylmethylaniline, N-(3-Benzyl-4-methylphenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-t-
butylphenoxy)-4-methylphenyl)-N-(ethanesulfonyl)pyrid-
5 3-ylmethylaniline, N-(3-(2-Methoxyphenoxy)benzyl)-N-
(2,2,2-trifluoroethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-(2-Methoxyphenoxy)benzyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-
Phenylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
10 ylmethylaniline, N-(3-(2-Phenylethyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(Prop-1-en-
1-yl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-(2-N,N-Diethylamidovinyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-
15 Ethoxycarbonylvinyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-Propylphenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-
Trifluoromethoxyphenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, , N-(3-
20 trifluoromethoxyphenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(4-trifluoromethylphenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-
trifluoromethoxyphenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-methoxyphenyl)-N-(2,2,2-
25 trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-
(prop-2-yl)phenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(2-
trifluoromethoxyphenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-
30 (prop-2-yloxy)phenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-
Benzyl-4-chlorophenyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(3-
Cyclobutylloxyphenyl)-N-(2,2,2-

-241-

- trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-isobutyloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-sec-butoxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-cyclopentyloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-cyclohexyloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(1-ethoxycarbonyl-1,1-dimethyl, methoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(1-ethoxycarbonyl-1-methylmethoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(1-(ethoxycarbonyl)-cyclobut-1-yloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-pent-3-yloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-pent-2-yloxyphenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(2,2,2-trifluoroethoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(2-methyl-butyloxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(ethoxycarbonyl, methoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(2-Fluoro-4-cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylanine, N-(4-(2-Fluoro-4-amidophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(2-Fluoro-4-cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(3-(2,4-Difluoro-4-cyanophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylanine, N-(4-(2-Fluoro-4-cyanophenoxy)phenyl)-N-(ethanesulfonyl)pyrid-

-242-

3-ylmethylaniline, N-(4-(2-Fluoro-4-amidophenoxy)phenyl)-
N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-
(Bromomethyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-(2-Methoxybenzyl)phenyl)-N-
5 (ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-
trifluoromethyl, benzyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-
cyanobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-(2-chlorobenzyl)phenyl)-N-
10 (ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-
fluorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-(thien-2-yl methyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(thien-3-yl
methyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
15 ylmethylaniline, N-(3-(2-bromobenzyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(5-methyl-
thiophen-2-yl)methyl phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(3-(2,4-difluorobenzyl)phenyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2,4-
20 dichlorobenzyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(1-(4-Bromophenyl)ethyl)-N-
(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(4-
Cyanophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-((2-Methoxy-5-phenyl)phenyl)-N-
25 (ethanesulfonyl)pyrid-3-ylmethylaniline, N-(1-(4-
Bromophenyl)ethyl)-N-(2,2,2-
trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-
Cyanophenyl)phenyl)-N-(2,2,2-
trifluoroethylsulfonyl)pyrid-3-ylmethylaniline, N-((3-
30 Iodophenyl)methyl)-N-(ethylsulfonyl)pyrid-3-ylamine, N-
((3-Iodophenyl)methyl)-N-(ethylsulfonyl)pyrid-3-
ylmethylaniline, N-(1-(4-(2,4-
Difluorophenyl)phenyl)ethyl)-N-(ethanesulfonyl)pyrid-3-
ylmethylaniline, N-(1-(4-(4-cyanophenyl)phenyl)ethyl)-N-

-243-

- (ethanesulfonyl)pyrid-3-ylmethylaniline, N-((3-(2,4-difluorophenyl)methyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-cyanophenyl)phenyl)methyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(3-(3-methanesulfonylaminophenyl)phenyl)methyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-N-methylamidophenyl)phenyl)methyl)-N-(ethylsulfonyl)pyrid-3-ylmethylaniline, N-(1-(3-(4-cyanophenyl)phenyl)ethyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2,4-difluorophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-N-methylamidophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-((3,5-bis-trifluoromethyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-((3-phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-((4-(2-trifluoroacetyl)amino), ethyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-acetylaminophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-methanephensulfonyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-trifluoromethoxyphenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(pyrid-4-yl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(3-trifluoromethylphenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-carboxyphenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-(N'-methanesulfonyl-N'-t-butoxycarbonylaminoethyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-methylphenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-methoxyphenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-trifluoromethylphenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-

-244-

chlorophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(2-fluorophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(3,5-difluorophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(3-acetylaminophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-((4-Methyl-3-(4-cyanophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-(2-Methanesulfonylaminoethyl)phenyl)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)pyrid-3-ylmethylaniline, N-((3-(4-Amidophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(3-(4-(2-Methanesulfonylaminoethyl)phenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-((3-(2-Methyl-4-cyanophenyl)phenyl)-N-(ethanesulfonyl)pyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)-2-fluororpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-2-fluororpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)-6-fluororpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-6-fluororpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)-2-methylrpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-2-methylrpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(ethanesulfonyl)-6-methylrpyrid-3-ylmethylaniline, N-(4-(2,4-Difluorophenoxy)phenyl)-N-(2,2,2-trifluoroethanesulfonyl)-6-methylrpyrid-3-ylmethylaniline, and N-(3-(N'-Methyl-N'-(2-chlorophenylsulfonamido)phenyl))-N-(ethanesulfonyl)pyrid-3-ylmethylaniline.

-245-

18. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable diluent.
19. A method of treating neurological and psychiatric disorders associated with glutamate dysfunction, comprising: administering to a patient in need thereof an effective amount of a compound of Claim 1.
20. A method of treating anxiety, comprising: administering to a patient in need thereof an effective amount of a compound of Claim 1.
21. A method of treating migraine, comprising: administering to a patient in need thereof an effective amount of a compound of Claim 1.
22. A method of treating schizophrenia, comprising: administering to a patient in need thereof an effective amount of a compound of Claim 1.
23. A method of treating epilepsy, comprising: administering to a patient in need thereof an effective amount of a compound of Claim 1.
24. The use of a compound of Claim 1 as a medicament.
25. The use of a compound of Claim 1 for the manufacture of a medicament for treating neurological and psychiatric disorders associated with glutamate dysfunction.
26. The use of a compound of Claim 1 for the manufacture of a medicament for treating anxiety.
27. The use of a compound of Claim 1 for the manufacture of a medicament for treating migraine.
28. The use of a compound of Claim 1 for the manufacture of a medicament for treating schizophrenia.
29. The use of a compound of Claim 1 for the manufacture of a medicament for treating epilepsy.
30. A method of treating neurological and psychiatric disorders associated with glutamate dysfunction,

-246-

comprising: administering to a patient in need thereof an effective amount of an mGluR potentiator.

31. A method of treating anxiety, comprising:
administering to a patient in need thereof an effective
amount of a compound of an mGluR potentiator.

32. A method of treating migraine, comprising:
administering to a patient in need thereof an effective
amount of an mGluR potentiator.

33. A method of treating schizophrenia, comprising:
administering to a patient in need thereof an effective
amount of an mGluR potentiator.

34. A method of treating epilepsy, comprising:
administering to a patient in need thereof an effective
amount of an mGluR potentiator.

35. A method according to anyone of Claims 30-34
wherein the mGluR potentiator is a mGluR₂ potentiator.

36. A method according to anyone of Claims 30-34
wherein the mGluR potentiator is a mGluR₃ potentiator.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/56990 A3

(51) International Patent Classification⁷: **C07D 213/42**,
213/40, 405/12, 213/643, 213/89, 213/38, 409/12, A61K
31/4406, 31/4427, A61P 25/06, 25/18, 25/08

(21) International Application Number: **PCT/US01/00643**

(22) International Filing Date: 22 January 2001 (22.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/180,047 3 February 2000 (03.02.2000) US
60/180,089 3 February 2000 (03.02.2000) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COLEMAN, Darrell, Stephen** [US/US]; 1036 Waterford Forest Circle, Cary, NC 27513 (US). **JAGDMANN, Gunnar, Erik, Junior** [US/US]; 1027 Oakgate Court, Apex, NC 27502 (US). **JOHNSON, Kirk, Willis** [US/US]; 1177 Helford Lane, Carmel, IN 46032 (US). **JOHNSON, Michael, Parvin** [US/US]; 4308 Powderhorn Court, Carmel, IN 46033 (US). **LARGE, Thomas, Hallett** [US/US]; 1357 James Court, Zionsville, IN 46077 (US). **MONN, James, Allen** [US/US]; 7518 Allenwood Court, Indianapolis, IN 46268 (US). **SCHOEPP, Darryle, Darwin** [US/US]; 638 North Senate Avenue, Indianapolis, IN 46202 (US). **TIZZANO, Joseph, Patrick** [US/US]; 6682 West Sweet Creek Drive, New Palestine, IN 46163 (US). **BARDA, David, Anthony** [US/US]; 6857 Washington Boulevard West Drive, Indianapolis, IN 46220 (US). **BRITTON,**

Thomas, Charles [US/US]; 4700 Royal Oak Lane, Carmel, IN 46033 (US). **DRESSMAN, Bruce, Anthony** [US/US]; 1430 North New Jersey, Indianapolis, IN 46202 (US). **FICHTNER, Michael, William** [US/US]; 6405 Stonecreek Drive, Indianapolis, IN 46268 (US). **HENRY, Steven, Scott** [US/US]; 3362 South Southway Drive, New Palestine, IN 46163 (US). **HORNBACK, William, Joseph** [US/US]; 10063 Bent Tree Lane, Fishers, IN 46038 (US).

(74) Agents: **STEMERICK, David, M. et al.**; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(88) Date of publication of the international search report:
25 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/56990 A3

(54) Title: PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS



(57) Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same for the treatment of eg. anxiety, migraine, schizophrenia or epilepsy.

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/US 01/00643

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D213/42 C07D213/40 C07D405/12 C07D213/643 C07D213/89
C07D213/38 C07D409/12 A61K31/4406 A61K31/4427 A61P25/06
A61P25/18 A61P25/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
CHEM ABS Data, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 99 06353 A (TOMISAWA KAZUYUKI ;CHAKI SHIGEYUKI (JP); HARADA KOICHIRO (JP); NAK) 11 February 1999 (1999-02-11) abstract -& EP 1 004 573 A (TAISHO PHARMA CO LTD) 31 May 2000 (2000-05-31) page 3, line 10 - line 38 page 42, line 9 - line 13 examples 57-62</p> <p style="text-align: center;">--- -/--</p>	<p>1,2, 12-16, 18-29</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

26 October 2001

Date of mailing of the international search report

17.01.2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 01/00643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
X	<p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKASATO, ATSUGO ET AL: "Aryloxy-substituted nitrogen-heteroarylamines, their use, and MDR ligands containing them" retrieved from STN Database accession no. 132:59185 XP002181343 abstract - & JP 2000 001476 A (TAISHO PHARMACEUTICAL CO., LTD., JAPAN; NIHON NOHYAKU CO., LTD.) 7 January 2000 (2000-01-07) examples 1-3,7-9</p> <p style="text-align: center;">---</p>	1,2,13, 18-29
X	<p>US 4 855 308 A (KESTER JEFFREY A ET AL) 8 August 1989 (1989-08-08) column 3, line 67 - line 68 column 2, line 45 - line 60 examples 17,18,32,33 claim 1</p> <p style="text-align: center;">---</p>	1,18-29
X	<p>DATABASE CAOLD [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. CA55:2110812000-05-31 XP002181344 CAS RN: 110491-53-7</p> <p style="text-align: center;">---</p>	1
X	<p>DATABASE CAOLD [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; retrieved from STN Database accession no. CA54:22631B2000-05-31 XP002181345 CAS RN: 108955-05-1</p> <p style="text-align: center;">---</p>	1
X	<p>EP 0 970 954 A (JAPAN TOBACCO INC) 12 January 2000 (2000-01-12) examples 4.1,5.1,8.1-11.1,14.1,16.1-37.1,40.1,41.1</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 01/00643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PARKER, JULIE A. ET AL: "Diastereoselective Methylations of Enolates Derived from Pyridyl Amides" retrieved from STN Database accession no. 129:148890 XP002181346 CAS RN: 210752-33-3; 210752-34-4; 210752-35-5; 210752-41-3; 210752-37-7; 210752-42-4 abstract & J. CHEM. RES., SYNOP. (1998), (7), 362-363, 1453-1460,</p>	1
X	<p>--- EP 0 617 891 A (BASF AG) 5 October 1994 (1994-10-05) examples 7,11,23,41,136,142,150,162,174,235,241,247 ,255,267 examples 322,328,334,534,535 ---</p>	1
X	<p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MEHTA, LINA K. ET AL: "The elimination of an alkoxy group in the photo-Graebe-Ullmann conversion of 1-(2,5-dialkoxyphenyl)triazolopyridines into carbolines, and the preparation of.alpha.-,.gamma.- and.delta.-carboline quinones" retrieved from STN Database accession no. 120:30745 XP002181347 CAS RN:151598-77-5 abstract & J. CHEM. SOC., PERKIN TRANS. 1 (1993), (11), 1261-7,</p>	1
X	<p>--- EP 0 434 357 A (ICI PLC) 26 June 1991 (1991-06-26) examples 11-16,35,36 ---</p>	1
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/00643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	
X	<p>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GREINER, ALFRED: "An improvement of the N-arylation of amides; application to the synthesis of substituted 3-(N-acetyl-N-phenylamino)pyridines" retrieved from STN Database accession no. 111:232522 XP002181348 CAS RN: 123846-74-2 - 123846-84-4 abstract & SYNTHESIS (1989), (4), 312-13,</p>	1
X	<p>--- DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TILLEY, JEFFERSON W. ET AL: "Palladium-catalyzed carbonyl insertion route to pyrido[2-1- b]quinazoline derivatives" retrieved from STN Database accession no. 107:39747 XP002181349 CAS RN: 107962-11-8 abstract & J. ORG. CHEM. (1987), 52(12), 2469-74,</p>	1
X	<p>--- EP 0 174 272 A (CIBA GEIGY AG) 12 March 1986 (1986-03-12) example 14</p>	1
X	<p>--- EP 0 124 154 A (SHELL INT RESEARCH) 7 November 1984 (1984-11-07) claim 1; examples 20-22</p>	1
X	<p>--- GB 2 056 974 A (SHELL INT RESEARCH) 25 March 1981 (1981-03-25) examples 5,7,13</p>	1
X	<p>--- DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MOERKVED, EVA H. ET AL: "Synthesis of some derivatives of 4-(dialkylamino)-2-aminopyridine" retrieved from STN Database accession no. 93:186108 XP002181350 CAS RN: 75291-52-0 abstract & J. PRAKT. CHEM. (1980), 322(2), 343-7,</p>	1
	<p>--- -/-</p>	

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/US 01/00643

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 083 980 A (SCHROMM KURT ET AL) 11 April 1978 (1978-04-11) examples 7,8 column 6, line 54 column 7, line 51,52 ---	1
X	US 3 923 992 A (RILEY THOMAS N ET AL) 2 December 1975 (1975-12-02) formula (VI) examples 2,6,12 ---	1
X	DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ABRAMOVITCH, R. A. ET AL: "Direct acylation of pyridine 1-oxides" retrieved from STN Database accession no. 81:91312 XP002181351 CAS RN: 51263-25-3 abstract & J. ORG. CHEM. (1974), 39(13), 1795-801, ---	1
A	WO 96 05818 A (NPS PHARMA INC) 29 February 1996 (1996-02-29) examples 2G,2F,2H ---	1,18
A	EP 0 860 428 A (LILLY CO ELI) 26 August 1998 (1998-08-26) claims 1,13; example 114 ---	1,18
A	EP 0 937 708 A (LILLY CO ELI) 25 August 1999 (1999-08-25) claim 26; example 19; table 1 -----	1,18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/00643

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 19-23 and 30-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1,2,4,11-13,15,17-36(all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,4,11-13,15,17-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -C(O)R3 and X is a bond as well as their pharmaceutical use and composition.

2. Claims: 1,2,4,11-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -C(O)R3 and X is -CH2- or -CHR7- as well their pharmaceutical use and composition.

3. Claims: 1,2,4,11-13,15,17-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -C(O)R3 and X is -CH2CH2- as well their pharmaceutical use and composition.

4. Claims: 1,2,4,5-13,15,17-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -C(O)OR4 and X is a bond as well as their pharmaceutical use and composition.

5. Claims: 1,2,4-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -C(O)OR4 and X is -CH2- or -CHR7- as well their pharmaceutical use and composition.

6. Claims: 1,2,4-13,17-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -C(O)OR4 and X is -CH2CH2- as well their pharmaceutical use and composition.

7. Claims: 1-4,6-13,17-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is -SO2R5 and X is a bond as well as their pharmaceutical use and composition.

8. Claims: 1-4,6-36 (all partially)

Compounds according to formula I of claim 1 for which R1 is

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

-SO₂R₅ and X is -CH₂- or -CHR₇- as well as their pharmaceutical use and composition.

9. Claims: 1-4,6-13,15,17-36 (all partially)

Compounds according to formula I of claim 1 for which R₁ is -SO₂R₅ and X is -CH₂CH₂- as well as their pharmaceutical use and composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/00643

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9906353	A	11-02-1999	
		AU 729000 B2	25-01-2001
		AU 8462598 A	22-02-1999
		CN 1265642 T	06-09-2000
		EP 1004573 A1	31-05-2000
		WO 9906353 A1	11-02-1999
		JP 11171844 A	29-06-1999
		US 6333358 B1	25-12-2001
JP 2000001476	A	07-01-2000	NONE
US 4855308	A	08-08-1989	NONE
EP 0970954	A	12-01-2000	
		JP 2959765 B2	06-10-1999
		JP 11228569 A	24-08-1999
		AU 717963 B2	06-04-2000
		AU 1506899 A	05-07-1999
		BR 9807339 A	21-03-2000
		EP 0970954 A1	12-01-2000
		HU 0001154 A2	28-04-2001
		NO 993868 A	12-10-1999
		SK 109399 A3	18-01-2000
		CN 1252068 T	03-05-2000
		WO 9931085 A1	24-06-1999
		TR 9901933 T1	21-03-2000
		US 6235730 B1	22-05-2001
EP 0617891	A	05-10-1994	
		DE 4308395 A1	22-09-1994
		AT 153501 T	15-06-1997
		AU 679958 B2	17-07-1997
		AU 5779994 A	22-09-1994
		CA 2118975 A1	18-09-1994
		DE 59402874 D1	03-07-1997
		DK 617891 T3	07-07-1997
		EP 0617891 A1	05-10-1994
		ES 2102706 T3	01-08-1997
		GR 3023777 T3	30-09-1997
		JP 6340631 A	13-12-1994
		NZ 260098 A	28-03-1995
		US 5453432 A	26-09-1995
		US 5569765 A	29-10-1996
		ZA 9401842 A	18-09-1995
EP 0434357	A	26-06-1991	
		AU 6812790 A	27-06-1991
		BR 9006566 A	01-10-1991
		CA 2032783 A1	23-06-1991
		EP 0434357 A2	26-06-1991
		HU 56069 A2	29-07-1991
		IE 904691 A1	17-07-1991
		JP 6056784 A	01-03-1994
		PL 288415 A1	15-06-1992
		US 5153199 A	06-10-1992
		ZA 9010196 A	28-08-1991
EP 0174272	A	12-03-1986	
		CA 1229617 A1	24-11-1987
		DE 3564677 D1	06-10-1988
		EP 0174272 A1	12-03-1986
		JP 1926686 C	25-04-1995
		JP 6057704 B	03-08-1994

INTERNATIONAL SEARCH REPORT

...nation on patent family members

International Application No

PCT/US 01/00643

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0174272	A		JP 61053277 A US 4644069 A	17-03-1986 17-02-1987
EP 0124154	A	07-11-1984	AU 570952 B2 AU 2687384 A CA 1266475 A1 EP 0124154 A2 US 4543413 A	31-03-1988 25-10-1984 06-03-1990 07-11-1984 24-09-1985
GB 2056974	A	25-03-1981	AT 369950 B AT 369180 A AU 536746 B2 AU 6044080 A BE 884340 A1 BG 35181 A3 BR 8004436 A CA 1231710 A1 CH 647649 A5 CS 8005048 A2 CU 35278 A2 DD 154468 A5 DE 3026926 A1 DK 307780 A ,B, ES 493416 D0 ES 8104990 A1 FI 802258 A ,B, FR 2461457 A1 GB 2124615 A ,B GR 69690 A1 HU 186300 B IE 50011 B1 IE 50012 B1 IL 60614 A IT 1132198 B JP 1578218 C JP 2004566 B JP 56016469 A LU 82630 A1 MW 2480 A1 NL 8004078 A NO 802135 A ,B, NZ 194365 A OA 6692 A PL 225696 A1 PT 71564 A RO 84716 A1 SE 452544 B SE 8005190 A SU 1186073 A3 TR 21816 A US 4358446 A US 4359576 A US 4441912 A ZA 8004285 A ZM 5980 A1	10-02-1983 15-07-1982 24-05-1984 22-01-1981 16-01-1981 15-02-1984 24-02-1981 19-01-1988 15-02-1985 14-03-1989 28-03-1982 24-03-1982 30-04-1981 20-01-1981 16-05-1981 01-08-1981 20-01-1981 06-02-1981 22-02-1984 08-07-1982 29-07-1985 22-01-1986 22-01-1986 31-08-1984 25-06-1986 13-09-1990 29-01-1990 17-02-1981 02-02-1981 09-12-1981 21-01-1981 20-01-1981 15-03-1983 31-05-1982 08-05-1981 01-08-1980 17-07-1984 07-12-1987 20-01-1981 15-10-1985 23-07-1985 09-11-1982 16-11-1982 10-04-1984 24-06-1981 21-05-1981
US 4083980	A	11-04-1978	DE 2557425 A1 AT 360030 B	30-06-1977 10-12-1980

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/00643

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4083980	A	AT 8479 A	15-05-1980
		AT 355033 B	11-02-1980
		AT 8579 A	15-07-1979
		AT 374478 B	25-04-1984
		AT 42580 A	15-09-1983
		AT 352736 B	10-10-1979
		AT 883976 A	15-03-1979
		AU 513469 B2	04-12-1980
		AU 2069576 A	22-06-1978
		BE 849542 A1	17-06-1977
		BG 25092 A3	12-07-1978
		BG 24673 A3	12-04-1978
		BG 25093 A3	12-07-1978
		CA 1199914 A1	28-01-1986
		CA 1191848 A2	13-08-1985
		CH 631983 A5	15-09-1982
		CH 625243 A5	15-09-1981
		CH 627754 A5	29-01-1982
		CH 625522 A5	30-09-1981
		CS 198226 B2	30-05-1980
		CS 198225 B2	30-05-1980
		CS 198223 B2	30-05-1980
		CS 198224 B2	30-05-1980
		CS 198222 B2	30-05-1980
		DD 128812 A5	14-12-1977
		DE 2560525 C2	13-07-1989
		DK 130982 A ,B,	23-03-1982
		DK 131082 A ,B,	23-03-1982
		DK 567376 A ,B,	20-06-1977
		ES 454405 A1	16-01-1978
		ES 464136 A1	01-09-1978
		ES 464162 A1	01-09-1978
		FI 763469 A ,B,	20-06-1977
		FR 2335229 A1	15-07-1977
		GB 1572707 A	30-07-1980
		GR 62109 A1	26-02-1979
		HK 12984 A	24-02-1984
		HU 172929 B	28-01-1979
		IE 45257 B1	28-07-1982
		IE 45256 B1	28-07-1982
		IL 51124 A	30-06-1980
		JP 1217802 C	17-07-1984
		JP 52077096 A	29-06-1977
		JP 58031350 B	05-07-1983
		LU 76417 A1	18-01-1978
		MX 4488 E	21-05-1982
		MY 7885 A	31-12-1985
		NL 7614013 A ,B,	21-06-1977
US 3923992	A	BE 829425 A1	24-11-1975
		CA 1041907 A1	07-11-1978
		DE 2522785 A1	27-11-1975
WO 9605818	A	AU 3414295 A	14-03-1996
		WO 9605818 A1	29-02-1996
EP 0860428	A	AU 6259598 A	25-08-1998
		BR 9807297 A	18-04-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/00643

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0860428	A	CN 1251523 T	26-04-2000
		EP 0860428 A2	26-08-1998
		HU 0002208 A2	28-10-2000
		JP 2001511781 T	14-08-2001
		NO 993667 A	20-09-1999
		PL 334963 A1	27-03-2000
		TR 9902368 T2	21-01-2000
		WO 9833496 A1	06-08-1998
		US 6303816 B1	16-10-2001
EP 0937708	A	US 6174922 B1	16-01-2001
		AU 2685299 A	15-09-1999
		BR 9908199 A	03-04-2001
		EP 0937708 A2	25-08-1999
		WO 9943285 A2	02-09-1999